'Bevacizumab'
(id=341392131 ; fe=Bevacizumab ; type=1 ; niveau=200 ; luminosité=25 ; somme entrante=105 creation date=2024-12-25 touchdate=2025-04-23 23:54:10.000)

≈ 5914 relations sortantes Bevacizumab -- r_associated #0: 5 / 1 -> anticorps monoclonal n1=Bevacizumab | n2=anticorps monoclonal | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> Beurmann n1=Bevacizumab | n2=Beurmann | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> Beurmann et Gougerot (maladie de) n1=Bevacizumab | n2=Beurmann et Gougerot (maladie de) | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> cancer bronchique n1=Bevacizumab | n2=cancer bronchique | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> cancer colo-rectal n1=Bevacizumab | n2=cancer colo-rectal | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> cancer colorectal n1=Bevacizumab | n2=cancer colorectal | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> cancer de l'ovaire n1=Bevacizumab | n2=cancer de l'ovaire | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> Cancer de l'ovaire n1=Bevacizumab | n2=Cancer de l'ovaire | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> cancer des ovaires n1=Bevacizumab | n2=cancer des ovaires | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> cancer du rein de l'adulte n1=Bevacizumab | n2=cancer du rein de l'adulte | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> carcinome colo-rectal n1=Bevacizumab | n2=carcinome colo-rectal | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> carcinome colorectal n1=Bevacizumab | n2=carcinome colorectal | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> carcinome du gros intestin n1=Bevacizumab | n2=carcinome du gros intestin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> carcinome recto-colique n1=Bevacizumab | n2=carcinome recto-colique | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> carcinome rectocolique n1=Bevacizumab | n2=carcinome rectocolique | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:(61)cu-atsm n1=Bevacizumab | n2=en:(61)cu-atsm | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:[18f]-labeled substance p antagonist receptor quantifier n1=Bevacizumab | n2=en:[18f]-labeled substance p antagonist receptor quantifier | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:[18f]l-fac n1=Bevacizumab | n2=en:[18f]l-fac | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:[18f]l-fmac n1=Bevacizumab | n2=en:[18f]l-fmac | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:1,2-carbon c 13-labeled glucose n1=Bevacizumab | n2=en:1,2-carbon c 13-labeled glucose | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:11c topotecan n1=Bevacizumab | n2=en:11c topotecan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:13-deoxydoxorubicin n1=Bevacizumab | n2=en:13-deoxydoxorubicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:14c bms-275183 n1=Bevacizumab | n2=en:14c bms-275183 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:16 ml bevacizumab 25 mg/ml injection [avastin] n1=Bevacizumab | n2=en:16 ml bevacizumab 25 mg/ml injection [avastin] | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:16,16-dimethyl prostaglandin e2 n1=Bevacizumab | n2=en:16,16-dimethyl prostaglandin e2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:18-f-fluoroacetate n1=Bevacizumab | n2=en:18-f-fluoroacetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:18f-fhbg n1=Bevacizumab | n2=en:18f-fhbg | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:18f-fluoroazomycin arabinoside n1=Bevacizumab | n2=en:18f-fluoroazomycin arabinoside | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:18f-fluoromisonidazole n1=Bevacizumab | n2=en:18f-fluoromisonidazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:18f-labeled mini-peg spacered rgd dimer n1=Bevacizumab | n2=en:18f-labeled mini-peg spacered rgd dimer | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:2-0, 3-0 desulfated heparin n1=Bevacizumab | n2=en:2-0, 3-0 desulfated heparin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:2-deoxy-d-glucose n1=Bevacizumab | n2=en:2-deoxy-d-glucose | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:2-fluoropropionyl-labeled pegylated dimeric rgd peptide n1=Bevacizumab | n2=en:2-fluoropropionyl-labeled pegylated dimeric rgd peptide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:2-hydroxyflutamide depot n1=Bevacizumab | n2=en:2-hydroxyflutamide depot | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:2-hydroxyoleic acid n1=Bevacizumab | n2=en:2-hydroxyoleic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:2-methoxyestradiol n1=Bevacizumab | n2=en:2-methoxyestradiol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:2-methoxyestradiol nanocrystal colloidal dispersion n1=Bevacizumab | n2=en:2-methoxyestradiol nanocrystal colloidal dispersion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:2'-f-ara-deoxyuridine n1=Bevacizumab | n2=en:2'-f-ara-deoxyuridine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:2g-1 tcr retroviral vector-transduced lymphocytes n1=Bevacizumab | n2=en:2g-1 tcr retroviral vector-transduced lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:3-deazauridine n1=Bevacizumab | n2=en:3-deazauridine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:3,4-methylenedioxymethamphetamine n1=Bevacizumab | n2=en:3,4-methylenedioxymethamphetamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:3'-aminomethyl nicotine-p. aeruginosa r-exoprotein a conjugate vaccine n1=Bevacizumab | n2=en:3'-aminomethyl nicotine-p. aeruginosa r-exoprotein a conjugate vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:3'-c-ethynylcytidine n1=Bevacizumab | n2=en:3'-c-ethynylcytidine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:4 ml bevacizumab 25 mg/ml injection [avastin] n1=Bevacizumab | n2=en:4 ml bevacizumab 25 mg/ml injection [avastin] | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:4-(n-(s-glutathionylacetyl)amino)phenylarsenoxide n1=Bevacizumab | n2=en:4-(n-(s-glutathionylacetyl)amino)phenylarsenoxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:4-1bb agonist monoclonal antibody pf-05082566 n1=Bevacizumab | n2=en:4-1bb agonist monoclonal antibody pf-05082566 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:4-nitroestrone 3-methyl ether n1=Bevacizumab | n2=en:4-nitroestrone 3-methyl ether | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:4-peptide melanoma vaccine n1=Bevacizumab | n2=en:4-peptide melanoma vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:4-thio-2-deoxycytidine n1=Bevacizumab | n2=en:4-thio-2-deoxycytidine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:4'-iodo-4'-deoxydoxorubicin n1=Bevacizumab | n2=en:4'-iodo-4'-deoxydoxorubicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:5-[18f]fluorouracil n1=Bevacizumab | n2=en:5-[18f]fluorouracil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:5-fitc-labeled colon-heptapeptide n1=Bevacizumab | n2=en:5-fitc-labeled colon-heptapeptide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:5-fitc-labeled gi-heptapeptide n1=Bevacizumab | n2=en:5-fitc-labeled gi-heptapeptide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:5-fluoro-2-deoxycytidine n1=Bevacizumab | n2=en:5-fluoro-2-deoxycytidine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:5-fluoropyrimidinone n1=Bevacizumab | n2=en:5-fluoropyrimidinone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:5-fluorouracil/salicylic acid topical solution n1=Bevacizumab | n2=en:5-fluorouracil/salicylic acid topical solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:5-ht3 receptor antagonist n1=Bevacizumab | n2=en:5-ht3 receptor antagonist | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:50% oxygen/50% nitrous oxide premix n1=Bevacizumab | n2=en:50% oxygen/50% nitrous oxide premix | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:6-azauridine n1=Bevacizumab | n2=en:6-azauridine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases isoform 3 inhibitor act-pfk-158 n1=Bevacizumab | n2=en:6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases isoform 3 inhibitor act-pfk-158 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:6,8-bis(benzylthio)octanoic acid n1=Bevacizumab | n2=en:6,8-bis(benzylthio)octanoic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:7-cyanoquinocarcinol n1=Bevacizumab | n2=en:7-cyanoquinocarcinol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:7-hydroxystaurosporine n1=Bevacizumab | n2=en:7-hydroxystaurosporine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:714-x n1=Bevacizumab | n2=en:714-x | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:8-hydroxyquinoline sulfate ointment n1=Bevacizumab | n2=en:8-hydroxyquinoline sulfate ointment | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:851b gel n1=Bevacizumab | n2=en:851b gel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:abacavir sulfate n1=Bevacizumab | n2=en:abacavir sulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:abagovomab n1=Bevacizumab | n2=en:abagovomab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:abarelix n1=Bevacizumab | n2=en:abarelix | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:abatacept n1=Bevacizumab | n2=en:abatacept | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:abbv-221 n1=Bevacizumab | n2=en:abbv-221 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:abciximab n1=Bevacizumab | n2=en:abciximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:abemaciclib n1=Bevacizumab | n2=en:abemaciclib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:abexinostat n1=Bevacizumab | n2=en:abexinostat | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:abiraterone acetate n1=Bevacizumab | n2=en:abiraterone acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:abortifacient agents n1=Bevacizumab | n2=en:abortifacient agents | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:abp 215 n1=Bevacizumab | n2=en:abp 215 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:abr-217620 n1=Bevacizumab | n2=en:abr-217620 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:absorbable adhesion barrier gel n1=Bevacizumab | n2=en:absorbable adhesion barrier gel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:absorbable fibrin sealant patch n1=Bevacizumab | n2=en:absorbable fibrin sealant patch | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:absorbable gelatin sponge n1=Bevacizumab | n2=en:absorbable gelatin sponge | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:absorbable modified polymer hemostatic powder n1=Bevacizumab | n2=en:absorbable modified polymer hemostatic powder | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:abt-510 n1=Bevacizumab | n2=en:abt-510 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:abt-751 n1=Bevacizumab | n2=en:abt-751 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:abvd regimen n1=Bevacizumab | n2=en:abvd regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:abve regimen n1=Bevacizumab | n2=en:abve regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ac regimen n1=Bevacizumab | n2=en:ac regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ac-t regimen n1=Bevacizumab | n2=en:ac-t regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:acadesine n1=Bevacizumab | n2=en:acadesine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:acai berry juice n1=Bevacizumab | n2=en:acai berry juice | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:acalabrutinib n1=Bevacizumab | n2=en:acalabrutinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:acarbose n1=Bevacizumab | n2=en:acarbose | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:acaricides n1=Bevacizumab | n2=en:acaricides | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ace inhibitor n1=Bevacizumab | n2=en:ace inhibitor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:acellular cadaveric dermal matrix n1=Bevacizumab | n2=en:acellular cadaveric dermal matrix | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:acenocoumarol n1=Bevacizumab | n2=en:acenocoumarol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:acetaminophen n1=Bevacizumab | n2=en:acetaminophen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:acetazolamide sodium n1=Bevacizumab | n2=en:acetazolamide sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:acetic acid n1=Bevacizumab | n2=en:acetic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:acetohexamide n1=Bevacizumab | n2=en:acetohexamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:acetyl-l-carnitine hydrochloride n1=Bevacizumab | n2=en:acetyl-l-carnitine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:acetylcysteine n1=Bevacizumab | n2=en:acetylcysteine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:acitretin n1=Bevacizumab | n2=en:acitretin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:acivicin n1=Bevacizumab | n2=en:acivicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aclarubicin n1=Bevacizumab | n2=en:aclarubicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:acodazole n1=Bevacizumab | n2=en:acodazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:acolbifene hydrochloride n1=Bevacizumab | n2=en:acolbifene hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:acoustic coupling fluid n1=Bevacizumab | n2=en:acoustic coupling fluid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:acridine carboxamide n1=Bevacizumab | n2=en:acridine carboxamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:actinium ac 225 lintuzumab n1=Bevacizumab | n2=en:actinium ac 225 lintuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:activated marrow infiltrating lymphocytes n1=Bevacizumab | n2=en:activated marrow infiltrating lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:activin type 2b receptor fc fusion protein stm 434 n1=Bevacizumab | n2=en:activin type 2b receptor fc fusion protein stm 434 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:acyclovir n1=Bevacizumab | n2=en:acyclovir | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:acyclovir sodium n1=Bevacizumab | n2=en:acyclovir sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ad-hcmv-flt3l n1=Bevacizumab | n2=en:ad-hcmv-flt3l | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ad-hcmv-tk n1=Bevacizumab | n2=en:ad-hcmv-tk | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ad-isf35 n1=Bevacizumab | n2=en:ad-isf35 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ad-reic/dkk3 vaccine n1=Bevacizumab | n2=en:ad-reic/dkk3 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ad-sig-hmuc-1/ecdcd40l vaccine n1=Bevacizumab | n2=en:ad-sig-hmuc-1/ecdcd40l vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ad5-cmv-nis n1=Bevacizumab | n2=en:ad5-cmv-nis | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ad5-ycd/muttk(sr39)rep-adp n1=Bevacizumab | n2=en:ad5-ycd/muttk(sr39)rep-adp | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ad5-ycd/muttksr39rep-hil12 n1=Bevacizumab | n2=en:ad5-ycd/muttksr39rep-hil12 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ad5.sstr/tk.rgd n1=Bevacizumab | n2=en:ad5.sstr/tk.rgd | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ad5cmv-p53 gene n1=Bevacizumab | n2=en:ad5cmv-p53 gene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ad5f35-lmp1/lmp2-transduced autologous dendritic cells n1=Bevacizumab | n2=en:ad5f35-lmp1/lmp2-transduced autologous dendritic cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adalimumab n1=Bevacizumab | n2=en:adalimumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ade regimen n1=Bevacizumab | n2=en:ade regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adecatumumab n1=Bevacizumab | n2=en:adecatumumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adefovir dipivoxil n1=Bevacizumab | n2=en:adefovir dipivoxil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenosine a2 receptor agonists n1=Bevacizumab | n2=en:adenosine a2 receptor agonists | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenosine a2a receptor antagonist pbf-509 n1=Bevacizumab | n2=en:adenosine a2a receptor antagonist pbf-509 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenosine a3 receptor agonist cf102 n1=Bevacizumab | n2=en:adenosine a3 receptor agonist cf102 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenosine triphosphate n1=Bevacizumab | n2=en:adenosine triphosphate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenosine-a2a receptor antagonist cpi-444 n1=Bevacizumab | n2=en:adenosine-a2a receptor antagonist cpi-444 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenovector encoding mda7 n1=Bevacizumab | n2=en:adenovector encoding mda7 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenovector-transduced ap1903-inducible myd88/cd40-expressing autologous psma-specific prostate cancer vaccine bpx-201 n1=Bevacizumab | n2=en:adenovector-transduced ap1903-inducible myd88/cd40-expressing autologous psma-specific prostate cancer vaccine bpx-201 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenoviral transduced hil-12-expressing autologous dendritic cells inxn-3001 plus activator ligand inxn-1001 n1=Bevacizumab | n2=en:adenoviral transduced hil-12-expressing autologous dendritic cells inxn-3001 plus activator ligand inxn-1001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenoviral vector ad5-cea(6d) vaccine n1=Bevacizumab | n2=en:adenoviral vector ad5-cea(6d) vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenovirus 5-cd40 ligand n1=Bevacizumab | n2=en:adenovirus 5-cd40 ligand | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenovirus 5-human guanylyl cyclase c-padre vaccine n1=Bevacizumab | n2=en:adenovirus 5-human guanylyl cyclase c-padre vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenovirus b7-1 n1=Bevacizumab | n2=en:adenovirus b7-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenovirus encoding human aquaporin-1 n1=Bevacizumab | n2=en:adenovirus encoding human aquaporin-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenovirus encoding rat her-2/neu n1=Bevacizumab | n2=en:adenovirus encoding rat her-2/neu | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenovirus encoding recombinant human endostatin n1=Bevacizumab | n2=en:adenovirus encoding recombinant human endostatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenovirus encoding tyrosinase/mart-1/magea6-transduced autologous dendritic cell vaccine n1=Bevacizumab | n2=en:adenovirus encoding tyrosinase/mart-1/magea6-transduced autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenovirus her2-transduced autologous dendritic cell vaccine n1=Bevacizumab | n2=en:adenovirus her2-transduced autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenovirus rsv-tk n1=Bevacizumab | n2=en:adenovirus rsv-tk | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenovirus vector n1=Bevacizumab | n2=en:adenovirus vector | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenovirus-encoding e.coli pnp n1=Bevacizumab | n2=en:adenovirus-encoding e.coli pnp | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenovirus-mediated human interleukin-12 n1=Bevacizumab | n2=en:adenovirus-mediated human interleukin-12 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenovirus-mediated human interleukin-12 inxn-2001 plus activator ligand inxn-1001 n1=Bevacizumab | n2=en:adenovirus-mediated human interleukin-12 inxn-2001 plus activator ligand inxn-1001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenovirus-p53 transduced dendritic cell vaccine n1=Bevacizumab | n2=en:adenovirus-p53 transduced dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenovirus-psa prostate cancer vaccine n1=Bevacizumab | n2=en:adenovirus-psa prostate cancer vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adenovirus/cytomegalovirus/epstein-barr virus-specific allogeneic cytotoxic t lymphocytes n1=Bevacizumab | n2=en:adenovirus/cytomegalovirus/epstein-barr virus-specific allogeneic cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adgmcaix-transduced autologous dendritic cells n1=Bevacizumab | n2=en:adgmcaix-transduced autologous dendritic cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adh-1 n1=Bevacizumab | n2=en:adh-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adipose-derived regenerative cells n1=Bevacizumab | n2=en:adipose-derived regenerative cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adipose-derived stromal vascular fraction cells n1=Bevacizumab | n2=en:adipose-derived stromal vascular fraction cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adozelesin n1=Bevacizumab | n2=en:adozelesin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:adrtvp-1-transduced prostate cancer cell-based vaccine n1=Bevacizumab | n2=en:adrtvp-1-transduced prostate cancer cell-based vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ae37 peptide/gm-csf vaccine n1=Bevacizumab | n2=en:ae37 peptide/gm-csf vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aee788 n1=Bevacizumab | n2=en:aee788 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aeg35156 n1=Bevacizumab | n2=en:aeg35156 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aerosol sargramostim n1=Bevacizumab | n2=en:aerosol sargramostim | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aerosolized aldesleukin n1=Bevacizumab | n2=en:aerosolized aldesleukin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aerosolized liposomal rubitecan n1=Bevacizumab | n2=en:aerosolized liposomal rubitecan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:afamelanotide n1=Bevacizumab | n2=en:afamelanotide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:afatinib dimaleate n1=Bevacizumab | n2=en:afatinib dimaleate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:afimoxifene n1=Bevacizumab | n2=en:afimoxifene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:afp gene hepatocellular carcinoma vaccine n1=Bevacizumab | n2=en:afp gene hepatocellular carcinoma vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:afp464 n1=Bevacizumab | n2=en:afp464 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:afuresertib n1=Bevacizumab | n2=en:afuresertib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ag-024322 n1=Bevacizumab | n2=en:ag-024322 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:agaricus blazei murill extract n1=Bevacizumab | n2=en:agaricus blazei murill extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:agatolimod sodium n1=Bevacizumab | n2=en:agatolimod sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:agent affecting cardiovascular system n1=Bevacizumab | n2=en:agent affecting cardiovascular system | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aglatimagene besadenovec n1=Bevacizumab | n2=en:aglatimagene besadenovec | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:agonistic anti-cd40 monoclonal antibody adc-1013 n1=Bevacizumab | n2=en:agonistic anti-cd40 monoclonal antibody adc-1013 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:agonistic anti-ox40 monoclonal antibody medi6383 n1=Bevacizumab | n2=en:agonistic anti-ox40 monoclonal antibody medi6383 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:agonistic anti-ox40 monoclonal antibody medi6469 n1=Bevacizumab | n2=en:agonistic anti-ox40 monoclonal antibody medi6469 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aim2(-1)/ht001(-1)/taf1b(-1) frameshift peptide vaccine n1=Bevacizumab | n2=en:aim2(-1)/ht001(-1)/taf1b(-1) frameshift peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ak 3012 n1=Bevacizumab | n2=en:ak 3012 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:akt 1/2 inhibitor bay1125976 n1=Bevacizumab | n2=en:akt 1/2 inhibitor bay1125976 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:akt inhibitor arq 092 n1=Bevacizumab | n2=en:akt inhibitor arq 092 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:akt inhibitor azd5363 n1=Bevacizumab | n2=en:akt inhibitor azd5363 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:akt inhibitor gsk2141795 n1=Bevacizumab | n2=en:akt inhibitor gsk2141795 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:akt inhibitor ly2780301 n1=Bevacizumab | n2=en:akt inhibitor ly2780301 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:akt inhibitor mk2206 n1=Bevacizumab | n2=en:akt inhibitor mk2206 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:akt inhibitor sr13668 n1=Bevacizumab | n2=en:akt inhibitor sr13668 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:akt-1/2 inhibitor-treated tumor infiltrating lymphocytes n1=Bevacizumab | n2=en:akt-1/2 inhibitor-treated tumor infiltrating lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:akt/erk inhibitor onc201 n1=Bevacizumab | n2=en:akt/erk inhibitor onc201 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:al721 n1=Bevacizumab | n2=en:al721 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alanosine n1=Bevacizumab | n2=en:alanosine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:albumin n1=Bevacizumab | n2=en:albumin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:albuterol sulfate n1=Bevacizumab | n2=en:albuterol sulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alcohol n1=Bevacizumab | n2=en:alcohol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alcohol deterrents n1=Bevacizumab | n2=en:alcohol deterrents | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alcohol products n1=Bevacizumab | n2=en:alcohol products | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aldesleukin n1=Bevacizumab | n2=en:aldesleukin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aldoxorubicin n1=Bevacizumab | n2=en:aldoxorubicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alectinib n1=Bevacizumab | n2=en:alectinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alefacept n1=Bevacizumab | n2=en:alefacept | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alemtuzumab n1=Bevacizumab | n2=en:alemtuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alendronate sodium n1=Bevacizumab | n2=en:alendronate sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alfentanil hydrochloride n1=Bevacizumab | n2=en:alfentanil hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alfuzosin hydrochloride n1=Bevacizumab | n2=en:alfuzosin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:algenpantucel-l n1=Bevacizumab | n2=en:algenpantucel-l | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alisertib n1=Bevacizumab | n2=en:alisertib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alitretinoin n1=Bevacizumab | n2=en:alitretinoin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alizapride n1=Bevacizumab | n2=en:alizapride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alk inhibitor asp3026 n1=Bevacizumab | n2=en:alk inhibitor asp3026 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alk inhibitor ro5424802 n1=Bevacizumab | n2=en:alk inhibitor ro5424802 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alk inhibitor x-396 n1=Bevacizumab | n2=en:alk inhibitor x-396 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alk-fak inhibitor cep-37440 n1=Bevacizumab | n2=en:alk-fak inhibitor cep-37440 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alk/fak/pyk2 inhibitor ct-707 n1=Bevacizumab | n2=en:alk/fak/pyk2 inhibitor ct-707 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alk/ros1 inhibitor pf-06463922 n1=Bevacizumab | n2=en:alk/ros1 inhibitor pf-06463922 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alk/trk inhibitor tsr-011 n1=Bevacizumab | n2=en:alk/trk inhibitor tsr-011 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alk5 inhibitor tew-7197 n1=Bevacizumab | n2=en:alk5 inhibitor tew-7197 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alkaline water n1=Bevacizumab | n2=en:alkaline water | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alkalinizing agent (substance) n1=Bevacizumab | n2=en:alkalinizing agent (substance) | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alkylating agent n1=Bevacizumab | n2=en:alkylating agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allergen product n1=Bevacizumab | n2=en:allergen product | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allergenic extract n1=Bevacizumab | n2=en:allergenic extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allodepleted haploidentical t cells-expressing inducible caspase 9 n1=Bevacizumab | n2=en:allodepleted haploidentical t cells-expressing inducible caspase 9 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allodepleted t cell immunotherapeutic atir101 n1=Bevacizumab | n2=en:allodepleted t cell immunotherapeutic atir101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic adenovirus-specific cytotoxic t lymphocytes n1=Bevacizumab | n2=en:allogeneic adenovirus-specific cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic aml antigen-expressing dendritic cell vaccine n1=Bevacizumab | n2=en:allogeneic aml antigen-expressing dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic b7.1/hla-a1 transfected tumor cell vaccine n1=Bevacizumab | n2=en:allogeneic b7.1/hla-a1 transfected tumor cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic cd19-specific car-modified cd8 plus central memory-derived virus-specific t cells n1=Bevacizumab | n2=en:allogeneic cd19-specific car-modified cd8 plus central memory-derived virus-specific t cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic cd4+ memory th1-like t cells/microparticle-bound anti-cd3/anti-cd28 n1=Bevacizumab | n2=en:allogeneic cd4+ memory th1-like t cells/microparticle-bound anti-cd3/anti-cd28 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic cd56-positive cd3-negative natural killer cells n1=Bevacizumab | n2=en:allogeneic cd56-positive cd3-negative natural killer cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic cmv/adv-specific cytotoxic t lymphocytes n1=Bevacizumab | n2=en:allogeneic cmv/adv-specific cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic cytomegalovirus-specific cytotoxic t lymphocytes n1=Bevacizumab | n2=en:allogeneic cytomegalovirus-specific cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic dendritic cell vaccine combig-dc n1=Bevacizumab | n2=en:allogeneic dendritic cell vaccine combig-dc | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic dendritic cell-myeloma idiotype vaccine n1=Bevacizumab | n2=en:allogeneic dendritic cell-myeloma idiotype vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic epstein-barr virus-specific cytotoxic t-lymphocytes n1=Bevacizumab | n2=en:allogeneic epstein-barr virus-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic glioblastoma stem-like cell line lysate-pulsed autologous dendritic cell vaccine n1=Bevacizumab | n2=en:allogeneic glioblastoma stem-like cell line lysate-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic gm-csf-based myeloma cell vaccine n1=Bevacizumab | n2=en:allogeneic gm-csf-based myeloma cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic gm-csf-secreting breast cancer vaccine n1=Bevacizumab | n2=en:allogeneic gm-csf-secreting breast cancer vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic gm-csf-secreting lethally irradiated whole melanoma cell vaccine n1=Bevacizumab | n2=en:allogeneic gm-csf-secreting lethally irradiated whole melanoma cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic gm-csf-secreting tumor vaccine panc 10.05 pcdna-1/gm-neo n1=Bevacizumab | n2=en:allogeneic gm-csf-secreting tumor vaccine panc 10.05 pcdna-1/gm-neo | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic gm-csf-secreting tumor vaccine panc 6.03 pcdna-1/gm-neo n1=Bevacizumab | n2=en:allogeneic gm-csf-secreting tumor vaccine panc 6.03 pcdna-1/gm-neo | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic hla-a2/4-1bb ligand-expressing melanoma vaccine n1=Bevacizumab | n2=en:allogeneic hla-a2/4-1bb ligand-expressing melanoma vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic il13-zetakine/hytk-expressing-glucocorticoid resistant cytotoxic t lymphocytes grm13z40-2 n1=Bevacizumab | n2=en:allogeneic il13-zetakine/hytk-expressing-glucocorticoid resistant cytotoxic t lymphocytes grm13z40-2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic irradiated melanoma cell vaccine csf470 n1=Bevacizumab | n2=en:allogeneic irradiated melanoma cell vaccine csf470 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic large multivalent immunogen breast cancer vaccine n1=Bevacizumab | n2=en:allogeneic large multivalent immunogen breast cancer vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic large multivalent immunogen melanoma vaccine lp2307 n1=Bevacizumab | n2=en:allogeneic large multivalent immunogen melanoma vaccine lp2307 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic lmp1/lmp2-specific cytotoxic t-lymphocytes n1=Bevacizumab | n2=en:allogeneic lmp1/lmp2-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic melanoma vaccine agi-101h n1=Bevacizumab | n2=en:allogeneic melanoma vaccine agi-101h | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic mesothelioma tumor lysate-pulsed autologous dendritic cell vaccine n1=Bevacizumab | n2=en:allogeneic mesothelioma tumor lysate-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic multipotent adult progenitor cells n1=Bevacizumab | n2=en:allogeneic multipotent adult progenitor cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic multivirus-specific cytotoxic t lymphocytes n1=Bevacizumab | n2=en:allogeneic multivirus-specific cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic natural killer cell line mg4101 n1=Bevacizumab | n2=en:allogeneic natural killer cell line mg4101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic natural killer cell line nk-92 n1=Bevacizumab | n2=en:allogeneic natural killer cell line nk-92 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic renal cell carcinoma vaccine mgn1601 n1=Bevacizumab | n2=en:allogeneic renal cell carcinoma vaccine mgn1601 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic t-lymphocytes bpx-501 n1=Bevacizumab | n2=en:allogeneic t-lymphocytes bpx-501 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allogeneic tumor cell vaccine n1=Bevacizumab | n2=en:allogeneic tumor cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allopurinol n1=Bevacizumab | n2=en:allopurinol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allosteric bcr-abl tyrosine kinase inhibitor abl001 n1=Bevacizumab | n2=en:allosteric bcr-abl tyrosine kinase inhibitor abl001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:allovectin-7 n1=Bevacizumab | n2=en:allovectin-7 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alloxan n1=Bevacizumab | n2=en:alloxan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:almurtide n1=Bevacizumab | n2=en:almurtide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aloe vera gel n1=Bevacizumab | n2=en:aloe vera gel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aloe/anise/ascorbic acid/clove/peppermint/spearmint/thyme-based mouthwash n1=Bevacizumab | n2=en:aloe/anise/ascorbic acid/clove/peppermint/spearmint/thyme-based mouthwash | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alogliptin n1=Bevacizumab | n2=en:alogliptin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alopecia preparation n1=Bevacizumab | n2=en:alopecia preparation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alpelisib n1=Bevacizumab | n2=en:alpelisib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alpha fetoprotein adenoviral vector vaccine n1=Bevacizumab | n2=en:alpha fetoprotein adenoviral vector vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alpha fetoprotein plasmid dna vaccine n1=Bevacizumab | n2=en:alpha fetoprotein plasmid dna vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alpha galactosylceramide n1=Bevacizumab | n2=en:alpha galactosylceramide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alpha-1-proteinase inhibitor human n1=Bevacizumab | n2=en:alpha-1-proteinase inhibitor human | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alpha-1,3-galactosyltransferase-expressing allogeneic renal cell carcinoma vaccine n1=Bevacizumab | n2=en:alpha-1,3-galactosyltransferase-expressing allogeneic renal cell carcinoma vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alpha-fetoprotein peptide-pulsed autologous dendritic cell vaccine n1=Bevacizumab | n2=en:alpha-fetoprotein peptide-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alpha-folate receptor-targeting thymidylate synthase inhibitor onx-0801 n1=Bevacizumab | n2=en:alpha-folate receptor-targeting thymidylate synthase inhibitor onx-0801 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alpha-gal glycosphingolipids n1=Bevacizumab | n2=en:alpha-gal glycosphingolipids | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alpha-galactosylceramide-pulsed autologous dendritic cells n1=Bevacizumab | n2=en:alpha-galactosylceramide-pulsed autologous dendritic cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alpha-lipoic acid n1=Bevacizumab | n2=en:alpha-lipoic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alpha-lipoic acid-palladium/vitamin/mineral supplement n1=Bevacizumab | n2=en:alpha-lipoic acid-palladium/vitamin/mineral supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alpha-tocopheryloxyacetic acid n1=Bevacizumab | n2=en:alpha-tocopheryloxyacetic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alpha-type-1 polarized dendritic cells n1=Bevacizumab | n2=en:alpha-type-1 polarized dendritic cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alprazolam n1=Bevacizumab | n2=en:alprazolam | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alprostadil n1=Bevacizumab | n2=en:alprostadil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alteplase n1=Bevacizumab | n2=en:alteplase | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:altiratinib n1=Bevacizumab | n2=en:altiratinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:altretamine n1=Bevacizumab | n2=en:altretamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aluminum hydroxide/magnesium hydroxide n1=Bevacizumab | n2=en:aluminum hydroxide/magnesium hydroxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aluminum sulfate n1=Bevacizumab | n2=en:aluminum sulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alvac-cea b7.1 vaccine n1=Bevacizumab | n2=en:alvac-cea b7.1 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alvac-cea vaccine n1=Bevacizumab | n2=en:alvac-cea vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alvac-eso-1 vaccine n1=Bevacizumab | n2=en:alvac-eso-1 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alvac-hb7.1 n1=Bevacizumab | n2=en:alvac-hb7.1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alvac-mart-1 vaccine n1=Bevacizumab | n2=en:alvac-mart-1 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alvac(2) melanoma multi-antigen therapeutic vaccine n1=Bevacizumab | n2=en:alvac(2) melanoma multi-antigen therapeutic vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alvac(2)-ny-eso-1 (m)/tricom vaccine n1=Bevacizumab | n2=en:alvac(2)-ny-eso-1 (m)/tricom vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alvelestat n1=Bevacizumab | n2=en:alvelestat | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alvespimycin hydrochloride n1=Bevacizumab | n2=en:alvespimycin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alvimopan n1=Bevacizumab | n2=en:alvimopan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:alvocidib hydrochloride n1=Bevacizumab | n2=en:alvocidib hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:amantadine hydrochloride n1=Bevacizumab | n2=en:amantadine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:amatuximab n1=Bevacizumab | n2=en:amatuximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ambazone n1=Bevacizumab | n2=en:ambazone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:american ginseng n1=Bevacizumab | n2=en:american ginseng | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ametantrone n1=Bevacizumab | n2=en:ametantrone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:amg 224 n1=Bevacizumab | n2=en:amg 224 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:amidino tic n1=Bevacizumab | n2=en:amidino tic | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:amifampridine n1=Bevacizumab | n2=en:amifampridine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:amifostine n1=Bevacizumab | n2=en:amifostine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:amikacin sulfate n1=Bevacizumab | n2=en:amikacin sulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:amilomer n1=Bevacizumab | n2=en:amilomer | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:amino acid injection n1=Bevacizumab | n2=en:amino acid injection | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aminobenzoate potassium n1=Bevacizumab | n2=en:aminobenzoate potassium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aminocamptothecin n1=Bevacizumab | n2=en:aminocamptothecin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aminocamptothecin colloidal dispersion n1=Bevacizumab | n2=en:aminocamptothecin colloidal dispersion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aminocaproic acid n1=Bevacizumab | n2=en:aminocaproic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aminoglutethimide n1=Bevacizumab | n2=en:aminoglutethimide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aminolevulinic acid n1=Bevacizumab | n2=en:aminolevulinic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aminolevulinic acid hydrochloride n1=Bevacizumab | n2=en:aminolevulinic acid hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aminophylline n1=Bevacizumab | n2=en:aminophylline | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aminopterin n1=Bevacizumab | n2=en:aminopterin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aminosyn n1=Bevacizumab | n2=en:aminosyn | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aminothiadiazole n1=Bevacizumab | n2=en:aminothiadiazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:amiodarone hydrochloride n1=Bevacizumab | n2=en:amiodarone hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:amitriptyline hydrochloride n1=Bevacizumab | n2=en:amitriptyline hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aml mrna positive lysate loaded autologous dendritic cell vaccine n1=Bevacizumab | n2=en:aml mrna positive lysate loaded autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ammonia n-13 n1=Bevacizumab | n2=en:ammonia n-13 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ammonium glycyrrhizate n1=Bevacizumab | n2=en:ammonium glycyrrhizate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:amnion-derived cellular cytokine solution n1=Bevacizumab | n2=en:amnion-derived cellular cytokine solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:amolimogene bepiplasmid n1=Bevacizumab | n2=en:amolimogene bepiplasmid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:amonafide dihydrochloride n1=Bevacizumab | n2=en:amonafide dihydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:amonafide l-malate n1=Bevacizumab | n2=en:amonafide l-malate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:amoxicillin n1=Bevacizumab | n2=en:amoxicillin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:amoxicillin-clavulanate potassium n1=Bevacizumab | n2=en:amoxicillin-clavulanate potassium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:amphotericin b deoxycholate n1=Bevacizumab | n2=en:amphotericin b deoxycholate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ampicillin sodium/sulbactam sodium n1=Bevacizumab | n2=en:ampicillin sodium/sulbactam sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:amrubicin hydrochloride n1=Bevacizumab | n2=en:amrubicin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:amsacrine n1=Bevacizumab | n2=en:amsacrine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:amsilarotene n1=Bevacizumab | n2=en:amsilarotene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:amt2003 n1=Bevacizumab | n2=en:amt2003 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:amuvatinib n1=Bevacizumab | n2=en:amuvatinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:amylin analog n1=Bevacizumab | n2=en:amylin analog | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anagrelide hydrochloride n1=Bevacizumab | n2=en:anagrelide hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anagrelide prolonged-release formulation n1=Bevacizumab | n2=en:anagrelide prolonged-release formulation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anakinra n1=Bevacizumab | n2=en:anakinra | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:analgesic agent n1=Bevacizumab | n2=en:analgesic agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:analysis aspect n1=Bevacizumab | n2=en:analysis aspect | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anamorelin hydrochloride n1=Bevacizumab | n2=en:anamorelin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anastrozole n1=Bevacizumab | n2=en:anastrozole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anaxirone n1=Bevacizumab | n2=en:anaxirone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ancestim n1=Bevacizumab | n2=en:ancestim | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ancitabine hydrochloride n1=Bevacizumab | n2=en:ancitabine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:androgen antagonist apc-100 n1=Bevacizumab | n2=en:androgen antagonist apc-100 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:androgen receptor antagonist arn-509 n1=Bevacizumab | n2=en:androgen receptor antagonist arn-509 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:androgen receptor antagonist shr3680 n1=Bevacizumab | n2=en:androgen receptor antagonist shr3680 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:androgen receptor antisense oligonucleotide azd5312 n1=Bevacizumab | n2=en:androgen receptor antisense oligonucleotide azd5312 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:androgen receptor antisense oligonucleotide ezn-4176 n1=Bevacizumab | n2=en:androgen receptor antisense oligonucleotide ezn-4176 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:androgen receptor inhibitor epi-506 n1=Bevacizumab | n2=en:androgen receptor inhibitor epi-506 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:androgen receptor ligand-binding domain-encoding plasmid dna vaccine mvi-118 n1=Bevacizumab | n2=en:androgen receptor ligand-binding domain-encoding plasmid dna vaccine mvi-118 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:andrographolide n1=Bevacizumab | n2=en:andrographolide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:androstane steroid he3235 n1=Bevacizumab | n2=en:androstane steroid he3235 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anesthetic agent n1=Bevacizumab | n2=en:anesthetic agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anetholtrithion n1=Bevacizumab | n2=en:anetholtrithion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anetumab ravtansine n1=Bevacizumab | n2=en:anetumab ravtansine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ang2/vegf-binding peptides-antibody fusion protein cvx-241 n1=Bevacizumab | n2=en:ang2/vegf-binding peptides-antibody fusion protein cvx-241 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:angelica sinensis root extract n1=Bevacizumab | n2=en:angelica sinensis root extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:angiogenesis activator inhibitor n1=Bevacizumab | n2=en:angiogenesis activator inhibitor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:angiogenesis inhibitor n1=Bevacizumab | n2=en:angiogenesis inhibitor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:angiogenesis inhibitor gt-111 n1=Bevacizumab | n2=en:angiogenesis inhibitor gt-111 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:angiogenesis inhibitor ji-101 n1=Bevacizumab | n2=en:angiogenesis inhibitor ji-101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:angiogenesis/heparanase inhibitor pg545 n1=Bevacizumab | n2=en:angiogenesis/heparanase inhibitor pg545 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:angiopoietin-2-specific fusion protein pf-04856884 n1=Bevacizumab | n2=en:angiopoietin-2-specific fusion protein pf-04856884 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:angiostatin n1=Bevacizumab | n2=en:angiostatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anguidine n1=Bevacizumab | n2=en:anguidine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anhydrovinblastine n1=Bevacizumab | n2=en:anhydrovinblastine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anidulafungin n1=Bevacizumab | n2=en:anidulafungin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aniline mustard n1=Bevacizumab | n2=en:aniline mustard | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anlotinib hydrochloride n1=Bevacizumab | n2=en:anlotinib hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:annamycin liposomal n1=Bevacizumab | n2=en:annamycin liposomal | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:annonaceous acetogenins n1=Bevacizumab | n2=en:annonaceous acetogenins | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anthocyanin-rich corn extract n1=Bevacizumab | n2=en:anthocyanin-rich corn extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anthracycline analogue gpx-150 n1=Bevacizumab | n2=en:anthracycline analogue gpx-150 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti c-kit antibody-drug conjugate lop628 n1=Bevacizumab | n2=en:anti c-kit antibody-drug conjugate lop628 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti glaucoma preparation n1=Bevacizumab | n2=en:anti glaucoma preparation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-5t4 antibody-drug conjugate pf-06263507 n1=Bevacizumab | n2=en:anti-5t4 antibody-drug conjugate pf-06263507 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-a33 monoclonal antibody krn330 n1=Bevacizumab | n2=en:anti-a33 monoclonal antibody krn330 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-a5b1 integrin monoclonal antibody pf-04605412 n1=Bevacizumab | n2=en:anti-a5b1 integrin monoclonal antibody pf-04605412 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ags-16 monoclonal antibody ags-16m18 n1=Bevacizumab | n2=en:anti-ags-16 monoclonal antibody ags-16m18 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ags-5 antibody-drug conjugate asg-5me n1=Bevacizumab | n2=en:anti-ags-5 antibody-drug conjugate asg-5me | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ags-8 monoclonal antibody ags-8m4 n1=Bevacizumab | n2=en:anti-ags-8 monoclonal antibody ags-8m4 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-alk-1 monoclonal antibody pf-03446962 n1=Bevacizumab | n2=en:anti-alk-1 monoclonal antibody pf-03446962 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-allergic agents n1=Bevacizumab | n2=en:anti-allergic agents | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-alpha5beta1 integrin antibody mint1526a n1=Bevacizumab | n2=en:anti-alpha5beta1 integrin antibody mint1526a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-alphavbeta3 monoclonal antibody emd 525797 n1=Bevacizumab | n2=en:anti-alphavbeta3 monoclonal antibody emd 525797 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-amyloid monoclonal antibody neod001 n1=Bevacizumab | n2=en:anti-amyloid monoclonal antibody neod001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-androgen n1=Bevacizumab | n2=en:anti-androgen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ang2 monoclonal antibody medi-3617 n1=Bevacizumab | n2=en:anti-ang2 monoclonal antibody medi-3617 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-angiopoietin monoclonal antibody amg 780 n1=Bevacizumab | n2=en:anti-angiopoietin monoclonal antibody amg 780 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-b4 blocked ricin immunotoxin n1=Bevacizumab | n2=en:anti-b4 blocked ricin immunotoxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-b7-h3 antibody ds-5573a n1=Bevacizumab | n2=en:anti-b7-h3 antibody ds-5573a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-bcma antibody-drug conjugate gsk2857916 n1=Bevacizumab | n2=en:anti-bcma antibody-drug conjugate gsk2857916 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-c-fms monoclonal antibody amg 820 n1=Bevacizumab | n2=en:anti-c-fms monoclonal antibody amg 820 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-c-kit monoclonal antibody ktn0158 n1=Bevacizumab | n2=en:anti-c-kit monoclonal antibody ktn0158 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-c-met monoclonal antibody abt-700 n1=Bevacizumab | n2=en:anti-c-met monoclonal antibody abt-700 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-c-met monoclonal antibody argx-111 n1=Bevacizumab | n2=en:anti-c-met monoclonal antibody argx-111 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-c-met monoclonal antibody ly2875358 n1=Bevacizumab | n2=en:anti-c-met monoclonal antibody ly2875358 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-c-met monoclonal antibody sait301 n1=Bevacizumab | n2=en:anti-c-met monoclonal antibody sait301 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-c4.4a antibody-drug conjugate bay1129980 n1=Bevacizumab | n2=en:anti-c4.4a antibody-drug conjugate bay1129980 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ca19-9 monoclonal antibody 5b1 n1=Bevacizumab | n2=en:anti-ca19-9 monoclonal antibody 5b1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ca6-dm4 immunoconjugate sar566658 n1=Bevacizumab | n2=en:anti-ca6-dm4 immunoconjugate sar566658 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd123 monoclonal antibody csl360 n1=Bevacizumab | n2=en:anti-cd123 monoclonal antibody csl360 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd123 monoclonal antibody csl362 n1=Bevacizumab | n2=en:anti-cd123 monoclonal antibody csl362 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd123 monoclonal antibody khk2823 n1=Bevacizumab | n2=en:anti-cd123 monoclonal antibody khk2823 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd123 x anti-cd3 bispecific antibody xmab1404 n1=Bevacizumab | n2=en:anti-cd123 x anti-cd3 bispecific antibody xmab1404 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd123/cd3 bispecific antibody jnj-63709178 n1=Bevacizumab | n2=en:anti-cd123/cd3 bispecific antibody jnj-63709178 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd123/cd3 monoclonal antibody mgd006 n1=Bevacizumab | n2=en:anti-cd123/cd3 monoclonal antibody mgd006 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd133-car vector-transduced allogeneic t lymphocytes n1=Bevacizumab | n2=en:anti-cd133-car vector-transduced allogeneic t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd157 monoclonal antibody men1112 n1=Bevacizumab | n2=en:anti-cd157 monoclonal antibody men1112 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd19 antibody-drug conjugate sgn-cd19b n1=Bevacizumab | n2=en:anti-cd19 antibody-drug conjugate sgn-cd19b | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd19 monoclonal antibody di-b4 n1=Bevacizumab | n2=en:anti-cd19 monoclonal antibody di-b4 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd19 monoclonal antibody mdx-1342 n1=Bevacizumab | n2=en:anti-cd19 monoclonal antibody mdx-1342 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd19 monoclonal antibody medi-551 n1=Bevacizumab | n2=en:anti-cd19 monoclonal antibody medi-551 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd19 monoclonal antibody xmab5574 n1=Bevacizumab | n2=en:anti-cd19 monoclonal antibody xmab5574 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd19-car fmc63-28z retroviral vector-transduced allogeneic t-lymphocytes n1=Bevacizumab | n2=en:anti-cd19-car fmc63-28z retroviral vector-transduced allogeneic t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd19-car retroviral vector-transduced autologous t cells n1=Bevacizumab | n2=en:anti-cd19-car retroviral vector-transduced autologous t cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd19-car-cd3zeta-4-1bb-expressing allogenic natural killer cells n1=Bevacizumab | n2=en:anti-cd19-car-cd3zeta-4-1bb-expressing allogenic natural killer cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd19-dm4 immunoconjugate sar3419 n1=Bevacizumab | n2=en:anti-cd19-dm4 immunoconjugate sar3419 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd19/anti-cd22 bispecific immunotoxin dt2219arl n1=Bevacizumab | n2=en:anti-cd19/anti-cd22 bispecific immunotoxin dt2219arl | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd19/cd28/cd3zeta car gammaretroviral vector-transduced autologous t lymphocytes kte-c19 n1=Bevacizumab | n2=en:anti-cd19/cd28/cd3zeta car gammaretroviral vector-transduced autologous t lymphocytes kte-c19 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd19/cd3 tetravalent antibody afm11 n1=Bevacizumab | n2=en:anti-cd19/cd3 tetravalent antibody afm11 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd20 b9e9 scfv-streptavidin fusion protein n1=Bevacizumab | n2=en:anti-cd20 b9e9 scfv-streptavidin fusion protein | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd20 monoclonal antibody pro131921 n1=Bevacizumab | n2=en:anti-cd20 monoclonal antibody pro131921 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd20 monoclonal antibody sct400 n1=Bevacizumab | n2=en:anti-cd20 monoclonal antibody sct400 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd20 monoclonal antibody tl011 n1=Bevacizumab | n2=en:anti-cd20 monoclonal antibody tl011 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd20 monoclonal antibody-interferon-alpha fusion protein ign002 n1=Bevacizumab | n2=en:anti-cd20 monoclonal antibody-interferon-alpha fusion protein ign002 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd20-car-cd3zeta-4-1bb-expressing autologous t-lymphocyte cells n1=Bevacizumab | n2=en:anti-cd20-car-cd3zeta-4-1bb-expressing autologous t-lymphocyte cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd20-engineered toxin body mt-3724 n1=Bevacizumab | n2=en:anti-cd20-engineered toxin body mt-3724 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd20/cd3 monoclonal antibody regn1979 n1=Bevacizumab | n2=en:anti-cd20/cd3 monoclonal antibody regn1979 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd200 monoclonal antibody alxn6000 n1=Bevacizumab | n2=en:anti-cd200 monoclonal antibody alxn6000 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd22 car-expressing t lymphocytes n1=Bevacizumab | n2=en:anti-cd22 car-expressing t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd22 monoclonal antibody-mmae conjugate dcdt2980s n1=Bevacizumab | n2=en:anti-cd22 monoclonal antibody-mmae conjugate dcdt2980s | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd22 scfv tcrz:41bb-car lentiviral vector-transduced autologous t-lymphocytes n1=Bevacizumab | n2=en:anti-cd22 scfv tcrz:41bb-car lentiviral vector-transduced autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd22-car m971-bbz lentiviral vector-transduced autologous t lymphocytes n1=Bevacizumab | n2=en:anti-cd22-car m971-bbz lentiviral vector-transduced autologous t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd25-pbd antibody-drug conjugate adct-301 n1=Bevacizumab | n2=en:anti-cd25-pbd antibody-drug conjugate adct-301 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd27l antibody-drug conjugate amg 172 n1=Bevacizumab | n2=en:anti-cd27l antibody-drug conjugate amg 172 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd3 immunotoxin a-dmdt390-bisfv(ucht1) n1=Bevacizumab | n2=en:anti-cd3 immunotoxin a-dmdt390-bisfv(ucht1) | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd3 okt3/humanized anti-gd2 3f8 bispecific antibody-activated t lymphocytes n1=Bevacizumab | n2=en:anti-cd3 okt3/humanized anti-gd2 3f8 bispecific antibody-activated t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd3 x anti-cd20 bispecific antibody-armed activated t cells n1=Bevacizumab | n2=en:anti-cd3 x anti-cd20 bispecific antibody-armed activated t cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd3/anti-cd20 trifunctional bispecific monoclonal antibody fbta05 n1=Bevacizumab | n2=en:anti-cd3/anti-cd20 trifunctional bispecific monoclonal antibody fbta05 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd3/anti-egfr-bispecific monoclonal antibody-armed activated autologous t-lymphocytes n1=Bevacizumab | n2=en:anti-cd3/anti-egfr-bispecific monoclonal antibody-armed activated autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd30 monoclonal antibody mdx-1401 n1=Bevacizumab | n2=en:anti-cd30 monoclonal antibody mdx-1401 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd30 monoclonal antibody xmab2513 n1=Bevacizumab | n2=en:anti-cd30 monoclonal antibody xmab2513 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd30/cd16a monoclonal antibody afm13 n1=Bevacizumab | n2=en:anti-cd30/cd16a monoclonal antibody afm13 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd33 antibody-drug conjugate imgn779 n1=Bevacizumab | n2=en:anti-cd33 antibody-drug conjugate imgn779 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd33 monoclonal antibody bi 836858 n1=Bevacizumab | n2=en:anti-cd33 monoclonal antibody bi 836858 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd33 monoclonal antibody-dm4 conjugate ave9633 n1=Bevacizumab | n2=en:anti-cd33 monoclonal antibody-dm4 conjugate ave9633 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd33/cd3 bite antibody amg 330 n1=Bevacizumab | n2=en:anti-cd33/cd3 bite antibody amg 330 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd37 antibody-drug conjugate imgn529 n1=Bevacizumab | n2=en:anti-cd37 antibody-drug conjugate imgn529 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd37 mmae antibody-drug conjugate ags67e n1=Bevacizumab | n2=en:anti-cd37 mmae antibody-drug conjugate ags67e | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd37 monoclonal antibody bi 836826 n1=Bevacizumab | n2=en:anti-cd37 monoclonal antibody bi 836826 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd38 monoclonal antibody mor03087 n1=Bevacizumab | n2=en:anti-cd38 monoclonal antibody mor03087 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd38 monoclonal antibody sar650984 n1=Bevacizumab | n2=en:anti-cd38 monoclonal antibody sar650984 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd40 monoclonal antibody chi lob 7/4 n1=Bevacizumab | n2=en:anti-cd40 monoclonal antibody chi lob 7/4 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd40 monoclonal antibody sea-cd40 n1=Bevacizumab | n2=en:anti-cd40 monoclonal antibody sea-cd40 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd40l fc-fusion protein bms-986004 n1=Bevacizumab | n2=en:anti-cd40l fc-fusion protein bms-986004 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd44 monoclonal antibody ro5429083 n1=Bevacizumab | n2=en:anti-cd44 monoclonal antibody ro5429083 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd45 bc8 monoclonal antibody-streptavidin conjugate n1=Bevacizumab | n2=en:anti-cd45 bc8 monoclonal antibody-streptavidin conjugate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd45 monoclonal antibody n1=Bevacizumab | n2=en:anti-cd45 monoclonal antibody | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd45 monoclonal antibody ahn-12 n1=Bevacizumab | n2=en:anti-cd45 monoclonal antibody ahn-12 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd45 monoclonal antibody bc8 n1=Bevacizumab | n2=en:anti-cd45 monoclonal antibody bc8 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd47 monoclonal antibody cc-90002 n1=Bevacizumab | n2=en:anti-cd47 monoclonal antibody cc-90002 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd47 monoclonal antibody hu5f9-g4 n1=Bevacizumab | n2=en:anti-cd47 monoclonal antibody hu5f9-g4 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd7 immunotoxin n1=Bevacizumab | n2=en:anti-cd7 immunotoxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd70 antibody-drug conjugate mdx-1203 n1=Bevacizumab | n2=en:anti-cd70 antibody-drug conjugate mdx-1203 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd70 antibody-drug conjugate sgn-cd70a n1=Bevacizumab | n2=en:anti-cd70 antibody-drug conjugate sgn-cd70a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd70 monoclonal antibody argx-110 n1=Bevacizumab | n2=en:anti-cd70 monoclonal antibody argx-110 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd70 monoclonal antibody mdx-1411 n1=Bevacizumab | n2=en:anti-cd70 monoclonal antibody mdx-1411 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd73 monoclonal antibody medi9447 n1=Bevacizumab | n2=en:anti-cd73 monoclonal antibody medi9447 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd98 monoclonal antibody ign523 n1=Bevacizumab | n2=en:anti-cd98 monoclonal antibody ign523 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cd98 monoclonal antibody khk2898 n1=Bevacizumab | n2=en:anti-cd98 monoclonal antibody khk2898 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cea bite monoclonal antibody amg211 n1=Bevacizumab | n2=en:anti-cea bite monoclonal antibody amg211 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cea igcd28tcr-transduced autologous t cells n1=Bevacizumab | n2=en:anti-cea igcd28tcr-transduced autologous t cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cea tcr retroviral vector-transduced autologous peripheral blood lymphocytes n1=Bevacizumab | n2=en:anti-cea tcr retroviral vector-transduced autologous peripheral blood lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cea-car autologous t lymphocytes n1=Bevacizumab | n2=en:anti-cea-car autologous t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cea/anti-dtpa-in (f6-734) bispecific antibody n1=Bevacizumab | n2=en:anti-cea/anti-dtpa-in (f6-734) bispecific antibody | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cea/anti-hsg bispecific monoclonal antibody tf2 n1=Bevacizumab | n2=en:anti-cea/anti-hsg bispecific monoclonal antibody tf2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cea/cd3 bispecific antibody ro6958688 n1=Bevacizumab | n2=en:anti-cea/cd3 bispecific antibody ro6958688 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ceacam1 monoclonal antibody cm-24 n1=Bevacizumab | n2=en:anti-ceacam1 monoclonal antibody cm-24 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ceacam5 antibody-drug conjugate sar408701 n1=Bevacizumab | n2=en:anti-ceacam5 antibody-drug conjugate sar408701 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ceacam6 afaikl2 antibody fragment/jack bean urease immunoconjugate l-dos47 n1=Bevacizumab | n2=en:anti-ceacam6 afaikl2 antibody fragment/jack bean urease immunoconjugate l-dos47 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-cldn6 monoclonal antibody imab027 n1=Bevacizumab | n2=en:anti-cldn6 monoclonal antibody imab027 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-csf1r monoclonal antibody fpa008 n1=Bevacizumab | n2=en:anti-csf1r monoclonal antibody fpa008 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-csf1r monoclonal antibody imc-cs4 n1=Bevacizumab | n2=en:anti-csf1r monoclonal antibody imc-cs4 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ctgf monoclonal antibody fg-3019 n1=Bevacizumab | n2=en:anti-ctgf monoclonal antibody fg-3019 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ctla-4 mab rna-transfected autologous dendritic cell vaccine n1=Bevacizumab | n2=en:anti-ctla-4 mab rna-transfected autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ctla-4 monoclonal antibody agen1884 n1=Bevacizumab | n2=en:anti-ctla-4 monoclonal antibody agen1884 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ctla4 moab rna/gitrl rna-transfected autologous dendritic cell vaccine n1=Bevacizumab | n2=en:anti-ctla4 moab rna/gitrl rna-transfected autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-denatured collagen monoclonal antibody trc093 n1=Bevacizumab | n2=en:anti-denatured collagen monoclonal antibody trc093 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-diabetic agent n1=Bevacizumab | n2=en:anti-diabetic agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-dkk-1 monoclonal antibody ly2812176 n1=Bevacizumab | n2=en:anti-dkk-1 monoclonal antibody ly2812176 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-dkk1 monoclonal antibody bhq880 n1=Bevacizumab | n2=en:anti-dkk1 monoclonal antibody bhq880 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-dll4 monoclonal antibody medi0639 n1=Bevacizumab | n2=en:anti-dll4 monoclonal antibody medi0639 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-dll4 monoclonal antibody regn421 n1=Bevacizumab | n2=en:anti-dll4 monoclonal antibody regn421 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-dll4/vegf bispecific monoclonal antibody omp-305b83 n1=Bevacizumab | n2=en:anti-dll4/vegf bispecific monoclonal antibody omp-305b83 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-dr5 agonist monoclonal antibody tra-8 n1=Bevacizumab | n2=en:anti-dr5 agonist monoclonal antibody tra-8 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-dr5 agonistic antibody ds-8273a n1=Bevacizumab | n2=en:anti-dr5 agonistic antibody ds-8273a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-egfr monoclonal antibody gc1118 n1=Bevacizumab | n2=en:anti-egfr monoclonal antibody gc1118 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-egfr monoclonal antibody gt-mab 5.2-gex n1=Bevacizumab | n2=en:anti-egfr monoclonal antibody gt-mab 5.2-gex | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-egfr monoclonal antibody mixture mm-151 n1=Bevacizumab | n2=en:anti-egfr monoclonal antibody mixture mm-151 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-egfr monoclonal antibody mixture sym004 n1=Bevacizumab | n2=en:anti-egfr monoclonal antibody mixture sym004 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-egfr monoclonal antibody ro5083945 n1=Bevacizumab | n2=en:anti-egfr monoclonal antibody ro5083945 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-egfr monoclonal antibody sct200 n1=Bevacizumab | n2=en:anti-egfr monoclonal antibody sct200 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-egfr monoclonal antibody syn004 n1=Bevacizumab | n2=en:anti-egfr monoclonal antibody syn004 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-egfr tap antibody-drug conjugate imgn289 n1=Bevacizumab | n2=en:anti-egfr tap antibody-drug conjugate imgn289 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-egfr/c-met bispecific antibody jnj-61186372 n1=Bevacizumab | n2=en:anti-egfr/c-met bispecific antibody jnj-61186372 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-egfrviii antibody drug conjugate amg 595 n1=Bevacizumab | n2=en:anti-egfrviii antibody drug conjugate amg 595 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-egfrviii car-transduced allogeneic t-lymphocytes n1=Bevacizumab | n2=en:anti-egfrviii car-transduced allogeneic t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-egfrviii immunotoxin mr1-1 n1=Bevacizumab | n2=en:anti-egfrviii immunotoxin mr1-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-egp-2 immunotoxin moc31-pe n1=Bevacizumab | n2=en:anti-egp-2 immunotoxin moc31-pe | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-endoglin chimeric monoclonal antibody trc105 n1=Bevacizumab | n2=en:anti-endoglin chimeric monoclonal antibody trc105 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-endosialin monoclonal antibody morab-004 n1=Bevacizumab | n2=en:anti-endosialin monoclonal antibody morab-004 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-enpp3 antibody-drug conjugate ags-16c3f n1=Bevacizumab | n2=en:anti-enpp3 antibody-drug conjugate ags-16c3f | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-enpp3/mmaf antibody-drug conjugate ags-16m8f n1=Bevacizumab | n2=en:anti-enpp3/mmaf antibody-drug conjugate ags-16m8f | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-epcam antibody fragment-pseudomonas-exotoxin fusion protein n1=Bevacizumab | n2=en:anti-epcam antibody fragment-pseudomonas-exotoxin fusion protein | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-epha2 monoclonal antibody ds-8895a n1=Bevacizumab | n2=en:anti-epha2 monoclonal antibody ds-8895a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-epha2 monoclonal antibody-mmaf immunoconjugate medi-547 n1=Bevacizumab | n2=en:anti-epha2 monoclonal antibody-mmaf immunoconjugate medi-547 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-epha3 monoclonal antibody kb004 n1=Bevacizumab | n2=en:anti-epha3 monoclonal antibody kb004 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-epidermal growth factor receptor 2 antibody expressing pluripotent killer t-lymphocytes n1=Bevacizumab | n2=en:anti-epidermal growth factor receptor 2 antibody expressing pluripotent killer t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-erbb2/anti-erbb3 bispecific monoclonal antibody mm-111 n1=Bevacizumab | n2=en:anti-erbb2/anti-erbb3 bispecific monoclonal antibody mm-111 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-erbb3 monoclonal antibody av-203 n1=Bevacizumab | n2=en:anti-erbb3 monoclonal antibody av-203 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-erbb3 monoclonal antibody ktn3379 n1=Bevacizumab | n2=en:anti-erbb3 monoclonal antibody ktn3379 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-erbb3 monoclonal antibody regn1400 n1=Bevacizumab | n2=en:anti-erbb3 monoclonal antibody regn1400 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-erbb3/anti-igf-1r bispecific monoclonal antibody mm-141 n1=Bevacizumab | n2=en:anti-erbb3/anti-igf-1r bispecific monoclonal antibody mm-141 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-etbr/mmae antibody-drug conjugate dedn6526a n1=Bevacizumab | n2=en:anti-etbr/mmae antibody-drug conjugate dedn6526a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-fgf23 igg1 monoclonal antibody krn23 n1=Bevacizumab | n2=en:anti-fgf23 igg1 monoclonal antibody krn23 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-fgfr2 antibody bay1179470 n1=Bevacizumab | n2=en:anti-fgfr2 antibody bay1179470 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-fgfr2 antibody-drug conjugate bay1187982 n1=Bevacizumab | n2=en:anti-fgfr2 antibody-drug conjugate bay1187982 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-fgfr2 monoclonal antibody fpa144 n1=Bevacizumab | n2=en:anti-fgfr2 monoclonal antibody fpa144 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-fgfr3 antibody-drug conjugate ly3076226 n1=Bevacizumab | n2=en:anti-fgfr3 antibody-drug conjugate ly3076226 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-fgfr3 monoclonal antibody b-701 n1=Bevacizumab | n2=en:anti-fgfr3 monoclonal antibody b-701 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-fgfr3 monoclonal antibody mfgr1877s n1=Bevacizumab | n2=en:anti-fgfr3 monoclonal antibody mfgr1877s | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-fgfr4 monoclonal antibody u3-1784 n1=Bevacizumab | n2=en:anti-fgfr4 monoclonal antibody u3-1784 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-flt3 monoclonal antibody imc-eb10 n1=Bevacizumab | n2=en:anti-flt3 monoclonal antibody imc-eb10 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-fucosyl-gm1 monoclonal antibody bms-986012 n1=Bevacizumab | n2=en:anti-fucosyl-gm1 monoclonal antibody bms-986012 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ganglioside gm2 monoclonal antibody biw-8962 n1=Bevacizumab | n2=en:anti-ganglioside gm2 monoclonal antibody biw-8962 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-gcc antibody-drug conjugate mln0264 n1=Bevacizumab | n2=en:anti-gcc antibody-drug conjugate mln0264 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-gd2 monoclonal antibody hu14.18k322a n1=Bevacizumab | n2=en:anti-gd2 monoclonal antibody hu14.18k322a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-gd2 monoclonal antibody morab-028 n1=Bevacizumab | n2=en:anti-gd2 monoclonal antibody morab-028 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-gitr agonistic monoclonal antibody incagn01876 n1=Bevacizumab | n2=en:anti-gitr agonistic monoclonal antibody incagn01876 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-gitr monoclonal antibody gwn 323 n1=Bevacizumab | n2=en:anti-gitr monoclonal antibody gwn 323 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-gitr monoclonal antibody mk-4166 n1=Bevacizumab | n2=en:anti-gitr monoclonal antibody mk-4166 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-gnrh vaccine pep223 n1=Bevacizumab | n2=en:anti-gnrh vaccine pep223 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-gpa33/cd3 monoclonal antibody mgd007 n1=Bevacizumab | n2=en:anti-gpa33/cd3 monoclonal antibody mgd007 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-gpc3 monoclonal antibody gc33 n1=Bevacizumab | n2=en:anti-gpc3 monoclonal antibody gc33 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-gpc3-car autologous t lymphocytes n1=Bevacizumab | n2=en:anti-gpc3-car autologous t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-grp78 monoclonal antibody pat-sm6 n1=Bevacizumab | n2=en:anti-grp78 monoclonal antibody pat-sm6 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-hb-egf monoclonal antibody khk2866 n1=Bevacizumab | n2=en:anti-hb-egf monoclonal antibody khk2866 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-hbegf monoclonal antibody u3-1565 n1=Bevacizumab | n2=en:anti-hbegf monoclonal antibody u3-1565 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-hcv e2 monoclonal antibody mbl-hcv1 n1=Bevacizumab | n2=en:anti-hcv e2 monoclonal antibody mbl-hcv1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-hepcidin monoclonal antibody ly2787106 n1=Bevacizumab | n2=en:anti-hepcidin monoclonal antibody ly2787106 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-her-2-car retroviral vector-transduced autologous peripheral blood lymphocytes n1=Bevacizumab | n2=en:anti-her-2-car retroviral vector-transduced autologous peripheral blood lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-her2 antibody-drug conjugate arx788 n1=Bevacizumab | n2=en:anti-her2 antibody-drug conjugate arx788 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-her2 antibody-drug conjugate medi4276 n1=Bevacizumab | n2=en:anti-her2 antibody-drug conjugate medi4276 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-her2 monoclonal antibody ct-p6 n1=Bevacizumab | n2=en:anti-her2 monoclonal antibody ct-p6 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-her2-car autologous cmv-specific cytotoxic t-lymphocytes n1=Bevacizumab | n2=en:anti-her2-car autologous cmv-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-her3 monoclonal antibody gsk2849330 n1=Bevacizumab | n2=en:anti-her3 monoclonal antibody gsk2849330 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-her3 monoclonal antibody ljm716 n1=Bevacizumab | n2=en:anti-her3 monoclonal antibody ljm716 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-hgf monoclonal antibody tak-701 n1=Bevacizumab | n2=en:anti-hgf monoclonal antibody tak-701 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-hif-1alpha lna antisense oligonucleotide ezn-2968 n1=Bevacizumab | n2=en:anti-hif-1alpha lna antisense oligonucleotide ezn-2968 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-hla-a2/ny-eso-1 tcr-transduced autologous t lymphocytes n1=Bevacizumab | n2=en:anti-hla-a2/ny-eso-1 tcr-transduced autologous t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-hla-dr monoclonal antibody immu-114 n1=Bevacizumab | n2=en:anti-hla-dr monoclonal antibody immu-114 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-human chorionic gonadotropin vaccine n1=Bevacizumab | n2=en:anti-human chorionic gonadotropin vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-human gitr monoclonal antibody trx518 n1=Bevacizumab | n2=en:anti-human gitr monoclonal antibody trx518 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-icam-1 monoclonal antibody bi-505 n1=Bevacizumab | n2=en:anti-icam-1 monoclonal antibody bi-505 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-icos agonist antibody gsk3359609 n1=Bevacizumab | n2=en:anti-icos agonist antibody gsk3359609 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-icos monoclonal antibody medi-570 n1=Bevacizumab | n2=en:anti-icos monoclonal antibody medi-570 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-idiotypic monoclonal antibody bec2 n1=Bevacizumab | n2=en:anti-idiotypic monoclonal antibody bec2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-igf-1r monoclonal antibody ave1642 n1=Bevacizumab | n2=en:anti-igf-1r monoclonal antibody ave1642 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-igf-1r recombinant monoclonal antibody biib022 n1=Bevacizumab | n2=en:anti-igf-1r recombinant monoclonal antibody biib022 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-igf1/2 monoclonal antibody medi-573 n1=Bevacizumab | n2=en:anti-igf1/2 monoclonal antibody medi-573 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-il-1 alpha monoclonal antibody ca-18c3 n1=Bevacizumab | n2=en:anti-il-1 alpha monoclonal antibody ca-18c3 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-il-1 alpha monoclonal antibody mabp1 n1=Bevacizumab | n2=en:anti-il-1 alpha monoclonal antibody mabp1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-il-13 humanized monoclonal antibody tnx-650 n1=Bevacizumab | n2=en:anti-il-13 humanized monoclonal antibody tnx-650 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-il-15 monoclonal antibody amg 714 n1=Bevacizumab | n2=en:anti-il-15 monoclonal antibody amg 714 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-il-4/il-13 combination agent qbx258 n1=Bevacizumab | n2=en:anti-il-4/il-13 combination agent qbx258 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-il-8 monoclonal antibody humax-il8 n1=Bevacizumab | n2=en:anti-il-8 monoclonal antibody humax-il8 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-infective agent n1=Bevacizumab | n2=en:anti-infective agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-inflammatory agents n1=Bevacizumab | n2=en:anti-inflammatory agents | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-inflammatory antibody alxn1007 n1=Bevacizumab | n2=en:anti-inflammatory antibody alxn1007 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-inhibitor coagulant complex feiba nf n1=Bevacizumab | n2=en:anti-inhibitor coagulant complex feiba nf | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-integrin monoclonal antibody-dm4 immunoconjugate imgn388 n1=Bevacizumab | n2=en:anti-integrin monoclonal antibody-dm4 immunoconjugate imgn388 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-interferon gamma monoclonal antibody ni-0501 n1=Bevacizumab | n2=en:anti-interferon gamma monoclonal antibody ni-0501 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-interleukin 6 monoclonal antibody ald518 n1=Bevacizumab | n2=en:anti-interleukin 6 monoclonal antibody ald518 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-kir monoclonal antibody iph 2101 n1=Bevacizumab | n2=en:anti-kir monoclonal antibody iph 2101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-kir3dl2 monoclonal antibody iph4102 n1=Bevacizumab | n2=en:anti-kir3dl2 monoclonal antibody iph4102 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ksp/anti-vegf sirnas aln-vsp02 n1=Bevacizumab | n2=en:anti-ksp/anti-vegf sirnas aln-vsp02 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-lag-3 monoclonal antibody bms-986016 n1=Bevacizumab | n2=en:anti-lag-3 monoclonal antibody bms-986016 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-lag-3 monoclonal antibody lag525 n1=Bevacizumab | n2=en:anti-lag-3 monoclonal antibody lag525 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-lamp1 antibody-drug conjugate sar428926 n1=Bevacizumab | n2=en:anti-lamp1 antibody-drug conjugate sar428926 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-lgr5 monoclonal antibody bnc101 n1=Bevacizumab | n2=en:anti-lgr5 monoclonal antibody bnc101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-liv-1 monoclonal antibody-mmae conjugate sgn-liv1a n1=Bevacizumab | n2=en:anti-liv-1 monoclonal antibody-mmae conjugate sgn-liv1a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ly6e antibody-drug conjugate dlye5953a n1=Bevacizumab | n2=en:anti-ly6e antibody-drug conjugate dlye5953a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-m-csf monoclonal antibody mcs110 n1=Bevacizumab | n2=en:anti-m-csf monoclonal antibody mcs110 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-masp-2 monoclonal antibody oms721 n1=Bevacizumab | n2=en:anti-masp-2 monoclonal antibody oms721 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-melanin monoclonal antibody pti-6d2 n1=Bevacizumab | n2=en:anti-melanin monoclonal antibody pti-6d2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-mesothelin antibody-drug conjugate bms-986148 n1=Bevacizumab | n2=en:anti-mesothelin antibody-drug conjugate bms-986148 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-mesothelin car vector-transduced autologous t-lymphocytes n1=Bevacizumab | n2=en:anti-mesothelin car vector-transduced autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-mesothelin cir mrna-electroporated autologous t cells n1=Bevacizumab | n2=en:anti-mesothelin cir mrna-electroporated autologous t cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-mesothelin icasp9m28z car-transduced autologous t lymphocytes n1=Bevacizumab | n2=en:anti-mesothelin icasp9m28z car-transduced autologous t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-mesothelin-pseudomonas exotoxin 24 cytolytic fusion protein lmb-100 n1=Bevacizumab | n2=en:anti-mesothelin-pseudomonas exotoxin 24 cytolytic fusion protein lmb-100 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-mesothelin/mmae antibody-drug conjugate dmot4039a n1=Bevacizumab | n2=en:anti-mesothelin/mmae antibody-drug conjugate dmot4039a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-met monoclonal antibody mixture sym015 n1=Bevacizumab | n2=en:anti-met monoclonal antibody mixture sym015 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-met/egfr monoclonal antibody ly3164530 n1=Bevacizumab | n2=en:anti-met/egfr monoclonal antibody ly3164530 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-mmp-9 monoclonal antibody gs-5745 n1=Bevacizumab | n2=en:anti-mmp-9 monoclonal antibody gs-5745 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-muc1 car-transduced autologous t-lymphocytes n1=Bevacizumab | n2=en:anti-muc1 car-transduced autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-muc1 monoclonal antibody bth1704 n1=Bevacizumab | n2=en:anti-muc1 monoclonal antibody bth1704 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-myeloma monoclonal antibody-dm4 immunoconjugate bt-062 n1=Bevacizumab | n2=en:anti-myeloma monoclonal antibody-dm4 immunoconjugate bt-062 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-myostatin monoclonal antibody ly2495655 n1=Bevacizumab | n2=en:anti-myostatin monoclonal antibody ly2495655 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-napi2b/mmae antibody-drug conjugate dnib0600a n1=Bevacizumab | n2=en:anti-napi2b/mmae antibody-drug conjugate dnib0600a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-nectin 4 antibody-drug conjugate asg-22ce n1=Bevacizumab | n2=en:anti-nectin 4 antibody-drug conjugate asg-22ce | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-nectin-4 monoclonal antibody-drug conjugate ags-22m6e n1=Bevacizumab | n2=en:anti-nectin-4 monoclonal antibody-drug conjugate ags-22m6e | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-neuropilin-1 monoclonal antibody mnrp1685a n1=Bevacizumab | n2=en:anti-neuropilin-1 monoclonal antibody mnrp1685a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-nf-p2x7 antibody ointment bil-010t n1=Bevacizumab | n2=en:anti-nf-p2x7 antibody ointment bil-010t | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-nucleolin aptamer as1411 n1=Bevacizumab | n2=en:anti-nucleolin aptamer as1411 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ny-eso-1 immunotherapeutic gsk-2241658a n1=Bevacizumab | n2=en:anti-ny-eso-1 immunotherapeutic gsk-2241658a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ny-eso1 tcr-transduced autologous cd62l+-derived t-lymphocytes n1=Bevacizumab | n2=en:anti-ny-eso1 tcr-transduced autologous cd62l+-derived t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ofa immunotherapeutic bb-mpi-03 n1=Bevacizumab | n2=en:anti-ofa immunotherapeutic bb-mpi-03 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ox40 antibody bms 986178 n1=Bevacizumab | n2=en:anti-ox40 antibody bms 986178 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ox40 antibody pf-04518600 n1=Bevacizumab | n2=en:anti-ox40 antibody pf-04518600 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ox40 monoclonal antibody n1=Bevacizumab | n2=en:anti-ox40 monoclonal antibody | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ox40 monoclonal antibody gsk3174998 n1=Bevacizumab | n2=en:anti-ox40 monoclonal antibody gsk3174998 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ox40 monoclonal antibody medi0562 n1=Bevacizumab | n2=en:anti-ox40 monoclonal antibody medi0562 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ox40 monoclonal antibody moxr0916 n1=Bevacizumab | n2=en:anti-ox40 monoclonal antibody moxr0916 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-p53 t-cell receptor-transduced peripheral blood lymphocytes n1=Bevacizumab | n2=en:anti-p53 t-cell receptor-transduced peripheral blood lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-pd-1 checkpoint inhibitor pf-06801591 n1=Bevacizumab | n2=en:anti-pd-1 checkpoint inhibitor pf-06801591 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-pd-1 fusion protein amp-224 n1=Bevacizumab | n2=en:anti-pd-1 fusion protein amp-224 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-pd-1 monoclonal antibody bgb-a317 n1=Bevacizumab | n2=en:anti-pd-1 monoclonal antibody bgb-a317 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-pd-1 monoclonal antibody medi0680 n1=Bevacizumab | n2=en:anti-pd-1 monoclonal antibody medi0680 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-pd-1 monoclonal antibody pdr001 n1=Bevacizumab | n2=en:anti-pd-1 monoclonal antibody pdr001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-pd-1 monoclonal antibody regn2810 n1=Bevacizumab | n2=en:anti-pd-1 monoclonal antibody regn2810 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-pd-1 monoclonal antibody shr-1210 n1=Bevacizumab | n2=en:anti-pd-1 monoclonal antibody shr-1210 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-pd-1 monoclonal antibody tsr-042 n1=Bevacizumab | n2=en:anti-pd-1 monoclonal antibody tsr-042 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-pd-l1 monoclonal antibody ly3300054 n1=Bevacizumab | n2=en:anti-pd-l1 monoclonal antibody ly3300054 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-pd-l1 monoclonal antibody mdx-1105 n1=Bevacizumab | n2=en:anti-pd-l1 monoclonal antibody mdx-1105 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-pd-l1/tgfbetarii fusion protein msb0011359c n1=Bevacizumab | n2=en:anti-pd-l1/tgfbetarii fusion protein msb0011359c | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-pdgfr alpha monoclonal antibody medi-575 n1=Bevacizumab | n2=en:anti-pdgfr alpha monoclonal antibody medi-575 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-pgf monoclonal antibody ro5323441 n1=Bevacizumab | n2=en:anti-pgf monoclonal antibody ro5323441 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-pkn3 sirna atu027 n1=Bevacizumab | n2=en:anti-pkn3 sirna atu027 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-plgf monoclonal antibody tb-403 n1=Bevacizumab | n2=en:anti-plgf monoclonal antibody tb-403 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-pr1/hla-a2 monoclonal antibody hu8f4 n1=Bevacizumab | n2=en:anti-pr1/hla-a2 monoclonal antibody hu8f4 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-prame immunotherapeutic gsk2302032a n1=Bevacizumab | n2=en:anti-prame immunotherapeutic gsk2302032a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-programmed cell death protein 1 antibody expressing pluripotent killer t-lymphocytes n1=Bevacizumab | n2=en:anti-programmed cell death protein 1 antibody expressing pluripotent killer t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-prolactin receptor antibody lfa102 n1=Bevacizumab | n2=en:anti-prolactin receptor antibody lfa102 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-psca fully human monoclonal antibody ags-1c4d4 n1=Bevacizumab | n2=en:anti-psca fully human monoclonal antibody ags-1c4d4 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-psma monoclonal antibody mdx1201-a488 n1=Bevacizumab | n2=en:anti-psma monoclonal antibody mdx1201-a488 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-psma monoclonal antibody-mmae conjugate n1=Bevacizumab | n2=en:anti-psma monoclonal antibody-mmae conjugate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-psma/cd3 bite monoclonal antibody mt112 n1=Bevacizumab | n2=en:anti-psma/cd3 bite monoclonal antibody mt112 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-psma/cd3 monoclonal antibody mor209/es414 n1=Bevacizumab | n2=en:anti-psma/cd3 monoclonal antibody mor209/es414 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-rspo3 monoclonal antibody omp-131r10 n1=Bevacizumab | n2=en:anti-rspo3 monoclonal antibody omp-131r10 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-sclu monoclonal antibody ab-16b5 n1=Bevacizumab | n2=en:anti-sclu monoclonal antibody ab-16b5 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-sema4d monoclonal antibody vx15/2503 n1=Bevacizumab | n2=en:anti-sema4d monoclonal antibody vx15/2503 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-slitrk6 monoclonal antibody-mmae conjugate ags15e n1=Bevacizumab | n2=en:anti-slitrk6 monoclonal antibody-mmae conjugate ags15e | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-ta-muc1 monoclonal antibody pankomab n1=Bevacizumab | n2=en:anti-ta-muc1 monoclonal antibody pankomab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-tf monoclonal antibody alt-836 n1=Bevacizumab | n2=en:anti-tf monoclonal antibody alt-836 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-tf monoclonal antibody-mmae conjugate n1=Bevacizumab | n2=en:anti-tf monoclonal antibody-mmae conjugate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-tgf-beta rii monoclonal antibody imc-tr1 n1=Bevacizumab | n2=en:anti-tgf-beta rii monoclonal antibody imc-tr1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-thymocyte globulin n1=Bevacizumab | n2=en:anti-thymocyte globulin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-thyroglobulin mtcr-transduced autologous peripheral blood lymphocytes n1=Bevacizumab | n2=en:anti-thyroglobulin mtcr-transduced autologous peripheral blood lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-tim-3 monoclonal antibody mbg453 n1=Bevacizumab | n2=en:anti-tim-3 monoclonal antibody mbg453 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-tissue factor monoclonal antibody morab-066 n1=Bevacizumab | n2=en:anti-tissue factor monoclonal antibody morab-066 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-tlr2 monoclonal antibody opn-305 n1=Bevacizumab | n2=en:anti-tlr2 monoclonal antibody opn-305 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-transthyretin sirna aln-ttr02 n1=Bevacizumab | n2=en:anti-transthyretin sirna aln-ttr02 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-tumor necrosis factor alpha drug n1=Bevacizumab | n2=en:anti-tumor necrosis factor alpha drug | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-tweak monoclonal antibody ro5458640 n1=Bevacizumab | n2=en:anti-tweak monoclonal antibody ro5458640 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-vegf anticalin prs-050-peg40 n1=Bevacizumab | n2=en:anti-vegf anticalin prs-050-peg40 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-vegf monoclonal antibody n1=Bevacizumab | n2=en:anti-vegf monoclonal antibody | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-vegf/ang2 nanobody bi 836880 n1=Bevacizumab | n2=en:anti-vegf/ang2 nanobody bi 836880 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-vegfc monoclonal antibody vgx-100 n1=Bevacizumab | n2=en:anti-vegfc monoclonal antibody vgx-100 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-vegfr2-car retroviral vector-transduced autologous t-lymphocytes n1=Bevacizumab | n2=en:anti-vegfr2-car retroviral vector-transduced autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-vegfr3 monoclonal antibody imc-3c5 n1=Bevacizumab | n2=en:anti-vegfr3 monoclonal antibody imc-3c5 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-vista monoclonal antibody jnj 61610588 n1=Bevacizumab | n2=en:anti-vista monoclonal antibody jnj 61610588 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anti-von willebrand factor nanobody n1=Bevacizumab | n2=en:anti-von willebrand factor nanobody | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antiangiogenic drug combination tl-118 n1=Bevacizumab | n2=en:antiangiogenic drug combination tl-118 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antiarrhythmic agent n1=Bevacizumab | n2=en:antiarrhythmic agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antiarthritic agent n1=Bevacizumab | n2=en:antiarthritic agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antibiotic n1=Bevacizumab | n2=en:antibiotic | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antibiotic sq109 n1=Bevacizumab | n2=en:antibiotic sq109 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antibody-drug conjugate abbv-085 n1=Bevacizumab | n2=en:antibody-drug conjugate abbv-085 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antibody-drug conjugate abbv-399 n1=Bevacizumab | n2=en:antibody-drug conjugate abbv-399 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antibody-drug conjugate abbv-838 n1=Bevacizumab | n2=en:antibody-drug conjugate abbv-838 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antibody-drug conjugate adct-402 n1=Bevacizumab | n2=en:antibody-drug conjugate adct-402 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antibody-drug conjugate bay79-4620 n1=Bevacizumab | n2=en:antibody-drug conjugate bay79-4620 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antibody-drug conjugate dfrf4539a n1=Bevacizumab | n2=en:antibody-drug conjugate dfrf4539a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antibody-drug conjugate pf-06647020 n1=Bevacizumab | n2=en:antibody-drug conjugate pf-06647020 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antibody-drug conjugate pf-06647263 n1=Bevacizumab | n2=en:antibody-drug conjugate pf-06647263 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antibody-drug conjugate pf-06664178 n1=Bevacizumab | n2=en:antibody-drug conjugate pf-06664178 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antibody-drug conjugate sc-002 n1=Bevacizumab | n2=en:antibody-drug conjugate sc-002 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antibody-drug conjugate sc-003 n1=Bevacizumab | n2=en:antibody-drug conjugate sc-003 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antibody-drug conjugate sc16ld6.5 n1=Bevacizumab | n2=en:antibody-drug conjugate sc16ld6.5 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anticachexia agent mt-102 n1=Bevacizumab | n2=en:anticachexia agent mt-102 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:anticarcinogenic agents n1=Bevacizumab | n2=en:anticarcinogenic agents | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antidiuretic n1=Bevacizumab | n2=en:antidiuretic | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antidote n1=Bevacizumab | n2=en:antidote | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antiestrogen n1=Bevacizumab | n2=en:antiestrogen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antifungal agent f901318 n1=Bevacizumab | n2=en:antifungal agent f901318 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antigen binding n1=Bevacizumab | n2=en:antigen binding | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antigen-targeted personalized breast cancer vaccine n1=Bevacizumab | n2=en:antigen-targeted personalized breast cancer vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antihemophilic factor, human recombinant n1=Bevacizumab | n2=en:antihemophilic factor, human recombinant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antihistamines n1=Bevacizumab | n2=en:antihistamines | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antihypertensive agent n1=Bevacizumab | n2=en:antihypertensive agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antileukemic agent n1=Bevacizumab | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antilipemic agent n1=Bevacizumab | n2=en:antilipemic agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antimetabolite n1=Bevacizumab | n2=en:antimetabolite | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antimetabolite chemotherapy n1=Bevacizumab | n2=en:antimetabolite chemotherapy | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antimetabolite ff-10502 n1=Bevacizumab | n2=en:antimetabolite ff-10502 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antimetastatic agent n1=Bevacizumab | n2=en:antimetastatic agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antimitotic agent n1=Bevacizumab | n2=en:antimitotic agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antimoniotungstate n1=Bevacizumab | n2=en:antimoniotungstate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antimony n1=Bevacizumab | n2=en:antimony | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antineoplastic adjuvants n1=Bevacizumab | n2=en:antineoplastic adjuvants | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antineoplastic agent n1=Bevacizumab | n2=en:antineoplastic agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antineoplastic agent combination sm-88 n1=Bevacizumab | n2=en:antineoplastic agent combination sm-88 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antineoplastic agent trx-818 n1=Bevacizumab | n2=en:antineoplastic agent trx-818 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antineoplastic agents, hormonal n1=Bevacizumab | n2=en:antineoplastic agents, hormonal | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antineoplastic agents, phytogenic n1=Bevacizumab | n2=en:antineoplastic agents, phytogenic | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antineoplastic alkaloid n1=Bevacizumab | n2=en:antineoplastic alkaloid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antineoplastic alkylating agent n1=Bevacizumab | n2=en:antineoplastic alkylating agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antineoplastic anthraquinone n1=Bevacizumab | n2=en:antineoplastic anthraquinone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antineoplastic antibiotic n1=Bevacizumab | n2=en:antineoplastic antibiotic | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antineoplastic hormones n1=Bevacizumab | n2=en:antineoplastic hormones | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antineoplastic metal complex agent n1=Bevacizumab | n2=en:antineoplastic metal complex agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antineoplastic metal complex preparation n1=Bevacizumab | n2=en:antineoplastic metal complex preparation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antineoplastic radiopharmaceuticals n1=Bevacizumab | n2=en:antineoplastic radiopharmaceuticals | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antineoplastic vinca alkaloid n1=Bevacizumab | n2=en:antineoplastic vinca alkaloid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antineoplastics, other n1=Bevacizumab | n2=en:antineoplastics, other | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antineoplaston a10 n1=Bevacizumab | n2=en:antineoplaston a10 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antineoplaston as2-1 n1=Bevacizumab | n2=en:antineoplaston as2-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antiperspirant cream f511 n1=Bevacizumab | n2=en:antiperspirant cream f511 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antiplatelet agent n1=Bevacizumab | n2=en:antiplatelet agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antirheumatic agents n1=Bevacizumab | n2=en:antirheumatic agents | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antispasmodic agent n1=Bevacizumab | n2=en:antispasmodic agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antitumor b n1=Bevacizumab | n2=en:antitumor b | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antivaricose agent n1=Bevacizumab | n2=en:antivaricose agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antiviral agent csj148 n1=Bevacizumab | n2=en:antiviral agent csj148 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antrodia cinnamomea supplement n1=Bevacizumab | n2=en:antrodia cinnamomea supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:antroquinonol capsule n1=Bevacizumab | n2=en:antroquinonol capsule | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:apatinib n1=Bevacizumab | n2=en:apatinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:apatorsen n1=Bevacizumab | n2=en:apatorsen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:apaziquone n1=Bevacizumab | n2=en:apaziquone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:apc8015/bevacizumab n1=Bevacizumab | n2=en:apc8015/bevacizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:apc8015f n1=Bevacizumab | n2=en:apc8015f | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:apf530 n1=Bevacizumab | n2=en:apf530 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:api 31510 topical cream n1=Bevacizumab | n2=en:api 31510 topical cream | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:apilimod dimesylate capsule n1=Bevacizumab | n2=en:apilimod dimesylate capsule | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:apixaban n1=Bevacizumab | n2=en:apixaban | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:apolizumab n1=Bevacizumab | n2=en:apolizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:apomab n1=Bevacizumab | n2=en:apomab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:apomine n1=Bevacizumab | n2=en:apomine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:apoptosis inducer bzl101 n1=Bevacizumab | n2=en:apoptosis inducer bzl101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:apoptosis inducer gcs-100 n1=Bevacizumab | n2=en:apoptosis inducer gcs-100 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:apoptosis inducer mpc-2130 n1=Bevacizumab | n2=en:apoptosis inducer mpc-2130 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:apoptotic autologous tumor cells-pulsed alpha-type-1 polarized dendritic cells n1=Bevacizumab | n2=en:apoptotic autologous tumor cells-pulsed alpha-type-1 polarized dendritic cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aprepitant n1=Bevacizumab | n2=en:aprepitant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:apricoxib n1=Bevacizumab | n2=en:apricoxib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aprotinin n1=Bevacizumab | n2=en:aprotinin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ar antagonist bms-641988 n1=Bevacizumab | n2=en:ar antagonist bms-641988 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ar antagonist odm-201 n1=Bevacizumab | n2=en:ar antagonist odm-201 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ar ligand binding domain-targeting agent azd3514 n1=Bevacizumab | n2=en:ar ligand binding domain-targeting agent azd3514 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:archexin n1=Bevacizumab | n2=en:archexin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:arcitumomab n1=Bevacizumab | n2=en:arcitumomab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:arginine butyrate n1=Bevacizumab | n2=en:arginine butyrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:arginine/omega-3 fatty acids/nucleotides oral supplement n1=Bevacizumab | n2=en:arginine/omega-3 fatty acids/nucleotides oral supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:argipressin n1=Bevacizumab | n2=en:argipressin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:armodafinil n1=Bevacizumab | n2=en:armodafinil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:arnebia indigo jade pearl topical cream n1=Bevacizumab | n2=en:arnebia indigo jade pearl topical cream | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aromatase inhibitor n1=Bevacizumab | n2=en:aromatase inhibitor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aromatase inhibitors, 3rd generation n1=Bevacizumab | n2=en:aromatase inhibitors, 3rd generation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:arsanilic acid n1=Bevacizumab | n2=en:arsanilic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:arsenic n1=Bevacizumab | n2=en:arsenic | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:arsenic trioxide n1=Bevacizumab | n2=en:arsenic trioxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:artemether sublingual spray n1=Bevacizumab | n2=en:artemether sublingual spray | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:artemisia vulgaris n1=Bevacizumab | n2=en:artemisia vulgaris | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:artesunate n1=Bevacizumab | n2=en:artesunate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:artichoke whole phytocomplex concentrate n1=Bevacizumab | n2=en:artichoke whole phytocomplex concentrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:arzoxifene hydrochloride n1=Bevacizumab | n2=en:arzoxifene hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:as03-adjuvanted h1n1 pandemic influenza vaccine n1=Bevacizumab | n2=en:as03-adjuvanted h1n1 pandemic influenza vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:asaley n1=Bevacizumab | n2=en:asaley | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ascorbic acid n1=Bevacizumab | n2=en:ascorbic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:asfotase alfa n1=Bevacizumab | n2=en:asfotase alfa | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ashwagandha root powder extract n1=Bevacizumab | n2=en:ashwagandha root powder extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:asian ginseng n1=Bevacizumab | n2=en:asian ginseng | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ask1 inhibitor gs-4997 n1=Bevacizumab | n2=en:ask1 inhibitor gs-4997 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:asp4132 n1=Bevacizumab | n2=en:asp4132 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:asp9521 n1=Bevacizumab | n2=en:asp9521 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:asp9853 n1=Bevacizumab | n2=en:asp9853 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:asparaginase n1=Bevacizumab | n2=en:asparaginase | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:asparaginase erwinia chrysanthemi n1=Bevacizumab | n2=en:asparaginase erwinia chrysanthemi | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aspects of adverse effects n1=Bevacizumab | n2=en:aspects of adverse effects | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aspects of radiation effects n1=Bevacizumab | n2=en:aspects of radiation effects | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aspirin n1=Bevacizumab | n2=en:aspirin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aspirin/simvastatin/atenolol/ramipril/thiazide capsule n1=Bevacizumab | n2=en:aspirin/simvastatin/atenolol/ramipril/thiazide capsule | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:astragalus-based formulation qing shu yi qi tang n1=Bevacizumab | n2=en:astragalus-based formulation qing shu yi qi tang | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:astringent n1=Bevacizumab | n2=en:astringent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:astuprotimut-r n1=Bevacizumab | n2=en:astuprotimut-r | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:asulacrine isethionate n1=Bevacizumab | n2=en:asulacrine isethionate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:asunaprevir n1=Bevacizumab | n2=en:asunaprevir | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:at 211 monoclonal antibody 81c6 n1=Bevacizumab | n2=en:at 211 monoclonal antibody 81c6 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:atamestane n1=Bevacizumab | n2=en:atamestane | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:atenolol n1=Bevacizumab | n2=en:atenolol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:atezolizumab n1=Bevacizumab | n2=en:atezolizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:atiprimod n1=Bevacizumab | n2=en:atiprimod | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:atm kinase inhibitor azd0156 n1=Bevacizumab | n2=en:atm kinase inhibitor azd0156 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:atn-161 n1=Bevacizumab | n2=en:atn-161 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:atomoxetine hydrochloride n1=Bevacizumab | n2=en:atomoxetine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:atorvastatin calcium n1=Bevacizumab | n2=en:atorvastatin calcium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:atr kinase inhibitor azd6738 n1=Bevacizumab | n2=en:atr kinase inhibitor azd6738 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:atr kinase inhibitor vx-970 n1=Bevacizumab | n2=en:atr kinase inhibitor vx-970 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:atr-101 n1=Bevacizumab | n2=en:atr-101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:atrasentan hydrochloride n1=Bevacizumab | n2=en:atrasentan hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:atropine sulfate n1=Bevacizumab | n2=en:atropine sulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:attenuated chimpanzee adenovirus 5t4 vaccine n1=Bevacizumab | n2=en:attenuated chimpanzee adenovirus 5t4 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:attenuated corynebacterium parvum n1=Bevacizumab | n2=en:attenuated corynebacterium parvum | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:attenuated listeria monocytogenes crs-100 n1=Bevacizumab | n2=en:attenuated listeria monocytogenes crs-100 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:attenuated live listeria encoding hpv 16 e7 vaccine adxs11-001 n1=Bevacizumab | n2=en:attenuated live listeria encoding hpv 16 e7 vaccine adxs11-001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:auranofin n1=Bevacizumab | n2=en:auranofin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aurora a kinase inhibitor mk5108 n1=Bevacizumab | n2=en:aurora a kinase inhibitor mk5108 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aurora a kinase inhibitor tas-119 n1=Bevacizumab | n2=en:aurora a kinase inhibitor tas-119 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aurora a kinase/tyrosine kinase inhibitor enmd-2076 n1=Bevacizumab | n2=en:aurora a kinase/tyrosine kinase inhibitor enmd-2076 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aurora b serine/threonine kinase inhibitor tak-901 n1=Bevacizumab | n2=en:aurora b serine/threonine kinase inhibitor tak-901 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aurora b/c kinase inhibitor gsk1070916a n1=Bevacizumab | n2=en:aurora b/c kinase inhibitor gsk1070916a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aurora kinase inhibitor amg 900 n1=Bevacizumab | n2=en:aurora kinase inhibitor amg 900 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aurora kinase inhibitor bi 811283 n1=Bevacizumab | n2=en:aurora kinase inhibitor bi 811283 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aurora kinase inhibitor mln8054 n1=Bevacizumab | n2=en:aurora kinase inhibitor mln8054 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aurora kinase inhibitor pf-03814735 n1=Bevacizumab | n2=en:aurora kinase inhibitor pf-03814735 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aurora kinase inhibitor sns-314 n1=Bevacizumab | n2=en:aurora kinase inhibitor sns-314 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aurora kinase inhibitor ttp607 n1=Bevacizumab | n2=en:aurora kinase inhibitor ttp607 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aurora kinase/vegfr2 inhibitor cyc116 n1=Bevacizumab | n2=en:aurora kinase/vegfr2 inhibitor cyc116 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous ad-cd154-transduced cll b cells n1=Bevacizumab | n2=en:autologous ad-cd154-transduced cll b cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous anti-cd123 car tcr/4-1bb-expressing t-lymphocytes n1=Bevacizumab | n2=en:autologous anti-cd123 car tcr/4-1bb-expressing t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous anti-cd19 car-expressing t lymphocytes n1=Bevacizumab | n2=en:autologous anti-cd19 car-expressing t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing cd4+/cd8+ central memory t-lymphocytes jcar014 n1=Bevacizumab | n2=en:autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing cd4+/cd8+ central memory t-lymphocytes jcar014 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing cd4+/cd8+ t-lymphocytes jcar017 n1=Bevacizumab | n2=en:autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing cd4+/cd8+ t-lymphocytes jcar017 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing t lymphocytes n1=Bevacizumab | n2=en:autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous anti-gp100:154-162 t-cell receptor gene-engineered peripheral blood lymphocytes n1=Bevacizumab | n2=en:autologous anti-gp100:154-162 t-cell receptor gene-engineered peripheral blood lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous anti-mart-1 f5 t-cell receptor gene-engineered peripheral blood lymphocytes n1=Bevacizumab | n2=en:autologous anti-mart-1 f5 t-cell receptor gene-engineered peripheral blood lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous anti-psma gene-modified t-lymphocytes n1=Bevacizumab | n2=en:autologous anti-psma gene-modified t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous beta-a(t87q)-globin gene-transduced cd34-positive cells n1=Bevacizumab | n2=en:autologous beta-a(t87q)-globin gene-transduced cd34-positive cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous bone marrow-derived cd34/cxcr4-positive stem cells amr-001 n1=Bevacizumab | n2=en:autologous bone marrow-derived cd34/cxcr4-positive stem cells amr-001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous cd123car-cd28-cd3zeta-egfrt-expressing t lymphocytes n1=Bevacizumab | n2=en:autologous cd123car-cd28-cd3zeta-egfrt-expressing t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous cd133-positive btsc mrna-pulsed autologous dendritic cell vaccine n1=Bevacizumab | n2=en:autologous cd133-positive btsc mrna-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous cd171-specific car-cd28 zeta-4-1-bb-egfrt-expressing t lymphocytes n1=Bevacizumab | n2=en:autologous cd171-specific car-cd28 zeta-4-1-bb-egfrt-expressing t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous cd19-28z chimeric antigen receptor-expressing t-lymphocytes n1=Bevacizumab | n2=en:autologous cd19-28z chimeric antigen receptor-expressing t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells n1=Bevacizumab | n2=en:autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous cd34-positive hematopoietic progenitor cells n1=Bevacizumab | n2=en:autologous cd34-positive hematopoietic progenitor cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous cd8 positive pbl sensitized to drosophila cell-presented melanoma peptides n1=Bevacizumab | n2=en:autologous cd8 positive pbl sensitized to drosophila cell-presented melanoma peptides | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous cd8+ melanoma specific t cells n1=Bevacizumab | n2=en:autologous cd8+ melanoma specific t cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous cea-specific cytotoxic t-lymphocytes n1=Bevacizumab | n2=en:autologous cea-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous colon cancer cell vaccine n1=Bevacizumab | n2=en:autologous colon cancer cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous colorectal tumor antigen-pulsed dendritic cell vaccine n1=Bevacizumab | n2=en:autologous colorectal tumor antigen-pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous ct7/mage-a3/wt1 mrna-electroporated langerhans-type dendritic cells n1=Bevacizumab | n2=en:autologous ct7/mage-a3/wt1 mrna-electroporated langerhans-type dendritic cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous cultured acute myeloid leukemia-specific cytotoxic t lymphocytes n1=Bevacizumab | n2=en:autologous cultured acute myeloid leukemia-specific cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous cytomegalovirus-specific cytotoxic t-lymphocytes n1=Bevacizumab | n2=en:autologous cytomegalovirus-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous cytotoxic t-lymphocytes induced with muc1 gene-transfected dendritic cells n1=Bevacizumab | n2=en:autologous cytotoxic t-lymphocytes induced with muc1 gene-transfected dendritic cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous cytotoxic t-lymphocytes induced with muc1 peptide-pulsed dendritic cells n1=Bevacizumab | n2=en:autologous cytotoxic t-lymphocytes induced with muc1 peptide-pulsed dendritic cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous dendritic cell vaccine act2001 n1=Bevacizumab | n2=en:autologous dendritic cell vaccine act2001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous dendritic cell-adenovirus ccl21 vaccine n1=Bevacizumab | n2=en:autologous dendritic cell-adenovirus ccl21 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous dendritic cell-adenovirus p53 vaccine n1=Bevacizumab | n2=en:autologous dendritic cell-adenovirus p53 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine n1=Bevacizumab | n2=en:autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous dendritic cell-autologous tumor mrna-human cd40l vaccine n1=Bevacizumab | n2=en:autologous dendritic cell-autologous tumor mrna-human cd40l vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous dendritic cell-based immunotherapeutic av0113 n1=Bevacizumab | n2=en:autologous dendritic cell-based immunotherapeutic av0113 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous dendritic cell-tumor fusion vaccine n1=Bevacizumab | n2=en:autologous dendritic cell-tumor fusion vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous dendritic cells/cmv pp65 peptide n1=Bevacizumab | n2=en:autologous dendritic cells/cmv pp65 peptide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous dinitrophenyl-modified ovarian cancer vaccine n1=Bevacizumab | n2=en:autologous dinitrophenyl-modified ovarian cancer vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous ebv-ctl cd19car zeta n1=Bevacizumab | n2=en:autologous ebv-ctl cd19car zeta | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous ebv-transformed b lymphoblastoid-tumor fusion cell vaccine n1=Bevacizumab | n2=en:autologous ebv-transformed b lymphoblastoid-tumor fusion cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous epstein-barr virus-transformed b-lymphoblastoid cell vaccine n1=Bevacizumab | n2=en:autologous epstein-barr virus-transformed b-lymphoblastoid cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous expanded mesenchymal stem cells oti-010 n1=Bevacizumab | n2=en:autologous expanded mesenchymal stem cells oti-010 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous glioma cell lysate n1=Bevacizumab | n2=en:autologous glioma cell lysate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous gm-csf-secreting breast cancer vaccine n1=Bevacizumab | n2=en:autologous gm-csf-secreting breast cancer vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous gm-csf-secreting lethally irradiated colorectal cancer cell vaccine n1=Bevacizumab | n2=en:autologous gm-csf-secreting lethally irradiated colorectal cancer cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous gm-csf-secreting lethally irradiated leukemia cell vaccine n1=Bevacizumab | n2=en:autologous gm-csf-secreting lethally irradiated leukemia cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous gm-csf-secreting melanoma vaccine n1=Bevacizumab | n2=en:autologous gm-csf-secreting melanoma vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous hbv-specific tcr-redirected t-lymphocytes n1=Bevacizumab | n2=en:autologous hbv-specific tcr-redirected t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous heat-shock protein 70 peptide vaccine ag-858 n1=Bevacizumab | n2=en:autologous heat-shock protein 70 peptide vaccine ag-858 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous her2 chimeric receptor/tgfbeta dominant negative receptor-expressing ebv-specific cytotoxic t lymphocytes n1=Bevacizumab | n2=en:autologous her2 chimeric receptor/tgfbeta dominant negative receptor-expressing ebv-specific cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous hnscc dna-transfected semi-allogeneic fibroblasts mrc-5 vaccine n1=Bevacizumab | n2=en:autologous hnscc dna-transfected semi-allogeneic fibroblasts mrc-5 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous hpv-16/18 e6/e7-specific tgf-beta-resistant t lymphocytes n1=Bevacizumab | n2=en:autologous hpv-16/18 e6/e7-specific tgf-beta-resistant t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous ic9-gd2-car-expressing vzv-specific t lymphocytes n1=Bevacizumab | n2=en:autologous ic9-gd2-car-expressing vzv-specific t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous il-21-modulated cd8+ mart1-specific t cells n1=Bevacizumab | n2=en:autologous il-21-modulated cd8+ mart1-specific t cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous immunoglobulin idiotype-klh conjugate vaccine n1=Bevacizumab | n2=en:autologous immunoglobulin idiotype-klh conjugate vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous interferon-producing killer dendritic cells n1=Bevacizumab | n2=en:autologous interferon-producing killer dendritic cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous lmp1-/lmp2- specific cytotoxic t-lymphocytes n1=Bevacizumab | n2=en:autologous lmp1-/lmp2- specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous lymphoid effector cells specific against tumor cells n1=Bevacizumab | n2=en:autologous lymphoid effector cells specific against tumor cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine n1=Bevacizumab | n2=en:autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine n1=Bevacizumab | n2=en:autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine n1=Bevacizumab | n2=en:autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous lymphoma immunoglobulin-derived scfv-chemokine dna vaccine n1=Bevacizumab | n2=en:autologous lymphoma immunoglobulin-derived scfv-chemokine dna vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous mage-a3-specific hla-a*01-restricted t cell receptor gene engineered lymphocytes n1=Bevacizumab | n2=en:autologous mage-a3-specific hla-a*01-restricted t cell receptor gene engineered lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous melanoma lysate-pulsed autologous dendritic cell vaccine n1=Bevacizumab | n2=en:autologous melanoma lysate-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous melanoma lysate/klh-pulsed autologous dendritic cell vaccine n1=Bevacizumab | n2=en:autologous melanoma lysate/klh-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous melanoma lysate/ny-eso-1-pulsed autologous dendritic cell vaccine n1=Bevacizumab | n2=en:autologous melanoma lysate/ny-eso-1-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous mesenchymal stem cells apceth_101 n1=Bevacizumab | n2=en:autologous mesenchymal stem cells apceth_101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous muc1-mannan fusion protein pulsed dendritic cell vaccine n1=Bevacizumab | n2=en:autologous muc1-mannan fusion protein pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous neuroblastoma lysate/klh-pulsed dendritic cell vaccine n1=Bevacizumab | n2=en:autologous neuroblastoma lysate/klh-pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous nsclc dna-transfected semi-allogeneic fibroblasts mrc-5 vaccine n1=Bevacizumab | n2=en:autologous nsclc dna-transfected semi-allogeneic fibroblasts mrc-5 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous nsclc peptide-specific dendritic cell vaccine n1=Bevacizumab | n2=en:autologous nsclc peptide-specific dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous ny-eso-1-melanoma-specific cd8+ t-lymphocytes n1=Bevacizumab | n2=en:autologous ny-eso-1-melanoma-specific cd8+ t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous ofa-ilrp rna-transfected dendritic cell vaccine n1=Bevacizumab | n2=en:autologous ofa-ilrp rna-transfected dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous ovarian tumor cell lysate-pulsed dendritic cell vaccine n1=Bevacizumab | n2=en:autologous ovarian tumor cell lysate-pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous oxidized ovarian tumor cell lysate vaccine n1=Bevacizumab | n2=en:autologous oxidized ovarian tumor cell lysate vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous peripheral blood lymphocytes cotransduced with retroviral vectors encoding inducible il-12 and anti-ny-eso-1 tcr n1=Bevacizumab | n2=en:autologous peripheral blood lymphocytes cotransduced with retroviral vectors encoding inducible il-12 and anti-ny-eso-1 tcr | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous pluripotent aldhbr stem cells ald-451 n1=Bevacizumab | n2=en:autologous pluripotent aldhbr stem cells ald-451 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous prostate cancer antigen-expressing dendritic cell vaccine bpx-101 n1=Bevacizumab | n2=en:autologous prostate cancer antigen-expressing dendritic cell vaccine bpx-101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous prostate stem cell antigen-specific car t cells bpx-601 n1=Bevacizumab | n2=en:autologous prostate stem cell antigen-specific car t cells bpx-601 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous renal cell carcinoma tumor lysate-pulsed dendritic cell vaccine n1=Bevacizumab | n2=en:autologous renal cell carcinoma tumor lysate-pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous sarcoma cell lysate n1=Bevacizumab | n2=en:autologous sarcoma cell lysate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous sarcoma lysate-pulsed dendritic cell vaccine n1=Bevacizumab | n2=en:autologous sarcoma lysate-pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous t-lymphocytes-expressing ny-eso-1-c259-specific enhanced t-cell receptors n1=Bevacizumab | n2=en:autologous t-lymphocytes-expressing ny-eso-1-c259-specific enhanced t-cell receptors | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous tarp peptide-pulsed dendritic cell vaccine n1=Bevacizumab | n2=en:autologous tarp peptide-pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous tns9.3.55-transduced cd34-positive cells n1=Bevacizumab | n2=en:autologous tns9.3.55-transduced cd34-positive cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous trimix-dc melanoma vaccine n1=Bevacizumab | n2=en:autologous trimix-dc melanoma vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous tumor cell proteoliposome chronic lymphocytic leukemia vaccine n1=Bevacizumab | n2=en:autologous tumor cell proteoliposome chronic lymphocytic leukemia vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous tumor cell vaccine n1=Bevacizumab | n2=en:autologous tumor cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous tumor infiltrating lymphocytes ln-144 n1=Bevacizumab | n2=en:autologous tumor infiltrating lymphocytes ln-144 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous tumor-associated peptide antigen-pulsed dendritic cell vaccine n1=Bevacizumab | n2=en:autologous tumor-associated peptide antigen-pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autologous wt1-tcrc4 gene-transduced cd8-positive tcm/tn lymphocytes n1=Bevacizumab | n2=en:autologous wt1-tcrc4 gene-transduced cd8-positive tcm/tn lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:autonomic agents n1=Bevacizumab | n2=en:autonomic agents | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:av2-dm antiviral spray n1=Bevacizumab | n2=en:av2-dm antiviral spray | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:avanafil n1=Bevacizumab | n2=en:avanafil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:avelumab n1=Bevacizumab | n2=en:avelumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:avitinib maleate n1=Bevacizumab | n2=en:avitinib maleate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:avn944 n1=Bevacizumab | n2=en:avn944 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:axitinib n1=Bevacizumab | n2=en:axitinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:axl inhibitor bgb324 n1=Bevacizumab | n2=en:axl inhibitor bgb324 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:axl inhibitor tp-0903 n1=Bevacizumab | n2=en:axl inhibitor tp-0903 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:azacitidine n1=Bevacizumab | n2=en:azacitidine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:azadirachta indica n1=Bevacizumab | n2=en:azadirachta indica | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:azapicyl n1=Bevacizumab | n2=en:azapicyl | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:azaribine n1=Bevacizumab | n2=en:azaribine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:azaserine n1=Bevacizumab | n2=en:azaserine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:azathioprine sodium n1=Bevacizumab | n2=en:azathioprine sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:azd5438 n1=Bevacizumab | n2=en:azd5438 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:azimexon n1=Bevacizumab | n2=en:azimexon | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:aziridinylbenzoquinone rh1 n1=Bevacizumab | n2=en:aziridinylbenzoquinone rh1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:azithromycin n1=Bevacizumab | n2=en:azithromycin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:azlocillin n1=Bevacizumab | n2=en:azlocillin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:azp n1=Bevacizumab | n2=en:azp | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:azurin:50-77 cell penetrating peptide p28 n1=Bevacizumab | n2=en:azurin:50-77 cell penetrating peptide p28 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:b [preparations] n1=Bevacizumab | n2=en:b [preparations] | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:b-raf/vegfr-2 inhibitor raf265 n1=Bevacizumab | n2=en:b-raf/vegfr-2 inhibitor raf265 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:b16alphagal melanoma vaccine n1=Bevacizumab | n2=en:b16alphagal melanoma vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:b43-genistein immunoconjugate n1=Bevacizumab | n2=en:b43-genistein immunoconjugate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:b43-pap immunotoxin n1=Bevacizumab | n2=en:b43-pap immunotoxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:b7-dc crosslinking antibody rhigm12b7 n1=Bevacizumab | n2=en:b7-dc crosslinking antibody rhigm12b7 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:baby oil n1=Bevacizumab | n2=en:baby oil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bacampicillin n1=Bevacizumab | n2=en:bacampicillin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bacitracin n1=Bevacizumab | n2=en:bacitracin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bacitracin / diperodon / neomycin / polymyxin b n1=Bevacizumab | n2=en:bacitracin / diperodon / neomycin / polymyxin b | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bacitracin / hydrocortisone / neomycin / polymyxin b n1=Bevacizumab | n2=en:bacitracin / hydrocortisone / neomycin / polymyxin b | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bacitracin / lidocaine / polymyxin b n1=Bevacizumab | n2=en:bacitracin / lidocaine / polymyxin b | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bacitracin / neomycin / polymyxin b n1=Bevacizumab | n2=en:bacitracin / neomycin / polymyxin b | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bacitracin / polymyxin b / pramoxine n1=Bevacizumab | n2=en:bacitracin / polymyxin b / pramoxine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bacitracin, polymyxin b drug combination n1=Bevacizumab | n2=en:bacitracin, polymyxin b drug combination | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bacitracin//neomycin/polymyxin/pramoxine n1=Bevacizumab | n2=en:bacitracin//neomycin/polymyxin/pramoxine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bacitracin/lidocaine/neomycin/polymyxin n1=Bevacizumab | n2=en:bacitracin/lidocaine/neomycin/polymyxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bacitracin/neomycin/polymyxin n1=Bevacizumab | n2=en:bacitracin/neomycin/polymyxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:baclofen n1=Bevacizumab | n2=en:baclofen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:baclofen/amitriptyline/ketamine gel n1=Bevacizumab | n2=en:baclofen/amitriptyline/ketamine gel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bacteriophage phi x 174 n1=Bevacizumab | n2=en:bacteriophage phi x 174 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bacteriuria test n1=Bevacizumab | n2=en:bacteriuria test | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bafetinib n1=Bevacizumab | n2=en:bafetinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bagenema/bisacodyl tab/castile soap/phospho-soda n1=Bevacizumab | n2=en:bagenema/bisacodyl tab/castile soap/phospho-soda | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bagenema/bisacodyl/castile soap/castor oil n1=Bevacizumab | n2=en:bagenema/bisacodyl/castile soap/castor oil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:baicalin n1=Bevacizumab | n2=en:baicalin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:baicalin,catechin/citrated zinc n1=Bevacizumab | n2=en:baicalin,catechin/citrated zinc | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:baking powder n1=Bevacizumab | n2=en:baking powder | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:balanced crystalloid solution n1=Bevacizumab | n2=en:balanced crystalloid solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:balanced salt solution n1=Bevacizumab | n2=en:balanced salt solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:balanced salt solution/bicarbonate/dextrose/glutathione n1=Bevacizumab | n2=en:balanced salt solution/bicarbonate/dextrose/glutathione | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:balsalazide n1=Bevacizumab | n2=en:balsalazide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:banaba n1=Bevacizumab | n2=en:banaba | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:banoxantrone n1=Bevacizumab | n2=en:banoxantrone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:barasertib n1=Bevacizumab | n2=en:barasertib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:barbital n1=Bevacizumab | n2=en:barbital | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:barbital/hyoscyamine/hyoscyamus/passion/scopolamine/valerian n1=Bevacizumab | n2=en:barbital/hyoscyamine/hyoscyamus/passion/scopolamine/valerian | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bardoxolone n1=Bevacizumab | n2=en:bardoxolone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bardoxolone methyl n1=Bevacizumab | n2=en:bardoxolone methyl | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:baricitinib n1=Bevacizumab | n2=en:baricitinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:barium sulfate n1=Bevacizumab | n2=en:barium sulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:barium sulfate/methylcellulose n1=Bevacizumab | n2=en:barium sulfate/methylcellulose | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:barley grass preparation n1=Bevacizumab | n2=en:barley grass preparation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:basic fuchsin n1=Bevacizumab | n2=en:basic fuchsin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:basiliximab n1=Bevacizumab | n2=en:basiliximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:basis n1=Bevacizumab | n2=en:basis | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:basle cream n1=Bevacizumab | n2=en:basle cream | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:batabulin sodium n1=Bevacizumab | n2=en:batabulin sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:batanopride n1=Bevacizumab | n2=en:batanopride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bath oil n1=Bevacizumab | n2=en:bath oil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bavituximab n1=Bevacizumab | n2=en:bavituximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bay 56-3722 n1=Bevacizumab | n2=en:bay 56-3722 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bay 86-4367 n1=Bevacizumab | n2=en:bay 86-4367 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bay 87-2243 n1=Bevacizumab | n2=en:bay 87-2243 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bay rum n1=Bevacizumab | n2=en:bay rum | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:baza cream n1=Bevacizumab | n2=en:baza cream | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:baza pro n1=Bevacizumab | n2=en:baza pro | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:baza/peri-wash n1=Bevacizumab | n2=en:baza/peri-wash | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bazedoxifene n1=Bevacizumab | n2=en:bazedoxifene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bazedoxifene/estrogens n1=Bevacizumab | n2=en:bazedoxifene/estrogens | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bbr 3464 n1=Bevacizumab | n2=en:bbr 3464 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bc-819 plasmid/polyethylenimine complex n1=Bevacizumab | n2=en:bc-819 plasmid/polyethylenimine complex | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bcg solution n1=Bevacizumab | n2=en:bcg solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bcg vaccine n1=Bevacizumab | n2=en:bcg vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bcl-2 inhibitor bcl201 n1=Bevacizumab | n2=en:bcl-2 inhibitor bcl201 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bcma-specific car-expressing t lymphocytes n1=Bevacizumab | n2=en:bcma-specific car-expressing t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bcr-abl (b2a2)-derived peptide vaccine n1=Bevacizumab | n2=en:bcr-abl (b2a2)-derived peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bcr-abl (b3a2)-derived peptide vaccine n1=Bevacizumab | n2=en:bcr-abl (b3a2)-derived peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bcr-abl p210-b3a2 breakpoint-derived pentapeptide vaccine n1=Bevacizumab | n2=en:bcr-abl p210-b3a2 breakpoint-derived pentapeptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bcr-abl peptide vaccine n1=Bevacizumab | n2=en:bcr-abl peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:beacopp regimen n1=Bevacizumab | n2=en:beacopp regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:becaplermin n1=Bevacizumab | n2=en:becaplermin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:becatecarin n1=Bevacizumab | n2=en:becatecarin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:beclomethasone dipropionate n1=Bevacizumab | n2=en:beclomethasone dipropionate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bee pollen n1=Bevacizumab | n2=en:bee pollen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:beeswax/mineral oil/rose oil/rose soluble/sodium borate/spermace n1=Bevacizumab | n2=en:beeswax/mineral oil/rose oil/rose soluble/sodium borate/spermace | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:beetroot juice n1=Bevacizumab | n2=en:beetroot juice | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:begelomab n1=Bevacizumab | n2=en:begelomab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:behenoxy dimethicone n1=Bevacizumab | n2=en:behenoxy dimethicone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:belagenpumatucel-l n1=Bevacizumab | n2=en:belagenpumatucel-l | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:belatacept n1=Bevacizumab | n2=en:belatacept | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:belimumab n1=Bevacizumab | n2=en:belimumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:belinostat n1=Bevacizumab | n2=en:belinostat | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:belladonna alkaloids / caffeine / ergotamine / pentobarbital n1=Bevacizumab | n2=en:belladonna alkaloids / caffeine / ergotamine / pentobarbital | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:belladonna extract, usp n1=Bevacizumab | n2=en:belladonna extract, usp | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:belladonna extract, usp / butabarbital n1=Bevacizumab | n2=en:belladonna extract, usp / butabarbital | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:belladonna/benzoic/gelsemium/methenamine/phenazopyridine/phenyl n1=Bevacizumab | n2=en:belladonna/benzoic/gelsemium/methenamine/phenazopyridine/phenyl | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:belladonna/bile salts/pancreatin/pepsin/phenobarbital n1=Bevacizumab | n2=en:belladonna/bile salts/pancreatin/pepsin/phenobarbital | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:belladonna/caffeine/ergotamine/phenobarbital n1=Bevacizumab | n2=en:belladonna/caffeine/ergotamine/phenobarbital | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:belladonna/charcoal n1=Bevacizumab | n2=en:belladonna/charcoal | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:belladonna/chlorpheniramine/ephedrine/phenobarbital n1=Bevacizumab | n2=en:belladonna/chlorpheniramine/ephedrine/phenobarbital | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:belladonna/chlorpheniramine/pheniramine/phenylpropanolamine n1=Bevacizumab | n2=en:belladonna/chlorpheniramine/pheniramine/phenylpropanolamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:belladonna/chlorpheniramine/phenylephrine/phenylpropanolamine n1=Bevacizumab | n2=en:belladonna/chlorpheniramine/phenylephrine/phenylpropanolamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:belladonna/chlorpheniramine/phenylephrine/pyrilamine n1=Bevacizumab | n2=en:belladonna/chlorpheniramine/phenylephrine/pyrilamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:belladonna/dehydrocholic acid/lipase/ox bile/pancreatin/pepsin n1=Bevacizumab | n2=en:belladonna/dehydrocholic acid/lipase/ox bile/pancreatin/pepsin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:belladonna/kaolin/opium/pectin n1=Bevacizumab | n2=en:belladonna/kaolin/opium/pectin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:belladonna/kaolin/pectin n1=Bevacizumab | n2=en:belladonna/kaolin/pectin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:belladonna/kaolin/pectin/sodium benzoate n1=Bevacizumab | n2=en:belladonna/kaolin/pectin/sodium benzoate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:belladonna/kaolin/phenobarbital n1=Bevacizumab | n2=en:belladonna/kaolin/phenobarbital | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:belladonna/methenamine/salicylamide n1=Bevacizumab | n2=en:belladonna/methenamine/salicylamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:belladonna/phenobarbital n1=Bevacizumab | n2=en:belladonna/phenobarbital | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:belladonna/phenobarbital/ergotamine n1=Bevacizumab | n2=en:belladonna/phenobarbital/ergotamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:beloranib n1=Bevacizumab | n2=en:beloranib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:belotecan hydrochloride n1=Bevacizumab | n2=en:belotecan hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bemiparin sodium n1=Bevacizumab | n2=en:bemiparin sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benactyzine n1=Bevacizumab | n2=en:benactyzine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benactyzine / meprobamate n1=Bevacizumab | n2=en:benactyzine / meprobamate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benaxibine n1=Bevacizumab | n2=en:benaxibine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benazepril hydrochloride n1=Bevacizumab | n2=en:benazepril hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benazepril/hydrochlorothiazide n1=Bevacizumab | n2=en:benazepril/hydrochlorothiazide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bendamustine n1=Bevacizumab | n2=en:bendamustine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bendamustine hydrochloride n1=Bevacizumab | n2=en:bendamustine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bendamustine-containing nanoparticle-based formulation rxdx-107 n1=Bevacizumab | n2=en:bendamustine-containing nanoparticle-based formulation rxdx-107 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bendamustine-vorinostat fusion molecule edo-s101 n1=Bevacizumab | n2=en:bendamustine-vorinostat fusion molecule edo-s101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bendroflumethiazide n1=Bevacizumab | n2=en:bendroflumethiazide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bendroflumethiazide / potassium chloride n1=Bevacizumab | n2=en:bendroflumethiazide / potassium chloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bendroflumethiazide + nadolol n1=Bevacizumab | n2=en:bendroflumethiazide + nadolol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bendroflumethiazide/potassium chloride/rauwolfia serpentina n1=Bevacizumab | n2=en:bendroflumethiazide/potassium chloride/rauwolfia serpentina | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bendroflumethiazide/rauwolfia serpentina n1=Bevacizumab | n2=en:bendroflumethiazide/rauwolfia serpentina | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benegrastim n1=Bevacizumab | n2=en:benegrastim | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benoxinate n1=Bevacizumab | n2=en:benoxinate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benoxinate/fluorescein n1=Bevacizumab | n2=en:benoxinate/fluorescein | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benphothiamine n1=Bevacizumab | n2=en:benphothiamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bentiromide n1=Bevacizumab | n2=en:bentiromide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bentone n1=Bevacizumab | n2=en:bentone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bentonite n1=Bevacizumab | n2=en:bentonite | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bentonite magma/calamine/calcium hydroxide/glycerin/zinc oxide n1=Bevacizumab | n2=en:bentonite magma/calamine/calcium hydroxide/glycerin/zinc oxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bentonite/potassium alum/talc n1=Bevacizumab | n2=en:bentonite/potassium alum/talc | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bentoquatam n1=Bevacizumab | n2=en:bentoquatam | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzaldehyde n1=Bevacizumab | n2=en:benzaldehyde | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzaldehyde dimethane sulfonate n1=Bevacizumab | n2=en:benzaldehyde dimethane sulfonate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzalkonium n1=Bevacizumab | n2=en:benzalkonium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzalkonium / lidocaine n1=Bevacizumab | n2=en:benzalkonium / lidocaine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzalkonium chloride/benzocaine n1=Bevacizumab | n2=en:benzalkonium chloride/benzocaine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzalkonium chloride/benzocaine/dibucaine/tetracaine n1=Bevacizumab | n2=en:benzalkonium chloride/benzocaine/dibucaine/tetracaine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzalkonium chloride/benzocaine/zinc chloride n1=Bevacizumab | n2=en:benzalkonium chloride/benzocaine/zinc chloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzalkonium chloride/chloroxylenol/hydrocortisone n1=Bevacizumab | n2=en:benzalkonium chloride/chloroxylenol/hydrocortisone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzalkonium chloride/edetate/polyvinyl alcohol n1=Bevacizumab | n2=en:benzalkonium chloride/edetate/polyvinyl alcohol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzalkonium chloride/edetate/sodium hydroxide n1=Bevacizumab | n2=en:benzalkonium chloride/edetate/sodium hydroxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzalkonium chloride/edta n1=Bevacizumab | n2=en:benzalkonium chloride/edta | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzalkonium chloride/hydroxypropyl methylcellulose/polyvinyl al n1=Bevacizumab | n2=en:benzalkonium chloride/hydroxypropyl methylcellulose/polyvinyl al | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzalkonium chloride/polyoxyethylene n1=Bevacizumab | n2=en:benzalkonium chloride/polyoxyethylene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzalkonium chloride/tyloxapol n1=Bevacizumab | n2=en:benzalkonium chloride/tyloxapol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzalkonium/calcium chloride/hydrochloric acid/magnesium chlori n1=Bevacizumab | n2=en:benzalkonium/calcium chloride/hydrochloric acid/magnesium chlori | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzalkonium/camphor/diperodon/ichthammol/juniper/phenol/thymol n1=Bevacizumab | n2=en:benzalkonium/camphor/diperodon/ichthammol/juniper/phenol/thymol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzalkonium/cetylpyridinium/chloroxylenol/sodium/triacetin n1=Bevacizumab | n2=en:benzalkonium/cetylpyridinium/chloroxylenol/sodium/triacetin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzalkonium/cetylpyridinium/chloroxylenol/triacetin n1=Bevacizumab | n2=en:benzalkonium/cetylpyridinium/chloroxylenol/triacetin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzalkonium/oxyquinoline n1=Bevacizumab | n2=en:benzalkonium/oxyquinoline | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzene n1=Bevacizumab | n2=en:benzene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzethonium chloride n1=Bevacizumab | n2=en:benzethonium chloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzethonium chloride/benzocaine n1=Bevacizumab | n2=en:benzethonium chloride/benzocaine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzethonium chloride/corn starch/kaolin/zinc oxide n1=Bevacizumab | n2=en:benzethonium chloride/corn starch/kaolin/zinc oxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzethonium chloride/lidocaine n1=Bevacizumab | n2=en:benzethonium chloride/lidocaine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzethonium chloride/menthol/zinc stearate n1=Bevacizumab | n2=en:benzethonium chloride/menthol/zinc stearate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzethonium/benzocaine/glycerin/polyethylene glycol n1=Bevacizumab | n2=en:benzethonium/benzocaine/glycerin/polyethylene glycol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzethonium/calamine/eucalyptol/zinc oxide n1=Bevacizumab | n2=en:benzethonium/calamine/eucalyptol/zinc oxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzethonium/chloroxylenol/menthol/thymol/zinc stearate n1=Bevacizumab | n2=en:benzethonium/chloroxylenol/menthol/thymol/zinc stearate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzethonium/triclosan n1=Bevacizumab | n2=en:benzethonium/triclosan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benznidazole n1=Bevacizumab | n2=en:benznidazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine n1=Bevacizumab | n2=en:benzocaine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine / bismuth subnitrate / cerium oxalate n1=Bevacizumab | n2=en:benzocaine / bismuth subnitrate / cerium oxalate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine / boric acid n1=Bevacizumab | n2=en:benzocaine / boric acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine / butamben / tetracaine n1=Bevacizumab | n2=en:benzocaine / butamben / tetracaine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine / calcium carbonate / magnesium carbonate / phenobarbital n1=Bevacizumab | n2=en:benzocaine / calcium carbonate / magnesium carbonate / phenobarbital | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine / cetalkonium chloride n1=Bevacizumab | n2=en:benzocaine / cetalkonium chloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine / chloroxylenol / zinc oxide n1=Bevacizumab | n2=en:benzocaine / chloroxylenol / zinc oxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine / clove oil n1=Bevacizumab | n2=en:benzocaine / clove oil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine / dextromethorphan n1=Bevacizumab | n2=en:benzocaine / dextromethorphan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine / dextromethorphan / menthol n1=Bevacizumab | n2=en:benzocaine / dextromethorphan / menthol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine / docusate n1=Bevacizumab | n2=en:benzocaine / docusate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine / glycerin n1=Bevacizumab | n2=en:benzocaine / glycerin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine / ichthammol n1=Bevacizumab | n2=en:benzocaine / ichthammol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine / isopropyl alcohol / menthol n1=Bevacizumab | n2=en:benzocaine / isopropyl alcohol / menthol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine / licorice / menthol n1=Bevacizumab | n2=en:benzocaine / licorice / menthol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine / methyl salicylate n1=Bevacizumab | n2=en:benzocaine / methyl salicylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine / phenylephrine / phenylpropanolamine n1=Bevacizumab | n2=en:benzocaine / phenylephrine / phenylpropanolamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine / salicylic acid n1=Bevacizumab | n2=en:benzocaine / salicylic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine + menthol n1=Bevacizumab | n2=en:benzocaine + menthol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine + phenol n1=Bevacizumab | n2=en:benzocaine + phenol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine + resorcinol n1=Bevacizumab | n2=en:benzocaine + resorcinol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine/bismuth subgallate/phenylmecuric nitrate/zinc oxide n1=Bevacizumab | n2=en:benzocaine/bismuth subgallate/phenylmecuric nitrate/zinc oxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine/calamine/diphenhydramine/menthol n1=Bevacizumab | n2=en:benzocaine/calamine/diphenhydramine/menthol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine/calamine/zinc oxide n1=Bevacizumab | n2=en:benzocaine/calamine/zinc oxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine/camphor/ephedrine/zinc oxide n1=Bevacizumab | n2=en:benzocaine/camphor/ephedrine/zinc oxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine/camphor/ichthammol/phenol/sulfur/tar n1=Bevacizumab | n2=en:benzocaine/camphor/ichthammol/phenol/sulfur/tar | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine/camphor/menthol n1=Bevacizumab | n2=en:benzocaine/camphor/menthol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine/cetylpyridinium chloride n1=Bevacizumab | n2=en:benzocaine/cetylpyridinium chloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine/cetylpyridinium chloride/terpin hydrate n1=Bevacizumab | n2=en:benzocaine/cetylpyridinium chloride/terpin hydrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine/chlorobutanol n1=Bevacizumab | n2=en:benzocaine/chlorobutanol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine/chlorobutanol/ethanol/menthol/tannic acid n1=Bevacizumab | n2=en:benzocaine/chlorobutanol/ethanol/menthol/tannic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine/chlorobutanol/eugenol/peruvian balsam n1=Bevacizumab | n2=en:benzocaine/chlorobutanol/eugenol/peruvian balsam | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine/chloroxylenol/isopropyl/resorcinol/salicylic acid n1=Bevacizumab | n2=en:benzocaine/chloroxylenol/isopropyl/resorcinol/salicylic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine/cinnamon oil/clove oil/eucalyptus oil/phenol n1=Bevacizumab | n2=en:benzocaine/cinnamon oil/clove oil/eucalyptus oil/phenol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine/ephedrine/hydrocortisone/ichthammol/oxyquinoline/zinc n1=Bevacizumab | n2=en:benzocaine/ephedrine/hydrocortisone/ichthammol/oxyquinoline/zinc | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine/phenol/povidone iodine n1=Bevacizumab | n2=en:benzocaine/phenol/povidone iodine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzocaine/phenol/vitamin e/zinc oxide n1=Bevacizumab | n2=en:benzocaine/phenol/vitamin e/zinc oxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzoic acid + salicylic acid n1=Bevacizumab | n2=en:benzoic acid + salicylic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzoic acid/boric acid/zinc oxide/zinc stearate n1=Bevacizumab | n2=en:benzoic acid/boric acid/zinc oxide/zinc stearate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzoin n1=Bevacizumab | n2=en:benzoin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzoin compound/isopropyl alcohol n1=Bevacizumab | n2=en:benzoin compound/isopropyl alcohol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzoin/camphor/eucalyptus oil/thymol n1=Bevacizumab | n2=en:benzoin/camphor/eucalyptus oil/thymol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzoin/camphor/tolu balsam n1=Bevacizumab | n2=en:benzoin/camphor/tolu balsam | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzoin/podophyllin n1=Bevacizumab | n2=en:benzoin/podophyllin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzophenone-3/lanolin/mineral oil/polyethylene glycol-4 n1=Bevacizumab | n2=en:benzophenone-3/lanolin/mineral oil/polyethylene glycol-4 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzophenone-3/para-aminobenzoic acid n1=Bevacizumab | n2=en:benzophenone-3/para-aminobenzoic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzothonium n1=Bevacizumab | n2=en:benzothonium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzoxiquine n1=Bevacizumab | n2=en:benzoxiquine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzoxiquine / ichthammol n1=Bevacizumab | n2=en:benzoxiquine / ichthammol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzoyl peroxide n1=Bevacizumab | n2=en:benzoyl peroxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzoyl peroxide + clindamycin n1=Bevacizumab | n2=en:benzoyl peroxide + clindamycin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzoyl peroxide + hydrocortisone n1=Bevacizumab | n2=en:benzoyl peroxide + hydrocortisone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzoyl peroxide + sulfur n1=Bevacizumab | n2=en:benzoyl peroxide + sulfur | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzoyl peroxide, erythromycin drug combination n1=Bevacizumab | n2=en:benzoyl peroxide, erythromycin drug combination | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzoyl peroxide/doxycycline n1=Bevacizumab | n2=en:benzoyl peroxide/doxycycline | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzoylphenylurea n1=Bevacizumab | n2=en:benzoylphenylurea | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzphetamine n1=Bevacizumab | n2=en:benzphetamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzquinamide n1=Bevacizumab | n2=en:benzquinamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzthiazide n1=Bevacizumab | n2=en:benzthiazide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzydamine hydrochloride n1=Bevacizumab | n2=en:benzydamine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzyl acetate n1=Bevacizumab | n2=en:benzyl acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzyl alcohol n1=Bevacizumab | n2=en:benzyl alcohol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzyl alcohol / sodium chloride n1=Bevacizumab | n2=en:benzyl alcohol / sodium chloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzyl alcohol/camphor/isopropyl alcohol/menthol n1=Bevacizumab | n2=en:benzyl alcohol/camphor/isopropyl alcohol/menthol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzyl alcohol/cetylpyridinium chloride n1=Bevacizumab | n2=en:benzyl alcohol/cetylpyridinium chloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzyl alcohol/water n1=Bevacizumab | n2=en:benzyl alcohol/water | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzyl benzoate n1=Bevacizumab | n2=en:benzyl benzoate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzyl benzoate/bismuth/calcium/coconut oil/vegetable oil/zinc o n1=Bevacizumab | n2=en:benzyl benzoate/bismuth/calcium/coconut oil/vegetable oil/zinc o | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzyl benzoate/bismuth/peruvian balsam/zinc oxide n1=Bevacizumab | n2=en:benzyl benzoate/bismuth/peruvian balsam/zinc oxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:benzylpenicilloyl polylysine n1=Bevacizumab | n2=en:benzylpenicilloyl polylysine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bep regimen n1=Bevacizumab | n2=en:bep regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bepridil n1=Bevacizumab | n2=en:bepridil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:berberine n1=Bevacizumab | n2=en:berberine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:berberine chloride n1=Bevacizumab | n2=en:berberine chloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:berberis extract n1=Bevacizumab | n2=en:berberis extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:berubicin hydrochloride n1=Bevacizumab | n2=en:berubicin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:besifloxacin n1=Bevacizumab | n2=en:besifloxacin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bet bromodomain inhibitor zen-3694 n1=Bevacizumab | n2=en:bet bromodomain inhibitor zen-3694 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bet bromodomains 2/3/4 inhibitor mk-8628 n1=Bevacizumab | n2=en:bet bromodomains 2/3/4 inhibitor mk-8628 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bet inhibitor n1=Bevacizumab | n2=en:bet inhibitor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bet inhibitor bay1238097 n1=Bevacizumab | n2=en:bet inhibitor bay1238097 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bet inhibitor bms-986158 n1=Bevacizumab | n2=en:bet inhibitor bms-986158 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bet inhibitor cpi-0610 n1=Bevacizumab | n2=en:bet inhibitor cpi-0610 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bet inhibitor ft-1101 n1=Bevacizumab | n2=en:bet inhibitor ft-1101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bet inhibitor gs-5829 n1=Bevacizumab | n2=en:bet inhibitor gs-5829 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bet inhibitor gsk2820151 n1=Bevacizumab | n2=en:bet inhibitor gsk2820151 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bet inhibitor gsk525762 n1=Bevacizumab | n2=en:bet inhibitor gsk525762 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bet inhibitor incb054329 n1=Bevacizumab | n2=en:bet inhibitor incb054329 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bet inhibitor incb057643 n1=Bevacizumab | n2=en:bet inhibitor incb057643 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bet inhibitor ten-010 n1=Bevacizumab | n2=en:bet inhibitor ten-010 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:beta alethine n1=Bevacizumab | n2=en:beta alethine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:beta carotene/vitamin a combination n1=Bevacizumab | n2=en:beta carotene/vitamin a combination | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:beta endophorin n1=Bevacizumab | n2=en:beta endophorin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:beta sitosterol / zinc citrate n1=Bevacizumab | n2=en:beta sitosterol / zinc citrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:beta-carotene n1=Bevacizumab | n2=en:beta-carotene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:beta-d-galactose/maltodextrin n1=Bevacizumab | n2=en:beta-d-galactose/maltodextrin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:beta-elemene n1=Bevacizumab | n2=en:beta-elemene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:beta-galactosidase n1=Bevacizumab | n2=en:beta-galactosidase | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:beta-glucan n1=Bevacizumab | n2=en:beta-glucan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:beta-glucan mm-10-001 n1=Bevacizumab | n2=en:beta-glucan mm-10-001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:beta-glucan/alginate/hyaluronic acid/squalene/avocado oil-containing emulsion n1=Bevacizumab | n2=en:beta-glucan/alginate/hyaluronic acid/squalene/avocado oil-containing emulsion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:beta-glucan/lactobacillus casei/bifidobacterium lactis-based supplement n1=Bevacizumab | n2=en:beta-glucan/lactobacillus casei/bifidobacterium lactis-based supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:beta-hydroxy-beta-methylbutyrate supplement n1=Bevacizumab | n2=en:beta-hydroxy-beta-methylbutyrate supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:beta-lapachone prodrug arq 761 n1=Bevacizumab | n2=en:beta-lapachone prodrug arq 761 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:beta-sitosterol n1=Bevacizumab | n2=en:beta-sitosterol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:beta-thioguanine deoxyriboside n1=Bevacizumab | n2=en:beta-thioguanine deoxyriboside | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:betahistine n1=Bevacizumab | n2=en:betahistine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:betaine n1=Bevacizumab | n2=en:betaine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:betaine/protease n1=Bevacizumab | n2=en:betaine/protease | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:betamethasone n1=Bevacizumab | n2=en:betamethasone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:betamethasone / calcipotriene n1=Bevacizumab | n2=en:betamethasone / calcipotriene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:betamethasone + clotrimazole n1=Bevacizumab | n2=en:betamethasone + clotrimazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:betazole n1=Bevacizumab | n2=en:betazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bethanechol n1=Bevacizumab | n2=en:bethanechol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:betony n1=Bevacizumab | n2=en:betony | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:betulinic acid n1=Bevacizumab | n2=en:betulinic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab n1=Bevacizumab | n2=en:bevacizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab-irdye 800cw n1=Bevacizumab | n2=en:bevacizumab-irdye 800cw | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/capecitabine n1=Bevacizumab | n2=en:bevacizumab/capecitabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/capecitabine/docetaxel n1=Bevacizumab | n2=en:bevacizumab/capecitabine/docetaxel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/capecitabine/gemcitabine n1=Bevacizumab | n2=en:bevacizumab/capecitabine/gemcitabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/capecitabine/oxaliplatin n1=Bevacizumab | n2=en:bevacizumab/capecitabine/oxaliplatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/carboplatin/paclitaxel n1=Bevacizumab | n2=en:bevacizumab/carboplatin/paclitaxel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/cetuximab n1=Bevacizumab | n2=en:bevacizumab/cetuximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/cetuximab/erlotinib n1=Bevacizumab | n2=en:bevacizumab/cetuximab/erlotinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/cetuximab/fluorouracil/leucovorin calcium/oxaliplatin n1=Bevacizumab | n2=en:bevacizumab/cetuximab/fluorouracil/leucovorin calcium/oxaliplatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/cetuximab/gemcitabine n1=Bevacizumab | n2=en:bevacizumab/cetuximab/gemcitabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/cetuximab/irinotecan n1=Bevacizumab | n2=en:bevacizumab/cetuximab/irinotecan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/cisplatin/etoposide n1=Bevacizumab | n2=en:bevacizumab/cisplatin/etoposide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/cisplatin/gemcitabine n1=Bevacizumab | n2=en:bevacizumab/cisplatin/gemcitabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/cisplatin/irinotecan n1=Bevacizumab | n2=en:bevacizumab/cisplatin/irinotecan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/cyclophosphamide n1=Bevacizumab | n2=en:bevacizumab/cyclophosphamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/cyclophosphamide/docetaxel/doxorubicin n1=Bevacizumab | n2=en:bevacizumab/cyclophosphamide/docetaxel/doxorubicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/cyclophosphamide/doxorubicin n1=Bevacizumab | n2=en:bevacizumab/cyclophosphamide/doxorubicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/cyclophosphamide/doxorubicin/prednisone/rituximab/vincristine n1=Bevacizumab | n2=en:bevacizumab/cyclophosphamide/doxorubicin/prednisone/rituximab/vincristine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/cyclophosphamide/methotrexate n1=Bevacizumab | n2=en:bevacizumab/cyclophosphamide/methotrexate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/cytarabine/idarubicin n1=Bevacizumab | n2=en:bevacizumab/cytarabine/idarubicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/docetaxel n1=Bevacizumab | n2=en:bevacizumab/docetaxel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/docetaxel/doxorubicin n1=Bevacizumab | n2=en:bevacizumab/docetaxel/doxorubicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/docetaxel/estramustine n1=Bevacizumab | n2=en:bevacizumab/docetaxel/estramustine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/docetaxel/prednisone n1=Bevacizumab | n2=en:bevacizumab/docetaxel/prednisone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/docetaxel/prednisone/thalidomide n1=Bevacizumab | n2=en:bevacizumab/docetaxel/prednisone/thalidomide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/doxorubicin n1=Bevacizumab | n2=en:bevacizumab/doxorubicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/erlotinib n1=Bevacizumab | n2=en:bevacizumab/erlotinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/erlotinib/fluorouracil/leucovorin calcium/oxaliplatin n1=Bevacizumab | n2=en:bevacizumab/erlotinib/fluorouracil/leucovorin calcium/oxaliplatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/erlotinib/gemcitabine n1=Bevacizumab | n2=en:bevacizumab/erlotinib/gemcitabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/fluorouracil n1=Bevacizumab | n2=en:bevacizumab/fluorouracil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/fluorouracil/hydroxyurea n1=Bevacizumab | n2=en:bevacizumab/fluorouracil/hydroxyurea | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/fluorouracil/irinotecan/leucovorin calcium n1=Bevacizumab | n2=en:bevacizumab/fluorouracil/irinotecan/leucovorin calcium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/fluorouracil/leucovorin calcium n1=Bevacizumab | n2=en:bevacizumab/fluorouracil/leucovorin calcium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/fluorouracil/leucovorin calcium/oxaliplatin n1=Bevacizumab | n2=en:bevacizumab/fluorouracil/leucovorin calcium/oxaliplatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/gemcitabine n1=Bevacizumab | n2=en:bevacizumab/gemcitabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/gemcitabine/oxaliplatin n1=Bevacizumab | n2=en:bevacizumab/gemcitabine/oxaliplatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/imatinib mesylate n1=Bevacizumab | n2=en:bevacizumab/imatinib mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/interferon alfa n1=Bevacizumab | n2=en:bevacizumab/interferon alfa | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/interleukin-2 n1=Bevacizumab | n2=en:bevacizumab/interleukin-2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/irinotecan n1=Bevacizumab | n2=en:bevacizumab/irinotecan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/irinotecan/oxaliplatin n1=Bevacizumab | n2=en:bevacizumab/irinotecan/oxaliplatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/oxaliplatin n1=Bevacizumab | n2=en:bevacizumab/oxaliplatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/paclitaxel n1=Bevacizumab | n2=en:bevacizumab/paclitaxel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/peg-interferon alfa-2b n1=Bevacizumab | n2=en:bevacizumab/peg-interferon alfa-2b | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/pemetrexed disodium n1=Bevacizumab | n2=en:bevacizumab/pemetrexed disodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/rituximab n1=Bevacizumab | n2=en:bevacizumab/rituximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/sorafenib n1=Bevacizumab | n2=en:bevacizumab/sorafenib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/temsirolimus n1=Bevacizumab | n2=en:bevacizumab/temsirolimus | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/thalidomide n1=Bevacizumab | n2=en:bevacizumab/thalidomide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bevacizumab/vinorelbine n1=Bevacizumab | n2=en:bevacizumab/vinorelbine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bexarotene n1=Bevacizumab | n2=en:bexarotene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bh3 mimetic abt-737 n1=Bevacizumab | n2=en:bh3 mimetic abt-737 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bi 2536 n1=Bevacizumab | n2=en:bi 2536 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bi 831266 n1=Bevacizumab | n2=en:bi 831266 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bi 894999 n1=Bevacizumab | n2=en:bi 894999 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bi-functional alkylating agent val-083 n1=Bevacizumab | n2=en:bi-functional alkylating agent val-083 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bi-shrna-furin/gm-csf-expressing autologous tumor cell vaccine n1=Bevacizumab | n2=en:bi-shrna-furin/gm-csf-expressing autologous tumor cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:biafine cream n1=Bevacizumab | n2=en:biafine cream | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bibx 1382 n1=Bevacizumab | n2=en:bibx 1382 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bicalutamide n1=Bevacizumab | n2=en:bicalutamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bicarbonate preparation n1=Bevacizumab | n2=en:bicarbonate preparation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bifidobacterium n1=Bevacizumab | n2=en:bifidobacterium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bifidobacterium lactis/lactobacillus acidophilus/l. plantarum/l. salivarius probiotic supplement n1=Bevacizumab | n2=en:bifidobacterium lactis/lactobacillus acidophilus/l. plantarum/l. salivarius probiotic supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bifidobacterium/lactobacillus n1=Bevacizumab | n2=en:bifidobacterium/lactobacillus | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bifidobacterium/lactobacillus/streptococcus n1=Bevacizumab | n2=en:bifidobacterium/lactobacillus/streptococcus | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bifunctional expression vector plasmid dna-bi-shrna ews/fli1 type 1 lipoplex n1=Bevacizumab | n2=en:bifunctional expression vector plasmid dna-bi-shrna ews/fli1 type 1 lipoplex | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bilberry extract n1=Bevacizumab | n2=en:bilberry extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bile salt n1=Bevacizumab | n2=en:bile salt | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bile salts/charcoal/pancreatin n1=Bevacizumab | n2=en:bile salts/charcoal/pancreatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bile salts/dehydrocholic acid/pancreatin/pepsin n1=Bevacizumab | n2=en:bile salts/dehydrocholic acid/pancreatin/pepsin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bile salts/pancreatin/pepsin n1=Bevacizumab | n2=en:bile salts/pancreatin/pepsin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bilirubin test kit n1=Bevacizumab | n2=en:bilirubin test kit | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bilirubin/blood,occult/glucose/ketone/nitrite/ph/protein/urobili n1=Bevacizumab | n2=en:bilirubin/blood,occult/glucose/ketone/nitrite/ph/protein/urobili | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bilirubin/blood,occult/glucose/ketone/ph/protein/urobilinogen te n1=Bevacizumab | n2=en:bilirubin/blood,occult/glucose/ketone/ph/protein/urobilinogen te | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bilirubin/blood/glucose/ketone/leukocytes/nitrite/ph/protein te n1=Bevacizumab | n2=en:bilirubin/blood/glucose/ketone/leukocytes/nitrite/ph/protein te | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bilirubin/blood/glucose/ketone/leukocytes/nitrite/ph/protein/spe n1=Bevacizumab | n2=en:bilirubin/blood/glucose/ketone/leukocytes/nitrite/ph/protein/spe | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bilirubin/blood/glucose/ketone/leukocytes/nitrite/ph/protein/uro n1=Bevacizumab | n2=en:bilirubin/blood/glucose/ketone/leukocytes/nitrite/ph/protein/uro | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bilirubin/blood/glucose/ketone/leukocytes/ph/protein test n1=Bevacizumab | n2=en:bilirubin/blood/glucose/ketone/leukocytes/ph/protein test | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bilirubin/blood/glucose/ketone/leukocytes/ph/protein/urobilinoge n1=Bevacizumab | n2=en:bilirubin/blood/glucose/ketone/leukocytes/ph/protein/urobilinoge | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bilirubin/blood/glucose/ketone/nitrite/ph/protein/specific/urobi n1=Bevacizumab | n2=en:bilirubin/blood/glucose/ketone/nitrite/ph/protein/specific/urobi | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bilirubin/blood/glucose/ketone/nitrite/ph/protein/urobilinogen n1=Bevacizumab | n2=en:bilirubin/blood/glucose/ketone/nitrite/ph/protein/urobilinogen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bilirubin/blood/glucose/ketone/ph/protein test n1=Bevacizumab | n2=en:bilirubin/blood/glucose/ketone/ph/protein test | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bilirubin/blood/glucose/ketone/ph/protein/specific gravity test n1=Bevacizumab | n2=en:bilirubin/blood/glucose/ketone/ph/protein/specific gravity test | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bilirubin/blood/glucose/ketone/ph/protein/specific gravity/urobi n1=Bevacizumab | n2=en:bilirubin/blood/glucose/ketone/ph/protein/specific gravity/urobi | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bilirubin/blood/glucose/ketone/ph/protein/urobilinogen test n1=Bevacizumab | n2=en:bilirubin/blood/glucose/ketone/ph/protein/urobilinogen test | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bimagrumab n1=Bevacizumab | n2=en:bimagrumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bimatoprost n1=Bevacizumab | n2=en:bimatoprost | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:binetrakin n1=Bevacizumab | n2=en:binetrakin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:binimetinib n1=Bevacizumab | n2=en:binimetinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bioflavonoid n1=Bevacizumab | n2=en:bioflavonoid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bioformation n1=Bevacizumab | n2=en:bioformation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:biolex n1=Bevacizumab | n2=en:biolex | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:biological agent n1=Bevacizumab | n2=en:biological agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:biological factors n1=Bevacizumab | n2=en:biological factors | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:biomed 101 n1=Bevacizumab | n2=en:biomed 101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:biotene n1=Bevacizumab | n2=en:biotene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:biotin n1=Bevacizumab | n2=en:biotin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:biricodar dicitrate n1=Bevacizumab | n2=en:biricodar dicitrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:birinapant n1=Bevacizumab | n2=en:birinapant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bis(choline)tetrathiomolybdate n1=Bevacizumab | n2=en:bis(choline)tetrathiomolybdate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bisacodyl n1=Bevacizumab | n2=en:bisacodyl | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bisacodyl / tannic acid n1=Bevacizumab | n2=en:bisacodyl / tannic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bisacodyl/castor oil n1=Bevacizumab | n2=en:bisacodyl/castor oil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bisacodyl/docusate/senna concentrate/senna extract/sucrose n1=Bevacizumab | n2=en:bisacodyl/docusate/senna concentrate/senna extract/sucrose | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bisacodyl/electrolytes/peg-3350 n1=Bevacizumab | n2=en:bisacodyl/electrolytes/peg-3350 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bisacodyl/magnesium citrate n1=Bevacizumab | n2=en:bisacodyl/magnesium citrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bisacodyl/magnesium citrate/magnesium sulfate/senna/sucrose n1=Bevacizumab | n2=en:bisacodyl/magnesium citrate/magnesium sulfate/senna/sucrose | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bisacodyl/magnesium citrate/phenolphthalein n1=Bevacizumab | n2=en:bisacodyl/magnesium citrate/phenolphthalein | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bisacodyl/phospho soda n1=Bevacizumab | n2=en:bisacodyl/phospho soda | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bisantrene hydrochloride n1=Bevacizumab | n2=en:bisantrene hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bismuth n1=Bevacizumab | n2=en:bismuth | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bismuth bi213 monoclonal antibody m195 n1=Bevacizumab | n2=en:bismuth bi213 monoclonal antibody m195 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bismuth compound n1=Bevacizumab | n2=en:bismuth compound | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bismuth hydroxide/kaolin/opium/pectin n1=Bevacizumab | n2=en:bismuth hydroxide/kaolin/opium/pectin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bismuth subcarbonate / kaolin / pectin n1=Bevacizumab | n2=en:bismuth subcarbonate / kaolin / pectin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bismuth subcarbonate / morphine n1=Bevacizumab | n2=en:bismuth subcarbonate / morphine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bismuth subcarbonate/kaolin/opium/pectin n1=Bevacizumab | n2=en:bismuth subcarbonate/kaolin/opium/pectin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bismuth subcitrate n1=Bevacizumab | n2=en:bismuth subcitrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bismuth subgallate/boric acid/zinc oxide n1=Bevacizumab | n2=en:bismuth subgallate/boric acid/zinc oxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bismuth subgallate/kaolin/opium/pectin/zinc phenosulfonate n1=Bevacizumab | n2=en:bismuth subgallate/kaolin/opium/pectin/zinc phenosulfonate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bismuth subnitrate / calcium carbonate / magnesium carbonate n1=Bevacizumab | n2=en:bismuth subnitrate / calcium carbonate / magnesium carbonate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bismuth subnitrate/castor oil/ceresin/lanolin/peru balsam n1=Bevacizumab | n2=en:bismuth subnitrate/castor oil/ceresin/lanolin/peru balsam | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bismuth subsalicylate n1=Bevacizumab | n2=en:bismuth subsalicylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bismuth subsalicylate / calcium carbonate n1=Bevacizumab | n2=en:bismuth subsalicylate / calcium carbonate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bismuth subsalicylate/codeine/kaolin/pectin n1=Bevacizumab | n2=en:bismuth subsalicylate/codeine/kaolin/pectin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bismuth subsalicylate/kaolin/opium/pectin n1=Bevacizumab | n2=en:bismuth subsalicylate/kaolin/opium/pectin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bismuth subsalicylate/magnesium silicate/salicylic acid/sodium s n1=Bevacizumab | n2=en:bismuth subsalicylate/magnesium silicate/salicylic acid/sodium s | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bismuth subsalicylate+metronidazole+tetracycline hydrochloride n1=Bevacizumab | n2=en:bismuth subsalicylate+metronidazole+tetracycline hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bismuth tribromophenate n1=Bevacizumab | n2=en:bismuth tribromophenate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bismuth-formic-iodide n1=Bevacizumab | n2=en:bismuth-formic-iodide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bismuth/calcium/opium/pectin/zinc n1=Bevacizumab | n2=en:bismuth/calcium/opium/pectin/zinc | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bismuth/kaolin/opium/pectin/potassium/salol/zinc n1=Bevacizumab | n2=en:bismuth/kaolin/opium/pectin/potassium/salol/zinc | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bismuth/metronidazole/tetracycline n1=Bevacizumab | n2=en:bismuth/metronidazole/tetracycline | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bisoprolol n1=Bevacizumab | n2=en:bisoprolol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bisoprolol fumarate n1=Bevacizumab | n2=en:bisoprolol fumarate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bisoprolol, hydrochlorothiazide drug combination n1=Bevacizumab | n2=en:bisoprolol, hydrochlorothiazide drug combination | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bispecific antibody 2b1 n1=Bevacizumab | n2=en:bispecific antibody 2b1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bispecific antibody 4g7xh22 n1=Bevacizumab | n2=en:bispecific antibody 4g7xh22 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bispecific antibody mdx-h210 n1=Bevacizumab | n2=en:bispecific antibody mdx-h210 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bispecific antibody mdx447 n1=Bevacizumab | n2=en:bispecific antibody mdx447 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bispecific human anti-ang-2/anti-vegf-a antibody ro5520985 n1=Bevacizumab | n2=en:bispecific human anti-ang-2/anti-vegf-a antibody ro5520985 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bitolterol n1=Bevacizumab | n2=en:bitolterol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bitter melon (pharmacologic substance) n1=Bevacizumab | n2=en:bitter melon (pharmacologic substance) | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bitter orange peel n1=Bevacizumab | n2=en:bitter orange peel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bivalent hpv16/18 therapeutic cervical cancer vaccine n1=Bevacizumab | n2=en:bivalent hpv16/18 therapeutic cervical cancer vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bivalirudin n1=Bevacizumab | n2=en:bivalirudin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bizelesin n1=Bevacizumab | n2=en:bizelesin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bl22 immunotoxin n1=Bevacizumab | n2=en:bl22 immunotoxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:black cohosh n1=Bevacizumab | n2=en:black cohosh | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:black currant preparation n1=Bevacizumab | n2=en:black currant preparation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:black haw preparation n1=Bevacizumab | n2=en:black haw preparation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:black radish n1=Bevacizumab | n2=en:black radish | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:black raspberry nectar n1=Bevacizumab | n2=en:black raspberry nectar | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:black seed oil n1=Bevacizumab | n2=en:black seed oil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:black tea n1=Bevacizumab | n2=en:black tea | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:black tea extract n1=Bevacizumab | n2=en:black tea extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:blackberry allergenic extract n1=Bevacizumab | n2=en:blackberry allergenic extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bleomycin n1=Bevacizumab | n2=en:bleomycin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bleomycin sulfate n1=Bevacizumab | n2=en:bleomycin sulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bleomycin/sodium chloride n1=Bevacizumab | n2=en:bleomycin/sodium chloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:blex 404 n1=Bevacizumab | n2=en:blex 404 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:blinatumomab n1=Bevacizumab | n2=en:blinatumomab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:blood test device n1=Bevacizumab | n2=en:blood test device | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:blood urea nitrogen test device n1=Bevacizumab | n2=en:blood urea nitrogen test device | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:blood/glucose/ketone/leukocytes/nitrite/ph/protein test n1=Bevacizumab | n2=en:blood/glucose/ketone/leukocytes/nitrite/ph/protein test | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:blood/glucose/ketone/leukocytes/nitrite/ph/protein/specific grav n1=Bevacizumab | n2=en:blood/glucose/ketone/leukocytes/nitrite/ph/protein/specific grav | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:blood/glucose/ketone/leukocytes/ph/protein test n1=Bevacizumab | n2=en:blood/glucose/ketone/leukocytes/ph/protein test | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:blood/glucose/ketone/ph/protein test n1=Bevacizumab | n2=en:blood/glucose/ketone/ph/protein test | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:blood/glucose/leukocytes/protein test n1=Bevacizumab | n2=en:blood/glucose/leukocytes/protein test | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:blood/glucose/ph/protein test n1=Bevacizumab | n2=en:blood/glucose/ph/protein test | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bloodstop n1=Bevacizumab | n2=en:bloodstop | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bloodstop ex n1=Bevacizumab | n2=en:bloodstop ex | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:blue citrus-based herbal capsule n1=Bevacizumab | n2=en:blue citrus-based herbal capsule | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:blueberry powder supplement n1=Bevacizumab | n2=en:blueberry powder supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bmi1 inhibitor ptc596 n1=Bevacizumab | n2=en:bmi1 inhibitor ptc596 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bms-184476 n1=Bevacizumab | n2=en:bms-184476 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bms-188797 n1=Bevacizumab | n2=en:bms-188797 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bms-214662 n1=Bevacizumab | n2=en:bms-214662 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bms-275183 n1=Bevacizumab | n2=en:bms-275183 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bms-817378 n1=Bevacizumab | n2=en:bms-817378 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bms-986156 n1=Bevacizumab | n2=en:bms-986156 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bms-986205 n1=Bevacizumab | n2=en:bms-986205 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:boanmycin hydrochloride n1=Bevacizumab | n2=en:boanmycin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:boceprevir n1=Bevacizumab | n2=en:boceprevir | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bone cements n1=Bevacizumab | n2=en:bone cements | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bone graft - material n1=Bevacizumab | n2=en:bone graft - material | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bone meal n1=Bevacizumab | n2=en:bone meal | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bone metastasis targeting peptide-11 n1=Bevacizumab | n2=en:bone metastasis targeting peptide-11 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bone resorption inhibitor n1=Bevacizumab | n2=en:bone resorption inhibitor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:borage oil n1=Bevacizumab | n2=en:borage oil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:borate buffer n1=Bevacizumab | n2=en:borate buffer | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:boric acid n1=Bevacizumab | n2=en:boric acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:boric acid / zinc oxide n1=Bevacizumab | n2=en:boric acid / zinc oxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:boric acid carbomer 940 n1=Bevacizumab | n2=en:boric acid carbomer 940 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:boric acid/edta/hydroxyethyl cellulose n1=Bevacizumab | n2=en:boric acid/edta/hydroxyethyl cellulose | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:boric acid/glycerin/sodium borate/tetrahydrozoline n1=Bevacizumab | n2=en:boric acid/glycerin/sodium borate/tetrahydrozoline | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:boric acid/lauramide dea/propylene glycol/tea-dodecylbenzenesulf n1=Bevacizumab | n2=en:boric acid/lauramide dea/propylene glycol/tea-dodecylbenzenesulf | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:boric acid/potassium chloride/sodium carbonate n1=Bevacizumab | n2=en:boric acid/potassium chloride/sodium carbonate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:boric acid/sodium borate n1=Bevacizumab | n2=en:boric acid/sodium borate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:boric acid/sodium borate/sodium chloride n1=Bevacizumab | n2=en:boric acid/sodium borate/sodium chloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:boric acid/sodium chloride n1=Bevacizumab | n2=en:boric acid/sodium chloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:boric acid/vitamin a/vitamin d/zinc oxide n1=Bevacizumab | n2=en:boric acid/vitamin a/vitamin d/zinc oxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:boron n1=Bevacizumab | n2=en:boron | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:boron (as citrate) n1=Bevacizumab | n2=en:boron (as citrate) | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:boron phenylalanine n1=Bevacizumab | n2=en:boron phenylalanine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:boronophenylalanine-fructose complex n1=Bevacizumab | n2=en:boronophenylalanine-fructose complex | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bortezomib n1=Bevacizumab | n2=en:bortezomib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bosentan n1=Bevacizumab | n2=en:bosentan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:boston pharmaceuticals n1=Bevacizumab | n2=en:boston pharmaceuticals | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bosutinib n1=Bevacizumab | n2=en:bosutinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:boswellia serrata extract n1=Bevacizumab | n2=en:boswellia serrata extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:botanical extracts rinse izn-6n4 n1=Bevacizumab | n2=en:botanical extracts rinse izn-6n4 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:botanical lotion cg428 n1=Bevacizumab | n2=en:botanical lotion cg428 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:botulinum antitoxin n1=Bevacizumab | n2=en:botulinum antitoxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:botulinum toxin type a n1=Bevacizumab | n2=en:botulinum toxin type a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bovine cartilage n1=Bevacizumab | n2=en:bovine cartilage | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bovine lactoferrin supplement n1=Bevacizumab | n2=en:bovine lactoferrin supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bowman-birk inhibitor concentrate n1=Bevacizumab | n2=en:bowman-birk inhibitor concentrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bp-cx1-platinum complex bp-c1 n1=Bevacizumab | n2=en:bp-cx1-platinum complex bp-c1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:br96-doxorubicin immunoconjugate n1=Bevacizumab | n2=en:br96-doxorubicin immunoconjugate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brachyury-expressing modified vaccinia ankara-tricom vaccine n1=Bevacizumab | n2=en:brachyury-expressing modified vaccinia ankara-tricom vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brachyury-expressing yeast vaccine gi-6301 n1=Bevacizumab | n2=en:brachyury-expressing yeast vaccine gi-6301 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:braf inhibitor n1=Bevacizumab | n2=en:braf inhibitor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:braf inhibitor arq 736 n1=Bevacizumab | n2=en:braf inhibitor arq 736 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:braf inhibitor plx8394 n1=Bevacizumab | n2=en:braf inhibitor plx8394 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:braf(v600e) inhibitor cep-32496 n1=Bevacizumab | n2=en:braf(v600e) inhibitor cep-32496 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:braf(v600e) kinase inhibitor ro5212054 n1=Bevacizumab | n2=en:braf(v600e) kinase inhibitor ro5212054 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:braf/egfr inhibitor bgb-283 n1=Bevacizumab | n2=en:braf/egfr inhibitor bgb-283 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brain tumor initiating cell vaccine n1=Bevacizumab | n2=en:brain tumor initiating cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:branched-chain amino acid supplement n1=Bevacizumab | n2=en:branched-chain amino acid supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brassica vegetable n1=Bevacizumab | n2=en:brassica vegetable | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brd4 inhibitor plx51107 n1=Bevacizumab | n2=en:brd4 inhibitor plx51107 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:breflate n1=Bevacizumab | n2=en:breflate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brentuximab vedotin n1=Bevacizumab | n2=en:brentuximab vedotin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brequinar n1=Bevacizumab | n2=en:brequinar | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bretylium n1=Bevacizumab | n2=en:bretylium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bretylium/dextrose n1=Bevacizumab | n2=en:bretylium/dextrose | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:briciclib sodium n1=Bevacizumab | n2=en:briciclib sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brigatinib n1=Bevacizumab | n2=en:brigatinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brilacidin oral rinse n1=Bevacizumab | n2=en:brilacidin oral rinse | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brilliant green n1=Bevacizumab | n2=en:brilliant green | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brilliant green / gentian violet / proflavine n1=Bevacizumab | n2=en:brilliant green / gentian violet / proflavine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brimonidine n1=Bevacizumab | n2=en:brimonidine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brimonidine / brinzolamide n1=Bevacizumab | n2=en:brimonidine / brinzolamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brimonidine + timolol n1=Bevacizumab | n2=en:brimonidine + timolol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brincidofovir n1=Bevacizumab | n2=en:brincidofovir | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brinzolamide n1=Bevacizumab | n2=en:brinzolamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brivanib n1=Bevacizumab | n2=en:brivanib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brivanib alaninate n1=Bevacizumab | n2=en:brivanib alaninate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brivudine n1=Bevacizumab | n2=en:brivudine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brivudine phosphoramidate n1=Bevacizumab | n2=en:brivudine phosphoramidate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brn01 n1=Bevacizumab | n2=en:brn01 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:broad-spectrum human papillomavirus vaccine v505 n1=Bevacizumab | n2=en:broad-spectrum human papillomavirus vaccine v505 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:broccoli sprout extract n1=Bevacizumab | n2=en:broccoli sprout extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:broccoli sprout/broccoli seed extract supplement n1=Bevacizumab | n2=en:broccoli sprout/broccoli seed extract supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bromacrylide n1=Bevacizumab | n2=en:bromacrylide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bromelains n1=Bevacizumab | n2=en:bromelains | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bromine compound agent n1=Bevacizumab | n2=en:bromine compound agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bromocriptine n1=Bevacizumab | n2=en:bromocriptine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bromocriptine mesylate n1=Bevacizumab | n2=en:bromocriptine mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bromodiphenhydramine n1=Bevacizumab | n2=en:bromodiphenhydramine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bromodiphenhydramine+codeine n1=Bevacizumab | n2=en:bromodiphenhydramine+codeine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bromodomain inhibitor abbv-075 n1=Bevacizumab | n2=en:bromodomain inhibitor abbv-075 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bromphenhiramine/dextromethorphan/pseudoephedrine n1=Bevacizumab | n2=en:bromphenhiramine/dextromethorphan/pseudoephedrine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brompheniramine n1=Bevacizumab | n2=en:brompheniramine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brompheniramine / codeine / phenylephrine n1=Bevacizumab | n2=en:brompheniramine / codeine / phenylephrine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brompheniramine / codeine / phenylpropanolamine n1=Bevacizumab | n2=en:brompheniramine / codeine / phenylpropanolamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brompheniramine / dextromethorphan / phenylephrine n1=Bevacizumab | n2=en:brompheniramine / dextromethorphan / phenylephrine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brompheniramine / dextromethorphan / pseudoephedrine n1=Bevacizumab | n2=en:brompheniramine / dextromethorphan / pseudoephedrine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brompheniramine / guaifenesin / pseudoephedrine n1=Bevacizumab | n2=en:brompheniramine / guaifenesin / pseudoephedrine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brompheniramine / phenylephrine / phenylpropanolamine n1=Bevacizumab | n2=en:brompheniramine / phenylephrine / phenylpropanolamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brompheniramine / phenylephrine / phenyltoloxamine n1=Bevacizumab | n2=en:brompheniramine / phenylephrine / phenyltoloxamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brompheniramine / phenylpropanolamine n1=Bevacizumab | n2=en:brompheniramine / phenylpropanolamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brompheniramine + pseudoephedrine n1=Bevacizumab | n2=en:brompheniramine + pseudoephedrine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brompheniramine maleate + dextromethorphan hydrobromide + phenylpropanolamine hydrochloride n1=Bevacizumab | n2=en:brompheniramine maleate + dextromethorphan hydrobromide + phenylpropanolamine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brompheniramine/codeine/guaifenesin/menthol/phenylephrine/phenyl n1=Bevacizumab | n2=en:brompheniramine/codeine/guaifenesin/menthol/phenylephrine/phenyl | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brompheniramine/codeine/guaifenesin/phenylephrine/phenylpropanol n1=Bevacizumab | n2=en:brompheniramine/codeine/guaifenesin/phenylephrine/phenylpropanol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brompheniramine/guaifenesin/menthol/phenylephrine/phenylpropanol n1=Bevacizumab | n2=en:brompheniramine/guaifenesin/menthol/phenylephrine/phenylpropanol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brompheniramine/guaifenesin/phenylephrine/phenylpropanolamine n1=Bevacizumab | n2=en:brompheniramine/guaifenesin/phenylephrine/phenylpropanolamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bronchogenic cancer n1=Bevacizumab | n2=en:bronchogenic cancer | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brontictuzumab n1=Bevacizumab | n2=en:brontictuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bropirimine n1=Bevacizumab | n2=en:bropirimine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brostallicin n1=Bevacizumab | n2=en:brostallicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brown algae n1=Bevacizumab | n2=en:brown algae | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:broxuridine n1=Bevacizumab | n2=en:broxuridine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bruceantin n1=Bevacizumab | n2=en:bruceantin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:brucine n1=Bevacizumab | n2=en:brucine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bryonia preparation n1=Bevacizumab | n2=en:bryonia preparation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bryonia/hydrastis/phenolphthalein n1=Bevacizumab | n2=en:bryonia/hydrastis/phenolphthalein | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bryostatin 1 n1=Bevacizumab | n2=en:bryostatin 1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:btct4465a n1=Bevacizumab | n2=en:btct4465a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:btk inhibitor bgb-3111 n1=Bevacizumab | n2=en:btk inhibitor bgb-3111 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:btk inhibitor gdc-0853 n1=Bevacizumab | n2=en:btk inhibitor gdc-0853 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:btk inhibitor ono-4059 n1=Bevacizumab | n2=en:btk inhibitor ono-4059 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:buclizine n1=Bevacizumab | n2=en:buclizine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:budesonide n1=Bevacizumab | n2=en:budesonide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:budesonide + formoterol n1=Bevacizumab | n2=en:budesonide + formoterol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:budesonide/formoterol fumarate dihydrate inhalation aerosol n1=Bevacizumab | n2=en:budesonide/formoterol fumarate dihydrate inhalation aerosol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:budotitane n1=Bevacizumab | n2=en:budotitane | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:buformin hydrochloride n1=Bevacizumab | n2=en:buformin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:buparlisib n1=Bevacizumab | n2=en:buparlisib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bupivacaine / fentanyl n1=Bevacizumab | n2=en:bupivacaine / fentanyl | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bupivacaine / hydromorphone n1=Bevacizumab | n2=en:bupivacaine / hydromorphone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bupivacaine hydrochloride n1=Bevacizumab | n2=en:bupivacaine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bupivacaine/dextrose/epinephrine/lidocaine n1=Bevacizumab | n2=en:bupivacaine/dextrose/epinephrine/lidocaine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bupivacaine/epinephrine/lidocaine n1=Bevacizumab | n2=en:bupivacaine/epinephrine/lidocaine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bupivacaine/epinephrine/lidocaine/sodium chloride n1=Bevacizumab | n2=en:bupivacaine/epinephrine/lidocaine/sodium chloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bupivacaine/sodium chloride n1=Bevacizumab | n2=en:bupivacaine/sodium chloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bupivacaine+epinephrine n1=Bevacizumab | n2=en:bupivacaine+epinephrine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bupivacaine+glucose n1=Bevacizumab | n2=en:bupivacaine+glucose | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bupleurum preparation n1=Bevacizumab | n2=en:bupleurum preparation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:buprenorphine transdermal matrix patch n1=Bevacizumab | n2=en:buprenorphine transdermal matrix patch | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:buprenorphine, naloxone drug combination n1=Bevacizumab | n2=en:buprenorphine, naloxone drug combination | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bupropion + naltrexone n1=Bevacizumab | n2=en:bupropion + naltrexone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bupropion hydrochloride n1=Bevacizumab | n2=en:bupropion hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:burdock preparation n1=Bevacizumab | n2=en:burdock preparation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:burixafor n1=Bevacizumab | n2=en:burixafor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:buserelin n1=Bevacizumab | n2=en:buserelin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:buspirone n1=Bevacizumab | n2=en:buspirone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:buspirone hydrochloride n1=Bevacizumab | n2=en:buspirone hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:busulfan n1=Bevacizumab | n2=en:busulfan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:busulfan/melphalan regimen n1=Bevacizumab | n2=en:busulfan/melphalan regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:butabarbital n1=Bevacizumab | n2=en:butabarbital | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:butabarbital / ephedrine / guaifenesin / theophylline n1=Bevacizumab | n2=en:butabarbital / ephedrine / guaifenesin / theophylline | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:butabarbital / epinephrine / theophylline n1=Bevacizumab | n2=en:butabarbital / epinephrine / theophylline | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:butabarbital / phenobarbital / secobarbital n1=Bevacizumab | n2=en:butabarbital / phenobarbital / secobarbital | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:butabarbital/guaifenesin/pseudoephedrine/theophylline n1=Bevacizumab | n2=en:butabarbital/guaifenesin/pseudoephedrine/theophylline | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:butacaine n1=Bevacizumab | n2=en:butacaine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:butalbital n1=Bevacizumab | n2=en:butalbital | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:butamben n1=Bevacizumab | n2=en:butamben | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:butanols n1=Bevacizumab | n2=en:butanols | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:butcher's broom preparation n1=Bevacizumab | n2=en:butcher's broom preparation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:buthionine sulfoximine n1=Bevacizumab | n2=en:buthionine sulfoximine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:butocin n1=Bevacizumab | n2=en:butocin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:butylated hydroxyanisole n1=Bevacizumab | n2=en:butylated hydroxyanisole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:butylated hydroxytoluene n1=Bevacizumab | n2=en:butylated hydroxytoluene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:butylparaben/cetyl alcohol/methylparaben/propylene glycol/propy n1=Bevacizumab | n2=en:butylparaben/cetyl alcohol/methylparaben/propylene glycol/propy | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:butylscopolamine bromide n1=Bevacizumab | n2=en:butylscopolamine bromide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:butyric acid n1=Bevacizumab | n2=en:butyric acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:butyrolactone n1=Bevacizumab | n2=en:butyrolactone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:bw a773u n1=Bevacizumab | n2=en:bw a773u | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:c-kit inhibitor plx9486 n1=Bevacizumab | n2=en:c-kit inhibitor plx9486 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:c-met inhibitor amg 208 n1=Bevacizumab | n2=en:c-met inhibitor amg 208 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:c-met inhibitor amg 337 n1=Bevacizumab | n2=en:c-met inhibitor amg 337 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:c-met inhibitor jnj-38877605 n1=Bevacizumab | n2=en:c-met inhibitor jnj-38877605 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:c-met inhibitor mk2461 n1=Bevacizumab | n2=en:c-met inhibitor mk2461 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:c-met inhibitor mk8033 n1=Bevacizumab | n2=en:c-met inhibitor mk8033 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:c-met inhibitor msc2156119j n1=Bevacizumab | n2=en:c-met inhibitor msc2156119j | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:c-myb antisense oligonucleotide g4460 n1=Bevacizumab | n2=en:c-myb antisense oligonucleotide g4460 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:c-visa bikdd:liposome n1=Bevacizumab | n2=en:c-visa bikdd:liposome | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:c3-targeted complement inhibitor apl-2 n1=Bevacizumab | n2=en:c3-targeted complement inhibitor apl-2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cabazitaxel n1=Bevacizumab | n2=en:cabazitaxel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cabergoline n1=Bevacizumab | n2=en:cabergoline | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cabozantinib s-malate n1=Bevacizumab | n2=en:cabozantinib s-malate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cadazolid n1=Bevacizumab | n2=en:cadazolid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:caf regimen n1=Bevacizumab | n2=en:caf regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:caffeine n1=Bevacizumab | n2=en:caffeine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cafusertib hydrochloride n1=Bevacizumab | n2=en:cafusertib hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:caix inhibitor dtp348 n1=Bevacizumab | n2=en:caix inhibitor dtp348 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:caix inhibitor slc-0111 n1=Bevacizumab | n2=en:caix inhibitor slc-0111 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:calamine n1=Bevacizumab | n2=en:calamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:calaspargase pegol n1=Bevacizumab | n2=en:calaspargase pegol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:calcipotriene n1=Bevacizumab | n2=en:calcipotriene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:calcitonin salmon n1=Bevacizumab | n2=en:calcitonin salmon | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:calcitriol n1=Bevacizumab | n2=en:calcitriol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:calcium aluminosilicate anti-diarrheal n1=Bevacizumab | n2=en:calcium aluminosilicate anti-diarrheal | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:calcium carbonate n1=Bevacizumab | n2=en:calcium carbonate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:calcium channel blocker n1=Bevacizumab | n2=en:calcium channel blocker | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:calcium chloride n1=Bevacizumab | n2=en:calcium chloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:calcium citrate n1=Bevacizumab | n2=en:calcium citrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:calcium gluconate n1=Bevacizumab | n2=en:calcium gluconate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:calcium regulating agent n1=Bevacizumab | n2=en:calcium regulating agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:calcium saccharate n1=Bevacizumab | n2=en:calcium saccharate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:calcium-41 chloride aqueous solution n1=Bevacizumab | n2=en:calcium-41 chloride aqueous solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:calcium-46 chloride aqueous solution n1=Bevacizumab | n2=en:calcium-46 chloride aqueous solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:calculus bovis/moschus/olibanum/myrrha capsule n1=Bevacizumab | n2=en:calculus bovis/moschus/olibanum/myrrha capsule | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:calendula officinalis/plantago major/cochlearia armoracia/hamamelis virginiana herbal toothpaste n1=Bevacizumab | n2=en:calendula officinalis/plantago major/cochlearia armoracia/hamamelis virginiana herbal toothpaste | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:calendula ointment n1=Bevacizumab | n2=en:calendula ointment | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:calfactant n1=Bevacizumab | n2=en:calfactant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:calusterone n1=Bevacizumab | n2=en:calusterone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:camptothecin n1=Bevacizumab | n2=en:camptothecin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:camptothecin analogue tlc388 n1=Bevacizumab | n2=en:camptothecin analogue tlc388 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:camptothecin-20(s)-o-propionate hydrate n1=Bevacizumab | n2=en:camptothecin-20(s)-o-propionate hydrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:campy cva agar n1=Bevacizumab | n2=en:campy cva agar | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:canada balsam n1=Bevacizumab | n2=en:canada balsam | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:canakinumab n1=Bevacizumab | n2=en:canakinumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:canarypox-hil-12 melanoma vaccine n1=Bevacizumab | n2=en:canarypox-hil-12 melanoma vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cancell n1=Bevacizumab | n2=en:cancell | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cancer peptide vaccine s-588410 n1=Bevacizumab | n2=en:cancer peptide vaccine s-588410 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cancer stemness kinase inhibitor bbi503 n1=Bevacizumab | n2=en:cancer stemness kinase inhibitor bbi503 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:candesartan cilexetil n1=Bevacizumab | n2=en:candesartan cilexetil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:candida albicans skin test reagent n1=Bevacizumab | n2=en:candida albicans skin test reagent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:canertinib dihydrochloride n1=Bevacizumab | n2=en:canertinib dihydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:canfosfamide hydrochloride n1=Bevacizumab | n2=en:canfosfamide hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cannabidiol n1=Bevacizumab | n2=en:cannabidiol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cannabinol n1=Bevacizumab | n2=en:cannabinol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cannabis extract oil sr capsule n1=Bevacizumab | n2=en:cannabis extract oil sr capsule | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cantuzumab ravtansine n1=Bevacizumab | n2=en:cantuzumab ravtansine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:capecitabine n1=Bevacizumab | n2=en:capecitabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:capecitabine rapidly disintegrating tablet n1=Bevacizumab | n2=en:capecitabine rapidly disintegrating tablet | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:capmatinib n1=Bevacizumab | n2=en:capmatinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:capox regimen n1=Bevacizumab | n2=en:capox regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:capox-bevacizumab regimen n1=Bevacizumab | n2=en:capox-bevacizumab regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:capsaicin n1=Bevacizumab | n2=en:capsaicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:captopril n1=Bevacizumab | n2=en:captopril | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:car.cd30-expressing autologous epstein-barr virus-specific cytotoxic t-lymphocytes n1=Bevacizumab | n2=en:car.cd30-expressing autologous epstein-barr virus-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:caracemide n1=Bevacizumab | n2=en:caracemide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbamazepine n1=Bevacizumab | n2=en:carbamazepine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbamide peroxide n1=Bevacizumab | n2=en:carbamide peroxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbendazim n1=Bevacizumab | n2=en:carbendazim | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbenicillin n1=Bevacizumab | n2=en:carbenicillin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbetimer n1=Bevacizumab | n2=en:carbetimer | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbidopa n1=Bevacizumab | n2=en:carbidopa | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbogen n1=Bevacizumab | n2=en:carbogen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbohydrate processing inhibitor n1=Bevacizumab | n2=en:carbohydrate processing inhibitor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbohydrate supplement drink n1=Bevacizumab | n2=en:carbohydrate supplement drink | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 11 alpha-methyltryptophan n1=Bevacizumab | n2=en:carbon c 11 alpha-methyltryptophan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 11 choline n1=Bevacizumab | n2=en:carbon c 11 choline | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 11 erlotinib hydrochloride n1=Bevacizumab | n2=en:carbon c 11 erlotinib hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 11 methylaminoisobutyrate n1=Bevacizumab | n2=en:carbon c 11 methylaminoisobutyrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 11 n-desmethyl-loperamide n1=Bevacizumab | n2=en:carbon c 11 n-desmethyl-loperamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 11 pbr-28 n1=Bevacizumab | n2=en:carbon c 11 pbr-28 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 11 sarcosine n1=Bevacizumab | n2=en:carbon c 11 sarcosine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 11 sepantronium bromide n1=Bevacizumab | n2=en:carbon c 11 sepantronium bromide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 13 acetate n1=Bevacizumab | n2=en:carbon c 13 acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 13 lycopene n1=Bevacizumab | n2=en:carbon c 13 lycopene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 13 octanoate n1=Bevacizumab | n2=en:carbon c 13 octanoate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 13 phytoene n1=Bevacizumab | n2=en:carbon c 13 phytoene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 13 phytofluene n1=Bevacizumab | n2=en:carbon c 13 phytofluene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 13/nitrogen n 15-labeled valine n1=Bevacizumab | n2=en:carbon c 13/nitrogen n 15-labeled valine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 14 anlotinib hydrochloride n1=Bevacizumab | n2=en:carbon c 14 anlotinib hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 14 eribulin acetate n1=Bevacizumab | n2=en:carbon c 14 eribulin acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 14 gilteritinib n1=Bevacizumab | n2=en:carbon c 14 gilteritinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 14 ibrutinib n1=Bevacizumab | n2=en:carbon c 14 ibrutinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 14 lenvatinib mesylate n1=Bevacizumab | n2=en:carbon c 14 lenvatinib mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 14 ombrabulin n1=Bevacizumab | n2=en:carbon c 14 ombrabulin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 14 oxaliplatin n1=Bevacizumab | n2=en:carbon c 14 oxaliplatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 14 roniciclib n1=Bevacizumab | n2=en:carbon c 14 roniciclib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 14 selumetinib n1=Bevacizumab | n2=en:carbon c 14 selumetinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 14 telotristat etiprate n1=Bevacizumab | n2=en:carbon c 14 telotristat etiprate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 14 vemurafenib n1=Bevacizumab | n2=en:carbon c 14 vemurafenib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c 14-labeled ixazomib n1=Bevacizumab | n2=en:carbon c 14-labeled ixazomib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c-13 dextromethorphan n1=Bevacizumab | n2=en:carbon c-13 dextromethorphan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c-14 dacomitinib n1=Bevacizumab | n2=en:carbon c-14 dacomitinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon c11 temozolomide n1=Bevacizumab | n2=en:carbon c11 temozolomide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon nanoparticle-based formulation n1=Bevacizumab | n2=en:carbon nanoparticle-based formulation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbon-11 acetate n1=Bevacizumab | n2=en:carbon-11 acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carboplatin n1=Bevacizumab | n2=en:carboplatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carboplatin-taxol regimen n1=Bevacizumab | n2=en:carboplatin-taxol regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carboplatin-taxol-bevacizumab regimen n1=Bevacizumab | n2=en:carboplatin-taxol-bevacizumab regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carboplatin/etoposide/melphalan regimen n1=Bevacizumab | n2=en:carboplatin/etoposide/melphalan regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carboxyamidotriazole n1=Bevacizumab | n2=en:carboxyamidotriazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carboxyamidotriazole orotate n1=Bevacizumab | n2=en:carboxyamidotriazole orotate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carboxylesterase-expressing allogeneic neural stem cells n1=Bevacizumab | n2=en:carboxylesterase-expressing allogeneic neural stem cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carboxymethylcellulose sodium n1=Bevacizumab | n2=en:carboxymethylcellulose sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carboxyphenyl retinamide n1=Bevacizumab | n2=en:carboxyphenyl retinamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carbutamide n1=Bevacizumab | n2=en:carbutamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carcinoembryonic antigen peptide 1 n1=Bevacizumab | n2=en:carcinoembryonic antigen peptide 1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carcinoembryonic antigen peptide 1-6d n1=Bevacizumab | n2=en:carcinoembryonic antigen peptide 1-6d | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carcinoembryonic antigen peptide 1-6d virus-like replicon particles vaccine n1=Bevacizumab | n2=en:carcinoembryonic antigen peptide 1-6d virus-like replicon particles vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carcinoembryonic antigen peptide vaccine n1=Bevacizumab | n2=en:carcinoembryonic antigen peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carcinoembryonic antigen rna-pulsed dc cancer vaccine n1=Bevacizumab | n2=en:carcinoembryonic antigen rna-pulsed dc cancer vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carcinoembryonic antigen-expressing measles virus n1=Bevacizumab | n2=en:carcinoembryonic antigen-expressing measles virus | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carcinogen n1=Bevacizumab | n2=en:carcinogen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carfilzomib n1=Bevacizumab | n2=en:carfilzomib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:caricotamide/tretazicar n1=Bevacizumab | n2=en:caricotamide/tretazicar | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carlumab n1=Bevacizumab | n2=en:carlumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carmustine n1=Bevacizumab | n2=en:carmustine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carmustine in ethanol n1=Bevacizumab | n2=en:carmustine in ethanol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carmustine sustained-release implant wafer n1=Bevacizumab | n2=en:carmustine sustained-release implant wafer | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carrageenan-containing gel n1=Bevacizumab | n2=en:carrageenan-containing gel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carrot juice n1=Bevacizumab | n2=en:carrot juice | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carrot/jilin ginseng/licorice root/tangerine peel/soy beverage n1=Bevacizumab | n2=en:carrot/jilin ginseng/licorice root/tangerine peel/soy beverage | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carubicin n1=Bevacizumab | n2=en:carubicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carvedilol n1=Bevacizumab | n2=en:carvedilol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carvedilol phosphate extended-release capsule n1=Bevacizumab | n2=en:carvedilol phosphate extended-release capsule | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:carzelesin n1=Bevacizumab | n2=en:carzelesin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:casein/whey protein/soy protein/pea protein/fat mix/epa/dha-based nutritional supplement n1=Bevacizumab | n2=en:casein/whey protein/soy protein/pea protein/fat mix/epa/dha-based nutritional supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:caseinate protein isolate n1=Bevacizumab | n2=en:caseinate protein isolate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:casopitant mesylate n1=Bevacizumab | n2=en:casopitant mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:caspofungin acetate n1=Bevacizumab | n2=en:caspofungin acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:castor oil / peruvian balsam / trypsin n1=Bevacizumab | n2=en:castor oil / peruvian balsam / trypsin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cathelicidin ll-37 n1=Bevacizumab | n2=en:cathelicidin ll-37 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cathepsin-activatable cy5 fluorescent imaging probe lum015 n1=Bevacizumab | n2=en:cathepsin-activatable cy5 fluorescent imaging probe lum015 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cationic liposome-encapsulated paclitaxel n1=Bevacizumab | n2=en:cationic liposome-encapsulated paclitaxel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:catumaxomab n1=Bevacizumab | n2=en:catumaxomab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cb10-277 n1=Bevacizumab | n2=en:cb10-277 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cbp-501 n1=Bevacizumab | n2=en:cbp-501 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cbp/beta-catenin antagonist pri-724 n1=Bevacizumab | n2=en:cbp/beta-catenin antagonist pri-724 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cc-1088 n1=Bevacizumab | n2=en:cc-1088 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cc-401 n1=Bevacizumab | n2=en:cc-401 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cc-8490 n1=Bevacizumab | n2=en:cc-8490 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ccl21-expressing h1944 cell vaccine n1=Bevacizumab | n2=en:ccl21-expressing h1944 cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ccr2 antagonist ccx872-b n1=Bevacizumab | n2=en:ccr2 antagonist ccx872-b | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ccr2 antagonist pf-04136309 n1=Bevacizumab | n2=en:ccr2 antagonist pf-04136309 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cd-expressing bifidobacterium aps001f n1=Bevacizumab | n2=en:cd-expressing bifidobacterium aps001f | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine n1=Bevacizumab | n2=en:cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cd133 antigen peptide-pulsed autologous dendritic cell vaccine n1=Bevacizumab | n2=en:cd133 antigen peptide-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cd138car-cd137/tcrzeta-expressing t lymphocytes n1=Bevacizumab | n2=en:cd138car-cd137/tcrzeta-expressing t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cd19/cd3 dual-affinity retargeting protein jnj-64052781 n1=Bevacizumab | n2=en:cd19/cd3 dual-affinity retargeting protein jnj-64052781 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cd19car-cd28zeta-4-1bb-expressing allogeneic t lymphocytes n1=Bevacizumab | n2=en:cd19car-cd28zeta-4-1bb-expressing allogeneic t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cd19car-cd3zeta-4-1bb-cd28-expressing autologous t-lymphocytes n1=Bevacizumab | n2=en:cd19car-cd3zeta-4-1bb-cd28-expressing autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cd19car-cd3zeta-4-1bb-expressing allogeneic t-lymphocyte cells n1=Bevacizumab | n2=en:cd19car-cd3zeta-4-1bb-expressing allogeneic t-lymphocyte cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cd19car-cd3zeta-4-1bb-expressing autologous t-lymphocytes n1=Bevacizumab | n2=en:cd19car-cd3zeta-4-1bb-expressing autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cd19car-cd3zeta-expressing autologous t lymphocytes n1=Bevacizumab | n2=en:cd19car-cd3zeta-expressing autologous t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cd20-targeted polypeptide tru-015 n1=Bevacizumab | n2=en:cd20-targeted polypeptide tru-015 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cd24 extracellular domain-igg1 fc domain recombinant fusion protein cd24fc n1=Bevacizumab | n2=en:cd24 extracellular domain-igg1 fc domain recombinant fusion protein cd24fc | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cd28car/cd137car-expressing t-lymphocytes n1=Bevacizumab | n2=en:cd28car/cd137car-expressing t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cd3/cd28 costimulated autologous t-cells n1=Bevacizumab | n2=en:cd3/cd28 costimulated autologous t-cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cd30 car-expressing autologous t lymphocytes n1=Bevacizumab | n2=en:cd30 car-expressing autologous t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cd33car-cd3zeta-4-1bb-expressing autologous t-lymphocytes n1=Bevacizumab | n2=en:cd33car-cd3zeta-4-1bb-expressing autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cd34/tk75-transduced donor lymphocytes n1=Bevacizumab | n2=en:cd34/tk75-transduced donor lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cd4+ cd25+ regulatory t cells n1=Bevacizumab | n2=en:cd4+ cd25+ regulatory t cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cd40 agonist monoclonal antibody cp-870,893 n1=Bevacizumab | n2=en:cd40 agonist monoclonal antibody cp-870,893 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cd40 agonist monoclonal antibody ro7009789 n1=Bevacizumab | n2=en:cd40 agonist monoclonal antibody ro7009789 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cd40 agonistic monoclonal antibody apx005m n1=Bevacizumab | n2=en:cd40 agonistic monoclonal antibody apx005m | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cd5789 cream n1=Bevacizumab | n2=en:cd5789 cream | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cd80 breast cancer vaccine n1=Bevacizumab | n2=en:cd80 breast cancer vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cd95 ecd/igg-fc fusion protein apg101 n1=Bevacizumab | n2=en:cd95 ecd/igg-fc fusion protein apg101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cda inhibitor e7727/decitabine combination agent astx727 n1=Bevacizumab | n2=en:cda inhibitor e7727/decitabine combination agent astx727 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cdc7 inhibitor tak-931 n1=Bevacizumab | n2=en:cdc7 inhibitor tak-931 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cdc7 kinase inhibitor bms-863233 n1=Bevacizumab | n2=en:cdc7 kinase inhibitor bms-863233 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cdc7 kinase inhibitor nms-1116354 n1=Bevacizumab | n2=en:cdc7 kinase inhibitor nms-1116354 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cdk inhibitor p276-00 n1=Bevacizumab | n2=en:cdk inhibitor p276-00 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cdk inhibitor sns-032 n1=Bevacizumab | n2=en:cdk inhibitor sns-032 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cdk/jak2/flt3 inhibitor tg02 citrate n1=Bevacizumab | n2=en:cdk/jak2/flt3 inhibitor tg02 citrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cdk2/5/9 inhibitor cyc065 n1=Bevacizumab | n2=en:cdk2/5/9 inhibitor cyc065 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cdk2/trka inhibitor pha-848125 ac n1=Bevacizumab | n2=en:cdk2/trka inhibitor pha-848125 ac | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cdk4 inhibitor p1446a-05 n1=Bevacizumab | n2=en:cdk4 inhibitor p1446a-05 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cdk4/6 inhibitor g1t28 n1=Bevacizumab | n2=en:cdk4/6 inhibitor g1t28 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cdk4/6 inhibitor shr6390 n1=Bevacizumab | n2=en:cdk4/6 inhibitor shr6390 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cdki at7519 n1=Bevacizumab | n2=en:cdki at7519 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cdki r547 n1=Bevacizumab | n2=en:cdki r547 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cea/tetanus toxoid t helper epitope fusion protein-expressing dna plasmid vaccine n1=Bevacizumab | n2=en:cea/tetanus toxoid t helper epitope fusion protein-expressing dna plasmid vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cebpa-targeting sarna mtl-cebpa liposome n1=Bevacizumab | n2=en:cebpa-targeting sarna mtl-cebpa liposome | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cebranopadol n1=Bevacizumab | n2=en:cebranopadol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cedefingol n1=Bevacizumab | n2=en:cedefingol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cediranib maleate n1=Bevacizumab | n2=en:cediranib maleate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cef regimen n1=Bevacizumab | n2=en:cef regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cefamandole n1=Bevacizumab | n2=en:cefamandole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cefazolin sodium n1=Bevacizumab | n2=en:cefazolin sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cefepime hydrochloride n1=Bevacizumab | n2=en:cefepime hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cefixime n1=Bevacizumab | n2=en:cefixime | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cefmetazole sodium n1=Bevacizumab | n2=en:cefmetazole sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cefotaxime n1=Bevacizumab | n2=en:cefotaxime | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cefpodoxime proxetil n1=Bevacizumab | n2=en:cefpodoxime proxetil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ceftazidime sodium n1=Bevacizumab | n2=en:ceftazidime sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ceftazidime/avibactam sodium n1=Bevacizumab | n2=en:ceftazidime/avibactam sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ceftobiprole medocaril n1=Bevacizumab | n2=en:ceftobiprole medocaril | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ceftriaxone sodium n1=Bevacizumab | n2=en:ceftriaxone sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:celecoxib n1=Bevacizumab | n2=en:celecoxib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cell cycle checkpoint/dna repair antagonist ic83 n1=Bevacizumab | n2=en:cell cycle checkpoint/dna repair antagonist ic83 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cell differentiating agent n1=Bevacizumab | n2=en:cell differentiating agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cellulose, oxidized n1=Bevacizumab | n2=en:cellulose, oxidized | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cemadotin hydrochloride n1=Bevacizumab | n2=en:cemadotin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cenersen n1=Bevacizumab | n2=en:cenersen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cenisertib n1=Bevacizumab | n2=en:cenisertib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cenp-e inhibitor gsk-923295 n1=Bevacizumab | n2=en:cenp-e inhibitor gsk-923295 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:central nervous system agents n1=Bevacizumab | n2=en:central nervous system agents | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cep-2563 dihydrochloride n1=Bevacizumab | n2=en:cep-2563 dihydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cephalexin n1=Bevacizumab | n2=en:cephalexin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cephalostatin n1=Bevacizumab | n2=en:cephalostatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cephalothin sodium n1=Bevacizumab | n2=en:cephalothin sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ceramide n1=Bevacizumab | n2=en:ceramide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ceritinib n1=Bevacizumab | n2=en:ceritinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:certolizumab n1=Bevacizumab | n2=en:certolizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:certolizumab pegol n1=Bevacizumab | n2=en:certolizumab pegol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ceruminolytic agent n1=Bevacizumab | n2=en:ceruminolytic agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cesium cs 137 n1=Bevacizumab | n2=en:cesium cs 137 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cesium cs-131 n1=Bevacizumab | n2=en:cesium cs-131 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ceteth-20 n1=Bevacizumab | n2=en:ceteth-20 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cetirizine n1=Bevacizumab | n2=en:cetirizine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cetrorelix n1=Bevacizumab | n2=en:cetrorelix | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cetuximab n1=Bevacizumab | n2=en:cetuximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cetuximab-ir700 conjugate rm-1929 n1=Bevacizumab | n2=en:cetuximab-ir700 conjugate rm-1929 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cetuximab-irdye 800cw n1=Bevacizumab | n2=en:cetuximab-irdye 800cw | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cevimeline hydrochloride n1=Bevacizumab | n2=en:cevimeline hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cfms tyrosine kinase inhibitor arry-382 n1=Bevacizumab | n2=en:cfms tyrosine kinase inhibitor arry-382 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cg7870 n1=Bevacizumab | n2=en:cg7870 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cgp-6809 n1=Bevacizumab | n2=en:cgp-6809 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chamomile n1=Bevacizumab | n2=en:chamomile | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:changchun marina n1=Bevacizumab | n2=en:changchun marina | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:checkpoint kinase inhibitor azd7762 n1=Bevacizumab | n2=en:checkpoint kinase inhibitor azd7762 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:checkpoint kinase inhibitor xl844 n1=Bevacizumab | n2=en:checkpoint kinase inhibitor xl844 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chelating agent n1=Bevacizumab | n2=en:chelating agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chelating agents and antidotes n1=Bevacizumab | n2=en:chelating agents and antidotes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chemical aspects n1=Bevacizumab | n2=en:chemical aspects | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chemotherapeutic topical agent n1=Bevacizumab | n2=en:chemotherapeutic topical agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chewing gum dosage form n1=Bevacizumab | n2=en:chewing gum dosage form | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chiauranib n1=Bevacizumab | n2=en:chiauranib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chidamide n1=Bevacizumab | n2=en:chidamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chimeric fibril-reactive monoclonal antibody 111f4 n1=Bevacizumab | n2=en:chimeric fibril-reactive monoclonal antibody 111f4 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chimeric humanized anti-cd47 antibody n1=Bevacizumab | n2=en:chimeric humanized anti-cd47 antibody | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chinese herbal formulation changtai keli n1=Bevacizumab | n2=en:chinese herbal formulation changtai keli | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chinese herbal formulation phy906 n1=Bevacizumab | n2=en:chinese herbal formulation phy906 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chinese herbal medicine compound tpe-1 n1=Bevacizumab | n2=en:chinese herbal medicine compound tpe-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chinese herbs n1=Bevacizumab | n2=en:chinese herbs | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chining decoction n1=Bevacizumab | n2=en:chining decoction | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chk1 inhibitor gdc-0425 n1=Bevacizumab | n2=en:chk1 inhibitor gdc-0425 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chk1 inhibitor gdc-0575 n1=Bevacizumab | n2=en:chk1 inhibitor gdc-0575 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chk1 inhibitor mk-8776 n1=Bevacizumab | n2=en:chk1 inhibitor mk-8776 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chk1 inhibitor pf-477736 n1=Bevacizumab | n2=en:chk1 inhibitor pf-477736 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chlorambucil n1=Bevacizumab | n2=en:chlorambucil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chlorambucil-prednisone regimen n1=Bevacizumab | n2=en:chlorambucil-prednisone regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chlorhexidine n1=Bevacizumab | n2=en:chlorhexidine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chlorhexidine gluconate n1=Bevacizumab | n2=en:chlorhexidine gluconate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chlorhexidine/ethyl alcohol mouthwash n1=Bevacizumab | n2=en:chlorhexidine/ethyl alcohol mouthwash | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chlorogenic acid n1=Bevacizumab | n2=en:chlorogenic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chloroquine n1=Bevacizumab | n2=en:chloroquine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chloroquinoxaline sulfonamide n1=Bevacizumab | n2=en:chloroquinoxaline sulfonamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chlorotoxin [131i] n1=Bevacizumab | n2=en:chlorotoxin [131i] | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chlorotoxin-indocyanine green imaging agent blz-100 n1=Bevacizumab | n2=en:chlorotoxin-indocyanine green imaging agent blz-100 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chlorozotocin n1=Bevacizumab | n2=en:chlorozotocin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chlorpromazine n1=Bevacizumab | n2=en:chlorpromazine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chlorpropamide n1=Bevacizumab | n2=en:chlorpropamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chlorzoxazone n1=Bevacizumab | n2=en:chlorzoxazone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cholecalciferol n1=Bevacizumab | n2=en:cholecalciferol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cholecalciferol/whey protein isolate/epa/dha-based nutritional supplement n1=Bevacizumab | n2=en:cholecalciferol/whey protein isolate/epa/dha-based nutritional supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cholelitholytic and/or choleretic agent n1=Bevacizumab | n2=en:cholelitholytic and/or choleretic agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:choleretic agent n1=Bevacizumab | n2=en:choleretic agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:choline kinase alpha inhibitor tcd-717 n1=Bevacizumab | n2=en:choline kinase alpha inhibitor tcd-717 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:choline magnesium trisalicylate n1=Bevacizumab | n2=en:choline magnesium trisalicylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:choline salicylate n1=Bevacizumab | n2=en:choline salicylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chop regimen n1=Bevacizumab | n2=en:chop regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chp-her-2 peptide vaccine n1=Bevacizumab | n2=en:chp-her-2 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chp-ny-eso-1 peptide vaccine imf-001 n1=Bevacizumab | n2=en:chp-ny-eso-1 peptide vaccine imf-001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:chromomycin a3 n1=Bevacizumab | n2=en:chromomycin a3 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ciclopirox olamine lotion n1=Bevacizumab | n2=en:ciclopirox olamine lotion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ciclopirox olamine oral n1=Bevacizumab | n2=en:ciclopirox olamine oral | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cidan herbal capsule n1=Bevacizumab | n2=en:cidan herbal capsule | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cidofovir n1=Bevacizumab | n2=en:cidofovir | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cilengitide n1=Bevacizumab | n2=en:cilengitide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cimetidine n1=Bevacizumab | n2=en:cimetidine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cinacalcet hydrochloride n1=Bevacizumab | n2=en:cinacalcet hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cinobufagin n1=Bevacizumab | n2=en:cinobufagin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cintredekin besudotox n1=Bevacizumab | n2=en:cintredekin besudotox | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cipatinib n1=Bevacizumab | n2=en:cipatinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ciprofloxacin n1=Bevacizumab | n2=en:ciprofloxacin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cirmtuzumab n1=Bevacizumab | n2=en:cirmtuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cis-urocanic acid n1=Bevacizumab | n2=en:cis-urocanic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cisapride n1=Bevacizumab | n2=en:cisapride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cisatracurium besylate n1=Bevacizumab | n2=en:cisatracurium besylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cisplatin n1=Bevacizumab | n2=en:cisplatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cisplatin liposomal n1=Bevacizumab | n2=en:cisplatin liposomal | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cisplatin-e therapeutic implant n1=Bevacizumab | n2=en:cisplatin-e therapeutic implant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:citalopram hydrobromide n1=Bevacizumab | n2=en:citalopram hydrobromide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:citatuzumab bogatox n1=Bevacizumab | n2=en:citatuzumab bogatox | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:citicoline n1=Bevacizumab | n2=en:citicoline | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:citric acid + magnesium oxide + sodium picosulfate n1=Bevacizumab | n2=en:citric acid + magnesium oxide + sodium picosulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:citrulline n1=Bevacizumab | n2=en:citrulline | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:citrus bergamia extract n1=Bevacizumab | n2=en:citrus bergamia extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cixutumumab n1=Bevacizumab | n2=en:cixutumumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ck2-targeting synthetic peptide cigb-300 n1=Bevacizumab | n2=en:ck2-targeting synthetic peptide cigb-300 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cl 246738 n1=Bevacizumab | n2=en:cl 246738 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cladribine n1=Bevacizumab | n2=en:cladribine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:clanfenur n1=Bevacizumab | n2=en:clanfenur | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:clarithromycin n1=Bevacizumab | n2=en:clarithromycin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:claudiximab n1=Bevacizumab | n2=en:claudiximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:clevidipine n1=Bevacizumab | n2=en:clevidipine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:clevudine n1=Bevacizumab | n2=en:clevudine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:clindamycin n1=Bevacizumab | n2=en:clindamycin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:clindamycin phosphate n1=Bevacizumab | n2=en:clindamycin phosphate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:clindamycin/hydrocortisone lotion n1=Bevacizumab | n2=en:clindamycin/hydrocortisone lotion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:clino-san vaginal lubricant n1=Bevacizumab | n2=en:clino-san vaginal lubricant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:clioquinol n1=Bevacizumab | n2=en:clioquinol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:clobetasol propionate n1=Bevacizumab | n2=en:clobetasol propionate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:clodronate disodium n1=Bevacizumab | n2=en:clodronate disodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:clofarabine n1=Bevacizumab | n2=en:clofarabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:clofibrate n1=Bevacizumab | n2=en:clofibrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:clomiphene citrate n1=Bevacizumab | n2=en:clomiphene citrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:clonidine hydrochloride n1=Bevacizumab | n2=en:clonidine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:clonidine-containing mucoadhesive buccal tablet n1=Bevacizumab | n2=en:clonidine-containing mucoadhesive buccal tablet | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:clopidogrel bisulfate n1=Bevacizumab | n2=en:clopidogrel bisulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:clostridium butyricum-containing probiotic n1=Bevacizumab | n2=en:clostridium butyricum-containing probiotic | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:clostridium novyi-nt spores n1=Bevacizumab | n2=en:clostridium novyi-nt spores | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:clotrimazole n1=Bevacizumab | n2=en:clotrimazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cmet car-mrna electroporated autologous t lymphocytes n1=Bevacizumab | n2=en:cmet car-mrna electroporated autologous t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cmf regimen n1=Bevacizumab | n2=en:cmf regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cmv n495 peptide n1=Bevacizumab | n2=en:cmv n495 peptide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cmv pp65 peptide-pulsed autologous dendritic cell vaccine n1=Bevacizumab | n2=en:cmv pp65 peptide-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cmvpp65-a*0201 peptide vaccine n1=Bevacizumab | n2=en:cmvpp65-a*0201 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cmvpp65/gb plasmid vaccine asp0113 n1=Bevacizumab | n2=en:cmvpp65/gb plasmid vaccine asp0113 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cndo-109-activated allogeneic natural killer cells n1=Bevacizumab | n2=en:cndo-109-activated allogeneic natural killer cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cngrc peptide-tnf alpha conjugate n1=Bevacizumab | n2=en:cngrc peptide-tnf alpha conjugate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cobalamin n1=Bevacizumab | n2=en:cobalamin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cobimetinib n1=Bevacizumab | n2=en:cobimetinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cobiprostone n1=Bevacizumab | n2=en:cobiprostone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cocculus/nux vomica/tabacum/petroleum extract n1=Bevacizumab | n2=en:cocculus/nux vomica/tabacum/petroleum extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cocoa extract n1=Bevacizumab | n2=en:cocoa extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:codeine phosphate n1=Bevacizumab | n2=en:codeine phosphate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:coenzyme q10 n1=Bevacizumab | n2=en:coenzyme q10 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:coffee dietary supplement n1=Bevacizumab | n2=en:coffee dietary supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:colchicine n1=Bevacizumab | n2=en:colchicine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cold contaminant-free iobenguane i-131 n1=Bevacizumab | n2=en:cold contaminant-free iobenguane i-131 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:colesevelam hydrochloride n1=Bevacizumab | n2=en:colesevelam hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:colistin sulfate n1=Bevacizumab | n2=en:colistin sulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:collagen n1=Bevacizumab | n2=en:collagen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:collagen/aloe vera/vitamin e/lidocaine topical hydrogel n1=Bevacizumab | n2=en:collagen/aloe vera/vitamin e/lidocaine topical hydrogel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:colloidal gold-bound tumor necrosis factor n1=Bevacizumab | n2=en:colloidal gold-bound tumor necrosis factor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:colloidal oatmeal cream n1=Bevacizumab | n2=en:colloidal oatmeal cream | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:colorectal tumor-associated peptides vaccine ima910 n1=Bevacizumab | n2=en:colorectal tumor-associated peptides vaccine ima910 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:combretastatin a1 diphosphate n1=Bevacizumab | n2=en:combretastatin a1 diphosphate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:complement c5 inhibitor alxn1210 n1=Bevacizumab | n2=en:complement c5 inhibitor alxn1210 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:compound kushen injection n1=Bevacizumab | n2=en:compound kushen injection | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:compound sodium lactate solution n1=Bevacizumab | n2=en:compound sodium lactate solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:conatumumab n1=Bevacizumab | n2=en:conatumumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:concentrated beet crystals n1=Bevacizumab | n2=en:concentrated beet crystals | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:concentrated fortified collagen protein hydrolysate liquid supplement n1=Bevacizumab | n2=en:concentrated fortified collagen protein hydrolysate liquid supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:conditionally replicative adenovirus 5/3-delta24 n1=Bevacizumab | n2=en:conditionally replicative adenovirus 5/3-delta24 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:conjugated estrogens/bazedoxifene n1=Bevacizumab | n2=en:conjugated estrogens/bazedoxifene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:conjugated linoleic acid n1=Bevacizumab | n2=en:conjugated linoleic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:contraindications aspect n1=Bevacizumab | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:contrast agent cs-1000 n1=Bevacizumab | n2=en:contrast agent cs-1000 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:controlled substance n1=Bevacizumab | n2=en:controlled substance | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:copanlisib n1=Bevacizumab | n2=en:copanlisib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:copdac regimen n1=Bevacizumab | n2=en:copdac regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:copovithane n1=Bevacizumab | n2=en:copovithane | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:copp regimen n1=Bevacizumab | n2=en:copp regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:copp-abv regimen n1=Bevacizumab | n2=en:copp-abv regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:copper cu 62 ethylglyoxal bis(thiosemicarbazone) n1=Bevacizumab | n2=en:copper cu 62 ethylglyoxal bis(thiosemicarbazone) | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:copper cu 62-atsm n1=Bevacizumab | n2=en:copper cu 62-atsm | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:copper cu 62-ptsm n1=Bevacizumab | n2=en:copper cu 62-ptsm | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:copper cu 64 anti-cea monoclonal antibody m5a n1=Bevacizumab | n2=en:copper cu 64 anti-cea monoclonal antibody m5a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:copper cu 64 plerixafor n1=Bevacizumab | n2=en:copper cu 64 plerixafor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:copper cu 64 tp3805 n1=Bevacizumab | n2=en:copper cu 64 tp3805 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:copper cu 64 trastuzumab n1=Bevacizumab | n2=en:copper cu 64 trastuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:copper cu 64-atsm n1=Bevacizumab | n2=en:copper cu 64-atsm | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:copper cu 64-dota b-fab n1=Bevacizumab | n2=en:copper cu 64-dota b-fab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:copper cu 64-dota-ae105 n1=Bevacizumab | n2=en:copper cu 64-dota-ae105 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:copper cu 64-dota-anti-her3 monoclonal antibody u3-1287 n1=Bevacizumab | n2=en:copper cu 64-dota-anti-her3 monoclonal antibody u3-1287 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:copper cu 64-dota-rituximab n1=Bevacizumab | n2=en:copper cu 64-dota-rituximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:copper cu 64-dota-trastuzumab n1=Bevacizumab | n2=en:copper cu 64-dota-trastuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:copper gluconate n1=Bevacizumab | n2=en:copper gluconate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:copper supplement n1=Bevacizumab | n2=en:copper supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cord blood-derived expanded natural killer cell infusion pnk-007 n1=Bevacizumab | n2=en:cord blood-derived expanded natural killer cell infusion pnk-007 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cordycepin n1=Bevacizumab | n2=en:cordycepin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:corifollitropin alfa n1=Bevacizumab | n2=en:corifollitropin alfa | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:coriolus versicolor extract n1=Bevacizumab | n2=en:coriolus versicolor extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:corticorelin acetate n1=Bevacizumab | n2=en:corticorelin acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:corticotropin n1=Bevacizumab | n2=en:corticotropin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:corticotropin releasing hormone n1=Bevacizumab | n2=en:corticotropin releasing hormone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:corynebacterium granulosum p40 n1=Bevacizumab | n2=en:corynebacterium granulosum p40 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cositecan n1=Bevacizumab | n2=en:cositecan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cosmeceuticals n1=Bevacizumab | n2=en:cosmeceuticals | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:coumarin n1=Bevacizumab | n2=en:coumarin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:counterfeit drugs n1=Bevacizumab | n2=en:counterfeit drugs | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:coxsackievirus a21 n1=Bevacizumab | n2=en:coxsackievirus a21 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cp 461 n1=Bevacizumab | n2=en:cp 461 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cp-547632 n1=Bevacizumab | n2=en:cp-547632 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cp-609,754 n1=Bevacizumab | n2=en:cp-609,754 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cp-724,714 n1=Bevacizumab | n2=en:cp-724,714 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cpg oligodeoxynucleotide gnkg168 n1=Bevacizumab | n2=en:cpg oligodeoxynucleotide gnkg168 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cpg-28 oligodeoxynucleotide n1=Bevacizumab | n2=en:cpg-28 oligodeoxynucleotide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cr2-fh fusion protein tt30 n1=Bevacizumab | n2=en:cr2-fh fusion protein tt30 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:creatine monohydrate n1=Bevacizumab | n2=en:creatine monohydrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:crenolanib n1=Bevacizumab | n2=en:crenolanib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:crenolanib besylate n1=Bevacizumab | n2=en:crenolanib besylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cridanimod sodium n1=Bevacizumab | n2=en:cridanimod sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:crisnatol mesylate n1=Bevacizumab | n2=en:crisnatol mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:crizotinib n1=Bevacizumab | n2=en:crizotinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:crl 1005 n1=Bevacizumab | n2=en:crl 1005 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:crolibulin n1=Bevacizumab | n2=en:crolibulin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cromolyn sodium inhalant pa101 n1=Bevacizumab | n2=en:cromolyn sodium inhalant pa101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:crotoxin n1=Bevacizumab | n2=en:crotoxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cryoprotective agent n1=Bevacizumab | n2=en:cryoprotective agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:crystalline genistein formulation axp107-11 n1=Bevacizumab | n2=en:crystalline genistein formulation axp107-11 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ct2584 hms n1=Bevacizumab | n2=en:ct2584 hms | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ctp-37-dt vaccine n1=Bevacizumab | n2=en:ctp-37-dt vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ctrp agent terminology n1=Bevacizumab | n2=en:ctrp agent terminology | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ctrp terminology n1=Bevacizumab | n2=en:ctrp terminology | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:curcumin n1=Bevacizumab | n2=en:curcumin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:curcumin-based gel n1=Bevacizumab | n2=en:curcumin-based gel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:curcumin/green tea extract/polygonum cuspidatum extract/soybean extract capsule n1=Bevacizumab | n2=en:curcumin/green tea extract/polygonum cuspidatum extract/soybean extract capsule | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:custirsen sodium n1=Bevacizumab | n2=en:custirsen sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cvp regimen n1=Bevacizumab | n2=en:cvp regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cxc chemokine receptor 2 antagonist azd5069 n1=Bevacizumab | n2=en:cxc chemokine receptor 2 antagonist azd5069 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cxcr4 antagonist bl-8040 n1=Bevacizumab | n2=en:cxcr4 antagonist bl-8040 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cxcr4 inhibitor msx-122 n1=Bevacizumab | n2=en:cxcr4 inhibitor msx-122 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cxcr4 inhibitor pol6326 n1=Bevacizumab | n2=en:cxcr4 inhibitor pol6326 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cxcr4 inhibitor x4p-001 n1=Bevacizumab | n2=en:cxcr4 inhibitor x4p-001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cxcr4 peptide antagonist ly2510924 n1=Bevacizumab | n2=en:cxcr4 peptide antagonist ly2510924 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cyanobacteria n1=Bevacizumab | n2=en:cyanobacteria | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cyanocobalamin n1=Bevacizumab | n2=en:cyanocobalamin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cyanocobalamin/dexamethasone/gentamicin/procaine formulation n1=Bevacizumab | n2=en:cyanocobalamin/dexamethasone/gentamicin/procaine formulation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cycle-phase nonspecific agent n1=Bevacizumab | n2=en:cycle-phase nonspecific agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cycle-phase specific agent n1=Bevacizumab | n2=en:cycle-phase specific agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cyclin b1 peptide-pulsed autologous dendritic cell vaccine n1=Bevacizumab | n2=en:cyclin b1 peptide-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cyclobenzaprine hydrochloride n1=Bevacizumab | n2=en:cyclobenzaprine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cyclodextrin-based polymer-camptothecin crlx101 n1=Bevacizumab | n2=en:cyclodextrin-based polymer-camptothecin crlx101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cycloleucine n1=Bevacizumab | n2=en:cycloleucine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cyclopentenyl cytosine n1=Bevacizumab | n2=en:cyclopentenyl cytosine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cyclophosphamide n1=Bevacizumab | n2=en:cyclophosphamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cyclophosphamide/dactinomycin/vincristine n1=Bevacizumab | n2=en:cyclophosphamide/dactinomycin/vincristine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cyclophosphamide/epirubicin/vincristine/prednisone n1=Bevacizumab | n2=en:cyclophosphamide/epirubicin/vincristine/prednisone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cycloserine n1=Bevacizumab | n2=en:cycloserine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cyclosporine n1=Bevacizumab | n2=en:cyclosporine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cyclosporine ophthalmic emulsion n1=Bevacizumab | n2=en:cyclosporine ophthalmic emulsion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cyl-02 plasmid dna n1=Bevacizumab | n2=en:cyl-02 plasmid dna | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cyp17 inhibitor cfg920 n1=Bevacizumab | n2=en:cyp17 inhibitor cfg920 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cyp17 inhibitor vt-464 n1=Bevacizumab | n2=en:cyp17 inhibitor vt-464 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cyp17 lyase inhibitor asn001 n1=Bevacizumab | n2=en:cyp17 lyase inhibitor asn001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cyp17/androgen receptor inhibitor odm 204 n1=Bevacizumab | n2=en:cyp17/androgen receptor inhibitor odm 204 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cyproheptadine hydrochloride n1=Bevacizumab | n2=en:cyproheptadine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cyproterone n1=Bevacizumab | n2=en:cyproterone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cyproterone acetate n1=Bevacizumab | n2=en:cyproterone acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cysteine-rich non-denatured whey protein isolate imn1207 n1=Bevacizumab | n2=en:cysteine-rich non-denatured whey protein isolate imn1207 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cystemustine n1=Bevacizumab | n2=en:cystemustine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cytarabine n1=Bevacizumab | n2=en:cytarabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cytarabine monophosphate prodrug mb07133 n1=Bevacizumab | n2=en:cytarabine monophosphate prodrug mb07133 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cytembena n1=Bevacizumab | n2=en:cytembena | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cytidine analog rx-3117 n1=Bevacizumab | n2=en:cytidine analog rx-3117 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cytochlor n1=Bevacizumab | n2=en:cytochlor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cytokine agent n1=Bevacizumab | n2=en:cytokine agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cytokine-induced killer cells n1=Bevacizumab | n2=en:cytokine-induced killer cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cytomegalovirus ie-1-specific cytotoxic t lymphocytes n1=Bevacizumab | n2=en:cytomegalovirus ie-1-specific cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cytomegalovirus pp65-specific cytotoxic t lymphocytes n1=Bevacizumab | n2=en:cytomegalovirus pp65-specific cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cytoprotective agent n1=Bevacizumab | n2=en:cytoprotective agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cytostatic agents n1=Bevacizumab | n2=en:cytostatic agents | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:cytotoxic agent n1=Bevacizumab | n2=en:cytotoxic agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:d vitamin n1=Bevacizumab | n2=en:d vitamin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:d-methionine formulation mrx-1024 n1=Bevacizumab | n2=en:d-methionine formulation mrx-1024 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:d1/3-mage-3-his fusion protein n1=Bevacizumab | n2=en:d1/3-mage-3-his fusion protein | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:d4064a n1=Bevacizumab | n2=en:d4064a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dab389 epidermal growth factor n1=Bevacizumab | n2=en:dab389 epidermal growth factor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dabigatran etexilate mesylate n1=Bevacizumab | n2=en:dabigatran etexilate mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dabrafenib n1=Bevacizumab | n2=en:dabrafenib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dacarbazine n1=Bevacizumab | n2=en:dacarbazine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dacetuzumab n1=Bevacizumab | n2=en:dacetuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dach polymer platinate ap5346 n1=Bevacizumab | n2=en:dach polymer platinate ap5346 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dach-platin micelle nc-4016 n1=Bevacizumab | n2=en:dach-platin micelle nc-4016 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:daclatasvir n1=Bevacizumab | n2=en:daclatasvir | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:daclizumab n1=Bevacizumab | n2=en:daclizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dacomitinib n1=Bevacizumab | n2=en:dacomitinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dactinomycin n1=Bevacizumab | n2=en:dactinomycin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:daflon 500 n1=Bevacizumab | n2=en:daflon 500 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dakins solution n1=Bevacizumab | n2=en:dakins solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dalantercept n1=Bevacizumab | n2=en:dalantercept | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dalbavancin n1=Bevacizumab | n2=en:dalbavancin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dalotuzumab n1=Bevacizumab | n2=en:dalotuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dalteparin n1=Bevacizumab | n2=en:dalteparin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:danazol n1=Bevacizumab | n2=en:danazol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:daniquidone n1=Bevacizumab | n2=en:daniquidone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:danusertib n1=Bevacizumab | n2=en:danusertib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:daporinad n1=Bevacizumab | n2=en:daporinad | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dapsone n1=Bevacizumab | n2=en:dapsone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dapsone gel n1=Bevacizumab | n2=en:dapsone gel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:daptomycin n1=Bevacizumab | n2=en:daptomycin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:daratumumab n1=Bevacizumab | n2=en:daratumumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:darbepoetin alfa n1=Bevacizumab | n2=en:darbepoetin alfa | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:darinaparsin n1=Bevacizumab | n2=en:darinaparsin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dasabuvir n1=Bevacizumab | n2=en:dasabuvir | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dasatinib n1=Bevacizumab | n2=en:dasatinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:daunorubicin hydrochloride n1=Bevacizumab | n2=en:daunorubicin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:daunorubicin-dna complex n1=Bevacizumab | n2=en:daunorubicin-dna complex | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dbve-pc regimen n1=Bevacizumab | n2=en:dbve-pc regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dc-cholesterol liposome n1=Bevacizumab | n2=en:dc-cholesterol liposome | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dc-ova vaccine n1=Bevacizumab | n2=en:dc-ova vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dcb-bo1202 n1=Bevacizumab | n2=en:dcb-bo1202 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dcds0780a n1=Bevacizumab | n2=en:dcds0780a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dcr ligand-bearing liposome-encapsulated melanoma antigens vaccine n1=Bevacizumab | n2=en:dcr ligand-bearing liposome-encapsulated melanoma antigens vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dec-205/ny-eso-1 fusion protein cdx-1401 n1=Bevacizumab | n2=en:dec-205/ny-eso-1 fusion protein cdx-1401 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:decitabine n1=Bevacizumab | n2=en:decitabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:declopramide n1=Bevacizumab | n2=en:declopramide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:defactinib n1=Bevacizumab | n2=en:defactinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:deferasirox n1=Bevacizumab | n2=en:deferasirox | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:deferiprone n1=Bevacizumab | n2=en:deferiprone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:deferoxamine mesylate n1=Bevacizumab | n2=en:deferoxamine mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:defibrotide sodium n1=Bevacizumab | n2=en:defibrotide sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:defined green tea catechin extract n1=Bevacizumab | n2=en:defined green tea catechin extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:degarelix n1=Bevacizumab | n2=en:degarelix | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:deglycosylated ricin a chain-conjugated anti-cd19/anti-cd22 immunotoxins n1=Bevacizumab | n2=en:deglycosylated ricin a chain-conjugated anti-cd19/anti-cd22 immunotoxins | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dehydrated human amnion/chorion membrane n1=Bevacizumab | n2=en:dehydrated human amnion/chorion membrane | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dehydroemetine n1=Bevacizumab | n2=en:dehydroemetine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:delanzomib n1=Bevacizumab | n2=en:delanzomib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:delta-8-tetrahydrocannabinol n1=Bevacizumab | n2=en:delta-8-tetrahydrocannabinol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:delta-tocopherol n1=Bevacizumab | n2=en:delta-tocopherol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:delta-tocotrienol n1=Bevacizumab | n2=en:delta-tocotrienol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:demcizumab n1=Bevacizumab | n2=en:demcizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:demeclocycline hydrochloride n1=Bevacizumab | n2=en:demeclocycline hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:demineralized bone matrix n1=Bevacizumab | n2=en:demineralized bone matrix | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dendritic cell-autologous lung tumor vaccine n1=Bevacizumab | n2=en:dendritic cell-autologous lung tumor vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dendritic cell-cea peptide vaccine n1=Bevacizumab | n2=en:dendritic cell-cea peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dendritic cell-gp100-mart-1 antigen vaccine n1=Bevacizumab | n2=en:dendritic cell-gp100-mart-1 antigen vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dendritic cell-idiotype-keyhole limpet hemocyanin vaccine n1=Bevacizumab | n2=en:dendritic cell-idiotype-keyhole limpet hemocyanin vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dendritic cell-mart-1 peptide vaccine n1=Bevacizumab | n2=en:dendritic cell-mart-1 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dendritic cell-precision multiple antigen t-lymphocytes n1=Bevacizumab | n2=en:dendritic cell-precision multiple antigen t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dendritic cell-recombinant prostate-specific membrane antigen vaccine n1=Bevacizumab | n2=en:dendritic cell-recombinant prostate-specific membrane antigen vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dendritic cell-targeting lentiviral vector id-lv305 n1=Bevacizumab | n2=en:dendritic cell-targeting lentiviral vector id-lv305 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:denenicokin n1=Bevacizumab | n2=en:denenicokin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:denibulin hydrochloride n1=Bevacizumab | n2=en:denibulin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:denileukin diftitox n1=Bevacizumab | n2=en:denileukin diftitox | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:denintuzumab mafodotin n1=Bevacizumab | n2=en:denintuzumab mafodotin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:denosumab n1=Bevacizumab | n2=en:denosumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dental agent n1=Bevacizumab | n2=en:dental agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dental disclosing preparation n1=Bevacizumab | n2=en:dental disclosing preparation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:deoxycytidine n1=Bevacizumab | n2=en:deoxycytidine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:deoxycytidine analogue tas-109 n1=Bevacizumab | n2=en:deoxycytidine analogue tas-109 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:depatuxizumab n1=Bevacizumab | n2=en:depatuxizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:depdc1/mphosh1 peptide vaccine n1=Bevacizumab | n2=en:depdc1/mphosh1 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:derma-membrane-structure topical cream n1=Bevacizumab | n2=en:derma-membrane-structure topical cream | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dermatologic agents n1=Bevacizumab | n2=en:dermatologic agents | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:desflurane n1=Bevacizumab | n2=en:desflurane | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:designer drugs n1=Bevacizumab | n2=en:designer drugs | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:desipramine hydrochloride n1=Bevacizumab | n2=en:desipramine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:deslorelin n1=Bevacizumab | n2=en:deslorelin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:desmethylmisonidazole n1=Bevacizumab | n2=en:desmethylmisonidazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:desmopressin acetate n1=Bevacizumab | n2=en:desmopressin acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:desogestrel n1=Bevacizumab | n2=en:desogestrel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:desvenlafaxine succinate n1=Bevacizumab | n2=en:desvenlafaxine succinate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:detorubicin n1=Bevacizumab | n2=en:detorubicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:detox-b adjuvant n1=Bevacizumab | n2=en:detox-b adjuvant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:detoxpc n1=Bevacizumab | n2=en:detoxpc | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:deuterated 3-methylhistidine n1=Bevacizumab | n2=en:deuterated 3-methylhistidine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:deuterated phenanthrene n1=Bevacizumab | n2=en:deuterated phenanthrene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:deuterium oxide n1=Bevacizumab | n2=en:deuterium oxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dexamethasone n1=Bevacizumab | n2=en:dexamethasone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dexamethasone intravitreal implant n1=Bevacizumab | n2=en:dexamethasone intravitreal implant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dexanabinol n1=Bevacizumab | n2=en:dexanabinol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dexmedetomidine hydrochloride n1=Bevacizumab | n2=en:dexmedetomidine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dexmethylphenidate n1=Bevacizumab | n2=en:dexmethylphenidate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dexniguldipine n1=Bevacizumab | n2=en:dexniguldipine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dexpanthenol n1=Bevacizumab | n2=en:dexpanthenol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dexpanthenol mouthwash n1=Bevacizumab | n2=en:dexpanthenol mouthwash | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dexrazoxane hydrochloride n1=Bevacizumab | n2=en:dexrazoxane hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dextran n1=Bevacizumab | n2=en:dextran | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dextran sulfate sodium n1=Bevacizumab | n2=en:dextran sulfate sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dextroamphetamine sulfate n1=Bevacizumab | n2=en:dextroamphetamine sulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dextroamphetamine-amphetamine n1=Bevacizumab | n2=en:dextroamphetamine-amphetamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dextromethorphan acetic acid n1=Bevacizumab | n2=en:dextromethorphan acetic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dextromethorphan hydrobromide n1=Bevacizumab | n2=en:dextromethorphan hydrobromide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dextropropoxyphene hydrochloride n1=Bevacizumab | n2=en:dextropropoxyphene hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dexverapamil n1=Bevacizumab | n2=en:dexverapamil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dezaguanine n1=Bevacizumab | n2=en:dezaguanine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dha-paclitaxel n1=Bevacizumab | n2=en:dha-paclitaxel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dhap regimen n1=Bevacizumab | n2=en:dhap regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dhea mustard n1=Bevacizumab | n2=en:dhea mustard | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dher2 vaccine+as15 adjuvant n1=Bevacizumab | n2=en:dher2 vaccine+as15 adjuvant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:di-dga-rfb4 immunotoxin n1=Bevacizumab | n2=en:di-dga-rfb4 immunotoxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:di-leu16-il2 immunocytokine n1=Bevacizumab | n2=en:di-leu16-il2 immunocytokine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diacetylmorphine hydrochloride n1=Bevacizumab | n2=en:diacetylmorphine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diagnostic agents n1=Bevacizumab | n2=en:diagnostic agents | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diammonium glycyrrhizinate n1=Bevacizumab | n2=en:diammonium glycyrrhizinate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dianhydrogalactitol n1=Bevacizumab | n2=en:dianhydrogalactitol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dianicline n1=Bevacizumab | n2=en:dianicline | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diarylsulfonylurea compound n1=Bevacizumab | n2=en:diarylsulfonylurea compound | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diazepinomicin n1=Bevacizumab | n2=en:diazepinomicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diaziquone n1=Bevacizumab | n2=en:diaziquone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diazooxonorleucine n1=Bevacizumab | n2=en:diazooxonorleucine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diazoxide n1=Bevacizumab | n2=en:diazoxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dichloromethotrexate n1=Bevacizumab | n2=en:dichloromethotrexate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diclofenac epolamine patch n1=Bevacizumab | n2=en:diclofenac epolamine patch | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diclofenac sodium gel n1=Bevacizumab | n2=en:diclofenac sodium gel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dicumarol n1=Bevacizumab | n2=en:dicumarol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:didanosine n1=Bevacizumab | n2=en:didanosine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:didemnin b n1=Bevacizumab | n2=en:didemnin b | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dideoxyadenosine n1=Bevacizumab | n2=en:dideoxyadenosine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:didox n1=Bevacizumab | n2=en:didox | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dienogest n1=Bevacizumab | n2=en:dienogest | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dietary product n1=Bevacizumab | n2=en:dietary product | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diethylhomospermine n1=Bevacizumab | n2=en:diethylhomospermine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diethylnorspermine n1=Bevacizumab | n2=en:diethylnorspermine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diethylstilbestrol n1=Bevacizumab | n2=en:diethylstilbestrol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diflomotecan n1=Bevacizumab | n2=en:diflomotecan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diflunisal n1=Bevacizumab | n2=en:diflunisal | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:digitoxin n1=Bevacizumab | n2=en:digitoxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:digoxin n1=Bevacizumab | n2=en:digoxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dihydro-5-azacytidine n1=Bevacizumab | n2=en:dihydro-5-azacytidine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dihydrolenperone n1=Bevacizumab | n2=en:dihydrolenperone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diindolylmethane n1=Bevacizumab | n2=en:diindolylmethane | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diltiazem hydrochloride n1=Bevacizumab | n2=en:diltiazem hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dimesna n1=Bevacizumab | n2=en:dimesna | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dimethicone-containing botanicals-based lotion n1=Bevacizumab | n2=en:dimethicone-containing botanicals-based lotion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dimethicone/polymer barrier cream n1=Bevacizumab | n2=en:dimethicone/polymer barrier cream | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dimethyl fumarate n1=Bevacizumab | n2=en:dimethyl fumarate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dimethyl sulfone n1=Bevacizumab | n2=en:dimethyl sulfone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dimethyl sulfoxide n1=Bevacizumab | n2=en:dimethyl sulfoxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dimethylmyleran n1=Bevacizumab | n2=en:dimethylmyleran | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dinaciclib n1=Bevacizumab | n2=en:dinaciclib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dinitrochlorobenzene n1=Bevacizumab | n2=en:dinitrochlorobenzene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dinitrofluorobenzene n1=Bevacizumab | n2=en:dinitrofluorobenzene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dinitrophenyl n1=Bevacizumab | n2=en:dinitrophenyl | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dinitrophenyl-modified autologous renal cell carcinoma tumor cell vaccine n1=Bevacizumab | n2=en:dinitrophenyl-modified autologous renal cell carcinoma tumor cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dinoprost tromethamine n1=Bevacizumab | n2=en:dinoprost tromethamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dinutuximab n1=Bevacizumab | n2=en:dinutuximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dioscorea nipponica makino extract dne3 n1=Bevacizumab | n2=en:dioscorea nipponica makino extract dne3 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diphencyprone n1=Bevacizumab | n2=en:diphencyprone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diphenhydramine hydrochloride n1=Bevacizumab | n2=en:diphenhydramine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diphenhydramine hydrochloride/dexamethasone/nystatin magic mouthwash n1=Bevacizumab | n2=en:diphenhydramine hydrochloride/dexamethasone/nystatin magic mouthwash | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diphenhydramine/lidocaine/antacid mouthwash n1=Bevacizumab | n2=en:diphenhydramine/lidocaine/antacid mouthwash | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diphtheria toxin fragment-interleukin-2 fusion protein e7777 n1=Bevacizumab | n2=en:diphtheria toxin fragment-interleukin-2 fusion protein e7777 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diphtheria toxoid/tetanus toxoid vaccine adsorbed n1=Bevacizumab | n2=en:diphtheria toxoid/tetanus toxoid vaccine adsorbed | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diphtheria toxoid/tetanus toxoid/acellular pertussis adsorbed, recombinant hepatitis b/inactivated poliovirus vaccine combined n1=Bevacizumab | n2=en:diphtheria toxoid/tetanus toxoid/acellular pertussis adsorbed, recombinant hepatitis b/inactivated poliovirus vaccine combined | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diphtheria toxoid/tetanus toxoid/acellular pertussis vaccine adsorbed n1=Bevacizumab | n2=en:diphtheria toxoid/tetanus toxoid/acellular pertussis vaccine adsorbed | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis-haemophilus influenzae type b vaccine n1=Bevacizumab | n2=en:diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis-haemophilus influenzae type b vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dipyridamole n1=Bevacizumab | n2=en:dipyridamole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:directly observed therapy n1=Bevacizumab | n2=en:directly observed therapy | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:disaccharide tripeptide glycerol dipalmitoyl n1=Bevacizumab | n2=en:disaccharide tripeptide glycerol dipalmitoyl | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:distilled water n1=Bevacizumab | n2=en:distilled water | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:disulfiram n1=Bevacizumab | n2=en:disulfiram | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ditiocarb n1=Bevacizumab | n2=en:ditiocarb | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:diuretic n1=Bevacizumab | n2=en:diuretic | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:divalproex sodium n1=Bevacizumab | n2=en:divalproex sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dkk1-neutralizing monoclonal antibody dkn-01 n1=Bevacizumab | n2=en:dkk1-neutralizing monoclonal antibody dkn-01 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dl-selenomethionine n1=Bevacizumab | n2=en:dl-selenomethionine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dlk1/epha2/hbb/nrp1/rgs5/tem1 peptide-pulsed alpha-type-1 polarized dendritic cell vaccine n1=Bevacizumab | n2=en:dlk1/epha2/hbb/nrp1/rgs5/tem1 peptide-pulsed alpha-type-1 polarized dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dm-choc-pen n1=Bevacizumab | n2=en:dm-choc-pen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dm4-conjugated anti-cripto monoclonal antibody biib015 n1=Bevacizumab | n2=en:dm4-conjugated anti-cripto monoclonal antibody biib015 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dmuc4064a n1=Bevacizumab | n2=en:dmuc4064a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dn-101 n1=Bevacizumab | n2=en:dn-101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dna binding agent n1=Bevacizumab | n2=en:dna binding agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dna interference oligonucleotide pnt2258 n1=Bevacizumab | n2=en:dna interference oligonucleotide pnt2258 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dna minor groove binding agent pm060184 n1=Bevacizumab | n2=en:dna minor groove binding agent pm060184 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dna minor groove binding agent sg2000 n1=Bevacizumab | n2=en:dna minor groove binding agent sg2000 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dna plasmid encoding interleukin-12 ino-9012 n1=Bevacizumab | n2=en:dna plasmid encoding interleukin-12 ino-9012 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dna plasmid-encoding interleukin-12/hpv dna plasmids therapeutic vaccine ino-3112 n1=Bevacizumab | n2=en:dna plasmid-encoding interleukin-12/hpv dna plasmids therapeutic vaccine ino-3112 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dna vaccine vb10.16 n1=Bevacizumab | n2=en:dna vaccine vb10.16 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dna vector ppra-psm vaccine n1=Bevacizumab | n2=en:dna vector ppra-psm vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dna-dependent protein kinase-targeting sidna dt01 n1=Bevacizumab | n2=en:dna-dependent protein kinase-targeting sidna dt01 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dna-pk inhibitor msc2490484a n1=Bevacizumab | n2=en:dna-pk inhibitor msc2490484a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dna-pk/tor kinase inhibitor cc-115 n1=Bevacizumab | n2=en:dna-pk/tor kinase inhibitor cc-115 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dna-rna transcription regulator n1=Bevacizumab | n2=en:dna-rna transcription regulator | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dnr-expressing nasopharyngeal carcinoma-specific cytotoxic t-lymphocytes n1=Bevacizumab | n2=en:dnr-expressing nasopharyngeal carcinoma-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dobutamine n1=Bevacizumab | n2=en:dobutamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:docetaxel n1=Bevacizumab | n2=en:docetaxel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:docetaxel emulsion anx-514 n1=Bevacizumab | n2=en:docetaxel emulsion anx-514 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:docetaxel formulation ckd-810 n1=Bevacizumab | n2=en:docetaxel formulation ckd-810 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:docetaxel lipid microspheres n1=Bevacizumab | n2=en:docetaxel lipid microspheres | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:docetaxel-loaded nanopharmaceutical crlx301 n1=Bevacizumab | n2=en:docetaxel-loaded nanopharmaceutical crlx301 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:docetaxel-pnp n1=Bevacizumab | n2=en:docetaxel-pnp | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:doconexent n1=Bevacizumab | n2=en:doconexent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:docosahexaenoic acid n1=Bevacizumab | n2=en:docosahexaenoic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:docusate n1=Bevacizumab | n2=en:docusate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dofequidar fumarate n1=Bevacizumab | n2=en:dofequidar fumarate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dolasetron mesylate n1=Bevacizumab | n2=en:dolasetron mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dolastatin 10 n1=Bevacizumab | n2=en:dolastatin 10 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dolutegravir n1=Bevacizumab | n2=en:dolutegravir | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:domperidone n1=Bevacizumab | n2=en:domperidone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:donafenib n1=Bevacizumab | n2=en:donafenib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:donepezil + memantine n1=Bevacizumab | n2=en:donepezil + memantine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:donepezil hydrochloride n1=Bevacizumab | n2=en:donepezil hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:donor lymphocytes n1=Bevacizumab | n2=en:donor lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:donor regulatory t-lymphocytes n1=Bevacizumab | n2=en:donor regulatory t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:donor-derived wt1/prame/ny-eso-1/survivin-specific t-lymphocytes n1=Bevacizumab | n2=en:donor-derived wt1/prame/ny-eso-1/survivin-specific t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dopamine-somatostatin chimeric molecule bim-23a760 n1=Bevacizumab | n2=en:dopamine-somatostatin chimeric molecule bim-23a760 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dornase alfa n1=Bevacizumab | n2=en:dornase alfa | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dornase alfa inhalation solution n1=Bevacizumab | n2=en:dornase alfa inhalation solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dot1l inhibitor epz-5676 n1=Bevacizumab | n2=en:dot1l inhibitor epz-5676 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dotap:cholesterol-fus1 liposome complex n1=Bevacizumab | n2=en:dotap:cholesterol-fus1 liposome complex | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dovitinib lactate n1=Bevacizumab | n2=en:dovitinib lactate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:doxazosin mesylate n1=Bevacizumab | n2=en:doxazosin mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:doxepin hydrochloride n1=Bevacizumab | n2=en:doxepin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:doxercalciferol n1=Bevacizumab | n2=en:doxercalciferol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:doxifluridine n1=Bevacizumab | n2=en:doxifluridine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:doxorubicin hcl inhalation solution n1=Bevacizumab | n2=en:doxorubicin hcl inhalation solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:doxorubicin hydrochloride n1=Bevacizumab | n2=en:doxorubicin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:doxorubicin-dna complex n1=Bevacizumab | n2=en:doxorubicin-dna complex | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:doxorubicin-eluting beads n1=Bevacizumab | n2=en:doxorubicin-eluting beads | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:doxorubicin-hpma conjugate n1=Bevacizumab | n2=en:doxorubicin-hpma conjugate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:doxorubicin-magnetic targeted carrier complex n1=Bevacizumab | n2=en:doxorubicin-magnetic targeted carrier complex | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:doxycycline n1=Bevacizumab | n2=en:doxycycline | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:doxycycline hyclate n1=Bevacizumab | n2=en:doxycycline hyclate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:doxycycline hyclate foam n1=Bevacizumab | n2=en:doxycycline hyclate foam | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:doxycycline hyclate injection n1=Bevacizumab | n2=en:doxycycline hyclate injection | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dpt/bcg/measles/serratia/pneumococcus vaccine n1=Bevacizumab | n2=en:dpt/bcg/measles/serratia/pneumococcus vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dpt/typhoid/staphylococcus aureus/paratyphoid a/paratyphoid b vaccine n1=Bevacizumab | n2=en:dpt/typhoid/staphylococcus aureus/paratyphoid a/paratyphoid b vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dr5-targeting tetrameric nanobody agonist tas266 n1=Bevacizumab | n2=en:dr5-targeting tetrameric nanobody agonist tas266 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dromostanolone propionate n1=Bevacizumab | n2=en:dromostanolone propionate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dronabinol n1=Bevacizumab | n2=en:dronabinol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:droperidol n1=Bevacizumab | n2=en:droperidol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:drotrecogin alfa (activated) n1=Bevacizumab | n2=en:drotrecogin alfa (activated) | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:drug combinations n1=Bevacizumab | n2=en:drug combinations | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:drug effect n1=Bevacizumab | n2=en:drug effect | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:drug groups primarily affecting the musculoskeletal system n1=Bevacizumab | n2=en:drug groups primarily affecting the musculoskeletal system | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:drug products by fda established pharmacologic class n1=Bevacizumab | n2=en:drug products by fda established pharmacologic class | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:drug products by generic ingredient combinations n1=Bevacizumab | n2=en:drug products by generic ingredient combinations | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:drug products by va class n1=Bevacizumab | n2=en:drug products by va class | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:drug values n1=Bevacizumab | n2=en:drug values | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:drug-device combination product n1=Bevacizumab | n2=en:drug-device combination product | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:drugs treating radiation contamination n1=Bevacizumab | n2=en:drugs treating radiation contamination | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:drugs used in metabolic disorders n1=Bevacizumab | n2=en:drugs used in metabolic disorders | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:drugs used to treat addiction n1=Bevacizumab | n2=en:drugs used to treat addiction | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:drugs, chinese herbal n1=Bevacizumab | n2=en:drugs, chinese herbal | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:drugs, essential n1=Bevacizumab | n2=en:drugs, essential | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dt(388)il3 fusion protein sl-401 n1=Bevacizumab | n2=en:dt(388)il3 fusion protein sl-401 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dta-h19 plasmid n1=Bevacizumab | n2=en:dta-h19 plasmid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dtgm fusion protein n1=Bevacizumab | n2=en:dtgm fusion protein | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dual igf-1r/insr inhibitor bms-754807 n1=Bevacizumab | n2=en:dual igf-1r/insr inhibitor bms-754807 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dual pi3 kinase/mtor inhibitor gdc-0980 n1=Bevacizumab | n2=en:dual pi3 kinase/mtor inhibitor gdc-0980 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dual variable domain immunoglobulin abt-165 n1=Bevacizumab | n2=en:dual variable domain immunoglobulin abt-165 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:duborimycin n1=Bevacizumab | n2=en:duborimycin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dulanermin n1=Bevacizumab | n2=en:dulanermin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:duligotuzumab n1=Bevacizumab | n2=en:duligotuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:duloxetine hydrochloride n1=Bevacizumab | n2=en:duloxetine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:durvalumab n1=Bevacizumab | n2=en:durvalumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dutasteride n1=Bevacizumab | n2=en:dutasteride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dutpase/dpd inhibitor tas-114 n1=Bevacizumab | n2=en:dutpase/dpd inhibitor tas-114 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:dwj1319 n1=Bevacizumab | n2=en:dwj1319 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:e-101 solution n1=Bevacizumab | n2=en:e-101 solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:e-selectin antagonist gmi-1271 n1=Bevacizumab | n2=en:e-selectin antagonist gmi-1271 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:e. coli cd-expressing genetically modified neural stem cells n1=Bevacizumab | n2=en:e. coli cd-expressing genetically modified neural stem cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:e1a lipid complex n1=Bevacizumab | n2=en:e1a lipid complex | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:e1m184v peptide vaccine n1=Bevacizumab | n2=en:e1m184v peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:e2f1 pathway activator arq 171 n1=Bevacizumab | n2=en:e2f1 pathway activator arq 171 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:e7046 n1=Bevacizumab | n2=en:e7046 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:e7820 n1=Bevacizumab | n2=en:e7820 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:east indian sandalwood oil mouth rinse n1=Bevacizumab | n2=en:east indian sandalwood oil mouth rinse | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ebselen-containing oral capsule spi-1005 n1=Bevacizumab | n2=en:ebselen-containing oral capsule spi-1005 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ebv-specific cytotoxic t-lymphocyte n1=Bevacizumab | n2=en:ebv-specific cytotoxic t-lymphocyte | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:echinomycin n1=Bevacizumab | n2=en:echinomycin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ecromeximab n1=Bevacizumab | n2=en:ecromeximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:eculizumab n1=Bevacizumab | n2=en:eculizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:edatrexate n1=Bevacizumab | n2=en:edatrexate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:edelfosine n1=Bevacizumab | n2=en:edelfosine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:edetate calcium disodium n1=Bevacizumab | n2=en:edetate calcium disodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:edotecarin n1=Bevacizumab | n2=en:edotecarin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:edoxaban tosylate n1=Bevacizumab | n2=en:edoxaban tosylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:edrecolomab n1=Bevacizumab | n2=en:edrecolomab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ef5 n1=Bevacizumab | n2=en:ef5 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:efalizumab n1=Bevacizumab | n2=en:efalizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:efaproxiral n1=Bevacizumab | n2=en:efaproxiral | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:efatutazone dihydrochloride n1=Bevacizumab | n2=en:efatutazone dihydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:efavirenz n1=Bevacizumab | n2=en:efavirenz | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:eflornithine n1=Bevacizumab | n2=en:eflornithine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:eflornithine hydrochloride ointment n1=Bevacizumab | n2=en:eflornithine hydrochloride ointment | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:efs-ada lentiviral vector-transduced cd34-positive autologous lymphocytes n1=Bevacizumab | n2=en:efs-ada lentiviral vector-transduced cd34-positive autologous lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:efungumab n1=Bevacizumab | n2=en:efungumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:eg5 kinesin-related motor protein inhibitor 4sc-205 n1=Bevacizumab | n2=en:eg5 kinesin-related motor protein inhibitor 4sc-205 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:eg5 kinesin-related motor protein inhibitor arq 621 n1=Bevacizumab | n2=en:eg5 kinesin-related motor protein inhibitor arq 621 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:egb761 n1=Bevacizumab | n2=en:egb761 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:egfr antagonist hemay022 n1=Bevacizumab | n2=en:egfr antagonist hemay022 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:egfr antisense dna n1=Bevacizumab | n2=en:egfr antisense dna | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:egfr car-cd3zeta-4-1bb-expressing autologous t-lymphocytes n1=Bevacizumab | n2=en:egfr car-cd3zeta-4-1bb-expressing autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:egfr inhibitor abt-414 n1=Bevacizumab | n2=en:egfr inhibitor abt-414 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:egfr inhibitor asp8273 n1=Bevacizumab | n2=en:egfr inhibitor asp8273 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:egfr inhibitor azd3759 n1=Bevacizumab | n2=en:egfr inhibitor azd3759 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:egfr inhibitor co-1686 n1=Bevacizumab | n2=en:egfr inhibitor co-1686 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:egfr inhibitor egf816 n1=Bevacizumab | n2=en:egfr inhibitor egf816 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:egfr inhibitor hm61713 n1=Bevacizumab | n2=en:egfr inhibitor hm61713 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:egfr mutation-selective inhibitor ac0010ma n1=Bevacizumab | n2=en:egfr mutation-selective inhibitor ac0010ma | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:egfr t790m inhibitor pf-06747775 n1=Bevacizumab | n2=en:egfr t790m inhibitor pf-06747775 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:egfr/her2 inhibitor ap32788 n1=Bevacizumab | n2=en:egfr/her2 inhibitor ap32788 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:egfr/her2 inhibitor av-412 n1=Bevacizumab | n2=en:egfr/her2 inhibitor av-412 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:egfr/her2 kinase inhibitor tak-285 n1=Bevacizumab | n2=en:egfr/her2 kinase inhibitor tak-285 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:egfrbi-armed autologous t cells n1=Bevacizumab | n2=en:egfrbi-armed autologous t cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:egfrviii-specific car-transduced autologous t lymphocytes n1=Bevacizumab | n2=en:egfrviii-specific car-transduced autologous t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:eicosapentaenoic acid n1=Bevacizumab | n2=en:eicosapentaenoic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:eicosapentaenoic acid-enriched nutritional supplement n1=Bevacizumab | n2=en:eicosapentaenoic acid-enriched nutritional supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:eif4e antisense oligonucleotide isis 183750 n1=Bevacizumab | n2=en:eif4e antisense oligonucleotide isis 183750 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:elacytarabine n1=Bevacizumab | n2=en:elacytarabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:electrokinetically modified water n1=Bevacizumab | n2=en:electrokinetically modified water | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:electrolyte-free parenteral nutrition emulsion n1=Bevacizumab | n2=en:electrolyte-free parenteral nutrition emulsion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:elesclomol n1=Bevacizumab | n2=en:elesclomol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:elesclomol sodium n1=Bevacizumab | n2=en:elesclomol sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:elinafide n1=Bevacizumab | n2=en:elinafide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:elisidepsin n1=Bevacizumab | n2=en:elisidepsin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ellagic acid/annona muricata supplement n1=Bevacizumab | n2=en:ellagic acid/annona muricata supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:elliptinium acetate n1=Bevacizumab | n2=en:elliptinium acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:elosulfase alfa n1=Bevacizumab | n2=en:elosulfase alfa | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:elotuzumab n1=Bevacizumab | n2=en:elotuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:elsamitrucin n1=Bevacizumab | n2=en:elsamitrucin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:elsiglutide n1=Bevacizumab | n2=en:elsiglutide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:eltrombopag olamine n1=Bevacizumab | n2=en:eltrombopag olamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:emactuzumab n1=Bevacizumab | n2=en:emactuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:embolic agent n1=Bevacizumab | n2=en:embolic agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:emepepimut-s n1=Bevacizumab | n2=en:emepepimut-s | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:emitefur n1=Bevacizumab | n2=en:emitefur | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:emollients n1=Bevacizumab | n2=en:emollients | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:emricasan n1=Bevacizumab | n2=en:emricasan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:emtricitabine n1=Bevacizumab | n2=en:emtricitabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:enadenotucirev n1=Bevacizumab | n2=en:enadenotucirev | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:enalapril maleate n1=Bevacizumab | n2=en:enalapril maleate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:enavatuzumab n1=Bevacizumab | n2=en:enavatuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:enclomiphene citrate n1=Bevacizumab | n2=en:enclomiphene citrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:endothelial cell n1=Bevacizumab | n2=en:endothelial cell | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:endothelial cell inhibitor n1=Bevacizumab | n2=en:endothelial cell inhibitor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:endothelial-specific integrin inhibitor n1=Bevacizumab | n2=en:endothelial-specific integrin inhibitor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:endothelial-specific integrin/survival signaling inhibitor n1=Bevacizumab | n2=en:endothelial-specific integrin/survival signaling inhibitor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:endothelin b receptor agonist spi-1620 n1=Bevacizumab | n2=en:endothelin b receptor agonist spi-1620 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:eniluracil n1=Bevacizumab | n2=en:eniluracil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:enobosarm n1=Bevacizumab | n2=en:enobosarm | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:enoxaparin n1=Bevacizumab | n2=en:enoxaparin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ensituximab n1=Bevacizumab | n2=en:ensituximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:entecavir n1=Bevacizumab | n2=en:entecavir | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:enteric transport medium n1=Bevacizumab | n2=en:enteric transport medium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:enteric-coated trpm8 agonist d-3263 hydrochloride n1=Bevacizumab | n2=en:enteric-coated trpm8 agonist d-3263 hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:enteric-coated zoledronic acid tablet mer-101 n1=Bevacizumab | n2=en:enteric-coated zoledronic acid tablet mer-101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:entinostat n1=Bevacizumab | n2=en:entinostat | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:entolimod n1=Bevacizumab | n2=en:entolimod | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:entospletinib n1=Bevacizumab | n2=en:entospletinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:entrectinib n1=Bevacizumab | n2=en:entrectinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:enzalutamide n1=Bevacizumab | n2=en:enzalutamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:enzastaurin hydrochloride n1=Bevacizumab | n2=en:enzastaurin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:enzymatically-hydrolyzed whey protein-based nutritional supplement n1=Bevacizumab | n2=en:enzymatically-hydrolyzed whey protein-based nutritional supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:enzyme agent n1=Bevacizumab | n2=en:enzyme agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:enzyme inhibitor n1=Bevacizumab | n2=en:enzyme inhibitor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ep4 receptor antagonist aat-007 n1=Bevacizumab | n2=en:ep4 receptor antagonist aat-007 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:epacadostat n1=Bevacizumab | n2=en:epacadostat | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:epcam-specific car-expressing autologous t-lymphocytes n1=Bevacizumab | n2=en:epcam-specific car-expressing autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:epha2-targeting dopc-encapsulated sirna n1=Bevacizumab | n2=en:epha2-targeting dopc-encapsulated sirna | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:epidermal growth factor ointment n1=Bevacizumab | n2=en:epidermal growth factor ointment | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:epidermal growth factor receptor tyrosine kinase inhibitor n1=Bevacizumab | n2=en:epidermal growth factor receptor tyrosine kinase inhibitor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:epigallocatechin gallate n1=Bevacizumab | n2=en:epigallocatechin gallate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:epipropidine n1=Bevacizumab | n2=en:epipropidine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:epirubicin hydrochloride n1=Bevacizumab | n2=en:epirubicin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:epithelial cell adhesion molecule n1=Bevacizumab | n2=en:epithelial cell adhesion molecule | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:eplerenone n1=Bevacizumab | n2=en:eplerenone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:epoch regimen n1=Bevacizumab | n2=en:epoch regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:epoetin alfa n1=Bevacizumab | n2=en:epoetin alfa | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:epoetin beta n1=Bevacizumab | n2=en:epoetin beta | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:epoetin zeta n1=Bevacizumab | n2=en:epoetin zeta | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:epothilone analog utd1 n1=Bevacizumab | n2=en:epothilone analog utd1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:epothilone compound n1=Bevacizumab | n2=en:epothilone compound | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:epothilone d n1=Bevacizumab | n2=en:epothilone d | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:epothilone kos-1584 n1=Bevacizumab | n2=en:epothilone kos-1584 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:epratuzumab n1=Bevacizumab | n2=en:epratuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:eprodisate disodium n1=Bevacizumab | n2=en:eprodisate disodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:era36 modulator icaritin n1=Bevacizumab | n2=en:era36 modulator icaritin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:erastin analogue prlx 93936 n1=Bevacizumab | n2=en:erastin analogue prlx 93936 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:erb-38 immunotoxin n1=Bevacizumab | n2=en:erb-38 immunotoxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:erbb-2 inhibitor arry-380 n1=Bevacizumab | n2=en:erbb-2 inhibitor arry-380 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ergocalciferol n1=Bevacizumab | n2=en:ergocalciferol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ergoline n1=Bevacizumab | n2=en:ergoline | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ergoline derivative n1=Bevacizumab | n2=en:ergoline derivative | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:eribulin mesylate n1=Bevacizumab | n2=en:eribulin mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:eritoran tetrasodium n1=Bevacizumab | n2=en:eritoran tetrasodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:erk inhibitor cc-90003 n1=Bevacizumab | n2=en:erk inhibitor cc-90003 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:erk inhibitor gdc-0994 n1=Bevacizumab | n2=en:erk inhibitor gdc-0994 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:erk inhibitor ltt462 n1=Bevacizumab | n2=en:erk inhibitor ltt462 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:erk inhibitor mk-8353 n1=Bevacizumab | n2=en:erk inhibitor mk-8353 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:erlotinib hydrochloride n1=Bevacizumab | n2=en:erlotinib hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ertapenem sodium n1=Bevacizumab | n2=en:ertapenem sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ertumaxomab n1=Bevacizumab | n2=en:ertumaxomab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:erythrocyte-encapsulated l-asparaginase suspension n1=Bevacizumab | n2=en:erythrocyte-encapsulated l-asparaginase suspension | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:erythromycin n1=Bevacizumab | n2=en:erythromycin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:erythromycin topical cream n1=Bevacizumab | n2=en:erythromycin topical cream | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:escherichia coli monoclonal antibody n1=Bevacizumab | n2=en:escherichia coli monoclonal antibody | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:escitalopram oxalate n1=Bevacizumab | n2=en:escitalopram oxalate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:eslicarbazepine n1=Bevacizumab | n2=en:eslicarbazepine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:esmolol n1=Bevacizumab | n2=en:esmolol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:esomeprazole magnesium n1=Bevacizumab | n2=en:esomeprazole magnesium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:esorubicin n1=Bevacizumab | n2=en:esorubicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:essiac n1=Bevacizumab | n2=en:essiac | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:estradiol vaginal ring n1=Bevacizumab | n2=en:estradiol vaginal ring | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:estradiol valerate n1=Bevacizumab | n2=en:estradiol valerate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:estradiol/norethindrone acetate tablet n1=Bevacizumab | n2=en:estradiol/norethindrone acetate tablet | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:estramustine phosphate sodium n1=Bevacizumab | n2=en:estramustine phosphate sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:estriol vaginal gel n1=Bevacizumab | n2=en:estriol vaginal gel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:estrogen receptor agonist gtx-758 n1=Bevacizumab | n2=en:estrogen receptor agonist gtx-758 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:estrogens, conjugated n1=Bevacizumab | n2=en:estrogens, conjugated | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:estrogens, esterified (usp) n1=Bevacizumab | n2=en:estrogens, esterified (usp) | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:eszopiclone n1=Bevacizumab | n2=en:eszopiclone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:etalocib n1=Bevacizumab | n2=en:etalocib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:etanercept n1=Bevacizumab | n2=en:etanercept | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:etanidazole n1=Bevacizumab | n2=en:etanidazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:etaracizumab n1=Bevacizumab | n2=en:etaracizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ethacridine n1=Bevacizumab | n2=en:ethacridine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ethacrynic acid n1=Bevacizumab | n2=en:ethacrynic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ethambutol n1=Bevacizumab | n2=en:ethambutol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ethaselen n1=Bevacizumab | n2=en:ethaselen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ethinyl estradiol n1=Bevacizumab | n2=en:ethinyl estradiol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ethinyl estradiol/levonorgestrel n1=Bevacizumab | n2=en:ethinyl estradiol/levonorgestrel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ethinyl estradiol/norethindrone n1=Bevacizumab | n2=en:ethinyl estradiol/norethindrone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ethiodized oil n1=Bevacizumab | n2=en:ethiodized oil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ethosuximide n1=Bevacizumab | n2=en:ethosuximide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ethyl alcohol mouthwash n1=Bevacizumab | n2=en:ethyl alcohol mouthwash | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ethylchlorformate n1=Bevacizumab | n2=en:ethylchlorformate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ethylchlorformate vaccine n1=Bevacizumab | n2=en:ethylchlorformate vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:etidronate-cytarabine conjugate mbc-11 n1=Bevacizumab | n2=en:etidronate-cytarabine conjugate mbc-11 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:etidronic acid n1=Bevacizumab | n2=en:etidronic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:etodolac n1=Bevacizumab | n2=en:etodolac | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:etoglucid n1=Bevacizumab | n2=en:etoglucid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:etoposide n1=Bevacizumab | n2=en:etoposide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:etoposide phosphate n1=Bevacizumab | n2=en:etoposide phosphate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:etoposide prodrug cap7.1 n1=Bevacizumab | n2=en:etoposide prodrug cap7.1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:etoricoxib n1=Bevacizumab | n2=en:etoricoxib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ets-family transcription factor inhibitor tk216 n1=Bevacizumab | n2=en:ets-family transcription factor inhibitor tk216 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:eucerin n1=Bevacizumab | n2=en:eucerin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:eutectic mixture of local anesthetics n1=Bevacizumab | n2=en:eutectic mixture of local anesthetics | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:evaux spring water-based cream n1=Bevacizumab | n2=en:evaux spring water-based cream | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:evaux spring water-based topical spray n1=Bevacizumab | n2=en:evaux spring water-based topical spray | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:evaux thermal spring water-based solution n1=Bevacizumab | n2=en:evaux thermal spring water-based solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:everolimus n1=Bevacizumab | n2=en:everolimus | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:everolimus tablets for oral suspension n1=Bevacizumab | n2=en:everolimus tablets for oral suspension | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:evolocumab n1=Bevacizumab | n2=en:evolocumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ex vivo-activated autologous lymph node lymphocytes n1=Bevacizumab | n2=en:ex vivo-activated autologous lymph node lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ex vivo-expanded her2-specific t cells n1=Bevacizumab | n2=en:ex vivo-expanded her2-specific t cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:exatecan mesylate n1=Bevacizumab | n2=en:exatecan mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:exemestane n1=Bevacizumab | n2=en:exemestane | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:exenatide n1=Bevacizumab | n2=en:exenatide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:exisulind n1=Bevacizumab | n2=en:exisulind | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:expanded umbilical cord blood product hsc835 n1=Bevacizumab | n2=en:expanded umbilical cord blood product hsc835 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:expectorant/mucolytic n1=Bevacizumab | n2=en:expectorant/mucolytic | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:exposure as collected domain n1=Bevacizumab | n2=en:exposure as collected domain | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:extended release bupivacaine hydrochloride resorbable matrix formulation n1=Bevacizumab | n2=en:extended release bupivacaine hydrochloride resorbable matrix formulation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:extended release flucytosine n1=Bevacizumab | n2=en:extended release flucytosine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:extended-release onapristone n1=Bevacizumab | n2=en:extended-release onapristone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:eye agent n1=Bevacizumab | n2=en:eye agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ezatiostat hydrochloride n1=Bevacizumab | n2=en:ezatiostat hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ezetimibe n1=Bevacizumab | n2=en:ezetimibe | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ezetimibe/simvastatin n1=Bevacizumab | n2=en:ezetimibe/simvastatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ezh1/2 inhibitor ds-3201 n1=Bevacizumab | n2=en:ezh1/2 inhibitor ds-3201 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ezh2 inhibitor cpi-1205 n1=Bevacizumab | n2=en:ezh2 inhibitor cpi-1205 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:f-18 16 alpha-fluoroestradiol n1=Bevacizumab | n2=en:f-18 16 alpha-fluoroestradiol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:f-18 fluoroethyltyrosine n1=Bevacizumab | n2=en:f-18 fluoroethyltyrosine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:f16-il2 fusion protein n1=Bevacizumab | n2=en:f16-il2 fusion protein | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fact complex-targeting curaxin cbl0137 n1=Bevacizumab | n2=en:fact complex-targeting curaxin cbl0137 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:factor viia inhibitor pci-27483 n1=Bevacizumab | n2=en:factor viia inhibitor pci-27483 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fadrozole hydrochloride n1=Bevacizumab | n2=en:fadrozole hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fak inhibitor gsk2256098 n1=Bevacizumab | n2=en:fak inhibitor gsk2256098 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fak inhibitor pf-00562271 n1=Bevacizumab | n2=en:fak inhibitor pf-00562271 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fak inhibitor vs-4718 n1=Bevacizumab | n2=en:fak inhibitor vs-4718 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:falimarev n1=Bevacizumab | n2=en:falimarev | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:famitinib n1=Bevacizumab | n2=en:famitinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:famotidine n1=Bevacizumab | n2=en:famotidine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fap-specific cd8-positive t cells n1=Bevacizumab | n2=en:fap-specific cd8-positive t cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:farletuzumab n1=Bevacizumab | n2=en:farletuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fas receptor agonist apo010 n1=Bevacizumab | n2=en:fas receptor agonist apo010 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fas-chimera transgene-expressing endothelial tumor cell-targeting adenovector vb-111 n1=Bevacizumab | n2=en:fas-chimera transgene-expressing endothelial tumor cell-targeting adenovector vb-111 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fasn inhibitor tvb-2640 n1=Bevacizumab | n2=en:fasn inhibitor tvb-2640 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fat emulsion n1=Bevacizumab | n2=en:fat emulsion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fazarabine n1=Bevacizumab | n2=en:fazarabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fda established names and unique ingredient identifier codes terminology n1=Bevacizumab | n2=en:fda established names and unique ingredient identifier codes terminology | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:febuxostat n1=Bevacizumab | n2=en:febuxostat | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fenofibrate n1=Bevacizumab | n2=en:fenofibrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fenretinide n1=Bevacizumab | n2=en:fenretinide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fenretinide lipid matrix n1=Bevacizumab | n2=en:fenretinide lipid matrix | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fentanyl buccal soluble film n1=Bevacizumab | n2=en:fentanyl buccal soluble film | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fentanyl citrate n1=Bevacizumab | n2=en:fentanyl citrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fentanyl citrate buccal tablet n1=Bevacizumab | n2=en:fentanyl citrate buccal tablet | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fentanyl citrate pectin-based nasal spray n1=Bevacizumab | n2=en:fentanyl citrate pectin-based nasal spray | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fentanyl citrate-containing nasal spray n1=Bevacizumab | n2=en:fentanyl citrate-containing nasal spray | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fentanyl matrix transdermal patch n1=Bevacizumab | n2=en:fentanyl matrix transdermal patch | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fentanyl sublingual spray n1=Bevacizumab | n2=en:fentanyl sublingual spray | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fermented soybean protein beverage n1=Bevacizumab | n2=en:fermented soybean protein beverage | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fermented wheat germ extract n1=Bevacizumab | n2=en:fermented wheat germ extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ferric carboxymaltose solution n1=Bevacizumab | n2=en:ferric carboxymaltose solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ferrosoferric oxide n1=Bevacizumab | n2=en:ferrosoferric oxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ferrous fumarate n1=Bevacizumab | n2=en:ferrous fumarate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ferrous sulfate n1=Bevacizumab | n2=en:ferrous sulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fertility agents n1=Bevacizumab | n2=en:fertility agents | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ferumoxides injectable solution n1=Bevacizumab | n2=en:ferumoxides injectable solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ferumoxsil oral suspension n1=Bevacizumab | n2=en:ferumoxsil oral suspension | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ferumoxtran-10 n1=Bevacizumab | n2=en:ferumoxtran-10 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fesoterodine fumarate n1=Bevacizumab | n2=en:fesoterodine fumarate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fexofenadine hydrochloride n1=Bevacizumab | n2=en:fexofenadine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fgf receptor antagonist hgs1036 n1=Bevacizumab | n2=en:fgf receptor antagonist hgs1036 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fgf/fgfr pathway inhibitor e7090 n1=Bevacizumab | n2=en:fgf/fgfr pathway inhibitor e7090 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fgf401 inhibitor fgf401 n1=Bevacizumab | n2=en:fgf401 inhibitor fgf401 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fgfr inhibitor asp5878 n1=Bevacizumab | n2=en:fgfr inhibitor asp5878 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fgfr inhibitor azd4547 n1=Bevacizumab | n2=en:fgfr inhibitor azd4547 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fgfr inhibitor debio 1347 n1=Bevacizumab | n2=en:fgfr inhibitor debio 1347 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fgfr inhibitor incb054828 n1=Bevacizumab | n2=en:fgfr inhibitor incb054828 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fgfr inhibitor ly2874455 n1=Bevacizumab | n2=en:fgfr inhibitor ly2874455 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fgfr inhibitor tas-120 n1=Bevacizumab | n2=en:fgfr inhibitor tas-120 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fgfr/vegfr/pdgfr/flt3/src inhibitor xl999 n1=Bevacizumab | n2=en:fgfr/vegfr/pdgfr/flt3/src inhibitor xl999 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fgfr4 inhibitor blu-554 n1=Bevacizumab | n2=en:fgfr4 inhibitor blu-554 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fibrin sealant n1=Bevacizumab | n2=en:fibrin sealant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ficlatuzumab n1=Bevacizumab | n2=en:ficlatuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fidaxomicin n1=Bevacizumab | n2=en:fidaxomicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:figitumumab n1=Bevacizumab | n2=en:figitumumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:filgrastim n1=Bevacizumab | n2=en:filgrastim | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:filgrastim-primed peripheral blood progenitor cells n1=Bevacizumab | n2=en:filgrastim-primed peripheral blood progenitor cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:finasteride n1=Bevacizumab | n2=en:finasteride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fingolimod n1=Bevacizumab | n2=en:fingolimod | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fingolimod hydrochloride n1=Bevacizumab | n2=en:fingolimod hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:firtecan pegol n1=Bevacizumab | n2=en:firtecan pegol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fish oil/glycerol/egg lecithin-based emulsion n1=Bevacizumab | n2=en:fish oil/glycerol/egg lecithin-based emulsion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:flanvotumab n1=Bevacizumab | n2=en:flanvotumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:flavonoid tablet n1=Bevacizumab | n2=en:flavonoid tablet | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:flaxseed n1=Bevacizumab | n2=en:flaxseed | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:flecainide acetate n1=Bevacizumab | n2=en:flecainide acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:floxuridine n1=Bevacizumab | n2=en:floxuridine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:flp injection n1=Bevacizumab | n2=en:flp injection | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:flt3/abl/aurora kinase inhibitor kw-2449 n1=Bevacizumab | n2=en:flt3/abl/aurora kinase inhibitor kw-2449 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:flt3/cdk4/6 inhibitor flx925 n1=Bevacizumab | n2=en:flt3/cdk4/6 inhibitor flx925 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:flt3/kit kinase inhibitor akn-028 n1=Bevacizumab | n2=en:flt3/kit kinase inhibitor akn-028 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:flu matrix peptide p58-66 n1=Bevacizumab | n2=en:flu matrix peptide p58-66 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluciclatide f-18 n1=Bevacizumab | n2=en:fluciclatide f-18 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluciclovine (18f) n1=Bevacizumab | n2=en:fluciclovine (18f) | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluconazole n1=Bevacizumab | n2=en:fluconazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:flucytosine n1=Bevacizumab | n2=en:flucytosine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fludarabine n1=Bevacizumab | n2=en:fludarabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fludarabine phosphate n1=Bevacizumab | n2=en:fludarabine phosphate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fludeoxyglucose f-18 n1=Bevacizumab | n2=en:fludeoxyglucose f-18 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fludrocortisone acetate n1=Bevacizumab | n2=en:fludrocortisone acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:flumatinib mesylate n1=Bevacizumab | n2=en:flumatinib mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluocinonide n1=Bevacizumab | n2=en:fluocinonide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorescein sodium injection n1=Bevacizumab | n2=en:fluorescein sodium injection | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorescence imaging agent emi-137 n1=Bevacizumab | n2=en:fluorescence imaging agent emi-137 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorescent antibody sgm-101 n1=Bevacizumab | n2=en:fluorescent antibody sgm-101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorescent crgdy peg-cy5.5 c dots n1=Bevacizumab | n2=en:fluorescent crgdy peg-cy5.5 c dots | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorescent imaging ligand otl38 n1=Bevacizumab | n2=en:fluorescent imaging ligand otl38 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorescent protease-activated peptide avb-620 n1=Bevacizumab | n2=en:fluorescent protease-activated peptide avb-620 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorides n1=Bevacizumab | n2=en:fluorides | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine 18 f fludarabine n1=Bevacizumab | n2=en:fluorine 18 f fludarabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 4-l-fluoroglutamine (2s,4r) n1=Bevacizumab | n2=en:fluorine f 18 4-l-fluoroglutamine (2s,4r) | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 5-fluoro-2-deoxycytidine n1=Bevacizumab | n2=en:fluorine f 18 5-fluoro-2-deoxycytidine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 alfatide ii n1=Bevacizumab | n2=en:fluorine f 18 alfatide ii | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 ara-g n1=Bevacizumab | n2=en:fluorine f 18 ara-g | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 bay 85-8050 n1=Bevacizumab | n2=en:fluorine f 18 bay 85-8050 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 bay 86-9596 n1=Bevacizumab | n2=en:fluorine f 18 bay 86-9596 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 bay1075553 n1=Bevacizumab | n2=en:fluorine f 18 bay1075553 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 choline n1=Bevacizumab | n2=en:fluorine f 18 choline | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 cp18 peptide n1=Bevacizumab | n2=en:fluorine f 18 cp18 peptide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 d-fmau n1=Bevacizumab | n2=en:fluorine f 18 d-fmau | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 dabrafenib n1=Bevacizumab | n2=en:fluorine f 18 dabrafenib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 dcfbc n1=Bevacizumab | n2=en:fluorine f 18 dcfbc | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 dcfpyl n1=Bevacizumab | n2=en:fluorine f 18 dcfpyl | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 ef5 n1=Bevacizumab | n2=en:fluorine f 18 ef5 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 fdht n1=Bevacizumab | n2=en:fluorine f 18 fdht | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 feqa n1=Bevacizumab | n2=en:fluorine f 18 feqa | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 fluoro furanyl norprogesterone n1=Bevacizumab | n2=en:fluorine f 18 fluoro furanyl norprogesterone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 fluoro-peg6-ipqa n1=Bevacizumab | n2=en:fluorine f 18 fluoro-peg6-ipqa | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 fluorobenzyl triphenyl phosphonium n1=Bevacizumab | n2=en:fluorine f 18 fluorobenzyl triphenyl phosphonium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 fluorodopa n1=Bevacizumab | n2=en:fluorine f 18 fluorodopa | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 fluoroethylcholine n1=Bevacizumab | n2=en:fluorine f 18 fluoroethylcholine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 fluoromethylcholine n1=Bevacizumab | n2=en:fluorine f 18 fluoromethylcholine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 fluorthanatrace n1=Bevacizumab | n2=en:fluorine f 18 fluorthanatrace | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 fmdht n1=Bevacizumab | n2=en:fluorine f 18 fmdht | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 fp-r01-mg-f2 n1=Bevacizumab | n2=en:fluorine f 18 fp-r01-mg-f2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 galacto-rgd peptide n1=Bevacizumab | n2=en:fluorine f 18 galacto-rgd peptide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 iso-1 n1=Bevacizumab | n2=en:fluorine f 18 iso-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 l-glutamate derivative bay94-9392 n1=Bevacizumab | n2=en:fluorine f 18 l-glutamate derivative bay94-9392 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 rgd-k5 n1=Bevacizumab | n2=en:fluorine f 18 rgd-k5 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 ski-249380 n1=Bevacizumab | n2=en:fluorine f 18 ski-249380 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18 sodium fluoride n1=Bevacizumab | n2=en:fluorine f 18 sodium fluoride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18-av-133 n1=Bevacizumab | n2=en:fluorine f 18-av-133 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18-labeled s-(3-fluoropropyl)homocysteine hydrochloride n1=Bevacizumab | n2=en:fluorine f 18-labeled s-(3-fluoropropyl)homocysteine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f 18-vm4-037 n1=Bevacizumab | n2=en:fluorine f 18-vm4-037 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f-18 6-fluorodopamine n1=Bevacizumab | n2=en:fluorine f-18 6-fluorodopamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f-18 fluoropaclitaxel n1=Bevacizumab | n2=en:fluorine f-18 fluoropaclitaxel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f-18 hx4 n1=Bevacizumab | n2=en:fluorine f-18 hx4 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorine f-18 ml-10 n1=Bevacizumab | n2=en:fluorine f-18 ml-10 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorodeoxygalactose f-18 n1=Bevacizumab | n2=en:fluorodeoxygalactose f-18 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorometholone acetate ophthalmic suspension n1=Bevacizumab | n2=en:fluorometholone acetate ophthalmic suspension | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorothymidine f-18 n1=Bevacizumab | n2=en:fluorothymidine f-18 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorouracil n1=Bevacizumab | n2=en:fluorouracil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorouracil implant n1=Bevacizumab | n2=en:fluorouracil implant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorouracil-e therapeutic implant n1=Bevacizumab | n2=en:fluorouracil-e therapeutic implant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluorouracil/leucovorin/rhumab-vegf n1=Bevacizumab | n2=en:fluorouracil/leucovorin/rhumab-vegf | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluosol-da n1=Bevacizumab | n2=en:fluosol-da | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluoxetine n1=Bevacizumab | n2=en:fluoxetine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluoxymesterone n1=Bevacizumab | n2=en:fluoxymesterone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluphenazine hydrochloride n1=Bevacizumab | n2=en:fluphenazine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:flurbiprofen n1=Bevacizumab | n2=en:flurbiprofen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:flurocitabine n1=Bevacizumab | n2=en:flurocitabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:flutamide n1=Bevacizumab | n2=en:flutamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:flutemetamol f 18 n1=Bevacizumab | n2=en:flutemetamol f 18 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluticasone + vilanterol n1=Bevacizumab | n2=en:fluticasone + vilanterol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluticasone propionate n1=Bevacizumab | n2=en:fluticasone propionate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluvastatin sodium n1=Bevacizumab | n2=en:fluvastatin sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluvoxamine maleate n1=Bevacizumab | n2=en:fluvoxamine maleate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fluzoparib n1=Bevacizumab | n2=en:fluzoparib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fms inhibitor jnj-40346527 n1=Bevacizumab | n2=en:fms inhibitor jnj-40346527 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fms/trk tyrosine kinase inhibitor plx7486 n1=Bevacizumab | n2=en:fms/trk tyrosine kinase inhibitor plx7486 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:folate binding protein e39 peptide vaccine n1=Bevacizumab | n2=en:folate binding protein e39 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:folate binding protein j65 peptide vaccine n1=Bevacizumab | n2=en:folate binding protein j65 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:folate receptor alpha-loaded dendritic cell vaccine n1=Bevacizumab | n2=en:folate receptor alpha-loaded dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:folate receptor targeted epothilone bms753493 n1=Bevacizumab | n2=en:folate receptor targeted epothilone bms753493 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:folate receptor-targeted technetium tc-99m ec20 n1=Bevacizumab | n2=en:folate receptor-targeted technetium tc-99m ec20 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:folate receptor-targeted tubulysin conjugate ec1456 n1=Bevacizumab | n2=en:folate receptor-targeted tubulysin conjugate ec1456 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:folate receptor-targeted vinca alkaloid ec0489 n1=Bevacizumab | n2=en:folate receptor-targeted vinca alkaloid ec0489 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:folate receptor-targeted vinca alkaloid/mitomycin c ec0225 n1=Bevacizumab | n2=en:folate receptor-targeted vinca alkaloid/mitomycin c ec0225 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:folate-fitc n1=Bevacizumab | n2=en:folate-fitc | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:folfiri regimen n1=Bevacizumab | n2=en:folfiri regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:folfiri-bevacizumab regimen n1=Bevacizumab | n2=en:folfiri-bevacizumab regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:folfiri-cetuximab regimen n1=Bevacizumab | n2=en:folfiri-cetuximab regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:folfirinox regimen n1=Bevacizumab | n2=en:folfirinox regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:folfox regimen n1=Bevacizumab | n2=en:folfox regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:folic acid n1=Bevacizumab | n2=en:folic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:folitixorin n1=Bevacizumab | n2=en:folitixorin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fondaparinux sodium n1=Bevacizumab | n2=en:fondaparinux sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:foretinib n1=Bevacizumab | n2=en:foretinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:formestane n1=Bevacizumab | n2=en:formestane | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:formoterol fumarate oral n1=Bevacizumab | n2=en:formoterol fumarate oral | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:formoterol fumarate/roxithromycin n1=Bevacizumab | n2=en:formoterol fumarate/roxithromycin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:forodesine n1=Bevacizumab | n2=en:forodesine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:forodesine hydrochloride n1=Bevacizumab | n2=en:forodesine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fosaprepitant dimeglumine n1=Bevacizumab | n2=en:fosaprepitant dimeglumine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fosbretabulin disodium n1=Bevacizumab | n2=en:fosbretabulin disodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fosbretabulin tromethamine n1=Bevacizumab | n2=en:fosbretabulin tromethamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:foscarnet sodium n1=Bevacizumab | n2=en:foscarnet sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fosfestrol n1=Bevacizumab | n2=en:fosfestrol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fosfomycin tromethamine n1=Bevacizumab | n2=en:fosfomycin tromethamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fosquidone n1=Bevacizumab | n2=en:fosquidone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fostamatinib disodium n1=Bevacizumab | n2=en:fostamatinib disodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fostriecin n1=Bevacizumab | n2=en:fostriecin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fotemustine n1=Bevacizumab | n2=en:fotemustine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fowlpox virus vaccine vector n1=Bevacizumab | n2=en:fowlpox virus vaccine vector | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fowlpox-ny-eso-1 vaccine n1=Bevacizumab | n2=en:fowlpox-ny-eso-1 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fowlpox-psa-tricom vaccine n1=Bevacizumab | n2=en:fowlpox-psa-tricom vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:freeze-dried black raspberry bioadhesive gel n1=Bevacizumab | n2=en:freeze-dried black raspberry bioadhesive gel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:french maritime pine bark extract n1=Bevacizumab | n2=en:french maritime pine bark extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fresolimumab n1=Bevacizumab | n2=en:fresolimumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:freund's adjuvant n1=Bevacizumab | n2=en:freund's adjuvant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fructooligosaccharide supplement n1=Bevacizumab | n2=en:fructooligosaccharide supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fructooligosaccharide/lactobacillus paracasei/lactobacillus rhamnosus/lactobacillus acidophilus/bifidobacterium lactis probiotic supplement n1=Bevacizumab | n2=en:fructooligosaccharide/lactobacillus paracasei/lactobacillus rhamnosus/lactobacillus acidophilus/bifidobacterium lactis probiotic supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fruit and vegetable extract n1=Bevacizumab | n2=en:fruit and vegetable extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fruquintinib n1=Bevacizumab | n2=en:fruquintinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ft-2102 n1=Bevacizumab | n2=en:ft-2102 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fu-lv regimen n1=Bevacizumab | n2=en:fu-lv regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fulranumab n1=Bevacizumab | n2=en:fulranumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fulvestrant n1=Bevacizumab | n2=en:fulvestrant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fumagillin-derived polymer conjugate xmt-1107 n1=Bevacizumab | n2=en:fumagillin-derived polymer conjugate xmt-1107 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:furosemide n1=Bevacizumab | n2=en:furosemide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fursultiamine n1=Bevacizumab | n2=en:fursultiamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:fusidic acid/betamethasone valerate topical cream n1=Bevacizumab | n2=en:fusidic acid/betamethasone valerate topical cream | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:g-quadruplex stabilizer bmvc n1=Bevacizumab | n2=en:g-quadruplex stabilizer bmvc | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:g207 n1=Bevacizumab | n2=en:g207 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:g250 peptide vaccine n1=Bevacizumab | n2=en:g250 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ga-68-labeled f(ab') 2- trastuzumab n1=Bevacizumab | n2=en:ga-68-labeled f(ab') 2- trastuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gabapentin n1=Bevacizumab | n2=en:gabapentin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gabapentin enacarbil n1=Bevacizumab | n2=en:gabapentin enacarbil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gadobenate dimeglumine n1=Bevacizumab | n2=en:gadobenate dimeglumine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gadobutrol n1=Bevacizumab | n2=en:gadobutrol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gadodiamide n1=Bevacizumab | n2=en:gadodiamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gadofosveset trisodium n1=Bevacizumab | n2=en:gadofosveset trisodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gadolinium-chelate n1=Bevacizumab | n2=en:gadolinium-chelate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gadopentetate dimeglumine n1=Bevacizumab | n2=en:gadopentetate dimeglumine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gadoterate meglumine n1=Bevacizumab | n2=en:gadoterate meglumine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gadoteridol n1=Bevacizumab | n2=en:gadoteridol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gadoxetate disodium n1=Bevacizumab | n2=en:gadoxetate disodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gag:267-274 peptide vaccine n1=Bevacizumab | n2=en:gag:267-274 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:galactomannan derivative n1=Bevacizumab | n2=en:galactomannan derivative | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:galactose n1=Bevacizumab | n2=en:galactose | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:galantamine hydrobromide n1=Bevacizumab | n2=en:galantamine hydrobromide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:galectin inhibitor gr-md-02 n1=Bevacizumab | n2=en:galectin inhibitor gr-md-02 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:galectin-1 inhibitor otx008 n1=Bevacizumab | n2=en:galectin-1 inhibitor otx008 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:galeterone n1=Bevacizumab | n2=en:galeterone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:galiximab n1=Bevacizumab | n2=en:galiximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gallium citrate ga-67 n1=Bevacizumab | n2=en:gallium citrate ga-67 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gallium ga 68 citrate n1=Bevacizumab | n2=en:gallium ga 68 citrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gallium ga 68 dota-jr11 n1=Bevacizumab | n2=en:gallium ga 68 dota-jr11 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gallium ga 68 ops202 n1=Bevacizumab | n2=en:gallium ga 68 ops202 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gallium ga 68-dota-exendin-4 n1=Bevacizumab | n2=en:gallium ga 68-dota-exendin-4 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gallium ga 68-dotanoc n1=Bevacizumab | n2=en:gallium ga 68-dotanoc | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gallium ga 68-dotatate n1=Bevacizumab | n2=en:gallium ga 68-dotatate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gallium ga 68-edotreotide n1=Bevacizumab | n2=en:gallium ga 68-edotreotide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gallium ga 68-labeled affibody aby-025 n1=Bevacizumab | n2=en:gallium ga 68-labeled affibody aby-025 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gallium ga 68-labeled bnota-prgd2 n1=Bevacizumab | n2=en:gallium ga 68-labeled bnota-prgd2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gallium ga 68-labeled dota di-hsg peptide imp-288 n1=Bevacizumab | n2=en:gallium ga 68-labeled dota di-hsg peptide imp-288 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gallium ga 68-labeled grpr antagonist bay86-7548 n1=Bevacizumab | n2=en:gallium ga 68-labeled grpr antagonist bay86-7548 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gallium ga 68-labeled mln6907 n1=Bevacizumab | n2=en:gallium ga 68-labeled mln6907 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gallium ga 68-labeled psma ligand glu-urea-lys(ahx)-hbed-cc n1=Bevacizumab | n2=en:gallium ga 68-labeled psma ligand glu-urea-lys(ahx)-hbed-cc | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gallium ga 68-labeled-nodaga-mj9 n1=Bevacizumab | n2=en:gallium ga 68-labeled-nodaga-mj9 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gallium ga 68-neb n1=Bevacizumab | n2=en:gallium ga 68-neb | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gallium ga 68-nota-aca-bbn(7-14) n1=Bevacizumab | n2=en:gallium ga 68-nota-aca-bbn(7-14) | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gallium ga 68-nota-ae105 n1=Bevacizumab | n2=en:gallium ga 68-nota-ae105 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gallium ga 68-nota-bbn(7-14)-rgd n1=Bevacizumab | n2=en:gallium ga 68-nota-bbn(7-14)-rgd | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gallium ga 68-nota-nfb n1=Bevacizumab | n2=en:gallium ga 68-nota-nfb | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gallium ga 68-rgd n1=Bevacizumab | n2=en:gallium ga 68-rgd | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gallium maltolate n1=Bevacizumab | n2=en:gallium maltolate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gallium nitrate n1=Bevacizumab | n2=en:gallium nitrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:galnac-anti-c5 sirna aln-cc5 n1=Bevacizumab | n2=en:galnac-anti-c5 sirna aln-cc5 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:galunisertib n1=Bevacizumab | n2=en:galunisertib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gamboge resin extract tsb-9-w1 n1=Bevacizumab | n2=en:gamboge resin extract tsb-9-w1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gamma secretase inhibitor pf-03084014 n1=Bevacizumab | n2=en:gamma secretase inhibitor pf-03084014 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gamma-delta tocotrienol n1=Bevacizumab | n2=en:gamma-delta tocotrienol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gamma-secretase inhibitor ly3039478 n1=Bevacizumab | n2=en:gamma-secretase inhibitor ly3039478 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gamma-secretase inhibitor ro4929097 n1=Bevacizumab | n2=en:gamma-secretase inhibitor ro4929097 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ganciclovir n1=Bevacizumab | n2=en:ganciclovir | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gandotinib n1=Bevacizumab | n2=en:gandotinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ganetespib n1=Bevacizumab | n2=en:ganetespib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ganglioside gd2 n1=Bevacizumab | n2=en:ganglioside gd2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ganglioside gm2 n1=Bevacizumab | n2=en:ganglioside gm2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ganitumab n1=Bevacizumab | n2=en:ganitumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ganoderma lucidum spores powder capsule n1=Bevacizumab | n2=en:ganoderma lucidum spores powder capsule | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:garlic extract n1=Bevacizumab | n2=en:garlic extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gastrin immunotoxin n1=Bevacizumab | n2=en:gastrin immunotoxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gastroenteral dosage form product n1=Bevacizumab | n2=en:gastroenteral dosage form product | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gastrointestinal agents n1=Bevacizumab | n2=en:gastrointestinal agents | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gataparsen sodium n1=Bevacizumab | n2=en:gataparsen sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gavilimomab n1=Bevacizumab | n2=en:gavilimomab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gd2 lactone/gd3 lactone-klh conjugate bivalent vaccine n1=Bevacizumab | n2=en:gd2 lactone/gd3 lactone-klh conjugate bivalent vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gd2-car-expressing autologous t-lymphocytes n1=Bevacizumab | n2=en:gd2-car-expressing autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gd2-klh vaccine n1=Bevacizumab | n2=en:gd2-klh vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gdc-0349 n1=Bevacizumab | n2=en:gdc-0349 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gedatolisib n1=Bevacizumab | n2=en:gedatolisib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gefitinib n1=Bevacizumab | n2=en:gefitinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gel protein, gelonium multiflorum n1=Bevacizumab | n2=en:gel protein, gelonium multiflorum | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gelatin n1=Bevacizumab | n2=en:gelatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gem 231 n1=Bevacizumab | n2=en:gem 231 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gemcitabine n1=Bevacizumab | n2=en:gemcitabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gemcitabine elaidate n1=Bevacizumab | n2=en:gemcitabine elaidate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gemcitabine hydrochloride n1=Bevacizumab | n2=en:gemcitabine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gemcitabine hydrochloride emulsion n1=Bevacizumab | n2=en:gemcitabine hydrochloride emulsion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gemcitabine prodrug ly2334737 n1=Bevacizumab | n2=en:gemcitabine prodrug ly2334737 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gemcitabine-cisplatin regimen n1=Bevacizumab | n2=en:gemcitabine-cisplatin regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gemcitabine-erlotinib regimen n1=Bevacizumab | n2=en:gemcitabine-erlotinib regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gemcitabine-oxaliplatin regimen n1=Bevacizumab | n2=en:gemcitabine-oxaliplatin regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gemcitabine-phosphoramidate hydrochloride nuc-1031 n1=Bevacizumab | n2=en:gemcitabine-phosphoramidate hydrochloride nuc-1031 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gemfibrozil n1=Bevacizumab | n2=en:gemfibrozil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gemigliptin n1=Bevacizumab | n2=en:gemigliptin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gemtuzumab ozogamicin n1=Bevacizumab | n2=en:gemtuzumab ozogamicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gene-modified hiv-protected hematopoietic stem cells n1=Bevacizumab | n2=en:gene-modified hiv-protected hematopoietic stem cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:generic drug n1=Bevacizumab | n2=en:generic drug | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:genetic aspects n1=Bevacizumab | n2=en:genetic aspects | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:genetically engineered ny-eso-1-specific t lymphocytes n1=Bevacizumab | n2=en:genetically engineered ny-eso-1-specific t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:genetically-modified mage-a3-expressing mg1 maraba virus vaccine n1=Bevacizumab | n2=en:genetically-modified mage-a3-expressing mg1 maraba virus vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:genistein n1=Bevacizumab | n2=en:genistein | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:genital system agent n1=Bevacizumab | n2=en:genital system agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gentamicin n1=Bevacizumab | n2=en:gentamicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:geranylgeranyltransferase i inhibitor n1=Bevacizumab | n2=en:geranylgeranyltransferase i inhibitor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ghrelin peptide analogue n1=Bevacizumab | n2=en:ghrelin peptide analogue | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gi-4000 vaccine n1=Bevacizumab | n2=en:gi-4000 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gilteritinib n1=Bevacizumab | n2=en:gilteritinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gimatecan n1=Bevacizumab | n2=en:gimatecan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gimeracil n1=Bevacizumab | n2=en:gimeracil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ginger extract n1=Bevacizumab | n2=en:ginger extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ginseng compound n1=Bevacizumab | n2=en:ginseng compound | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ginsenoside rg3 capsule n1=Bevacizumab | n2=en:ginsenoside rg3 capsule | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:giracodazole n1=Bevacizumab | n2=en:giracodazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:girentuximab n1=Bevacizumab | n2=en:girentuximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gitr agonist medi1873 n1=Bevacizumab | n2=en:gitr agonist medi1873 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gitrl rna-transfected autologous dendritic cell vaccine n1=Bevacizumab | n2=en:gitrl rna-transfected autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:givinostat n1=Bevacizumab | n2=en:givinostat | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gk567 n1=Bevacizumab | n2=en:gk567 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glembatumumab vedotin n1=Bevacizumab | n2=en:glembatumumab vedotin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glibornuride n1=Bevacizumab | n2=en:glibornuride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gliclazide n1=Bevacizumab | n2=en:gliclazide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glimepiride n1=Bevacizumab | n2=en:glimepiride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glioblastoma cancer vaccine erc1671 n1=Bevacizumab | n2=en:glioblastoma cancer vaccine erc1671 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glioblastoma multiforme multipeptide vaccine ima950 n1=Bevacizumab | n2=en:glioblastoma multiforme multipeptide vaccine ima950 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine n1=Bevacizumab | n2=en:glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glioma-associated peptide-loaded dendritic cell vaccine sl-701 n1=Bevacizumab | n2=en:glioma-associated peptide-loaded dendritic cell vaccine sl-701 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glipizide n1=Bevacizumab | n2=en:glipizide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gliquidone n1=Bevacizumab | n2=en:gliquidone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glisoxepide n1=Bevacizumab | n2=en:glisoxepide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:globo h-dt vaccine obi-833 n1=Bevacizumab | n2=en:globo h-dt vaccine obi-833 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:globo h-gm2-lewis-y-muc1-32-mer-tf(c)-tn(c)-klh conjugate vaccine n1=Bevacizumab | n2=en:globo h-gm2-lewis-y-muc1-32-mer-tf(c)-tn(c)-klh conjugate vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:globo h-klh immunostimulant opt-822 n1=Bevacizumab | n2=en:globo h-klh immunostimulant opt-822 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:globo-h-gm2-lewis-y-muc1-32(aa)-stn(c)-tf(c)-tn(c)-klh conjugate vaccine n1=Bevacizumab | n2=en:globo-h-gm2-lewis-y-muc1-32(aa)-stn(c)-tf(c)-tn(c)-klh conjugate vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:globulin component macrophage-activating factor n1=Bevacizumab | n2=en:globulin component macrophage-activating factor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glse compound n1=Bevacizumab | n2=en:glse compound | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glucagon n1=Bevacizumab | n2=en:glucagon | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glucarpidase n1=Bevacizumab | n2=en:glucarpidase | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glucocorticoid receptor antagonist cort125134 n1=Bevacizumab | n2=en:glucocorticoid receptor antagonist cort125134 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glucosamine sulfate/chondroitin sulfate tablet n1=Bevacizumab | n2=en:glucosamine sulfate/chondroitin sulfate tablet | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glucuronic acid n1=Bevacizumab | n2=en:glucuronic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glufosfamide n1=Bevacizumab | n2=en:glufosfamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glutamic acid n1=Bevacizumab | n2=en:glutamic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glutaminase inhibitor cb-839 n1=Bevacizumab | n2=en:glutaminase inhibitor cb-839 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glutaminase-asparaginase n1=Bevacizumab | n2=en:glutaminase-asparaginase | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glutamine n1=Bevacizumab | n2=en:glutamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glutathione n1=Bevacizumab | n2=en:glutathione | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glutathione disulfide nov-002 n1=Bevacizumab | n2=en:glutathione disulfide nov-002 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glutathione pegylated liposomal doxorubicin hydrochloride formulation 2b3-101 n1=Bevacizumab | n2=en:glutathione pegylated liposomal doxorubicin hydrochloride formulation 2b3-101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gluten-free compact nutritional supplement drink n1=Bevacizumab | n2=en:gluten-free compact nutritional supplement drink | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gluten-free dha/epa/gla/antioxidant-rich nutritional liquid n1=Bevacizumab | n2=en:gluten-free dha/epa/gla/antioxidant-rich nutritional liquid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gluten-free/fiber-enriched compact nutritional supplement drink n1=Bevacizumab | n2=en:gluten-free/fiber-enriched compact nutritional supplement drink | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glyburide n1=Bevacizumab | n2=en:glyburide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glycerin cream (10%) n1=Bevacizumab | n2=en:glycerin cream (10%) | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glycerin enema n1=Bevacizumab | n2=en:glycerin enema | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glycine n1=Bevacizumab | n2=en:glycine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glycooptimized trastuzumab-gex n1=Bevacizumab | n2=en:glycooptimized trastuzumab-gex | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glycopeptide antibiotic n1=Bevacizumab | n2=en:glycopeptide antibiotic | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glycopyrrolate n1=Bevacizumab | n2=en:glycopyrrolate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glycosylated recombinant human g-csf avi-014 n1=Bevacizumab | n2=en:glycosylated recombinant human g-csf avi-014 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glycosylated recombinant human interleukin-7 n1=Bevacizumab | n2=en:glycosylated recombinant human interleukin-7 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glycyrrhiza glabra root n1=Bevacizumab | n2=en:glycyrrhiza glabra root | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glycyrrhizin n1=Bevacizumab | n2=en:glycyrrhizin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glymidine n1=Bevacizumab | n2=en:glymidine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:glyt2/5ht2a antagonist vvz-149 n1=Bevacizumab | n2=en:glyt2/5ht2a antagonist vvz-149 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gm-csf-encoding oncolytic adenovirus cgtg-102 n1=Bevacizumab | n2=en:gm-csf-encoding oncolytic adenovirus cgtg-102 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gm-k562 cell vaccine n1=Bevacizumab | n2=en:gm-k562 cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gm.cd40l cell vaccine n1=Bevacizumab | n2=en:gm.cd40l cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gm2-klh vaccine n1=Bevacizumab | n2=en:gm2-klh vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gm2/gd2/gd3 lactone-klh conjugate trivalent vaccine n1=Bevacizumab | n2=en:gm2/gd2/gd3 lactone-klh conjugate trivalent vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gnrh antagonist tak-385 n1=Bevacizumab | n2=en:gnrh antagonist tak-385 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gold sodium thiomalate n1=Bevacizumab | n2=en:gold sodium thiomalate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:goldenrod n1=Bevacizumab | n2=en:goldenrod | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:golimumab n1=Bevacizumab | n2=en:golimumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:golnerminogene pradenovec n1=Bevacizumab | n2=en:golnerminogene pradenovec | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:golotimod n1=Bevacizumab | n2=en:golotimod | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:golvatinib n1=Bevacizumab | n2=en:golvatinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gomiliximab n1=Bevacizumab | n2=en:gomiliximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gonadotropin-releasing hormone analog n1=Bevacizumab | n2=en:gonadotropin-releasing hormone analog | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:goserelin acetate n1=Bevacizumab | n2=en:goserelin acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gossypol n1=Bevacizumab | n2=en:gossypol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gout suppressants n1=Bevacizumab | n2=en:gout suppressants | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gp100 antigen n1=Bevacizumab | n2=en:gp100 antigen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gp100-fowlpox vaccine n1=Bevacizumab | n2=en:gp100-fowlpox vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gp100:154-162 peptide vaccine n1=Bevacizumab | n2=en:gp100:154-162 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gp100:209-217(210m) peptide vaccine n1=Bevacizumab | n2=en:gp100:209-217(210m) peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gp100:280-288(288v) peptide vaccine n1=Bevacizumab | n2=en:gp100:280-288(288v) peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gp2 peptide/gm-csf vaccine n1=Bevacizumab | n2=en:gp2 peptide/gm-csf vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gp2013 n1=Bevacizumab | n2=en:gp2013 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gp209-2m antigen n1=Bevacizumab | n2=en:gp209-2m antigen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gp96-secreting allogeneic bladder cancer cell vaccine hs-410 n1=Bevacizumab | n2=en:gp96-secreting allogeneic bladder cancer cell vaccine hs-410 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gpi 1485 n1=Bevacizumab | n2=en:gpi 1485 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gpi-0100 n1=Bevacizumab | n2=en:gpi-0100 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:granisetron hydrochloride n1=Bevacizumab | n2=en:granisetron hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:granisetron hydrochloride nasal spray n1=Bevacizumab | n2=en:granisetron hydrochloride nasal spray | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:granisetron transdermal patch n1=Bevacizumab | n2=en:granisetron transdermal patch | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:green tea n1=Bevacizumab | n2=en:green tea | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:green tea extract n1=Bevacizumab | n2=en:green tea extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:green tea extract-based antioxidant supplement n1=Bevacizumab | n2=en:green tea extract-based antioxidant supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:green tea lozenge n1=Bevacizumab | n2=en:green tea lozenge | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:growth factor inhibition n1=Bevacizumab | n2=en:growth factor inhibition | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gs/pan-notch inhibitor bms-906024 n1=Bevacizumab | n2=en:gs/pan-notch inhibitor bms-906024 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gs/pan-notch inhibitor bms-986115 n1=Bevacizumab | n2=en:gs/pan-notch inhibitor bms-986115 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gsk-3 inhibitor ly2090314 n1=Bevacizumab | n2=en:gsk-3 inhibitor ly2090314 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gti-2040 n1=Bevacizumab | n2=en:gti-2040 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:guadecitabine n1=Bevacizumab | n2=en:guadecitabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:guanabenz acetate n1=Bevacizumab | n2=en:guanabenz acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:guanazole n1=Bevacizumab | n2=en:guanazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:guar gum n1=Bevacizumab | n2=en:guar gum | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:guarana supplement n1=Bevacizumab | n2=en:guarana supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gusperimus trihydrochloride n1=Bevacizumab | n2=en:gusperimus trihydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gvax lung cancer vaccine n1=Bevacizumab | n2=en:gvax lung cancer vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gvax pancreatic cancer vaccine n1=Bevacizumab | n2=en:gvax pancreatic cancer vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:gvax prostate cancer vaccine n1=Bevacizumab | n2=en:gvax prostate cancer vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:h1299 tumor cell lysate vaccine n1=Bevacizumab | n2=en:h1299 tumor cell lysate vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:haemophilus influenzae b vaccine n1=Bevacizumab | n2=en:haemophilus influenzae b vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hafnium oxide-containing nanoparticles nbtxr3 n1=Bevacizumab | n2=en:hafnium oxide-containing nanoparticles nbtxr3 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:halofuginone hydrobromide n1=Bevacizumab | n2=en:halofuginone hydrobromide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:halometasone n1=Bevacizumab | n2=en:halometasone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:haloperidol n1=Bevacizumab | n2=en:haloperidol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:harringtonines n1=Bevacizumab | n2=en:harringtonines | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hcv antigen therapeutic bivalent vaccine v5 n1=Bevacizumab | n2=en:hcv antigen therapeutic bivalent vaccine v5 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hcv dna vaccine ino-8000 n1=Bevacizumab | n2=en:hcv dna vaccine ino-8000 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hdac inhibitor 4sc-202 n1=Bevacizumab | n2=en:hdac inhibitor 4sc-202 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hdac inhibitor acy-241 n1=Bevacizumab | n2=en:hdac inhibitor acy-241 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hdac inhibitor ar-42 n1=Bevacizumab | n2=en:hdac inhibitor ar-42 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hdac inhibitor cg200745 n1=Bevacizumab | n2=en:hdac inhibitor cg200745 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hdac inhibitor chr-2845 n1=Bevacizumab | n2=en:hdac inhibitor chr-2845 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hdac inhibitor chr-3996 n1=Bevacizumab | n2=en:hdac inhibitor chr-3996 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hdac inhibitor cxd101 n1=Bevacizumab | n2=en:hdac inhibitor cxd101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hdac inhibitor mpt0e028 n1=Bevacizumab | n2=en:hdac inhibitor mpt0e028 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hdac inhibitor obp-801 n1=Bevacizumab | n2=en:hdac inhibitor obp-801 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hdac inhibitor shp-141 n1=Bevacizumab | n2=en:hdac inhibitor shp-141 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hdac/egfr/her2 inhibitor cudc-101 n1=Bevacizumab | n2=en:hdac/egfr/her2 inhibitor cudc-101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hdm2 antagonist jnj-26854165 n1=Bevacizumab | n2=en:hdm2 antagonist jnj-26854165 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hdm2 inhibitor hdm201 n1=Bevacizumab | n2=en:hdm2 inhibitor hdm201 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hdm2 inhibitor mk-8242 n1=Bevacizumab | n2=en:hdm2 inhibitor mk-8242 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:heat shock protein inhibitor n1=Bevacizumab | n2=en:heat shock protein inhibitor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:heat-killed mycobacterial product imm-101 n1=Bevacizumab | n2=en:heat-killed mycobacterial product imm-101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:heat-treated varicella-zoster virus vaccine v212 n1=Bevacizumab | n2=en:heat-treated varicella-zoster virus vaccine v212 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hedgehog inhibitor pf-04449913 n1=Bevacizumab | n2=en:hedgehog inhibitor pf-04449913 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hematologic agents n1=Bevacizumab | n2=en:hematologic agents | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hematoporphyrin derivative n1=Bevacizumab | n2=en:hematoporphyrin derivative | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hemiasterlin analog e7974 n1=Bevacizumab | n2=en:hemiasterlin analog e7974 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hemorrhoid preparation n1=Bevacizumab | n2=en:hemorrhoid preparation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:henatinib maleate n1=Bevacizumab | n2=en:henatinib maleate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:heparan sulfate glycosaminoglycan mimetic m402 n1=Bevacizumab | n2=en:heparan sulfate glycosaminoglycan mimetic m402 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:heparan sulfate glycosaminoglycan mimetic nanopolymer mouthwash n1=Bevacizumab | n2=en:heparan sulfate glycosaminoglycan mimetic nanopolymer mouthwash | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:heparin n1=Bevacizumab | n2=en:heparin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:heparin derivative sst0001 n1=Bevacizumab | n2=en:heparin derivative sst0001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hepatitis a vaccine n1=Bevacizumab | n2=en:hepatitis a vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hepatitis b antigen vaccine n1=Bevacizumab | n2=en:hepatitis b antigen vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hepatitis b vaccine n1=Bevacizumab | n2=en:hepatitis b vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hepsulfam n1=Bevacizumab | n2=en:hepsulfam | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:her-2-neu, cea peptides, gm-csf, montanide isa-51 vaccine n1=Bevacizumab | n2=en:her-2-neu, cea peptides, gm-csf, montanide isa-51 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:her-2-positive b-cell peptide antigen p467-dt-crm197/montanide vaccine imu-131 n1=Bevacizumab | n2=en:her-2-positive b-cell peptide antigen p467-dt-crm197/montanide vaccine imu-131 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:her-2/neu intracellular domain protein n1=Bevacizumab | n2=en:her-2/neu intracellular domain protein | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:her-2/neu peptide vaccine n1=Bevacizumab | n2=en:her-2/neu peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:her2 ecd+tm virus-like replicon particles vaccine avx901 n1=Bevacizumab | n2=en:her2 ecd+tm virus-like replicon particles vaccine avx901 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:her2-pulsed autologous type-1 polarized dendritic cell vaccine n1=Bevacizumab | n2=en:her2-pulsed autologous type-1 polarized dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:her2-targeted liposomal doxorubicin hydrochloride mm-302 n1=Bevacizumab | n2=en:her2-targeted liposomal doxorubicin hydrochloride mm-302 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:her2-targeting antibody fc fragment fs102 n1=Bevacizumab | n2=en:her2-targeting antibody fc fragment fs102 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:her2bi-armed activated t cells n1=Bevacizumab | n2=en:her2bi-armed activated t cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:herba scutellaria barbata n1=Bevacizumab | n2=en:herba scutellaria barbata | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:herbal medicine (product) n1=Bevacizumab | n2=en:herbal medicine (product) | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:herbal medicine agent n1=Bevacizumab | n2=en:herbal medicine agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:herbal polysaccharide saliva substitute n1=Bevacizumab | n2=en:herbal polysaccharide saliva substitute | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:herpes zoster vaccine gsk1437173a n1=Bevacizumab | n2=en:herpes zoster vaccine gsk1437173a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hetastarch n1=Bevacizumab | n2=en:hetastarch | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:heterodimeric interleukin-15 n1=Bevacizumab | n2=en:heterodimeric interleukin-15 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hexamethylene bisacetamide n1=Bevacizumab | n2=en:hexamethylene bisacetamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hexaminolevulinate n1=Bevacizumab | n2=en:hexaminolevulinate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hexaminolevulinate hydrochloride n1=Bevacizumab | n2=en:hexaminolevulinate hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hif-1alpha inhibitor px-478 n1=Bevacizumab | n2=en:hif-1alpha inhibitor px-478 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hif-2alpha inhibitor pt2385 n1=Bevacizumab | n2=en:hif-2alpha inhibitor pt2385 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:high-selenium baker's yeast n1=Bevacizumab | n2=en:high-selenium baker's yeast | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:high-selenium brassica juncea n1=Bevacizumab | n2=en:high-selenium brassica juncea | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:high-titer rsv immune globulin ri-001 n1=Bevacizumab | n2=en:high-titer rsv immune globulin ri-001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:highly purified staphylococcal protein a prtx-100 n1=Bevacizumab | n2=en:highly purified staphylococcal protein a prtx-100 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:histamine dihydrochloride n1=Bevacizumab | n2=en:histamine dihydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:histone-lysine n-methyltransferase ezh2 inhibitor gsk2816126 n1=Bevacizumab | n2=en:histone-lysine n-methyltransferase ezh2 inhibitor gsk2816126 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:historical aspects qualifier n1=Bevacizumab | n2=en:historical aspects qualifier | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:histrelin acetate n1=Bevacizumab | n2=en:histrelin acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-a*0201 restricted tert(572y)/tert(572) peptides vaccine vx-001 n1=Bevacizumab | n2=en:hla-a*0201 restricted tert(572y)/tert(572) peptides vaccine vx-001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-a*0201-restricted trp2-gp100-epha2-her2 multipeptide vaccine n1=Bevacizumab | n2=en:hla-a*0201-restricted trp2-gp100-epha2-her2 multipeptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-a*0201-restricted urlc10-vegfr1-vegfr2 multipeptide vaccine n1=Bevacizumab | n2=en:hla-a*0201-restricted urlc10-vegfr1-vegfr2 multipeptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-a*0201-restricted vegfr1 peptide vaccine n1=Bevacizumab | n2=en:hla-a*0201-restricted vegfr1 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-a*0201-restricted vegfr1-vegfr2 multipeptide vaccine n1=Bevacizumab | n2=en:hla-a*0201-restricted vegfr1-vegfr2 multipeptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-a*2402-restricted cdca1-a24-56 peptide vaccine n1=Bevacizumab | n2=en:hla-a*2402-restricted cdca1-a24-56 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-a*2402-restricted cdca1-kif20a multipeptide vaccine n1=Bevacizumab | n2=en:hla-a*2402-restricted cdca1-kif20a multipeptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-a*2402-restricted koc1-ttk-co16-depdc1-mphosph1 multipeptide vaccine n1=Bevacizumab | n2=en:hla-a*2402-restricted koc1-ttk-co16-depdc1-mphosph1 multipeptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-a*2402-restricted multipeptide vaccine s-488410 n1=Bevacizumab | n2=en:hla-a*2402-restricted multipeptide vaccine s-488410 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-a*2402-restricted urlc10 peptides vaccine n1=Bevacizumab | n2=en:hla-a*2402-restricted urlc10 peptides vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-a*2402-restricted urlc10-cdca1-kif20a multipeptide vaccine n1=Bevacizumab | n2=en:hla-a*2402-restricted urlc10-cdca1-kif20a multipeptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-a*2402-restricted urlc10-cdca1-vegfr1-vegfr2 multipeptide vaccine n1=Bevacizumab | n2=en:hla-a*2402-restricted urlc10-cdca1-vegfr1-vegfr2 multipeptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-a*2402-restricted urlc10-koc1-vegfr1-vegfr2 multipeptide vaccine n1=Bevacizumab | n2=en:hla-a*2402-restricted urlc10-koc1-vegfr1-vegfr2 multipeptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-a*2402-restricted urlc10-ttk-koc1 multipeptide vaccine n1=Bevacizumab | n2=en:hla-a*2402-restricted urlc10-ttk-koc1 multipeptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-a*2402-restricted urlc10-ttk-vegfr1-vegfr2 multipeptide vaccine n1=Bevacizumab | n2=en:hla-a*2402-restricted urlc10-ttk-vegfr1-vegfr2 multipeptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-a*2402-restricted vegfr1 peptide vaccine n1=Bevacizumab | n2=en:hla-a*2402-restricted vegfr1 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-a*2402-restricted vegfr1/2 multipeptide vaccine n1=Bevacizumab | n2=en:hla-a*2402-restricted vegfr1/2 multipeptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-a*2404-restricted rnf43-tomm34-vegfr1-vegfr2 multipeptide vaccine n1=Bevacizumab | n2=en:hla-a*2404-restricted rnf43-tomm34-vegfr1-vegfr2 multipeptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-a1-binding mage-1/mage-3 multipeptide-pulsed autologous dendritic cell vaccine n1=Bevacizumab | n2=en:hla-a1-binding mage-1/mage-3 multipeptide-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-a1, a2, b35-restricted survivin peptides/montanide isa-51 vaccine n1=Bevacizumab | n2=en:hla-a1, a2, b35-restricted survivin peptides/montanide isa-51 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-a2-binding tyr/mart-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine n1=Bevacizumab | n2=en:hla-a2-binding tyr/mart-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-a2-restricted synthetic glioma antigen peptides vaccine n1=Bevacizumab | n2=en:hla-a2-restricted synthetic glioma antigen peptides vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-a2, a3-restricted fgf-5 peptides/montanide isa-51 vaccine n1=Bevacizumab | n2=en:hla-a2, a3-restricted fgf-5 peptides/montanide isa-51 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-dp0401/0402-restricted mage-a3-reactive t cell receptor-transduced autologous t cells n1=Bevacizumab | n2=en:hla-dp0401/0402-restricted mage-a3-reactive t cell receptor-transduced autologous t cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hla-matched donor mononuclear cell-enriched leukocytes apocell n1=Bevacizumab | n2=en:hla-matched donor mononuclear cell-enriched leukocytes apocell | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ho 166 dotmp n1=Bevacizumab | n2=en:ho 166 dotmp | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ho/02/02 n1=Bevacizumab | n2=en:ho/02/02 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hodgkin's antigens-gm-csf-expressing cell vaccine n1=Bevacizumab | n2=en:hodgkin's antigens-gm-csf-expressing cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:holmium ho 166 poly(l-lactic acid) microspheres n1=Bevacizumab | n2=en:holmium ho 166 poly(l-lactic acid) microspheres | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:homeopathic remedies n1=Bevacizumab | n2=en:homeopathic remedies | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:honey n1=Bevacizumab | n2=en:honey | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:honey-containing mouthwash n1=Bevacizumab | n2=en:honey-containing mouthwash | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hormone, hormone metabolite, hormone precursor, synthetic hormone substitute, and/or hormone antagonist n1=Bevacizumab | n2=en:hormone, hormone metabolite, hormone precursor, synthetic hormone substitute, and/or hormone antagonist | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hormones, synthetic substitutes and antagonists n1=Bevacizumab | n2=en:hormones, synthetic substitutes and antagonists | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:host dendritic cell vaccine-001 mssm/biir n1=Bevacizumab | n2=en:host dendritic cell vaccine-001 mssm/biir | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hpph n1=Bevacizumab | n2=en:hpph | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hpv 16 e7 antigen-expressing lactobacillis casei vaccine bls-ilb-e710c n1=Bevacizumab | n2=en:hpv 16 e7 antigen-expressing lactobacillis casei vaccine bls-ilb-e710c | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hpv 16 e7:12-20 peptide vaccine n1=Bevacizumab | n2=en:hpv 16 e7:12-20 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hpv 16 e7:86-93 peptide vaccine n1=Bevacizumab | n2=en:hpv 16 e7:86-93 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hpv dna plasmids therapeutic vaccine vgx-3100 n1=Bevacizumab | n2=en:hpv dna plasmids therapeutic vaccine vgx-3100 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hpv e1/e2 interaction inhibitor gel ap611074 n1=Bevacizumab | n2=en:hpv e1/e2 interaction inhibitor gel ap611074 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hpv e6/e7 dna vaccine gx-188e n1=Bevacizumab | n2=en:hpv e6/e7 dna vaccine gx-188e | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hpv-16 e6 peptides vaccine/candida albicans extract n1=Bevacizumab | n2=en:hpv-16 e6 peptides vaccine/candida albicans extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hpv-6-targeting immunotherapeutic vaccine ino-3106 n1=Bevacizumab | n2=en:hpv-6-targeting immunotherapeutic vaccine ino-3106 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hpv16 l2/e6/e7 fusion protein vaccine ta-cin n1=Bevacizumab | n2=en:hpv16 l2/e6/e7 fusion protein vaccine ta-cin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hsp70-peptide tkd/il-2-activated autologous natural killer cells n1=Bevacizumab | n2=en:hsp70-peptide tkd/il-2-activated autologous natural killer cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hsp90 antagonist kw-2478 n1=Bevacizumab | n2=en:hsp90 antagonist kw-2478 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hsp90 inhibitor ab-010 n1=Bevacizumab | n2=en:hsp90 inhibitor ab-010 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hsp90 inhibitor auy922 n1=Bevacizumab | n2=en:hsp90 inhibitor auy922 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hsp90 inhibitor biib021 n1=Bevacizumab | n2=en:hsp90 inhibitor biib021 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hsp90 inhibitor biib028 n1=Bevacizumab | n2=en:hsp90 inhibitor biib028 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hsp90 inhibitor debio 0932 n1=Bevacizumab | n2=en:hsp90 inhibitor debio 0932 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hsp90 inhibitor ds-2248 n1=Bevacizumab | n2=en:hsp90 inhibitor ds-2248 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hsp90 inhibitor hsp990 n1=Bevacizumab | n2=en:hsp90 inhibitor hsp990 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hsp90 inhibitor mpc-3100 n1=Bevacizumab | n2=en:hsp90 inhibitor mpc-3100 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hsp90 inhibitor pu-h71 n1=Bevacizumab | n2=en:hsp90 inhibitor pu-h71 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hsp90 inhibitor snx-5542 mesylate n1=Bevacizumab | n2=en:hsp90 inhibitor snx-5542 mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hsp90 inhibitor xl888 n1=Bevacizumab | n2=en:hsp90 inhibitor xl888 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hsv-1 hf10 n1=Bevacizumab | n2=en:hsv-1 hf10 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hsv-tk-transduced donor lymphocytes n1=Bevacizumab | n2=en:hsv-tk-transduced donor lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:htert i540/r572y/d988y multipeptide vaccine n1=Bevacizumab | n2=en:htert i540/r572y/d988y multipeptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:htert mrna/survivin peptide-double-loaded autologous dendritic cell vaccine n1=Bevacizumab | n2=en:htert mrna/survivin peptide-double-loaded autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:htert multipeptide/montanide isa-51 vg/imiquimod gx 301 n1=Bevacizumab | n2=en:htert multipeptide/montanide isa-51 vg/imiquimod gx 301 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:htert vaccine v934/v935 n1=Bevacizumab | n2=en:htert vaccine v934/v935 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:htert-encoding dna vaccine invac-1 n1=Bevacizumab | n2=en:htert-encoding dna vaccine invac-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:htert-lamp mrna-loaded autologous dendritic cell vaccine grnvac1 n1=Bevacizumab | n2=en:htert-lamp mrna-loaded autologous dendritic cell vaccine grnvac1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:htert/survivin/cmv multipeptide vaccine n1=Bevacizumab | n2=en:htert/survivin/cmv multipeptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:htert/survivin/melanoma tumor cell-derived mrna-transfected dendritic cell vaccine n1=Bevacizumab | n2=en:htert/survivin/melanoma tumor cell-derived mrna-transfected dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hu14.18-il2 fusion protein n1=Bevacizumab | n2=en:hu14.18-il2 fusion protein | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:huachansu n1=Bevacizumab | n2=en:huachansu | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:huaier extract granule n1=Bevacizumab | n2=en:huaier extract granule | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:huang lian n1=Bevacizumab | n2=en:huang lian | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hubc1-huil12 fusion protein as1409 n1=Bevacizumab | n2=en:hubc1-huil12 fusion protein as1409 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:human combinatorial antibody library-based monoclonal antibody vay736 n1=Bevacizumab | n2=en:human combinatorial antibody library-based monoclonal antibody vay736 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:human gp100 plasmid dna vaccine n1=Bevacizumab | n2=en:human gp100 plasmid dna vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:human lactoferrin peptide hlf1-11 n1=Bevacizumab | n2=en:human lactoferrin peptide hlf1-11 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:human menopausal gonadotropin n1=Bevacizumab | n2=en:human menopausal gonadotropin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:human mhc non-restricted cytotoxic t-cell line tall-104 n1=Bevacizumab | n2=en:human mhc non-restricted cytotoxic t-cell line tall-104 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:human monoclonal antibody 216 n1=Bevacizumab | n2=en:human monoclonal antibody 216 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:human monoclonal antibody b11-hcg beta fusion protein cdx-1307 n1=Bevacizumab | n2=en:human monoclonal antibody b11-hcg beta fusion protein cdx-1307 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:human myeloid progenitor cells clt-008 n1=Bevacizumab | n2=en:human myeloid progenitor cells clt-008 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:human papilloma virus l1 virus-like particle v504 vaccine n1=Bevacizumab | n2=en:human papilloma virus l1 virus-like particle v504 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:human papillomavirus 16/18 l1 virus-like particle/as04 vaccine n1=Bevacizumab | n2=en:human papillomavirus 16/18 l1 virus-like particle/as04 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:human papillomavirus tumor antigen vaccine n1=Bevacizumab | n2=en:human papillomavirus tumor antigen vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:human papillomavirus vaccine v503 n1=Bevacizumab | n2=en:human papillomavirus vaccine v503 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:human prostate-specific membrane antigen plasmid dna vaccine n1=Bevacizumab | n2=en:human prostate-specific membrane antigen plasmid dna vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:human trefoil factor 1-secreting lactococcus lactis ag013 n1=Bevacizumab | n2=en:human trefoil factor 1-secreting lactococcus lactis ag013 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:human varicella zoster immune globulin n1=Bevacizumab | n2=en:human varicella zoster immune globulin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:humanized monoclonal antibody n1=Bevacizumab | n2=en:humanized monoclonal antibody | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:humanized monoclonal antibody 3f8 n1=Bevacizumab | n2=en:humanized monoclonal antibody 3f8 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hvegf26-104/rfase peptide vaccine n1=Bevacizumab | n2=en:hvegf26-104/rfase peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hyaluronic acid n1=Bevacizumab | n2=en:hyaluronic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hyaluronic acid-based hydrating vaginal gel n1=Bevacizumab | n2=en:hyaluronic acid-based hydrating vaginal gel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hyaluronic acid-containing topical cream n1=Bevacizumab | n2=en:hyaluronic acid-containing topical cream | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hyb2055 n1=Bevacizumab | n2=en:hyb2055 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hycanthone n1=Bevacizumab | n2=en:hycanthone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hydralazine hydrochloride n1=Bevacizumab | n2=en:hydralazine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hydrated sodium calcium aluminosilicate n1=Bevacizumab | n2=en:hydrated sodium calcium aluminosilicate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hydrazine sulfate n1=Bevacizumab | n2=en:hydrazine sulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hydrocodone/acetaminophen n1=Bevacizumab | n2=en:hydrocodone/acetaminophen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hydrocortisone sodium succinate n1=Bevacizumab | n2=en:hydrocortisone sodium succinate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hydromorphone hydrochloride n1=Bevacizumab | n2=en:hydromorphone hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hydroxychloroquine n1=Bevacizumab | n2=en:hydroxychloroquine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hydroxyprogesterone caproate n1=Bevacizumab | n2=en:hydroxyprogesterone caproate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hydroxytyrosol n1=Bevacizumab | n2=en:hydroxytyrosol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hydroxyurea n1=Bevacizumab | n2=en:hydroxyurea | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hyperbaric oxygen n1=Bevacizumab | n2=en:hyperbaric oxygen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hypercvad regimen n1=Bevacizumab | n2=en:hypercvad regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hyperglycemic agent n1=Bevacizumab | n2=en:hyperglycemic agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hyperimmune bovine colostrum n1=Bevacizumab | n2=en:hyperimmune bovine colostrum | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hyperpolarized carbon c 13 pyruvate n1=Bevacizumab | n2=en:hyperpolarized carbon c 13 pyruvate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hyperpolarized helium 3 n1=Bevacizumab | n2=en:hyperpolarized helium 3 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hyperpolarized xenon 129 n1=Bevacizumab | n2=en:hyperpolarized xenon 129 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hypertonic saline n1=Bevacizumab | n2=en:hypertonic saline | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hypoglycemic agents n1=Bevacizumab | n2=en:hypoglycemic agents | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hypoxia-activated prodrug th-302 n1=Bevacizumab | n2=en:hypoxia-activated prodrug th-302 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:hypoxia-activated prodrug th-4000 n1=Bevacizumab | n2=en:hypoxia-activated prodrug th-4000 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:i 123 monoclonal antibody 81c6 n1=Bevacizumab | n2=en:i 123 monoclonal antibody 81c6 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:i 131 antiferritin immunoglobulin n1=Bevacizumab | n2=en:i 131 antiferritin immunoglobulin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:i 131 monoclonal antibody a33 n1=Bevacizumab | n2=en:i 131 monoclonal antibody a33 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:i 131 monoclonal antibody cc49 n1=Bevacizumab | n2=en:i 131 monoclonal antibody cc49 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:i 131 monoclonal antibody f19 n1=Bevacizumab | n2=en:i 131 monoclonal antibody f19 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:i 131 monoclonal antibody lym-1 n1=Bevacizumab | n2=en:i 131 monoclonal antibody lym-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iap inhibitor at-406 n1=Bevacizumab | n2=en:iap inhibitor at-406 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iap inhibitor hgs1029 n1=Bevacizumab | n2=en:iap inhibitor hgs1029 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iapa-based dendritic cells/cytotoxic t lymphocytes n1=Bevacizumab | n2=en:iapa-based dendritic cells/cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ibandronate sodium n1=Bevacizumab | n2=en:ibandronate sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ibritumomab n1=Bevacizumab | n2=en:ibritumomab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ibritumomab tiuxetan n1=Bevacizumab | n2=en:ibritumomab tiuxetan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ibrutinib n1=Bevacizumab | n2=en:ibrutinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ibuprofen n1=Bevacizumab | n2=en:ibuprofen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ibuprofen injection n1=Bevacizumab | n2=en:ibuprofen injection | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ic9-gd2-cd28-ox40-expressing t lymphocytes n1=Bevacizumab | n2=en:ic9-gd2-cd28-ox40-expressing t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:icatibant n1=Bevacizumab | n2=en:icatibant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ice regimen n1=Bevacizumab | n2=en:ice regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:icodextrin solution n1=Bevacizumab | n2=en:icodextrin solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:icotinib hydrochloride n1=Bevacizumab | n2=en:icotinib hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:icrucumab n1=Bevacizumab | n2=en:icrucumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:idarubicin hydrochloride n1=Bevacizumab | n2=en:idarubicin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:idarubicin-eluting beads n1=Bevacizumab | n2=en:idarubicin-eluting beads | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:idasanutlin n1=Bevacizumab | n2=en:idasanutlin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:idelalisib n1=Bevacizumab | n2=en:idelalisib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:idh1 inhibitor ag-120 n1=Bevacizumab | n2=en:idh1 inhibitor ag-120 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:idh1(r132) inhibitor idh305 n1=Bevacizumab | n2=en:idh1(r132) inhibitor idh305 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:idh1r132h mutation-targeting idh1 peptide vaccine n1=Bevacizumab | n2=en:idh1r132h mutation-targeting idh1 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:idh1r132h-specific peptide vaccine pepidh1m n1=Bevacizumab | n2=en:idh1r132h-specific peptide vaccine pepidh1m | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:idh2 inhibitor ag-221 n1=Bevacizumab | n2=en:idh2 inhibitor ag-221 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:idiotype-pulsed autologous dendritic cell vaccine apc8020 n1=Bevacizumab | n2=en:idiotype-pulsed autologous dendritic cell vaccine apc8020 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ido inhibitor nlg919 n1=Bevacizumab | n2=en:ido inhibitor nlg919 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:idoxifene n1=Bevacizumab | n2=en:idoxifene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:idoxuridine n1=Bevacizumab | n2=en:idoxuridine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:idronoxil n1=Bevacizumab | n2=en:idronoxil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ifl-bevacizumab regimen n1=Bevacizumab | n2=en:ifl-bevacizumab regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ifosfamide n1=Bevacizumab | n2=en:ifosfamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:igf ligand neutralizing antibody bi 836845 n1=Bevacizumab | n2=en:igf ligand neutralizing antibody bi 836845 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:igf-1r antisense oligodeoxynucleotide-treated autologous glioma cells n1=Bevacizumab | n2=en:igf-1r antisense oligodeoxynucleotide-treated autologous glioma cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:igf-1r inhibitor pl225b n1=Bevacizumab | n2=en:igf-1r inhibitor pl225b | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:igf-1r/ir inhibitor kw-2450 n1=Bevacizumab | n2=en:igf-1r/ir inhibitor kw-2450 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:igf-methotrexate conjugate n1=Bevacizumab | n2=en:igf-methotrexate conjugate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ih636 grape seed proanthocyanidin extract n1=Bevacizumab | n2=en:ih636 grape seed proanthocyanidin extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:il-10 immunomodulator mk-1966 n1=Bevacizumab | n2=en:il-10 immunomodulator mk-1966 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:il-12-expressing hsv-1 n1=Bevacizumab | n2=en:il-12-expressing hsv-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:il-12-expressing mesenchymal stem cell vaccine gx-051 n1=Bevacizumab | n2=en:il-12-expressing mesenchymal stem cell vaccine gx-051 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:il-2 plasmid dna/lipid complex n1=Bevacizumab | n2=en:il-2 plasmid dna/lipid complex | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:il-2 recombinant fusion protein alt-801 n1=Bevacizumab | n2=en:il-2 recombinant fusion protein alt-801 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:il-2/lptn gene-modified allogeneic neuroblastoma tumor cell vaccine n1=Bevacizumab | n2=en:il-2/lptn gene-modified allogeneic neuroblastoma tumor cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:il13ralpha2-specific hinge-optimized 41bb-co-stimulatory car truncated cd19-expressing autologous t-lymphocytes n1=Bevacizumab | n2=en:il13ralpha2-specific hinge-optimized 41bb-co-stimulatory car truncated cd19-expressing autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:il4-pseudomonas exotoxin fusion protein prx321 n1=Bevacizumab | n2=en:il4-pseudomonas exotoxin fusion protein prx321 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ilaprazole n1=Bevacizumab | n2=en:ilaprazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iloprost n1=Bevacizumab | n2=en:iloprost | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ilorasertib n1=Bevacizumab | n2=en:ilorasertib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ilx-295501 n1=Bevacizumab | n2=en:ilx-295501 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ilx23-7553 n1=Bevacizumab | n2=en:ilx23-7553 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:imalumab n1=Bevacizumab | n2=en:imalumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:imatinib mesylate n1=Bevacizumab | n2=en:imatinib mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:imetelstat sodium n1=Bevacizumab | n2=en:imetelstat sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:imexon n1=Bevacizumab | n2=en:imexon | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:imidazole mustard n1=Bevacizumab | n2=en:imidazole mustard | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:imidazolyl ethanamide pentandioic acid n1=Bevacizumab | n2=en:imidazolyl ethanamide pentandioic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:imipenem n1=Bevacizumab | n2=en:imipenem | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:imipenem-cilastatin sodium n1=Bevacizumab | n2=en:imipenem-cilastatin sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:imiquimod n1=Bevacizumab | n2=en:imiquimod | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:imisopasem manganese n1=Bevacizumab | n2=en:imisopasem manganese | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:immediate-release onapristone n1=Bevacizumab | n2=en:immediate-release onapristone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:immediate-release oral liquid formulation oxymorphone hydrochloride n1=Bevacizumab | n2=en:immediate-release oral liquid formulation oxymorphone hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:immediate-release tablet afuresertib n1=Bevacizumab | n2=en:immediate-release tablet afuresertib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:immunoadjuvant qs-dg n1=Bevacizumab | n2=en:immunoadjuvant qs-dg | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:immunoconjugate ro5479599 n1=Bevacizumab | n2=en:immunoconjugate ro5479599 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:immunocytokine nhs-il12 n1=Bevacizumab | n2=en:immunocytokine nhs-il12 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:immunocytokine nhs-il2-lt n1=Bevacizumab | n2=en:immunocytokine nhs-il2-lt | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:immunology aspects n1=Bevacizumab | n2=en:immunology aspects | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:immunomodulating agent n1=Bevacizumab | n2=en:immunomodulating agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:immunomodulator ohr/avr118 n1=Bevacizumab | n2=en:immunomodulator ohr/avr118 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:immunomodulators n1=Bevacizumab | n2=en:immunomodulators | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:immunomodulatory agent cc-11006 n1=Bevacizumab | n2=en:immunomodulatory agent cc-11006 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:immunotherapeutic agent n1=Bevacizumab | n2=en:immunotherapeutic agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:immunotherapeutic combination product cmb305 n1=Bevacizumab | n2=en:immunotherapeutic combination product cmb305 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:immunotherapeutic gsk1572932a n1=Bevacizumab | n2=en:immunotherapeutic gsk1572932a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:immunotherapy regimen mkc-1106-mt n1=Bevacizumab | n2=en:immunotherapy regimen mkc-1106-mt | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:immunotoxin cmd-193 n1=Bevacizumab | n2=en:immunotoxin cmd-193 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:immunotoxin d2c7-(scdsfv)-pe38kdel n1=Bevacizumab | n2=en:immunotoxin d2c7-(scdsfv)-pe38kdel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:imp321 n1=Bevacizumab | n2=en:imp321 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:imreg-1 n1=Bevacizumab | n2=en:imreg-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:imt-1012 immunotherapeutic vaccine n1=Bevacizumab | n2=en:imt-1012 immunotherapeutic vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:imuvert n1=Bevacizumab | n2=en:imuvert | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:in 111 folic acid n1=Bevacizumab | n2=en:in 111 folic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:in 111 monoclonal antibody b3 n1=Bevacizumab | n2=en:in 111 monoclonal antibody b3 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:in 111 monoclonal antibody hu3s193 n1=Bevacizumab | n2=en:in 111 monoclonal antibody hu3s193 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:in 111 monoclonal antibody ll2 n1=Bevacizumab | n2=en:in 111 monoclonal antibody ll2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:in 111 monoclonal antibody lym-1 n1=Bevacizumab | n2=en:in 111 monoclonal antibody lym-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:in 111 monoclonal antibody m170 n1=Bevacizumab | n2=en:in 111 monoclonal antibody m170 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:in 111 monoclonal antibody mn-14 n1=Bevacizumab | n2=en:in 111 monoclonal antibody mn-14 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:in 111 satumomab pendetide n1=Bevacizumab | n2=en:in 111 satumomab pendetide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:in blood n1=Bevacizumab | n2=en:in blood | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:in cerebrospinal fluid n1=Bevacizumab | n2=en:in cerebrospinal fluid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:in urine n1=Bevacizumab | n2=en:in urine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:inactivated poliovirus vaccine n1=Bevacizumab | n2=en:inactivated poliovirus vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:inalimarev n1=Bevacizumab | n2=en:inalimarev | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:incomplete freund's adjuvant n1=Bevacizumab | n2=en:incomplete freund's adjuvant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:incyclinide n1=Bevacizumab | n2=en:incyclinide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indibulin n1=Bevacizumab | n2=en:indibulin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indicine-n-oxide n1=Bevacizumab | n2=en:indicine-n-oxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indinavir sulfate n1=Bevacizumab | n2=en:indinavir sulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indisulam n1=Bevacizumab | n2=en:indisulam | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indium in 111 anti-cd45 monoclonal antibody bc8 n1=Bevacizumab | n2=en:indium in 111 anti-cd45 monoclonal antibody bc8 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indium in 111 anti-egfr monoclonal antibody abt-806 n1=Bevacizumab | n2=en:indium in 111 anti-egfr monoclonal antibody abt-806 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indium in 111 bevacizumab n1=Bevacizumab | n2=en:indium in 111 bevacizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indium in 111 capromab pendetide n1=Bevacizumab | n2=en:indium in 111 capromab pendetide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indium in 111 chimeric monoclonal antibody 806 n1=Bevacizumab | n2=en:indium in 111 chimeric monoclonal antibody 806 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indium in 111 chx-a dtpa trastuzumab n1=Bevacizumab | n2=en:indium in 111 chx-a dtpa trastuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indium in 111 girentuximab n1=Bevacizumab | n2=en:indium in 111 girentuximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indium in 111 her2-specific high-affinity protein aby-025 n1=Bevacizumab | n2=en:indium in 111 her2-specific high-affinity protein aby-025 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indium in 111 monoclonal antibody bre-3 n1=Bevacizumab | n2=en:indium in 111 monoclonal antibody bre-3 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indium in 111 monoclonal antibody hupam4 n1=Bevacizumab | n2=en:indium in 111 monoclonal antibody hupam4 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indium in 111 pentetate n1=Bevacizumab | n2=en:indium in 111 pentetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indium in 111 pertuzumab n1=Bevacizumab | n2=en:indium in 111 pertuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indium in 111-cmd-193 n1=Bevacizumab | n2=en:indium in 111-cmd-193 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indium in 111-dota-biotin n1=Bevacizumab | n2=en:indium in 111-dota-biotin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indium in 111-dota-di-hsg peptide imp-288 n1=Bevacizumab | n2=en:indium in 111-dota-di-hsg peptide imp-288 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indium in 111-dota-exendin-4 n1=Bevacizumab | n2=en:indium in 111-dota-exendin-4 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indium in 111-labeled autologous peripheral blood mononuclear cells n1=Bevacizumab | n2=en:indium in 111-labeled autologous peripheral blood mononuclear cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indium in 111-labeled autologous polymorphonuclear leukocytes n1=Bevacizumab | n2=en:indium in 111-labeled autologous polymorphonuclear leukocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indium in 111-labeled macroaggregated albumin n1=Bevacizumab | n2=en:indium in 111-labeled macroaggregated albumin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indium in 111/yttrium y90-dota-biotin n1=Bevacizumab | n2=en:indium in 111/yttrium y90-dota-biotin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indium in-111 ibritumomab tiuxetan n1=Bevacizumab | n2=en:indium in-111 ibritumomab tiuxetan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indium in-111 pentetreotide n1=Bevacizumab | n2=en:indium in-111 pentetreotide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indocyanine green solution n1=Bevacizumab | n2=en:indocyanine green solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indocyanine green/albumin solution n1=Bevacizumab | n2=en:indocyanine green/albumin solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indole-3-carbinol n1=Bevacizumab | n2=en:indole-3-carbinol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indole-3-carbinol/calcium/schizandra/vitamin d3/milk thistle/stinging nettle/lignan-based nutritional capsule n1=Bevacizumab | n2=en:indole-3-carbinol/calcium/schizandra/vitamin d3/milk thistle/stinging nettle/lignan-based nutritional capsule | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indoleamine 2,3-dioxygenase peptide vaccine n1=Bevacizumab | n2=en:indoleamine 2,3-dioxygenase peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indomethacin n1=Bevacizumab | n2=en:indomethacin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:indoximod n1=Bevacizumab | n2=en:indoximod | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:inducible cd4+cd25+ regulatory t cells n1=Bevacizumab | n2=en:inducible cd4+cd25+ regulatory t cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:inecalcitol n1=Bevacizumab | n2=en:inecalcitol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:infliximab n1=Bevacizumab | n2=en:infliximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ingenol derivative leo 43204 gel n1=Bevacizumab | n2=en:ingenol derivative leo 43204 gel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ingenol mebutate n1=Bevacizumab | n2=en:ingenol mebutate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ingenol mebutate gel n1=Bevacizumab | n2=en:ingenol mebutate gel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:inhibition of cell proliferation n1=Bevacizumab | n2=en:inhibition of cell proliferation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iniparib n1=Bevacizumab | n2=en:iniparib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:injectable astragalus membranaceus polysaccharide n1=Bevacizumab | n2=en:injectable astragalus membranaceus polysaccharide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:injectable liposomal vinorelbine n1=Bevacizumab | n2=en:injectable liposomal vinorelbine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:innate defense regulator sgx942 n1=Bevacizumab | n2=en:innate defense regulator sgx942 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:innate immunostimulator rbbx-01 n1=Bevacizumab | n2=en:innate immunostimulator rbbx-01 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ino-1001 n1=Bevacizumab | n2=en:ino-1001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:inosine 5'-monophosphate dehydrogenase inhibitor ff-10501-01 n1=Bevacizumab | n2=en:inosine 5'-monophosphate dehydrogenase inhibitor ff-10501-01 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:inosine dialdehyde n1=Bevacizumab | n2=en:inosine dialdehyde | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:inosine pranobex n1=Bevacizumab | n2=en:inosine pranobex | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:inositol n1=Bevacizumab | n2=en:inositol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:inotropic agent n1=Bevacizumab | n2=en:inotropic agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:inotuzumab ozogamicin n1=Bevacizumab | n2=en:inotuzumab ozogamicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:inproquone n1=Bevacizumab | n2=en:inproquone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ins316 n1=Bevacizumab | n2=en:ins316 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:insulin aspart n1=Bevacizumab | n2=en:insulin aspart | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:insulin degludec n1=Bevacizumab | n2=en:insulin degludec | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:insulin glargine n1=Bevacizumab | n2=en:insulin glargine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:insulin lispro n1=Bevacizumab | n2=en:insulin lispro | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:insulin sensitizer s-707106 n1=Bevacizumab | n2=en:insulin sensitizer s-707106 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:insulin, nph n1=Bevacizumab | n2=en:insulin, nph | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:insulin, regular n1=Bevacizumab | n2=en:insulin, regular | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:integrin receptor antagonist glpg0187 n1=Bevacizumab | n2=en:integrin receptor antagonist glpg0187 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:interferon alfacon-1 n1=Bevacizumab | n2=en:interferon alfacon-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:interferon beta-secreting mesenchymal stem cells n1=Bevacizumab | n2=en:interferon beta-secreting mesenchymal stem cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:interferon-gamma-expressing adenovirus vaccine asn-002 n1=Bevacizumab | n2=en:interferon-gamma-expressing adenovirus vaccine asn-002 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:interleukin-10 n1=Bevacizumab | n2=en:interleukin-10 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:interleukin-12 gene n1=Bevacizumab | n2=en:interleukin-12 gene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:interleukin-2 fusion protein msb0010445 n1=Bevacizumab | n2=en:interleukin-2 fusion protein msb0010445 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:interleukin-2 gene n1=Bevacizumab | n2=en:interleukin-2 gene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:interleukin-2 liposome n1=Bevacizumab | n2=en:interleukin-2 liposome | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:interleukin-4 pe38kdel immunotoxin n1=Bevacizumab | n2=en:interleukin-4 pe38kdel immunotoxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:interleukin-6 n1=Bevacizumab | n2=en:interleukin-6 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:intermediate-affinity interleukin-2 receptor agonist alks 4230 n1=Bevacizumab | n2=en:intermediate-affinity interleukin-2 receptor agonist alks 4230 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:intetumumab n1=Bevacizumab | n2=en:intetumumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:intiquinatine n1=Bevacizumab | n2=en:intiquinatine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:intoplicine n1=Bevacizumab | n2=en:intoplicine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:intranasal ketamine n1=Bevacizumab | n2=en:intranasal ketamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:intravesical bcg n1=Bevacizumab | n2=en:intravesical bcg | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:inulin n1=Bevacizumab | n2=en:inulin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:investigational new drug n1=Bevacizumab | n2=en:investigational new drug | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iobenguane i-124 n1=Bevacizumab | n2=en:iobenguane i-124 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iobenguane i-131 n1=Bevacizumab | n2=en:iobenguane i-131 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iobenguane sulfate i-123 n1=Bevacizumab | n2=en:iobenguane sulfate i-123 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iobitridol n1=Bevacizumab | n2=en:iobitridol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodinated contrast agent n1=Bevacizumab | n2=en:iodinated contrast agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine 131-6-beta-iodomethyl-19-norcholesterol n1=Bevacizumab | n2=en:iodine 131-6-beta-iodomethyl-19-norcholesterol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine compounds n1=Bevacizumab | n2=en:iodine compounds | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 123 anti-cea recombinant diabody t84.66 n1=Bevacizumab | n2=en:iodine i 123 anti-cea recombinant diabody t84.66 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 123 iodobenzamide n1=Bevacizumab | n2=en:iodine i 123 iodobenzamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 124 n1=Bevacizumab | n2=en:iodine i 124 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 124 anti-phosphatidylserine monoclonal antibody pgn650 n1=Bevacizumab | n2=en:iodine i 124 anti-phosphatidylserine monoclonal antibody pgn650 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 124 cpd-1028 n1=Bevacizumab | n2=en:iodine i 124 cpd-1028 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 124 iododeoxyuridine n1=Bevacizumab | n2=en:iodine i 124 iododeoxyuridine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 124 monoclonal antibody 3f8 n1=Bevacizumab | n2=en:iodine i 124 monoclonal antibody 3f8 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 124 monoclonal antibody 8h9 n1=Bevacizumab | n2=en:iodine i 124 monoclonal antibody 8h9 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 124 monoclonal antibody a33 n1=Bevacizumab | n2=en:iodine i 124 monoclonal antibody a33 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 124 nm404 n1=Bevacizumab | n2=en:iodine i 124 nm404 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 124 phospholipid ether analogue clr1404 n1=Bevacizumab | n2=en:iodine i 124 phospholipid ether analogue clr1404 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 124 pu-ad n1=Bevacizumab | n2=en:iodine i 124 pu-ad | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 124-crgdy-peg-c dots n1=Bevacizumab | n2=en:iodine i 124-crgdy-peg-c dots | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 124-iodo-azomycin galactopyranoside n1=Bevacizumab | n2=en:iodine i 124-iodo-azomycin galactopyranoside | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 124-labeled anti-psca a11 minibody n1=Bevacizumab | n2=en:iodine i 124-labeled anti-psca a11 minibody | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 124-labeled hsp90 inhibitor puh71 n1=Bevacizumab | n2=en:iodine i 124-labeled hsp90 inhibitor puh71 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 125-anti-egfr-425 monoclonal antibody n1=Bevacizumab | n2=en:iodine i 125-anti-egfr-425 monoclonal antibody | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 131 anti-fibronectin antibody fragment l19-sip n1=Bevacizumab | n2=en:iodine i 131 anti-fibronectin antibody fragment l19-sip | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 131 ethiodized oil n1=Bevacizumab | n2=en:iodine i 131 ethiodized oil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 131 monoclonal antibody 3f8 n1=Bevacizumab | n2=en:iodine i 131 monoclonal antibody 3f8 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 131 monoclonal antibody 81c6 n1=Bevacizumab | n2=en:iodine i 131 monoclonal antibody 81c6 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 131 monoclonal antibody 8h9 n1=Bevacizumab | n2=en:iodine i 131 monoclonal antibody 8h9 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 131 monoclonal antibody bc8 n1=Bevacizumab | n2=en:iodine i 131 monoclonal antibody bc8 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 131 monoclonal antibody cc49-deltach2 n1=Bevacizumab | n2=en:iodine i 131 monoclonal antibody cc49-deltach2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 131 monoclonal antibody f16sip n1=Bevacizumab | n2=en:iodine i 131 monoclonal antibody f16sip | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 131 monoclonal antibody g-250 n1=Bevacizumab | n2=en:iodine i 131 monoclonal antibody g-250 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 131 monoclonal antibody muj591 n1=Bevacizumab | n2=en:iodine i 131 monoclonal antibody muj591 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 131 monoclonal antibody tnt-1/b n1=Bevacizumab | n2=en:iodine i 131 monoclonal antibody tnt-1/b | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 131 nm404 n1=Bevacizumab | n2=en:iodine i 131 nm404 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 131 phospholipid ether analogue clr1404 n1=Bevacizumab | n2=en:iodine i 131 phospholipid ether analogue clr1404 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 131 rituximab n1=Bevacizumab | n2=en:iodine i 131 rituximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 131 sgmib-anti-her2 vhh1 n1=Bevacizumab | n2=en:iodine i 131 sgmib-anti-her2 vhh1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 131 tenatumomab n1=Bevacizumab | n2=en:iodine i 131 tenatumomab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 131 tm-601 n1=Bevacizumab | n2=en:iodine i 131 tm-601 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 131 tositumomab n1=Bevacizumab | n2=en:iodine i 131 tositumomab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i 131-labeled anti-cea/anti-hsg bispecific monoclonal antibody tf2 n1=Bevacizumab | n2=en:iodine i 131-labeled anti-cea/anti-hsg bispecific monoclonal antibody tf2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i-123 n1=Bevacizumab | n2=en:iodine i-123 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i-123 adam n1=Bevacizumab | n2=en:iodine i-123 adam | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i-123 iodometomidate n1=Bevacizumab | n2=en:iodine i-123 iodometomidate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i-123 mip-1095 n1=Bevacizumab | n2=en:iodine i-123 mip-1095 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i-124 fiau n1=Bevacizumab | n2=en:iodine i-124 fiau | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i-124 girentuximab n1=Bevacizumab | n2=en:iodine i-124 girentuximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i-125 n1=Bevacizumab | n2=en:iodine i-125 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine i-131 n1=Bevacizumab | n2=en:iodine i-131 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodine norcholestenol n1=Bevacizumab | n2=en:iodine norcholestenol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodixanol n1=Bevacizumab | n2=en:iodixanol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodocholesterol i^131^ n1=Bevacizumab | n2=en:iodocholesterol i^131^ | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iodophore product n1=Bevacizumab | n2=en:iodophore product | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ioflubenzamide i-131 n1=Bevacizumab | n2=en:ioflubenzamide i-131 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iofolastat i123 n1=Bevacizumab | n2=en:iofolastat i123 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iohexol n1=Bevacizumab | n2=en:iohexol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ionic silver-impregnated sodium carboxymethylcellulose antimicrobial dressing n1=Bevacizumab | n2=en:ionic silver-impregnated sodium carboxymethylcellulose antimicrobial dressing | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ionomycin n1=Bevacizumab | n2=en:ionomycin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iopromide n1=Bevacizumab | n2=en:iopromide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ipafricept n1=Bevacizumab | n2=en:ipafricept | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ipamorelin n1=Bevacizumab | n2=en:ipamorelin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ipatasertib n1=Bevacizumab | n2=en:ipatasertib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ipilimumab n1=Bevacizumab | n2=en:ipilimumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ipomeanol n1=Bevacizumab | n2=en:ipomeanol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ipp-204106n n1=Bevacizumab | n2=en:ipp-204106n | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iproplatin n1=Bevacizumab | n2=en:iproplatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iratumumab n1=Bevacizumab | n2=en:iratumumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iridium ir 192 n1=Bevacizumab | n2=en:iridium ir 192 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:irinotecan n1=Bevacizumab | n2=en:irinotecan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:irinotecan hydrochloride n1=Bevacizumab | n2=en:irinotecan hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:irinotecan-eluting beads n1=Bevacizumab | n2=en:irinotecan-eluting beads | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:irinotecan/p-glycoprotein inhibitor hm30181ak combination tablet n1=Bevacizumab | n2=en:irinotecan/p-glycoprotein inhibitor hm30181ak combination tablet | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:irofulven n1=Bevacizumab | n2=en:irofulven | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iron n1=Bevacizumab | n2=en:iron | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iron dextran complex n1=Bevacizumab | n2=en:iron dextran complex | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iron isomaltoside 1000 n1=Bevacizumab | n2=en:iron isomaltoside 1000 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iron sucrose injection n1=Bevacizumab | n2=en:iron sucrose injection | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:irosustat n1=Bevacizumab | n2=en:irosustat | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:irritants n1=Bevacizumab | n2=en:irritants | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:irx-2 n1=Bevacizumab | n2=en:irx-2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:isavuconazole n1=Bevacizumab | n2=en:isavuconazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iseganan hydrochloride n1=Bevacizumab | n2=en:iseganan hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:isis 2503 n1=Bevacizumab | n2=en:isis 2503 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:isis 3521 n1=Bevacizumab | n2=en:isis 3521 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:isis 5132 n1=Bevacizumab | n2=en:isis 5132 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iso-fludelone n1=Bevacizumab | n2=en:iso-fludelone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:isoflurane n1=Bevacizumab | n2=en:isoflurane | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:isoniazid n1=Bevacizumab | n2=en:isoniazid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:isoquercetin n1=Bevacizumab | n2=en:isoquercetin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:isosulfan blue n1=Bevacizumab | n2=en:isosulfan blue | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:isotretinoin n1=Bevacizumab | n2=en:isotretinoin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ispinesib n1=Bevacizumab | n2=en:ispinesib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:iss 1018 cpg oligodeoxynucleotide n1=Bevacizumab | n2=en:iss 1018 cpg oligodeoxynucleotide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:itraconazole n1=Bevacizumab | n2=en:itraconazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:itraconazole dispersion in polymer matrix n1=Bevacizumab | n2=en:itraconazole dispersion in polymer matrix | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ivabradine n1=Bevacizumab | n2=en:ivabradine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ivac mutanome vaccine n1=Bevacizumab | n2=en:ivac mutanome vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ixabepilone n1=Bevacizumab | n2=en:ixabepilone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ixazomib citrate n1=Bevacizumab | n2=en:ixazomib citrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:j5 antiserum n1=Bevacizumab | n2=en:j5 antiserum | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:jak inhibitor incb047986 n1=Bevacizumab | n2=en:jak inhibitor incb047986 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:jak1 inhibitor incb039110 n1=Bevacizumab | n2=en:jak1 inhibitor incb039110 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:jak1 inhibitor incb052793 n1=Bevacizumab | n2=en:jak1 inhibitor incb052793 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:jak2 inhibitor azd1480 n1=Bevacizumab | n2=en:jak2 inhibitor azd1480 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:jak2 inhibitor bms-911543 n1=Bevacizumab | n2=en:jak2 inhibitor bms-911543 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:jak2 inhibitor tg101348 n1=Bevacizumab | n2=en:jak2 inhibitor tg101348 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:jak2 inhibitor wp1066 n1=Bevacizumab | n2=en:jak2 inhibitor wp1066 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:jak2 inhibitor xl019 n1=Bevacizumab | n2=en:jak2 inhibitor xl019 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:jak2/src inhibitor ns-018 n1=Bevacizumab | n2=en:jak2/src inhibitor ns-018 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:jeb regimen n1=Bevacizumab | n2=en:jeb regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:jin fu kang n1=Bevacizumab | n2=en:jin fu kang | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:juven n1=Bevacizumab | n2=en:juven | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:kanamycin sulfate n1=Bevacizumab | n2=en:kanamycin sulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:kanglaite n1=Bevacizumab | n2=en:kanglaite | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:kava-based supplement n1=Bevacizumab | n2=en:kava-based supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ketamine hydrochloride n1=Bevacizumab | n2=en:ketamine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ketamine/amitriptyline np-h cream n1=Bevacizumab | n2=en:ketamine/amitriptyline np-h cream | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ketoconazole n1=Bevacizumab | n2=en:ketoconazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ketoprofen n1=Bevacizumab | n2=en:ketoprofen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ketorolac n1=Bevacizumab | n2=en:ketorolac | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ketorolac + phenylephrine n1=Bevacizumab | n2=en:ketorolac + phenylephrine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ketorolac tromethamine n1=Bevacizumab | n2=en:ketorolac tromethamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:keyhole limpet hemocyanin n1=Bevacizumab | n2=en:keyhole limpet hemocyanin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:kit/pdgfr inhibitor dcc-2618 n1=Bevacizumab | n2=en:kit/pdgfr inhibitor dcc-2618 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:klebsiella pneumoniae glycoprotein n1=Bevacizumab | n2=en:klebsiella pneumoniae glycoprotein | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:klh-fitc n1=Bevacizumab | n2=en:klh-fitc | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:krn5500 n1=Bevacizumab | n2=en:krn5500 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ksa-klh conjugate vaccine n1=Bevacizumab | n2=en:ksa-klh conjugate vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ksp inhibitor arry-520 n1=Bevacizumab | n2=en:ksp inhibitor arry-520 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ksp inhibitor azd4877 n1=Bevacizumab | n2=en:ksp inhibitor azd4877 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:kunecatechins ointment n1=Bevacizumab | n2=en:kunecatechins ointment | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:kw-2149 n1=Bevacizumab | n2=en:kw-2149 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:l-377,202 n1=Bevacizumab | n2=en:l-377,202 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:l-4-chlorokynurenine n1=Bevacizumab | n2=en:l-4-chlorokynurenine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:l-778,123 n1=Bevacizumab | n2=en:l-778,123 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:l-arginine/korean ginseng/ginkgo biloba/damiana-based supplement n1=Bevacizumab | n2=en:l-arginine/korean ginseng/ginkgo biloba/damiana-based supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:l-carnitine l-tartrate n1=Bevacizumab | n2=en:l-carnitine l-tartrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:l-gossypol n1=Bevacizumab | n2=en:l-gossypol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:l-leucyl-l-leucine methyl ester n1=Bevacizumab | n2=en:l-leucyl-l-leucine methyl ester | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:l-lysine n1=Bevacizumab | n2=en:l-lysine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:l-menthol preparation npo-11 n1=Bevacizumab | n2=en:l-menthol preparation npo-11 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:l-methylfolate n1=Bevacizumab | n2=en:l-methylfolate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:l-ornithine l-aspartate n1=Bevacizumab | n2=en:l-ornithine l-aspartate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:l-tryptophan/thymine-based supplement n1=Bevacizumab | n2=en:l-tryptophan/thymine-based supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:l19-il2 monoclonal antibody-cytokine fusion protein n1=Bevacizumab | n2=en:l19-il2 monoclonal antibody-cytokine fusion protein | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:labetuzumab-sn-38 immunoconjugate immu-130 n1=Bevacizumab | n2=en:labetuzumab-sn-38 immunoconjugate immu-130 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:labradimil n1=Bevacizumab | n2=en:labradimil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lacosamide n1=Bevacizumab | n2=en:lacosamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lactated ringer solution n1=Bevacizumab | n2=en:lactated ringer solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lactobacillus acidophilus n1=Bevacizumab | n2=en:lactobacillus acidophilus | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lactobacillus acidophilus/estriol vaginal tablet n1=Bevacizumab | n2=en:lactobacillus acidophilus/estriol vaginal tablet | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lactobacillus acidophilus/streptococcus thermophilus/bifidobacterium lactis/l. rhamnosus/b. longum/b. bifidum-based probiotic supplement n1=Bevacizumab | n2=en:lactobacillus acidophilus/streptococcus thermophilus/bifidobacterium lactis/l. rhamnosus/b. longum/b. bifidum-based probiotic supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lactobacillus brevis cd2 lozenge n1=Bevacizumab | n2=en:lactobacillus brevis cd2 lozenge | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lactobacillus fermented extract n1=Bevacizumab | n2=en:lactobacillus fermented extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lactobacillus plantarum 299v/lactobacillus acidophilus/bifidobacterium lactis probiotic supplement n1=Bevacizumab | n2=en:lactobacillus plantarum 299v/lactobacillus acidophilus/bifidobacterium lactis probiotic supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lactobacillus plantarum strain 299 n1=Bevacizumab | n2=en:lactobacillus plantarum strain 299 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lactobacillus plantarum strain 299v n1=Bevacizumab | n2=en:lactobacillus plantarum strain 299v | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lactobacillus rhamnosus gg n1=Bevacizumab | n2=en:lactobacillus rhamnosus gg | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lactobacillus rhamnosus/l. jensenii/l. crispatus/l. gasseri oral supplement n1=Bevacizumab | n2=en:lactobacillus rhamnosus/l. jensenii/l. crispatus/l. gasseri oral supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lactobacillus-based probiotic capsule n1=Bevacizumab | n2=en:lactobacillus-based probiotic capsule | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lactoferrin-derived lytic peptide ltx-315 n1=Bevacizumab | n2=en:lactoferrin-derived lytic peptide ltx-315 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lactoperoxidase/lysozyme/lactoferrin-based prebiotic vaginal lubricant n1=Bevacizumab | n2=en:lactoperoxidase/lysozyme/lactoferrin-based prebiotic vaginal lubricant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:laetrile n1=Bevacizumab | n2=en:laetrile | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lamellar body mimetic mouth spray lms-611 n1=Bevacizumab | n2=en:lamellar body mimetic mouth spray lms-611 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lamivudine n1=Bevacizumab | n2=en:lamivudine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lamotrigine n1=Bevacizumab | n2=en:lamotrigine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:laniquidar n1=Bevacizumab | n2=en:laniquidar | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lanreotide acetate n1=Bevacizumab | n2=en:lanreotide acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lanreotide acetate copolymer microparticles n1=Bevacizumab | n2=en:lanreotide acetate copolymer microparticles | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lanreotide long-acting aqueous gel n1=Bevacizumab | n2=en:lanreotide long-acting aqueous gel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lapachone n1=Bevacizumab | n2=en:lapachone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lapatinib ditosylate n1=Bevacizumab | n2=en:lapatinib ditosylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lapuleucel-t n1=Bevacizumab | n2=en:lapuleucel-t | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:largetrifoliolious bugbane rhizome supplement n1=Bevacizumab | n2=en:largetrifoliolious bugbane rhizome supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:laromustine n1=Bevacizumab | n2=en:laromustine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:laronidase n1=Bevacizumab | n2=en:laronidase | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:larotaxel n1=Bevacizumab | n2=en:larotaxel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:las41007 n1=Bevacizumab | n2=en:las41007 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lasw1510 n1=Bevacizumab | n2=en:lasw1510 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lawsone n1=Bevacizumab | n2=en:lawsone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lead pb 212 tcmc-trastuzumab n1=Bevacizumab | n2=en:lead pb 212 tcmc-trastuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:leflunomide n1=Bevacizumab | n2=en:leflunomide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lenalidomide n1=Bevacizumab | n2=en:lenalidomide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lenapenem n1=Bevacizumab | n2=en:lenapenem | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lenograstim n1=Bevacizumab | n2=en:lenograstim | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lenti-d/abcd1-transduced autologous hematopoietic stem cells n1=Bevacizumab | n2=en:lenti-d/abcd1-transduced autologous hematopoietic stem cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lentivirus vector ccr5 shrna/trim5alpha/tar decoy-transduced autologous cd34-positive hematopoietic progenitor cells n1=Bevacizumab | n2=en:lentivirus vector ccr5 shrna/trim5alpha/tar decoy-transduced autologous cd34-positive hematopoietic progenitor cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lentivirus vector rhiv7-shi-tar-ccr5rz-transduced hematopoietic progenitor cells n1=Bevacizumab | n2=en:lentivirus vector rhiv7-shi-tar-ccr5rz-transduced hematopoietic progenitor cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lenvatinib mesylate n1=Bevacizumab | n2=en:lenvatinib mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lenzilumab n1=Bevacizumab | n2=en:lenzilumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lepirudin n1=Bevacizumab | n2=en:lepirudin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:leridistim n1=Bevacizumab | n2=en:leridistim | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lerisetron n1=Bevacizumab | n2=en:lerisetron | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lesinurad n1=Bevacizumab | n2=en:lesinurad | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lestaurtinib n1=Bevacizumab | n2=en:lestaurtinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:letermovir n1=Bevacizumab | n2=en:letermovir | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:letrozole n1=Bevacizumab | n2=en:letrozole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:leucine-enhanced essential amino acid dietary supplement n1=Bevacizumab | n2=en:leucine-enhanced essential amino acid dietary supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:leucovorin calcium n1=Bevacizumab | n2=en:leucovorin calcium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:leukemic apoptotic corpse-pulsed autologous dendritic cells n1=Bevacizumab | n2=en:leukemic apoptotic corpse-pulsed autologous dendritic cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:leuprolide n1=Bevacizumab | n2=en:leuprolide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:leuprolide acetate n1=Bevacizumab | n2=en:leuprolide acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:leuprolide mesylate injectable suspension n1=Bevacizumab | n2=en:leuprolide mesylate injectable suspension | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:levamisole hydrochloride n1=Bevacizumab | n2=en:levamisole hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:levetiracetam n1=Bevacizumab | n2=en:levetiracetam | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:levobupivacaine hydrochloride n1=Bevacizumab | n2=en:levobupivacaine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:levocarnitine n1=Bevacizumab | n2=en:levocarnitine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:levocetirizine dihydrochloride n1=Bevacizumab | n2=en:levocetirizine dihydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:levodopa n1=Bevacizumab | n2=en:levodopa | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:levofloxacin n1=Bevacizumab | n2=en:levofloxacin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:levoleucovorin n1=Bevacizumab | n2=en:levoleucovorin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:levoleucovorin calcium n1=Bevacizumab | n2=en:levoleucovorin calcium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:levomenol n1=Bevacizumab | n2=en:levomenol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:levonantradol n1=Bevacizumab | n2=en:levonantradol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:levonorgestrel n1=Bevacizumab | n2=en:levonorgestrel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:levonorgestrel-releasing intrauterine system n1=Bevacizumab | n2=en:levonorgestrel-releasing intrauterine system | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:levothyroxine sodium n1=Bevacizumab | n2=en:levothyroxine sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lexatumumab n1=Bevacizumab | n2=en:lexatumumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lexibulin n1=Bevacizumab | n2=en:lexibulin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liarozole fumarate n1=Bevacizumab | n2=en:liarozole fumarate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:licartin n1=Bevacizumab | n2=en:licartin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lidocaine n1=Bevacizumab | n2=en:lidocaine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lidocaine patch n1=Bevacizumab | n2=en:lidocaine patch | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:light-emitting oncolytic vaccinia virus gl-onc1 n1=Bevacizumab | n2=en:light-emitting oncolytic vaccinia virus gl-onc1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:limonene n1=Bevacizumab | n2=en:limonene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:linaclotide acetate n1=Bevacizumab | n2=en:linaclotide acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:linagliptin + metformin n1=Bevacizumab | n2=en:linagliptin + metformin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:linezolid n1=Bevacizumab | n2=en:linezolid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:linifanib n1=Bevacizumab | n2=en:linifanib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:linoleyl carbonate-paclitaxel n1=Bevacizumab | n2=en:linoleyl carbonate-paclitaxel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:linsitinib n1=Bevacizumab | n2=en:linsitinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lintuzumab n1=Bevacizumab | n2=en:lintuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liothyronine n1=Bevacizumab | n2=en:liothyronine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liothyronine i-131 n1=Bevacizumab | n2=en:liothyronine i-131 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liothyronine sodium n1=Bevacizumab | n2=en:liothyronine sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lipegfilgrastim n1=Bevacizumab | n2=en:lipegfilgrastim | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lipid n1=Bevacizumab | n2=en:lipid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lipid encapsulated anti-plk1 sirna tkm-plk1 n1=Bevacizumab | n2=en:lipid encapsulated anti-plk1 sirna tkm-plk1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lipopolysaccharide n1=Bevacizumab | n2=en:lipopolysaccharide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liposomal amphotericin b n1=Bevacizumab | n2=en:liposomal amphotericin b | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liposomal bupivacaine n1=Bevacizumab | n2=en:liposomal bupivacaine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liposomal c-raf antisense oligonucleotide n1=Bevacizumab | n2=en:liposomal c-raf antisense oligonucleotide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liposomal curcumin n1=Bevacizumab | n2=en:liposomal curcumin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liposomal cytarabine n1=Bevacizumab | n2=en:liposomal cytarabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liposomal cytarabine-daunorubicin cpx-351 n1=Bevacizumab | n2=en:liposomal cytarabine-daunorubicin cpx-351 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liposomal daunorubicin citrate n1=Bevacizumab | n2=en:liposomal daunorubicin citrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liposomal docetaxel n1=Bevacizumab | n2=en:liposomal docetaxel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liposomal eribulin mesylate n1=Bevacizumab | n2=en:liposomal eribulin mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liposomal hpv-16 e6/e7 multipeptide vaccine pds0101 n1=Bevacizumab | n2=en:liposomal hpv-16 e6/e7 multipeptide vaccine pds0101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liposomal irinotecan n1=Bevacizumab | n2=en:liposomal irinotecan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liposomal mitoxantrone hydrochloride n1=Bevacizumab | n2=en:liposomal mitoxantrone hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liposomal mnsod plasmid n1=Bevacizumab | n2=en:liposomal mnsod plasmid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liposomal muc1/pet-lipid a vaccine n1=Bevacizumab | n2=en:liposomal muc1/pet-lipid a vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liposomal nddp n1=Bevacizumab | n2=en:liposomal nddp | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liposomal oxaliplatin n1=Bevacizumab | n2=en:liposomal oxaliplatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liposomal rhenium re 186 n1=Bevacizumab | n2=en:liposomal rhenium re 186 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liposomal sn-38 n1=Bevacizumab | n2=en:liposomal sn-38 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liposome-encapsulated doxorubicin citrate n1=Bevacizumab | n2=en:liposome-encapsulated doxorubicin citrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liposome-encapsulated mir-34 mimic mrx34 n1=Bevacizumab | n2=en:liposome-encapsulated mir-34 mimic mrx34 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liposome-encapsulated rb94 plasmid dna gene therapy agent sgt-94 n1=Bevacizumab | n2=en:liposome-encapsulated rb94 plasmid dna gene therapy agent sgt-94 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liposome-encapsulated recombinant human cu/zn superoxide-dismutase n1=Bevacizumab | n2=en:liposome-encapsulated recombinant human cu/zn superoxide-dismutase | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liposome-incorporated grb2 antisense oligodeoxynucleotide n1=Bevacizumab | n2=en:liposome-incorporated grb2 antisense oligodeoxynucleotide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liraglutide n1=Bevacizumab | n2=en:liraglutide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lirilumab n1=Bevacizumab | n2=en:lirilumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lisdexamfetamine dimesylate n1=Bevacizumab | n2=en:lisdexamfetamine dimesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lisinopril n1=Bevacizumab | n2=en:lisinopril | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lisofylline n1=Bevacizumab | n2=en:lisofylline | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:listeria monocytogenes-llo-psa vaccine adxs31-142 n1=Bevacizumab | n2=en:listeria monocytogenes-llo-psa vaccine adxs31-142 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lithium carbonate n1=Bevacizumab | n2=en:lithium carbonate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:litronesib n1=Bevacizumab | n2=en:litronesib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:live attenuated measles virus vaccine n1=Bevacizumab | n2=en:live attenuated measles virus vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:live freeze-dried lactic acid bacteria probiotic n1=Bevacizumab | n2=en:live freeze-dried lactic acid bacteria probiotic | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:live-attenuated double-deleted listeria monocytogenes bacteria jnj-64041809 n1=Bevacizumab | n2=en:live-attenuated double-deleted listeria monocytogenes bacteria jnj-64041809 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:live-attenuated listeria encoding human mesothelin vaccine crs-207 n1=Bevacizumab | n2=en:live-attenuated listeria encoding human mesothelin vaccine crs-207 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:live-attenuated listeria monocytogenes encoding egfrviii-mesothelin vaccine jnj-64041757 n1=Bevacizumab | n2=en:live-attenuated listeria monocytogenes encoding egfrviii-mesothelin vaccine jnj-64041757 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:live-attenuated listeria monocytogenes-encoding egfrviii-ny-eso-1 vaccine adu-623 n1=Bevacizumab | n2=en:live-attenuated listeria monocytogenes-encoding egfrviii-ny-eso-1 vaccine adu-623 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:liver extract n1=Bevacizumab | n2=en:liver extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lmb-1 immunotoxin n1=Bevacizumab | n2=en:lmb-1 immunotoxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lmb-2 immunotoxin n1=Bevacizumab | n2=en:lmb-2 immunotoxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lmb-7 immunotoxin n1=Bevacizumab | n2=en:lmb-7 immunotoxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lmb-9 immunotoxin n1=Bevacizumab | n2=en:lmb-9 immunotoxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lmdda-llo-chher2 fusion protein-secreting live-attenuated listeria cancer vaccine adxs31-164 n1=Bevacizumab | n2=en:lmdda-llo-chher2 fusion protein-secreting live-attenuated listeria cancer vaccine adxs31-164 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lmp-2:340-349 peptide vaccine n1=Bevacizumab | n2=en:lmp-2:340-349 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lmp-2:419-427 peptide vaccine n1=Bevacizumab | n2=en:lmp-2:419-427 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lmp1/barf1/ebna1-specific cytotoxic t-lymphocytes n1=Bevacizumab | n2=en:lmp1/barf1/ebna1-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lmp2a-specific cytotoxic t-lymphocytes n1=Bevacizumab | n2=en:lmp2a-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lna-based antimir-155 mrg-106 n1=Bevacizumab | n2=en:lna-based antimir-155 mrg-106 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lobaplatin n1=Bevacizumab | n2=en:lobaplatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lometrexol n1=Bevacizumab | n2=en:lometrexol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lomustine n1=Bevacizumab | n2=en:lomustine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lonafarnib n1=Bevacizumab | n2=en:lonafarnib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lonaprisan n1=Bevacizumab | n2=en:lonaprisan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:long peptide vaccine 7 n1=Bevacizumab | n2=en:long peptide vaccine 7 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:long-acting granulocyte colony-stimulating factor analog spi-2012 n1=Bevacizumab | n2=en:long-acting granulocyte colony-stimulating factor analog spi-2012 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:long-acting release pasireotide n1=Bevacizumab | n2=en:long-acting release pasireotide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lonidamine n1=Bevacizumab | n2=en:lonidamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:loperamide hydrochloride n1=Bevacizumab | n2=en:loperamide hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lopinavir n1=Bevacizumab | n2=en:lopinavir | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:loratadine n1=Bevacizumab | n2=en:loratadine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lorazepam n1=Bevacizumab | n2=en:lorazepam | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lorvotuzumab mertansine n1=Bevacizumab | n2=en:lorvotuzumab mertansine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:losartan potassium n1=Bevacizumab | n2=en:losartan potassium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:losoxantrone n1=Bevacizumab | n2=en:losoxantrone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lovastatin n1=Bevacizumab | n2=en:lovastatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:loxoribine n1=Bevacizumab | n2=en:loxoribine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lps/cd40l-activated klh- and melanoma/hiv peptides-loaded autologous dendritic cell vaccine n1=Bevacizumab | n2=en:lps/cd40l-activated klh- and melanoma/hiv peptides-loaded autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lsd1 inhibitor gsk2879552 n1=Bevacizumab | n2=en:lsd1 inhibitor gsk2879552 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lubiprostone n1=Bevacizumab | n2=en:lubiprostone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lucanthone n1=Bevacizumab | n2=en:lucanthone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lucatumumab n1=Bevacizumab | n2=en:lucatumumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lucitanib n1=Bevacizumab | n2=en:lucitanib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lugol's solution n1=Bevacizumab | n2=en:lugol's solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lung tumor associated antigen n1=Bevacizumab | n2=en:lung tumor associated antigen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lung-targeted immunomodulator qbkpn n1=Bevacizumab | n2=en:lung-targeted immunomodulator qbkpn | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lurasidone n1=Bevacizumab | n2=en:lurasidone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lurbinectedin n1=Bevacizumab | n2=en:lurbinectedin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lurtotecan n1=Bevacizumab | n2=en:lurtotecan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lurtotecan liposome n1=Bevacizumab | n2=en:lurtotecan liposome | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:luspatercept n1=Bevacizumab | n2=en:luspatercept | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lutetium lu 177 dota-biotin n1=Bevacizumab | n2=en:lutetium lu 177 dota-biotin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lutetium lu 177 dota-jr11 n1=Bevacizumab | n2=en:lutetium lu 177 dota-jr11 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lutetium lu 177 dota-tetulomab n1=Bevacizumab | n2=en:lutetium lu 177 dota-tetulomab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lutetium lu 177 monoclonal antibody cc49 n1=Bevacizumab | n2=en:lutetium lu 177 monoclonal antibody cc49 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lutetium lu 177 monoclonal antibody j591 n1=Bevacizumab | n2=en:lutetium lu 177 monoclonal antibody j591 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lutetium lu 177 peptide receptor radionuclide n1=Bevacizumab | n2=en:lutetium lu 177 peptide receptor radionuclide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lutetium lu 177 pp-f11n n1=Bevacizumab | n2=en:lutetium lu 177 pp-f11n | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lutetium lu 177-dota-di-hsg peptide imp-288 n1=Bevacizumab | n2=en:lutetium lu 177-dota-di-hsg peptide imp-288 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lutetium lu 177-dota-octreotate n1=Bevacizumab | n2=en:lutetium lu 177-dota-octreotate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lutetium lu 177-dota-tate n1=Bevacizumab | n2=en:lutetium lu 177-dota-tate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lutetium lu 177-edotreotide n1=Bevacizumab | n2=en:lutetium lu 177-edotreotide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lutetium lu-177 capromab n1=Bevacizumab | n2=en:lutetium lu-177 capromab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lutetium lu-177 girentuximab n1=Bevacizumab | n2=en:lutetium lu-177 girentuximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lv.il-2/b7.1-transduced aml blast vaccine n1=Bevacizumab | n2=en:lv.il-2/b7.1-transduced aml blast vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ly2624587 n1=Bevacizumab | n2=en:ly2624587 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ly2880070 n1=Bevacizumab | n2=en:ly2880070 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ly6k/vegfr1/vegfr2 multipeptide vaccine n1=Bevacizumab | n2=en:ly6k/vegfr1/vegfr2 multipeptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lycopene n1=Bevacizumab | n2=en:lycopene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lymphokine-activated killer cells n1=Bevacizumab | n2=en:lymphokine-activated killer cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lymphoma taa-specific cytotoxic t lymphocytes n1=Bevacizumab | n2=en:lymphoma taa-specific cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lyophilized black raspberry lozenge n1=Bevacizumab | n2=en:lyophilized black raspberry lozenge | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lyophilized black raspberry saliva substitute n1=Bevacizumab | n2=en:lyophilized black raspberry saliva substitute | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lysine-specific demethylase 1 inhibitor incb059872 n1=Bevacizumab | n2=en:lysine-specific demethylase 1 inhibitor incb059872 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:lyso-thermosensitive liposome doxorubicin n1=Bevacizumab | n2=en:lyso-thermosensitive liposome doxorubicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:m-azidopyrimethamine n1=Bevacizumab | n2=en:m-azidopyrimethamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:m87o-transduced cd34+ peripheral blood stem cells n1=Bevacizumab | n2=en:m87o-transduced cd34+ peripheral blood stem cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mac321 n1=Bevacizumab | n2=en:mac321 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:macimorelin n1=Bevacizumab | n2=en:macimorelin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:macitentan n1=Bevacizumab | n2=en:macitentan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:macrogol 3350-based iso-osmotic laxative n1=Bevacizumab | n2=en:macrogol 3350-based iso-osmotic laxative | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mafosfamide n1=Bevacizumab | n2=en:mafosfamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mag-tn3/as15 vaccine n1=Bevacizumab | n2=en:mag-tn3/as15 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mage-10.a2 n1=Bevacizumab | n2=en:mage-10.a2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mage-12 peptide vaccine n1=Bevacizumab | n2=en:mage-12 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mage-3.a1 peptide vaccine n1=Bevacizumab | n2=en:mage-3.a1 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mage-a1, her-2/neu, fbp peptides cancer vaccine n1=Bevacizumab | n2=en:mage-a1, her-2/neu, fbp peptides cancer vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mage-a1/mage-a3/ny-eso-1 peptides vaccine n1=Bevacizumab | n2=en:mage-a1/mage-a3/ny-eso-1 peptides vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mage-a3 peptide vaccine n1=Bevacizumab | n2=en:mage-a3 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mage-a3 reactive t cell receptor-transduced autologous t cells n1=Bevacizumab | n2=en:mage-a3 reactive t cell receptor-transduced autologous t cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mage-a3-expressing adenovirus type 5 vaccine n1=Bevacizumab | n2=en:mage-a3-expressing adenovirus type 5 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mage-a3/12-specific tcr gene-transduced autologous pbls n1=Bevacizumab | n2=en:mage-a3/12-specific tcr gene-transduced autologous pbls | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mage-a3/hpv 16 peptide vaccine n1=Bevacizumab | n2=en:mage-a3/hpv 16 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mage-a4-specific tcr gene-transduced autologous t lymphocytes tbi-1201 n1=Bevacizumab | n2=en:mage-a4-specific tcr gene-transduced autologous t lymphocytes tbi-1201 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:magnesium citrate n1=Bevacizumab | n2=en:magnesium citrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:magnesium hydroxide n1=Bevacizumab | n2=en:magnesium hydroxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:magnesium isoglycyrrhizinate n1=Bevacizumab | n2=en:magnesium isoglycyrrhizinate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:magnesium l-threonate n1=Bevacizumab | n2=en:magnesium l-threonate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:magnesium oxide n1=Bevacizumab | n2=en:magnesium oxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:magnesium sulfate n1=Bevacizumab | n2=en:magnesium sulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:magnesium valproate n1=Bevacizumab | n2=en:magnesium valproate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:maitake mushroom extract n1=Bevacizumab | n2=en:maitake mushroom extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine n1=Bevacizumab | n2=en:malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:malignant neoplasm of ovary n1=Bevacizumab | n2=en:malignant neoplasm of ovary | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:malignant ovarian neoplasm n1=Bevacizumab | n2=en:malignant ovarian neoplasm | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:maltodextrin n1=Bevacizumab | n2=en:maltodextrin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:maltose n1=Bevacizumab | n2=en:maltose | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:maltose tetrapalmitate n1=Bevacizumab | n2=en:maltose tetrapalmitate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mammaglobin-a dna vaccine n1=Bevacizumab | n2=en:mammaglobin-a dna vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mangafodipir trisodium n1=Bevacizumab | n2=en:mangafodipir trisodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mannitol n1=Bevacizumab | n2=en:mannitol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mannose-binding lectin n1=Bevacizumab | n2=en:mannose-binding lectin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:manuka honey n1=Bevacizumab | n2=en:manuka honey | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mapatumumab n1=Bevacizumab | n2=en:mapatumumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:maraviroc n1=Bevacizumab | n2=en:maraviroc | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:marcellomycin n1=Bevacizumab | n2=en:marcellomycin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:margetuximab n1=Bevacizumab | n2=en:margetuximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:maribavir n1=Bevacizumab | n2=en:maribavir | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:marijuana n1=Bevacizumab | n2=en:marijuana | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:marimastat n1=Bevacizumab | n2=en:marimastat | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:marizomib n1=Bevacizumab | n2=en:marizomib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mart-1 reactive cd8+ lymphocytes n1=Bevacizumab | n2=en:mart-1 reactive cd8+ lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mart-1:26-35(27l) peptide vaccine n1=Bevacizumab | n2=en:mart-1:26-35(27l) peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mart-1:27-35 peptide vaccine n1=Bevacizumab | n2=en:mart-1:27-35 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mart-1/gp100/tyrosinase/mage-a3 peptides-loaded irradiated allogeneic plasmacytoid dendritic cells n1=Bevacizumab | n2=en:mart-1/gp100/tyrosinase/mage-a3 peptides-loaded irradiated allogeneic plasmacytoid dendritic cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:masitinib mesylate n1=Bevacizumab | n2=en:masitinib mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:masoprocol n1=Bevacizumab | n2=en:masoprocol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mast cell stabilizer n1=Bevacizumab | n2=en:mast cell stabilizer | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mast cell stabilizer tf002 n1=Bevacizumab | n2=en:mast cell stabilizer tf002 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:materia medica n1=Bevacizumab | n2=en:materia medica | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:matricaria recutita gel n1=Bevacizumab | n2=en:matricaria recutita gel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:matricaria recutita topical infusion n1=Bevacizumab | n2=en:matricaria recutita topical infusion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:matuzumab n1=Bevacizumab | n2=en:matuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:maxzide n1=Bevacizumab | n2=en:maxzide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:maytansine n1=Bevacizumab | n2=en:maytansine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mcl-1 inhibitor amg 176 n1=Bevacizumab | n2=en:mcl-1 inhibitor amg 176 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mcpyv tag-specific polyclonal autologous cd8-positive t cells n1=Bevacizumab | n2=en:mcpyv tag-specific polyclonal autologous cd8-positive t cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mcs-5 n1=Bevacizumab | n2=en:mcs-5 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mct/lct lipid emulsion n1=Bevacizumab | n2=en:mct/lct lipid emulsion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mct/lct/fish oil omega-3 fatty acid lipid emulsion n1=Bevacizumab | n2=en:mct/lct/fish oil omega-3 fatty acid lipid emulsion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mdm2 antagonist ro5045337 n1=Bevacizumab | n2=en:mdm2 antagonist ro5045337 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mdm2 antagonist ro6839921 n1=Bevacizumab | n2=en:mdm2 antagonist ro6839921 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mdm2 inhibitor amg-232 n1=Bevacizumab | n2=en:mdm2 inhibitor amg-232 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mdm2 inhibitor ds-3032b n1=Bevacizumab | n2=en:mdm2 inhibitor ds-3032b | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mdm2/mdmx inhibitor alrn-6924 n1=Bevacizumab | n2=en:mdm2/mdmx inhibitor alrn-6924 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mdr modulator cbt-1 n1=Bevacizumab | n2=en:mdr modulator cbt-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mdx-1379 melanoma vaccine n1=Bevacizumab | n2=en:mdx-1379 melanoma vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:me-143 n1=Bevacizumab | n2=en:me-143 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:measles/mumps/rubella vaccine n1=Bevacizumab | n2=en:measles/mumps/rubella vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mebendazole n1=Bevacizumab | n2=en:mebendazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mechanism of action qualifier n1=Bevacizumab | n2=en:mechanism of action qualifier | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mechlorethamine n1=Bevacizumab | n2=en:mechlorethamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mechlorethamine hydrochloride n1=Bevacizumab | n2=en:mechlorethamine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mechlorethamine hydrochloride gel n1=Bevacizumab | n2=en:mechlorethamine hydrochloride gel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:meclocycline sulfosalicylate n1=Bevacizumab | n2=en:meclocycline sulfosalicylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:meclofenamate sodium n1=Bevacizumab | n2=en:meclofenamate sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:medical gases n1=Bevacizumab | n2=en:medical gases | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:medical marijuana n1=Bevacizumab | n2=en:medical marijuana | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:medication n1=Bevacizumab | n2=en:medication | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:medroxyprogesterone n1=Bevacizumab | n2=en:medroxyprogesterone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mefloquine n1=Bevacizumab | n2=en:mefloquine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:megestrol n1=Bevacizumab | n2=en:megestrol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:megestrol acetate n1=Bevacizumab | n2=en:megestrol acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:meglumine ioxithalamate n1=Bevacizumab | n2=en:meglumine ioxithalamate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mek 1/2 inhibitor as703988/msc2015103b n1=Bevacizumab | n2=en:mek 1/2 inhibitor as703988/msc2015103b | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mek inhibitor azd8330 n1=Bevacizumab | n2=en:mek inhibitor azd8330 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mek inhibitor ci-1040 n1=Bevacizumab | n2=en:mek inhibitor ci-1040 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mek inhibitor gdc-0623 n1=Bevacizumab | n2=en:mek inhibitor gdc-0623 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mek inhibitor ro4987655 n1=Bevacizumab | n2=en:mek inhibitor ro4987655 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mek inhibitor tak-733 n1=Bevacizumab | n2=en:mek inhibitor tak-733 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mek inhibitor wx-554 n1=Bevacizumab | n2=en:mek inhibitor wx-554 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mek-1/mekk-1 inhibitor e6201 n1=Bevacizumab | n2=en:mek-1/mekk-1 inhibitor e6201 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mek/aurora kinase inhibitor bi 847325 n1=Bevacizumab | n2=en:mek/aurora kinase inhibitor bi 847325 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:melan-a vlp vaccine n1=Bevacizumab | n2=en:melan-a vlp vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:melan-a/mage-3.dp4 peptide vaccine n1=Bevacizumab | n2=en:melan-a/mage-3.dp4 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:melanoma antigen recognized by t-cells 1 n1=Bevacizumab | n2=en:melanoma antigen recognized by t-cells 1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:melanoma helper peptide vaccine n1=Bevacizumab | n2=en:melanoma helper peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:melanoma trp2 ctl epitope vaccine scib1 n1=Bevacizumab | n2=en:melanoma trp2 ctl epitope vaccine scib1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:melitac 12.1 peptide vaccine n1=Bevacizumab | n2=en:melitac 12.1 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:melk inhibitor ots167 n1=Bevacizumab | n2=en:melk inhibitor ots167 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mellaril n1=Bevacizumab | n2=en:mellaril | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:meloxicam n1=Bevacizumab | n2=en:meloxicam | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:melphalan n1=Bevacizumab | n2=en:melphalan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:melphalan hydrochloride n1=Bevacizumab | n2=en:melphalan hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:melphalan hydrochloride/sulfobutyl ether beta-cyclodextrin complex n1=Bevacizumab | n2=en:melphalan hydrochloride/sulfobutyl ether beta-cyclodextrin complex | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:melphalan-flufenamide prodrug n1=Bevacizumab | n2=en:melphalan-flufenamide prodrug | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:memantine hydrochloride n1=Bevacizumab | n2=en:memantine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:membrane-disrupting peptide ep-100 n1=Bevacizumab | n2=en:membrane-disrupting peptide ep-100 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:menadione topical lotion n1=Bevacizumab | n2=en:menadione topical lotion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:menatetrenone n1=Bevacizumab | n2=en:menatetrenone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:menogaril n1=Bevacizumab | n2=en:menogaril | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:menthol n1=Bevacizumab | n2=en:menthol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:meperidine hydrochloride n1=Bevacizumab | n2=en:meperidine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mepivacaine hydrochloride n1=Bevacizumab | n2=en:mepivacaine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:merbarone n1=Bevacizumab | n2=en:merbarone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mercaptopurine n1=Bevacizumab | n2=en:mercaptopurine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mercaptopurine anhydrous n1=Bevacizumab | n2=en:mercaptopurine anhydrous | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mercaptopurine oral suspension n1=Bevacizumab | n2=en:mercaptopurine oral suspension | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mercuric cyanide n1=Bevacizumab | n2=en:mercuric cyanide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:merestinib n1=Bevacizumab | n2=en:merestinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:meropenem n1=Bevacizumab | n2=en:meropenem | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mesalamine n1=Bevacizumab | n2=en:mesalamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mesna n1=Bevacizumab | n2=en:mesna | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mesothelin-specific chimeric antigen receptor-engineered peripheral blood lymphocytes n1=Bevacizumab | n2=en:mesothelin-specific chimeric antigen receptor-engineered peripheral blood lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mesothelioma tumor lysate-pulsed autologous dendritic cell vaccine n1=Bevacizumab | n2=en:mesothelioma tumor lysate-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:met tyrosine kinase inhibitor bms-777607 n1=Bevacizumab | n2=en:met tyrosine kinase inhibitor bms-777607 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:met tyrosine kinase inhibitor emd 1204831 n1=Bevacizumab | n2=en:met tyrosine kinase inhibitor emd 1204831 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:met tyrosine kinase inhibitor pf-04217903 n1=Bevacizumab | n2=en:met tyrosine kinase inhibitor pf-04217903 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:met tyrosine kinase inhibitor sar125844 n1=Bevacizumab | n2=en:met tyrosine kinase inhibitor sar125844 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:met tyrosine kinase inhibitor sgx523 n1=Bevacizumab | n2=en:met tyrosine kinase inhibitor sgx523 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:meta-fluorine f 18 fluorobenzylguanidine n1=Bevacizumab | n2=en:meta-fluorine f 18 fluorobenzylguanidine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:metabolic aspects n1=Bevacizumab | n2=en:metabolic aspects | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:metahexamide n1=Bevacizumab | n2=en:metahexamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:metaiodobenzylguanidine[131i] n1=Bevacizumab | n2=en:metaiodobenzylguanidine[131i] | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:metap2 inhibitor sdx-7320 n1=Bevacizumab | n2=en:metap2 inhibitor sdx-7320 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:metatinib tromethamine n1=Bevacizumab | n2=en:metatinib tromethamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:metformin hydrochloride n1=Bevacizumab | n2=en:metformin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:methadone hydrochloride n1=Bevacizumab | n2=en:methadone hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:methanol extraction residue of bcg n1=Bevacizumab | n2=en:methanol extraction residue of bcg | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:methazolamide n1=Bevacizumab | n2=en:methazolamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:methimazole n1=Bevacizumab | n2=en:methimazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:methionine c 11 n1=Bevacizumab | n2=en:methionine c 11 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:methotrexate n1=Bevacizumab | n2=en:methotrexate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:methotrexate-e therapeutic implant n1=Bevacizumab | n2=en:methotrexate-e therapeutic implant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:methotrexate-encapsulating autologous tumor-derived microparticles n1=Bevacizumab | n2=en:methotrexate-encapsulating autologous tumor-derived microparticles | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:methoxsalen n1=Bevacizumab | n2=en:methoxsalen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:methoxy polyethylene glycol-epoetin beta n1=Bevacizumab | n2=en:methoxy polyethylene glycol-epoetin beta | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:methoxyamine n1=Bevacizumab | n2=en:methoxyamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:methoxyamine hydrochloride n1=Bevacizumab | n2=en:methoxyamine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:methoxyflurane n1=Bevacizumab | n2=en:methoxyflurane | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:methyl-5-aminolevulinate hydrochloride cream n1=Bevacizumab | n2=en:methyl-5-aminolevulinate hydrochloride cream | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:methylcellulose n1=Bevacizumab | n2=en:methylcellulose | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:methylene blue n1=Bevacizumab | n2=en:methylene blue | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:methylene dimethane sulfonate n1=Bevacizumab | n2=en:methylene dimethane sulfonate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:methylmercaptopurine riboside n1=Bevacizumab | n2=en:methylmercaptopurine riboside | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:methylnaltrexone n1=Bevacizumab | n2=en:methylnaltrexone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:methylphenidate hydrochloride n1=Bevacizumab | n2=en:methylphenidate hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:methylprednisolone n1=Bevacizumab | n2=en:methylprednisolone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:methylselenocysteine n1=Bevacizumab | n2=en:methylselenocysteine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:methyltestosterone n1=Bevacizumab | n2=en:methyltestosterone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:metoclopramide hydrochloride n1=Bevacizumab | n2=en:metoclopramide hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:metoprine n1=Bevacizumab | n2=en:metoprine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:metoprolol n1=Bevacizumab | n2=en:metoprolol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:metreleptin n1=Bevacizumab | n2=en:metreleptin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:metronidazole hydrochloride n1=Bevacizumab | n2=en:metronidazole hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:metyrosine n1=Bevacizumab | n2=en:metyrosine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mezlocillin n1=Bevacizumab | n2=en:mezlocillin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mfe23 scfv-expressing autologous anti-cea mfez t lymphocytes n1=Bevacizumab | n2=en:mfe23 scfv-expressing autologous anti-cea mfez t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mg 98 n1=Bevacizumab | n2=en:mg 98 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mgmtp140k-encoding retroviral vector n1=Bevacizumab | n2=en:mgmtp140k-encoding retroviral vector | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mibefradil dihydrochloride n1=Bevacizumab | n2=en:mibefradil dihydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:micafungin n1=Bevacizumab | n2=en:micafungin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:micafungin sodium n1=Bevacizumab | n2=en:micafungin sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:micellar nanoparticle-encapsulated cisplatin nc-6004 n1=Bevacizumab | n2=en:micellar nanoparticle-encapsulated cisplatin nc-6004 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:micronutrient-fortified probiotic yogurt n1=Bevacizumab | n2=en:micronutrient-fortified probiotic yogurt | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:microtubule-targeted agent bal101553 n1=Bevacizumab | n2=en:microtubule-targeted agent bal101553 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:midazolam hydrochloride n1=Bevacizumab | n2=en:midazolam hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:midazolam-containing buccal liquid n1=Bevacizumab | n2=en:midazolam-containing buccal liquid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:midostaurin n1=Bevacizumab | n2=en:midostaurin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mifamurtide n1=Bevacizumab | n2=en:mifamurtide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mifepristone n1=Bevacizumab | n2=en:mifepristone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:miglitol n1=Bevacizumab | n2=en:miglitol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:miglustat n1=Bevacizumab | n2=en:miglustat | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:miha-loaded pd-l1/l2-silenced dendritic cell vaccine n1=Bevacizumab | n2=en:miha-loaded pd-l1/l2-silenced dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:milatuzumab n1=Bevacizumab | n2=en:milatuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:milatuzumab-doxorubicin antibody-drug conjugate n1=Bevacizumab | n2=en:milatuzumab-doxorubicin antibody-drug conjugate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:milk protein-based energy drink n1=Bevacizumab | n2=en:milk protein-based energy drink | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:milk thistle n1=Bevacizumab | n2=en:milk thistle | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:milodistim n1=Bevacizumab | n2=en:milodistim | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:miltefosine n1=Bevacizumab | n2=en:miltefosine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mimotope-p10s-padre peptide vaccine n1=Bevacizumab | n2=en:mimotope-p10s-padre peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:minocycline hydrochloride n1=Bevacizumab | n2=en:minocycline hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:minocycline-edta n1=Bevacizumab | n2=en:minocycline-edta | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:miotics n1=Bevacizumab | n2=en:miotics | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mipsagargin n1=Bevacizumab | n2=en:mipsagargin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mirabegron n1=Bevacizumab | n2=en:mirabegron | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:miracle mouthwash plus hydrocortisone n1=Bevacizumab | n2=en:miracle mouthwash plus hydrocortisone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mirtazapine n1=Bevacizumab | n2=en:mirtazapine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mirvetuximab soravtansine n1=Bevacizumab | n2=en:mirvetuximab soravtansine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:misonidazole n1=Bevacizumab | n2=en:misonidazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:misoprostol n1=Bevacizumab | n2=en:misoprostol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mistletoe extract n1=Bevacizumab | n2=en:mistletoe extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mitoflaxone n1=Bevacizumab | n2=en:mitoflaxone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mitogen n1=Bevacizumab | n2=en:mitogen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mitoguazone n1=Bevacizumab | n2=en:mitoguazone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mitolactol n1=Bevacizumab | n2=en:mitolactol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mitomycin n1=Bevacizumab | n2=en:mitomycin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mitoquidone n1=Bevacizumab | n2=en:mitoquidone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mitotane n1=Bevacizumab | n2=en:mitotane | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mitoxantrone n1=Bevacizumab | n2=en:mitoxantrone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mitoxantrone hydrochloride n1=Bevacizumab | n2=en:mitoxantrone hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mitozolomide n1=Bevacizumab | n2=en:mitozolomide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mivobulin isethionate n1=Bevacizumab | n2=en:mivobulin isethionate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mixed bacteria vaccine n1=Bevacizumab | n2=en:mixed bacteria vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mk-1248 n1=Bevacizumab | n2=en:mk-1248 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mk-4280 n1=Bevacizumab | n2=en:mk-4280 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mk-6592 n1=Bevacizumab | n2=en:mk-6592 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mk-8808 n1=Bevacizumab | n2=en:mk-8808 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mk0429 n1=Bevacizumab | n2=en:mk0429 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mk0731 n1=Bevacizumab | n2=en:mk0731 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mkc-1 n1=Bevacizumab | n2=en:mkc-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mknk1 inhibitor bay 1143269 n1=Bevacizumab | n2=en:mknk1 inhibitor bay 1143269 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mln2704 n1=Bevacizumab | n2=en:mln2704 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mnk1/2 inhibitor eft508 n1=Bevacizumab | n2=en:mnk1/2 inhibitor eft508 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mnsod mimetic bmx-001 n1=Bevacizumab | n2=en:mnsod mimetic bmx-001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mocetinostat n1=Bevacizumab | n2=en:mocetinostat | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:modafinil n1=Bevacizumab | n2=en:modafinil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:modified citrus pectin supplement n1=Bevacizumab | n2=en:modified citrus pectin supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:modified vaccinia ankara (bavarian nordic)-her2 vaccine n1=Bevacizumab | n2=en:modified vaccinia ankara (bavarian nordic)-her2 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:modified vaccinia virus ankara vaccine expressing p53 n1=Bevacizumab | n2=en:modified vaccinia virus ankara vaccine expressing p53 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:modified-release calcifediol capsule n1=Bevacizumab | n2=en:modified-release calcifediol capsule | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mogamulizumab n1=Bevacizumab | n2=en:mogamulizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:molecular target inhibitors n1=Bevacizumab | n2=en:molecular target inhibitors | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:molybdenum n1=Bevacizumab | n2=en:molybdenum | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:momelotinib n1=Bevacizumab | n2=en:momelotinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mometasone furoate n1=Bevacizumab | n2=en:mometasone furoate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monalizumab n1=Bevacizumab | n2=en:monalizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoacetyldiglyceride ec-18 n1=Bevacizumab | n2=en:monoacetyldiglyceride ec-18 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monobenzone n1=Bevacizumab | n2=en:monobenzone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monocarboxylate transporter 1 inhibitor azd3965 n1=Bevacizumab | n2=en:monocarboxylate transporter 1 inhibitor azd3965 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibodies, antineoplastic n1=Bevacizumab | n2=en:monoclonal antibodies, antineoplastic | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody 105ad7 anti-idiotype vaccine n1=Bevacizumab | n2=en:monoclonal antibody 105ad7 anti-idiotype vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody 11d10 n1=Bevacizumab | n2=en:monoclonal antibody 11d10 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody 11d10 anti-idiotype vaccine n1=Bevacizumab | n2=en:monoclonal antibody 11d10 anti-idiotype vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody 14g2a n1=Bevacizumab | n2=en:monoclonal antibody 14g2a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody 3622w94 n1=Bevacizumab | n2=en:monoclonal antibody 3622w94 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody 3f8 n1=Bevacizumab | n2=en:monoclonal antibody 3f8 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody 3h1 anti-idiotype vaccine n1=Bevacizumab | n2=en:monoclonal antibody 3h1 anti-idiotype vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody 4b5 anti-idiotype vaccine n1=Bevacizumab | n2=en:monoclonal antibody 4b5 anti-idiotype vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody a1g4 anti-idiotype vaccine n1=Bevacizumab | n2=en:monoclonal antibody a1g4 anti-idiotype vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody a27.15 n1=Bevacizumab | n2=en:monoclonal antibody a27.15 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody a33 n1=Bevacizumab | n2=en:monoclonal antibody a33 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody abgn-7 n1=Bevacizumab | n2=en:monoclonal antibody abgn-7 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody agent n1=Bevacizumab | n2=en:monoclonal antibody agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody amg 228 n1=Bevacizumab | n2=en:monoclonal antibody amg 228 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody c-58 n1=Bevacizumab | n2=en:monoclonal antibody c-58 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody cal n1=Bevacizumab | n2=en:monoclonal antibody cal | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody cbe-11 n1=Bevacizumab | n2=en:monoclonal antibody cbe-11 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody cc49 n1=Bevacizumab | n2=en:monoclonal antibody cc49 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody cc49-delta ch2 n1=Bevacizumab | n2=en:monoclonal antibody cc49-delta ch2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody cc49-streptavidin conjugate n1=Bevacizumab | n2=en:monoclonal antibody cc49-streptavidin conjugate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody cd19 n1=Bevacizumab | n2=en:monoclonal antibody cd19 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody cep-37250/khk2804 n1=Bevacizumab | n2=en:monoclonal antibody cep-37250/khk2804 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody d6.12 n1=Bevacizumab | n2=en:monoclonal antibody d6.12 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody e2.3 n1=Bevacizumab | n2=en:monoclonal antibody e2.3 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody f19 n1=Bevacizumab | n2=en:monoclonal antibody f19 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody gd2 anti-idiotype vaccine n1=Bevacizumab | n2=en:monoclonal antibody gd2 anti-idiotype vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody hefi-1 n1=Bevacizumab | n2=en:monoclonal antibody hefi-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody hu3s193 n1=Bevacizumab | n2=en:monoclonal antibody hu3s193 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody huafp31 n1=Bevacizumab | n2=en:monoclonal antibody huafp31 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody huhmfg1 n1=Bevacizumab | n2=en:monoclonal antibody huhmfg1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody huj591 n1=Bevacizumab | n2=en:monoclonal antibody huj591 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody hupam4 n1=Bevacizumab | n2=en:monoclonal antibody hupam4 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody idec-159 n1=Bevacizumab | n2=en:monoclonal antibody idec-159 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody ing-1 n1=Bevacizumab | n2=en:monoclonal antibody ing-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody l6 n1=Bevacizumab | n2=en:monoclonal antibody l6 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody lym-1 n1=Bevacizumab | n2=en:monoclonal antibody lym-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody m170 n1=Bevacizumab | n2=en:monoclonal antibody m170 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody me1-14 f(ab')2 n1=Bevacizumab | n2=en:monoclonal antibody me1-14 f(ab')2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody mga271 n1=Bevacizumab | n2=en:monoclonal antibody mga271 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody mik-beta-1 n1=Bevacizumab | n2=en:monoclonal antibody mik-beta-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody mono-dga-rfb4 n1=Bevacizumab | n2=en:monoclonal antibody mono-dga-rfb4 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody muj591 n1=Bevacizumab | n2=en:monoclonal antibody muj591 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody mx35 f(ab')2 n1=Bevacizumab | n2=en:monoclonal antibody mx35 f(ab')2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody r24 n1=Bevacizumab | n2=en:monoclonal antibody r24 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody rav12 n1=Bevacizumab | n2=en:monoclonal antibody rav12 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody sgn-30 n1=Bevacizumab | n2=en:monoclonal antibody sgn-30 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal antibody t101 n1=Bevacizumab | n2=en:monoclonal antibody t101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monoclonal t-cell receptor anti-cd3 scfv fusion protein imcgp100 n1=Bevacizumab | n2=en:monoclonal t-cell receptor anti-cd3 scfv fusion protein imcgp100 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monophosphoryl lipid a n1=Bevacizumab | n2=en:monophosphoryl lipid a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:monosialotetrahexosylganglioside n1=Bevacizumab | n2=en:monosialotetrahexosylganglioside | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:montanide isa 51 vg n1=Bevacizumab | n2=en:montanide isa 51 vg | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:montanide isa 720 n1=Bevacizumab | n2=en:montanide isa 720 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:montelukast sodium n1=Bevacizumab | n2=en:montelukast sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mopidamol n1=Bevacizumab | n2=en:mopidamol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mopp regimen n1=Bevacizumab | n2=en:mopp regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:morinda citrifolia fruit extract n1=Bevacizumab | n2=en:morinda citrifolia fruit extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:morphine n1=Bevacizumab | n2=en:morphine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:morphine sulfate n1=Bevacizumab | n2=en:morphine sulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:morphine sulfate sustained-release tablet n1=Bevacizumab | n2=en:morphine sulfate sustained-release tablet | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mosapride n1=Bevacizumab | n2=en:mosapride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:motesanib diphosphate n1=Bevacizumab | n2=en:motesanib diphosphate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:motexafin gadolinium n1=Bevacizumab | n2=en:motexafin gadolinium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:motexafin lutetium n1=Bevacizumab | n2=en:motexafin lutetium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mouse gp100 plasmid dna vaccine n1=Bevacizumab | n2=en:mouse gp100 plasmid dna vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mouse monoclonal antibody n1=Bevacizumab | n2=en:mouse monoclonal antibody | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mouse prostate-specific membrane antigen plasmid dna vaccine n1=Bevacizumab | n2=en:mouse prostate-specific membrane antigen plasmid dna vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mouse renal adenocarcinoma cell-encapsulated agarose-agarose macrobeads n1=Bevacizumab | n2=en:mouse renal adenocarcinoma cell-encapsulated agarose-agarose macrobeads | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mov-gamma chimeric receptor gene n1=Bevacizumab | n2=en:mov-gamma chimeric receptor gene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:moxalactam n1=Bevacizumab | n2=en:moxalactam | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:moxetumomab pasudotox n1=Bevacizumab | n2=en:moxetumomab pasudotox | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:moxifloxacin hydrochloride n1=Bevacizumab | n2=en:moxifloxacin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mps1 inhibitor bay 1217389 n1=Bevacizumab | n2=en:mps1 inhibitor bay 1217389 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mps1 kinase inhibitor bay1161909 n1=Bevacizumab | n2=en:mps1 kinase inhibitor bay1161909 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mrna-derived lung cancer vaccine cv9202 n1=Bevacizumab | n2=en:mrna-derived lung cancer vaccine cv9202 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mrna-derived prostate cancer vaccine cv9103 n1=Bevacizumab | n2=en:mrna-derived prostate cancer vaccine cv9103 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mrna-derived prostate cancer vaccine cv9104 n1=Bevacizumab | n2=en:mrna-derived prostate cancer vaccine cv9104 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mtf-1 inhibitor apto-253 hcl n1=Bevacizumab | n2=en:mtf-1 inhibitor apto-253 hcl | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mtig7192a n1=Bevacizumab | n2=en:mtig7192a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mtor kinase inhibitor azd8055 n1=Bevacizumab | n2=en:mtor kinase inhibitor azd8055 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mtor kinase inhibitor cc-223 n1=Bevacizumab | n2=en:mtor kinase inhibitor cc-223 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mtor kinase inhibitor osi-027 n1=Bevacizumab | n2=en:mtor kinase inhibitor osi-027 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mtor1/2 kinase inhibitor me-344 n1=Bevacizumab | n2=en:mtor1/2 kinase inhibitor me-344 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mtorc1/2 kinase inhibitor bi 860585 n1=Bevacizumab | n2=en:mtorc1/2 kinase inhibitor bi 860585 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mtorc1/mtorc2/dhfr inhibitor abtl0812 n1=Bevacizumab | n2=en:mtorc1/mtorc2/dhfr inhibitor abtl0812 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:muc-1 antigen n1=Bevacizumab | n2=en:muc-1 antigen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:muc-1 peptide vaccine n1=Bevacizumab | n2=en:muc-1 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:muc-2-globo h-klh conjugate vaccine n1=Bevacizumab | n2=en:muc-2-globo h-klh conjugate vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:muc-2-klh vaccine n1=Bevacizumab | n2=en:muc-2-klh vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:muc1 antigen/sb as-2 n1=Bevacizumab | n2=en:muc1 antigen/sb as-2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:muc1 peptide-poly-iclc adjuvant vaccine n1=Bevacizumab | n2=en:muc1 peptide-poly-iclc adjuvant vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:muc1-klh conjugate vaccine n1=Bevacizumab | n2=en:muc1-klh conjugate vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:muc1-klh vaccine/qs21 n1=Bevacizumab | n2=en:muc1-klh vaccine/qs21 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:muc1-targeted peptide go-203-2c n1=Bevacizumab | n2=en:muc1-targeted peptide go-203-2c | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:muc16-targeted antibody-drug conjugate dmuc5754a n1=Bevacizumab | n2=en:muc16-targeted antibody-drug conjugate dmuc5754a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mucoadhesive hydrogel gargle n1=Bevacizumab | n2=en:mucoadhesive hydrogel gargle | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mucoadhesive oral wound rinse n1=Bevacizumab | n2=en:mucoadhesive oral wound rinse | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mucoadhesive paclitaxel formulation n1=Bevacizumab | n2=en:mucoadhesive paclitaxel formulation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mucoprotective agent xer2020 n1=Bevacizumab | n2=en:mucoprotective agent xer2020 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:multi-agc kinase inhibitor at13148 n1=Bevacizumab | n2=en:multi-agc kinase inhibitor at13148 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:multi-epitope folate receptor alpha peptide vaccine n1=Bevacizumab | n2=en:multi-epitope folate receptor alpha peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:multi-epitope melanoma peptide vaccine n1=Bevacizumab | n2=en:multi-epitope melanoma peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:multi-glioblastoma-peptide-targeting autologous dendritic cell vaccine ict-107 n1=Bevacizumab | n2=en:multi-glioblastoma-peptide-targeting autologous dendritic cell vaccine ict-107 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:multi-peptide cmv-modified vaccinia ankara vaccine n1=Bevacizumab | n2=en:multi-peptide cmv-modified vaccinia ankara vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:multi-subtype natural human leukocyte interferon alpha n1=Bevacizumab | n2=en:multi-subtype natural human leukocyte interferon alpha | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:multi-targeted cyclin-dependent protein kinase inhibitor rgb-286638 n1=Bevacizumab | n2=en:multi-targeted cyclin-dependent protein kinase inhibitor rgb-286638 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:multicarotenoid supplement mcs-8 n1=Bevacizumab | n2=en:multicarotenoid supplement mcs-8 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:multidrug resistance modulator n1=Bevacizumab | n2=en:multidrug resistance modulator | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:multifunctional/multitargeted anticancer agent omn54 n1=Bevacizumab | n2=en:multifunctional/multitargeted anticancer agent omn54 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:multikinase inhibitor 4sc-203 n1=Bevacizumab | n2=en:multikinase inhibitor 4sc-203 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:multikinase inhibitor arry614 n1=Bevacizumab | n2=en:multikinase inhibitor arry614 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:multikinase inhibitor at9283 n1=Bevacizumab | n2=en:multikinase inhibitor at9283 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:multikinase inhibitor sar103168 n1=Bevacizumab | n2=en:multikinase inhibitor sar103168 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:multipeptide vaccine s-588210 n1=Bevacizumab | n2=en:multipeptide vaccine s-588210 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:multitargeted kinase inhibitor mgcd516 n1=Bevacizumab | n2=en:multitargeted kinase inhibitor mgcd516 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:multitargeted tyrosine kinase inhibitor jnj-26483327 n1=Bevacizumab | n2=en:multitargeted tyrosine kinase inhibitor jnj-26483327 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:multitargeted tyrosine kinase inhibitor mgcd265 n1=Bevacizumab | n2=en:multitargeted tyrosine kinase inhibitor mgcd265 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:multivitamin n1=Bevacizumab | n2=en:multivitamin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mureletecan n1=Bevacizumab | n2=en:mureletecan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:murine tyrp2 plasmid dna vaccine n1=Bevacizumab | n2=en:murine tyrp2 plasmid dna vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:murine-human monoclonal igg antibody n1=Bevacizumab | n2=en:murine-human monoclonal igg antibody | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:muromonab-cd3 n1=Bevacizumab | n2=en:muromonab-cd3 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:muscadine grape skin extract n1=Bevacizumab | n2=en:muscadine grape skin extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:muscarinic agonist apd515 n1=Bevacizumab | n2=en:muscarinic agonist apd515 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:muscle relaxant n1=Bevacizumab | n2=en:muscle relaxant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mutagen n1=Bevacizumab | n2=en:mutagen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mutant p53 activator coti-2 n1=Bevacizumab | n2=en:mutant p53 activator coti-2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mutant p53 peptide pulsed dendritic cell vaccine n1=Bevacizumab | n2=en:mutant p53 peptide pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mutant-selective egfr inhibitor pf-06459988 n1=Bevacizumab | n2=en:mutant-selective egfr inhibitor pf-06459988 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mva-ebna1/lmp2 vaccine n1=Bevacizumab | n2=en:mva-ebna1/lmp2 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mva-fcu1 tg4023 n1=Bevacizumab | n2=en:mva-fcu1 tg4023 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mva-muc1-il2 vaccine n1=Bevacizumab | n2=en:mva-muc1-il2 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mva-psa/pap prostate cancer vaccine n1=Bevacizumab | n2=en:mva-psa/pap prostate cancer vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mvf-her-2(597-626)/mvf-her-2 (266-296) peptide vaccine n1=Bevacizumab | n2=en:mvf-her-2(597-626)/mvf-her-2 (266-296) peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mvf-her-2(628-647)-crl 1005 vaccine n1=Bevacizumab | n2=en:mvf-her-2(628-647)-crl 1005 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mvx-1-loaded macrocapsule/autologous tumor cell vaccine mvx-onco-1 n1=Bevacizumab | n2=en:mvx-1-loaded macrocapsule/autologous tumor cell vaccine mvx-onco-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:myc-targeting sirna dcr-myc n1=Bevacizumab | n2=en:myc-targeting sirna dcr-myc | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mycobacterial cell wall-dna complex n1=Bevacizumab | n2=en:mycobacterial cell wall-dna complex | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mycobacterium tuberculosis arabinomannan z-100 n1=Bevacizumab | n2=en:mycobacterium tuberculosis arabinomannan z-100 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mycobacterium w n1=Bevacizumab | n2=en:mycobacterium w | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mycophenolate mofetil n1=Bevacizumab | n2=en:mycophenolate mofetil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:mycophenolic acid n1=Bevacizumab | n2=en:mycophenolic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:myeloablative agonist n1=Bevacizumab | n2=en:myeloablative agonist | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:n-butoxyethanol n1=Bevacizumab | n2=en:n-butoxyethanol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:n-methylformamide n1=Bevacizumab | n2=en:n-methylformamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:na-17/mage-3.a2/ny-eso-1 peptide vaccine n1=Bevacizumab | n2=en:na-17/mage-3.a2/ny-eso-1 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:na17-a antigen n1=Bevacizumab | n2=en:na17-a antigen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:na17.a2 peptide vaccine n1=Bevacizumab | n2=en:na17.a2 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nabilone n1=Bevacizumab | n2=en:nabilone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nabiximols n1=Bevacizumab | n2=en:nabiximols | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nadolol n1=Bevacizumab | n2=en:nadolol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nadroparin calcium n1=Bevacizumab | n2=en:nadroparin calcium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nafarelin n1=Bevacizumab | n2=en:nafarelin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nafazatrom n1=Bevacizumab | n2=en:nafazatrom | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nafoxidine hydrochloride n1=Bevacizumab | n2=en:nafoxidine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:naloxegol n1=Bevacizumab | n2=en:naloxegol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:naloxone + oxycodone n1=Bevacizumab | n2=en:naloxone + oxycodone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:naloxone hydrochloride n1=Bevacizumab | n2=en:naloxone hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:naltrexone hydrochloride n1=Bevacizumab | n2=en:naltrexone hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nandrolone decanoate n1=Bevacizumab | n2=en:nandrolone decanoate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nanocell-encapsulated mir-16-based microrna mimic n1=Bevacizumab | n2=en:nanocell-encapsulated mir-16-based microrna mimic | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nanoparticle albumin-bound docetaxel n1=Bevacizumab | n2=en:nanoparticle albumin-bound docetaxel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nanoparticle albumin-bound rapamycin n1=Bevacizumab | n2=en:nanoparticle albumin-bound rapamycin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nanoparticle albumin-bound thiocolchicine dimer nab-5404 n1=Bevacizumab | n2=en:nanoparticle albumin-bound thiocolchicine dimer nab-5404 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nanoparticle-encapsulated docetaxel n1=Bevacizumab | n2=en:nanoparticle-encapsulated docetaxel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nanoparticle-encapsulated doxorubicin hydrochloride n1=Bevacizumab | n2=en:nanoparticle-encapsulated doxorubicin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nanosomal docetaxel lipid suspension n1=Bevacizumab | n2=en:nanosomal docetaxel lipid suspension | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:napabucasin n1=Bevacizumab | n2=en:napabucasin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:naphthalimide analogue unbs5162 n1=Bevacizumab | n2=en:naphthalimide analogue unbs5162 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:naproxen n1=Bevacizumab | n2=en:naproxen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:naptumomab n1=Bevacizumab | n2=en:naptumomab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:narnatumab n1=Bevacizumab | n2=en:narnatumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nasal dosage form product n1=Bevacizumab | n2=en:nasal dosage form product | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nasal saline irrigation solution n1=Bevacizumab | n2=en:nasal saline irrigation solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:natalizumab n1=Bevacizumab | n2=en:natalizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nateglinide n1=Bevacizumab | n2=en:nateglinide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:natural ifn-alpha opc-18 n1=Bevacizumab | n2=en:natural ifn-alpha opc-18 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:natural killer cells zrx101 n1=Bevacizumab | n2=en:natural killer cells zrx101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:navitoclax n1=Bevacizumab | n2=en:navitoclax | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:navy bean powder n1=Bevacizumab | n2=en:navy bean powder | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ncit antineoplastic agent terminology n1=Bevacizumab | n2=en:ncit antineoplastic agent terminology | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ncmtrna oligonucleotide andes-1537 n1=Bevacizumab | n2=en:ncmtrna oligonucleotide andes-1537 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nd-420 n1=Bevacizumab | n2=en:nd-420 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:necitumumab n1=Bevacizumab | n2=en:necitumumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nedaplatin n1=Bevacizumab | n2=en:nedaplatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nefopam hydrochloride n1=Bevacizumab | n2=en:nefopam hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:negative regulation of angiogenesis n1=Bevacizumab | n2=en:negative regulation of angiogenesis | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:neihulizumab n1=Bevacizumab | n2=en:neihulizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nelarabine n1=Bevacizumab | n2=en:nelarabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nelfinavir mesylate n1=Bevacizumab | n2=en:nelfinavir mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nelipepimut-s plus gm-csf vaccine n1=Bevacizumab | n2=en:nelipepimut-s plus gm-csf vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:neoantigen-based glioblastoma vaccine n1=Bevacizumab | n2=en:neoantigen-based glioblastoma vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:neoantigen-based melanoma-poly-iclc vaccine n1=Bevacizumab | n2=en:neoantigen-based melanoma-poly-iclc vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:neomycin n1=Bevacizumab | n2=en:neomycin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nepidermin n1=Bevacizumab | n2=en:nepidermin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:neratinib n1=Bevacizumab | n2=en:neratinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nesiritide n1=Bevacizumab | n2=en:nesiritide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nesvacumab n1=Bevacizumab | n2=en:nesvacumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:netazepide n1=Bevacizumab | n2=en:netazepide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:netupitant n1=Bevacizumab | n2=en:netupitant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:netupitant/palonosetron hydrochloride n1=Bevacizumab | n2=en:netupitant/palonosetron hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:neuromuscular blocking agents n1=Bevacizumab | n2=en:neuromuscular blocking agents | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:neuropharmacologic agent n1=Bevacizumab | n2=en:neuropharmacologic agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:neutrophil activation probe imaging agent n1=Bevacizumab | n2=en:neutrophil activation probe imaging agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nevirapine n1=Bevacizumab | n2=en:nevirapine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ng-nitro-l-arginine n1=Bevacizumab | n2=en:ng-nitro-l-arginine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ngfr-transduced autologous t lymphocytes n1=Bevacizumab | n2=en:ngfr-transduced autologous t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:niacin n1=Bevacizumab | n2=en:niacin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:niacinamide n1=Bevacizumab | n2=en:niacinamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nicardipine n1=Bevacizumab | n2=en:nicardipine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:niclosamide n1=Bevacizumab | n2=en:niclosamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nicotine n1=Bevacizumab | n2=en:nicotine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nicotine gum n1=Bevacizumab | n2=en:nicotine gum | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nicotine lozenge n1=Bevacizumab | n2=en:nicotine lozenge | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nicotine nasal spray n1=Bevacizumab | n2=en:nicotine nasal spray | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nicotine patch n1=Bevacizumab | n2=en:nicotine patch | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nifurtimox n1=Bevacizumab | n2=en:nifurtimox | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nilotinib n1=Bevacizumab | n2=en:nilotinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nilutamide n1=Bevacizumab | n2=en:nilutamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nimodipine n1=Bevacizumab | n2=en:nimodipine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nimorazole n1=Bevacizumab | n2=en:nimorazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nimotuzumab n1=Bevacizumab | n2=en:nimotuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nimustine n1=Bevacizumab | n2=en:nimustine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nintedanib n1=Bevacizumab | n2=en:nintedanib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:niraparib n1=Bevacizumab | n2=en:niraparib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nitazoxanide n1=Bevacizumab | n2=en:nitazoxanide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nitric oxide-releasing acetylsalicylic acid derivative n1=Bevacizumab | n2=en:nitric oxide-releasing acetylsalicylic acid derivative | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nitroglycerin n1=Bevacizumab | n2=en:nitroglycerin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nitroglycerin transdermal patch n1=Bevacizumab | n2=en:nitroglycerin transdermal patch | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nitroglycerin/sodium citrate/ethanol solution n1=Bevacizumab | n2=en:nitroglycerin/sodium citrate/ethanol solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nivolumab n1=Bevacizumab | n2=en:nivolumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nm-3 n1=Bevacizumab | n2=en:nm-3 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nolatrexed dihydrochloride n1=Bevacizumab | n2=en:nolatrexed dihydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:non-adjuvanted a(h1n1) influenza vaccine n1=Bevacizumab | n2=en:non-adjuvanted a(h1n1) influenza vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:non-small cell lung cancer mrna-derived vaccine cv9201 n1=Bevacizumab | n2=en:non-small cell lung cancer mrna-derived vaccine cv9201 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nonenzyme proteolytic agent n1=Bevacizumab | n2=en:nonenzyme proteolytic agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:norepinephrine, dl- n1=Bevacizumab | n2=en:norepinephrine, dl- | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:norethindrone acetate n1=Bevacizumab | n2=en:norethindrone acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:norgestrel n1=Bevacizumab | n2=en:norgestrel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:north american ginseng extract afx-2 n1=Bevacizumab | n2=en:north american ginseng extract afx-2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nortriptyline hydrochloride n1=Bevacizumab | n2=en:nortriptyline hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:noscapine hydrochloride n1=Bevacizumab | n2=en:noscapine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nostrums n1=Bevacizumab | n2=en:nostrums | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:notch signaling inhibitor pf-06650808 n1=Bevacizumab | n2=en:notch signaling inhibitor pf-06650808 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:notch signaling pathway inhibitor mk0752 n1=Bevacizumab | n2=en:notch signaling pathway inhibitor mk0752 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:novobiocin n1=Bevacizumab | n2=en:novobiocin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nrf2 activator rta 408 n1=Bevacizumab | n2=en:nrf2 activator rta 408 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ns-9 n1=Bevacizumab | n2=en:ns-9 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ns5b polymerase inhibitor bms-791325 n1=Bevacizumab | n2=en:ns5b polymerase inhibitor bms-791325 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nsclc antigen-loaded dendritic cell-derived exosomesnon-small cell lung cancer tumor antigen-loaded dendritic cell-derived exosomes n1=Bevacizumab | n2=en:nsclc antigen-loaded dendritic cell-derived exosomesnon-small cell lung cancer tumor antigen-loaded dendritic cell-derived exosomes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ntrk/ros1 inhibitor ds-6051b n1=Bevacizumab | n2=en:ntrk/ros1 inhibitor ds-6051b | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nucleolin antagonist ipp-204106n n1=Bevacizumab | n2=en:nucleolin antagonist ipp-204106n | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nucleoside analog dfp-10917 n1=Bevacizumab | n2=en:nucleoside analog dfp-10917 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nucleotide analogue gs 9219 n1=Bevacizumab | n2=en:nucleotide analogue gs 9219 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nutlin-3a n1=Bevacizumab | n2=en:nutlin-3a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nutraceutical tbl-12 n1=Bevacizumab | n2=en:nutraceutical tbl-12 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nutrient-rich whole wheat flour supplement n1=Bevacizumab | n2=en:nutrient-rich whole wheat flour supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nutritional supplement drink n1=Bevacizumab | n2=en:nutritional supplement drink | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nv1020 n1=Bevacizumab | n2=en:nv1020 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nx-1207 n1=Bevacizumab | n2=en:nx-1207 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ny-eso-1 peptide vaccine n1=Bevacizumab | n2=en:ny-eso-1 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ny-eso-1 plasmid dna cancer vaccine n1=Bevacizumab | n2=en:ny-eso-1 plasmid dna cancer vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ny-eso-1 protein vaccine plus montanide isa-51 vg n1=Bevacizumab | n2=en:ny-eso-1 protein vaccine plus montanide isa-51 vg | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ny-eso-1 reactive tcr retroviral vector transduced autologous pbl n1=Bevacizumab | n2=en:ny-eso-1 reactive tcr retroviral vector transduced autologous pbl | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ny-eso-1-specific cd4-positive t lymphocytes n1=Bevacizumab | n2=en:ny-eso-1-specific cd4-positive t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ny-eso-1-specific tcr gene-transduced t lymphocytes tbi-1301 n1=Bevacizumab | n2=en:ny-eso-1-specific tcr gene-transduced t lymphocytes tbi-1301 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ny-eso-1(157-165) peptide-pulsed autologous dendritic cell vaccine n1=Bevacizumab | n2=en:ny-eso-1(157-165) peptide-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ny-eso-1/gla-se vaccine id-g305 n1=Bevacizumab | n2=en:ny-eso-1/gla-se vaccine id-g305 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ny-eso-1/lage-1 peptide vaccine n1=Bevacizumab | n2=en:ny-eso-1/lage-1 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ny-eso-1/mage-a4/prame/survivin/ssx-specific autologous cytotoxic t lymphoyctes n1=Bevacizumab | n2=en:ny-eso-1/mage-a4/prame/survivin/ssx-specific autologous cytotoxic t lymphoyctes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ny-eso-1/mart-1 peptide-pulsed dendritic cell vaccine n1=Bevacizumab | n2=en:ny-eso-1/mart-1 peptide-pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ny-eso-1/prame/mage-a3/wt-1 peptide vaccine n1=Bevacizumab | n2=en:ny-eso-1/prame/mage-a3/wt-1 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ny-eso-1b peptide vaccine n1=Bevacizumab | n2=en:ny-eso-1b peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ny-eso-b n1=Bevacizumab | n2=en:ny-eso-b | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:nystatin n1=Bevacizumab | n2=en:nystatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:o-chloroacetylcarbamoylfumagillol n1=Bevacizumab | n2=en:o-chloroacetylcarbamoylfumagillol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:o6-benzylguanine n1=Bevacizumab | n2=en:o6-benzylguanine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oat biscuit n1=Bevacizumab | n2=en:oat biscuit | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:obatoclax n1=Bevacizumab | n2=en:obatoclax | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:obatoclax mesylate n1=Bevacizumab | n2=en:obatoclax mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:obinutuzumab n1=Bevacizumab | n2=en:obinutuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oblimersen n1=Bevacizumab | n2=en:oblimersen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oblimersen sodium n1=Bevacizumab | n2=en:oblimersen sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ocaratuzumab n1=Bevacizumab | n2=en:ocaratuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ocrelizumab n1=Bevacizumab | n2=en:ocrelizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ocriplasmin n1=Bevacizumab | n2=en:ocriplasmin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:octreotide acetate n1=Bevacizumab | n2=en:octreotide acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:octreotide pamoate n1=Bevacizumab | n2=en:octreotide pamoate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ocular dosage form product n1=Bevacizumab | n2=en:ocular dosage form product | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ocv-103 n1=Bevacizumab | n2=en:ocv-103 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ocv-104 n1=Bevacizumab | n2=en:ocv-104 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:odanacatib n1=Bevacizumab | n2=en:odanacatib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oepa regimen n1=Bevacizumab | n2=en:oepa regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ofatumumab n1=Bevacizumab | n2=en:ofatumumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:off regimen n1=Bevacizumab | n2=en:off regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ofloxacin n1=Bevacizumab | n2=en:ofloxacin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oglufanide disodium n1=Bevacizumab | n2=en:oglufanide disodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:olanzapine n1=Bevacizumab | n2=en:olanzapine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:olaparib n1=Bevacizumab | n2=en:olaparib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:olaratumab n1=Bevacizumab | n2=en:olaratumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oleandrin n1=Bevacizumab | n2=en:oleandrin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oligofructose-enriched inulin n1=Bevacizumab | n2=en:oligofructose-enriched inulin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oligonucleotide spc2996 n1=Bevacizumab | n2=en:oligonucleotide spc2996 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:olive oil extract/curcumin-based capsule n1=Bevacizumab | n2=en:olive oil extract/curcumin-based capsule | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:olive oil/soya oil/egg lecithin-based emulsion n1=Bevacizumab | n2=en:olive oil/soya oil/egg lecithin-based emulsion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:olive oil/soybean oil/multi-amino acid/glucose parenteral nutrition emulsion n1=Bevacizumab | n2=en:olive oil/soybean oil/multi-amino acid/glucose parenteral nutrition emulsion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:olodaterol n1=Bevacizumab | n2=en:olodaterol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:olsalazine n1=Bevacizumab | n2=en:olsalazine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oltipraz n1=Bevacizumab | n2=en:oltipraz | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:omacetaxine mepesuccinate n1=Bevacizumab | n2=en:omacetaxine mepesuccinate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:omalizumab n1=Bevacizumab | n2=en:omalizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ombitasvir/paritaprevir/ritonavir n1=Bevacizumab | n2=en:ombitasvir/paritaprevir/ritonavir | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ombrabulin n1=Bevacizumab | n2=en:ombrabulin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:omega 3-marine triglycerides n1=Bevacizumab | n2=en:omega 3-marine triglycerides | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:omega-3 fatty acid n1=Bevacizumab | n2=en:omega-3 fatty acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:omeprazole n1=Bevacizumab | n2=en:omeprazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:omiganan pentahydrochloride n1=Bevacizumab | n2=en:omiganan pentahydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:onalespib n1=Bevacizumab | n2=en:onalespib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:onartuzumab n1=Bevacizumab | n2=en:onartuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oncolytic adenovirus ad5-dnx-2401 n1=Bevacizumab | n2=en:oncolytic adenovirus ad5-dnx-2401 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oncolytic adenovirus encoding gm-csf n1=Bevacizumab | n2=en:oncolytic adenovirus encoding gm-csf | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oncolytic adenovirus icovir5-infected autologous mesenchymal stem cells n1=Bevacizumab | n2=en:oncolytic adenovirus icovir5-infected autologous mesenchymal stem cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oncolytic herpes simplex virus-1-encoding gm-csf n1=Bevacizumab | n2=en:oncolytic herpes simplex virus-1-encoding gm-csf | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oncolytic hsv-1 rrp450 n1=Bevacizumab | n2=en:oncolytic hsv-1 rrp450 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oncolytic hsv1716 n1=Bevacizumab | n2=en:oncolytic hsv1716 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oncolytic measles virus encoding thyroidal sodium iodide symporter n1=Bevacizumab | n2=en:oncolytic measles virus encoding thyroidal sodium iodide symporter | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oncolytic newcastle disease virus n1=Bevacizumab | n2=en:oncolytic newcastle disease virus | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ondansetron n1=Bevacizumab | n2=en:ondansetron | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ondansetron hydrochloride n1=Bevacizumab | n2=en:ondansetron hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:onyx-015 n1=Bevacizumab | n2=en:onyx-015 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:opb-111001 n1=Bevacizumab | n2=en:opb-111001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:opcs/green tea/spirullina/curcumin/antrodia camphorate/fermented soymilk extract capsule n1=Bevacizumab | n2=en:opcs/green tea/spirullina/curcumin/antrodia camphorate/fermented soymilk extract capsule | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:opebacan n1=Bevacizumab | n2=en:opebacan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:opioid agonist gic-1001 n1=Bevacizumab | n2=en:opioid agonist gic-1001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:opioid agonist gic-1002 n1=Bevacizumab | n2=en:opioid agonist gic-1002 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:opioid growth factor n1=Bevacizumab | n2=en:opioid growth factor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:opium tincture n1=Bevacizumab | n2=en:opium tincture | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:opium+belladonna n1=Bevacizumab | n2=en:opium+belladonna | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oppa regimen n1=Bevacizumab | n2=en:oppa regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oprelvekin n1=Bevacizumab | n2=en:oprelvekin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oprozomib n1=Bevacizumab | n2=en:oprozomib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:orabase with benzocaine n1=Bevacizumab | n2=en:orabase with benzocaine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oral aminolevulinic acid hydrochloride n1=Bevacizumab | n2=en:oral aminolevulinic acid hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oral azacitidine n1=Bevacizumab | n2=en:oral azacitidine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oral dosage form product n1=Bevacizumab | n2=en:oral dosage form product | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oral fludarabine phosphate n1=Bevacizumab | n2=en:oral fludarabine phosphate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oral hsp90 inhibitor ipi-493 n1=Bevacizumab | n2=en:oral hsp90 inhibitor ipi-493 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oral ixabepilone n1=Bevacizumab | n2=en:oral ixabepilone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oral medication n1=Bevacizumab | n2=en:oral medication | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oral microencapsulated diindolylmethane n1=Bevacizumab | n2=en:oral microencapsulated diindolylmethane | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oral milataxel n1=Bevacizumab | n2=en:oral milataxel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oral picoplatin n1=Bevacizumab | n2=en:oral picoplatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oral rehydration solution os-1 n1=Bevacizumab | n2=en:oral rehydration solution os-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oral sodium phenylbutyrate n1=Bevacizumab | n2=en:oral sodium phenylbutyrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oral topotecan hydrochloride n1=Bevacizumab | n2=en:oral topotecan hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:orantinib n1=Bevacizumab | n2=en:orantinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oraxol n1=Bevacizumab | n2=en:oraxol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oregovomab n1=Bevacizumab | n2=en:oregovomab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:organic sulfone compound n1=Bevacizumab | n2=en:organic sulfone compound | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ormaplatin n1=Bevacizumab | n2=en:ormaplatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oropharyngeal dosage form product n1=Bevacizumab | n2=en:oropharyngeal dosage form product | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ortataxel n1=Bevacizumab | n2=en:ortataxel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:orteronel n1=Bevacizumab | n2=en:orteronel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ose 2101 n1=Bevacizumab | n2=en:ose 2101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oseltamivir phosphate n1=Bevacizumab | n2=en:oseltamivir phosphate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oshadi d n1=Bevacizumab | n2=en:oshadi d | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oshadi r n1=Bevacizumab | n2=en:oshadi r | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:osi-7904l n1=Bevacizumab | n2=en:osi-7904l | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:osimertinib n1=Bevacizumab | n2=en:osimertinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:otd70derm n1=Bevacizumab | n2=en:otd70derm | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oteracil potassium n1=Bevacizumab | n2=en:oteracil potassium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:otic preparation n1=Bevacizumab | n2=en:otic preparation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:otlertuzumab n1=Bevacizumab | n2=en:otlertuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:otsgc-a24 vaccine n1=Bevacizumab | n2=en:otsgc-a24 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ova bip peptide n1=Bevacizumab | n2=en:ova bip peptide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ovapuldencel-t n1=Bevacizumab | n2=en:ovapuldencel-t | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ovarian cancer n1=Bevacizumab | n2=en:ovarian cancer | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ovarian cancer peptide vaccine n1=Bevacizumab | n2=en:ovarian cancer peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ovarian cancer stem cell/htert/survivin mrnas-loaded autologous dendritic cell vaccine n1=Bevacizumab | n2=en:ovarian cancer stem cell/htert/survivin mrnas-loaded autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ovarian tumor antigen-activated autologous dendritic cell vaccine n1=Bevacizumab | n2=en:ovarian tumor antigen-activated autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:over the counter product n1=Bevacizumab | n2=en:over the counter product | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ovine submaxillary mucin n1=Bevacizumab | n2=en:ovine submaxillary mucin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oxacillin sodium n1=Bevacizumab | n2=en:oxacillin sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oxaliplatin n1=Bevacizumab | n2=en:oxaliplatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oxaliplatin-encapsulated transferrin-conjugated n-glutaryl phosphatidylethanolamine liposome n1=Bevacizumab | n2=en:oxaliplatin-encapsulated transferrin-conjugated n-glutaryl phosphatidylethanolamine liposome | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oxandrolone n1=Bevacizumab | n2=en:oxandrolone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oxcarbazepine n1=Bevacizumab | n2=en:oxcarbazepine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oxidized avidin n1=Bevacizumab | n2=en:oxidized avidin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oxidopamine n1=Bevacizumab | n2=en:oxidopamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oxitriptan n1=Bevacizumab | n2=en:oxitriptan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oxphos inhibitor vlx600 n1=Bevacizumab | n2=en:oxphos inhibitor vlx600 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oxycodone hydrochloride n1=Bevacizumab | n2=en:oxycodone hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oxycodone hydrochloride/naloxone hydrochloride prolonged-release tablet n1=Bevacizumab | n2=en:oxycodone hydrochloride/naloxone hydrochloride prolonged-release tablet | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oxycodone/acetaminophen n1=Bevacizumab | n2=en:oxycodone/acetaminophen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oxymetholone n1=Bevacizumab | n2=en:oxymetholone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oxymorphone hydrochloride n1=Bevacizumab | n2=en:oxymorphone hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:oxytocics n1=Bevacizumab | n2=en:oxytocics | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ozarelix n1=Bevacizumab | n2=en:ozarelix | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ozone-based agent n1=Bevacizumab | n2=en:ozone-based agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:p-cadherin antagonist pf-03732010 n1=Bevacizumab | n2=en:p-cadherin antagonist pf-03732010 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:p-cadherin inhibitor pca062 n1=Bevacizumab | n2=en:p-cadherin inhibitor pca062 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:p-cadherin-targeting agent pf-06671008 n1=Bevacizumab | n2=en:p-cadherin-targeting agent pf-06671008 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:p-glycoprotein inhibitor hm30181ak n1=Bevacizumab | n2=en:p-glycoprotein inhibitor hm30181ak | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:p-p68 inhibitor rx-5902 n1=Bevacizumab | n2=en:p-p68 inhibitor rx-5902 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:p-tefb inhibitor bay1143572 n1=Bevacizumab | n2=en:p-tefb inhibitor bay1143572 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:p.dom-wt1-126 dna vaccine n1=Bevacizumab | n2=en:p.dom-wt1-126 dna vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:p.dom-wt1-37 dna vaccine n1=Bevacizumab | n2=en:p.dom-wt1-37 dna vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:p110beta/delta pi3k inhibitor gs-9820 n1=Bevacizumab | n2=en:p110beta/delta pi3k inhibitor gs-9820 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:p16_37-63 peptide vaccine n1=Bevacizumab | n2=en:p16_37-63 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:p38 mapk inhibitor ly2228820 dimesylate n1=Bevacizumab | n2=en:p38 mapk inhibitor ly2228820 dimesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:p38 mapk inhibitor ly3007113 n1=Bevacizumab | n2=en:p38 mapk inhibitor ly3007113 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:p501-as15 vaccine n1=Bevacizumab | n2=en:p501-as15 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:p53 peptide vaccine n1=Bevacizumab | n2=en:p53 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:p53-hdm2 interaction inhibitor mi-773 n1=Bevacizumab | n2=en:p53-hdm2 interaction inhibitor mi-773 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:p53-synthetic long peptides vaccine n1=Bevacizumab | n2=en:p53-synthetic long peptides vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:p53/hdm2 interaction inhibitor cgm097 n1=Bevacizumab | n2=en:p53/hdm2 interaction inhibitor cgm097 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:p70s6k inhibitor ly2584702 n1=Bevacizumab | n2=en:p70s6k inhibitor ly2584702 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:p70s6k/akt inhibitor msc2363318a n1=Bevacizumab | n2=en:p70s6k/akt inhibitor msc2363318a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:p97 inhibitor cb-5083 n1=Bevacizumab | n2=en:p97 inhibitor cb-5083 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pa-1-stk ovarian carcinoma vaccine n1=Bevacizumab | n2=en:pa-1-stk ovarian carcinoma vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:paclitaxel n1=Bevacizumab | n2=en:paclitaxel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:paclitaxel albumin-stabilized nanoparticle formulation n1=Bevacizumab | n2=en:paclitaxel albumin-stabilized nanoparticle formulation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:paclitaxel injection concentrate for nanodispersion n1=Bevacizumab | n2=en:paclitaxel injection concentrate for nanodispersion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:paclitaxel liposome n1=Bevacizumab | n2=en:paclitaxel liposome | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:paclitaxel poliglumex n1=Bevacizumab | n2=en:paclitaxel poliglumex | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:paclitaxel trevatide n1=Bevacizumab | n2=en:paclitaxel trevatide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:paclitaxel vitamin e-based emulsion n1=Bevacizumab | n2=en:paclitaxel vitamin e-based emulsion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:paclitaxel-loaded polymeric micelle n1=Bevacizumab | n2=en:paclitaxel-loaded polymeric micelle | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pacritinib n1=Bevacizumab | n2=en:pacritinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pad regimen n1=Bevacizumab | n2=en:pad regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:padeliporfin n1=Bevacizumab | n2=en:padeliporfin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:padre 965.10 n1=Bevacizumab | n2=en:padre 965.10 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:padre-cmv fusion peptide vaccine n1=Bevacizumab | n2=en:padre-cmv fusion peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pak4 inhibitor pf-03758309 n1=Bevacizumab | n2=en:pak4 inhibitor pf-03758309 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pak4/nampt inhibitor kpt-9274 n1=Bevacizumab | n2=en:pak4/nampt inhibitor kpt-9274 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:palbociclib n1=Bevacizumab | n2=en:palbociclib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:palifermin n1=Bevacizumab | n2=en:palifermin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:palifosfamide n1=Bevacizumab | n2=en:palifosfamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:palifosfamide tromethamine n1=Bevacizumab | n2=en:palifosfamide tromethamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:palivizumab n1=Bevacizumab | n2=en:palivizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:palladium pd-103 n1=Bevacizumab | n2=en:palladium pd-103 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:palladium-bacteriopheophorbide n1=Bevacizumab | n2=en:palladium-bacteriopheophorbide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:palm extract phytonutrient supplement n1=Bevacizumab | n2=en:palm extract phytonutrient supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:palonosetron hydrochloride n1=Bevacizumab | n2=en:palonosetron hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pamidronate disodium n1=Bevacizumab | n2=en:pamidronate disodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pan fgfr inhibitor arq 087 n1=Bevacizumab | n2=en:pan fgfr inhibitor arq 087 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pan fgfr inhibitor prn1371 n1=Bevacizumab | n2=en:pan fgfr inhibitor prn1371 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pan fgfr kinase inhibitor bgj398 n1=Bevacizumab | n2=en:pan fgfr kinase inhibitor bgj398 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pan her/vegfr2 receptor tyrosine kinase inhibitor bms-690514 n1=Bevacizumab | n2=en:pan her/vegfr2 receptor tyrosine kinase inhibitor bms-690514 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pan-akt inhibitor arq751 n1=Bevacizumab | n2=en:pan-akt inhibitor arq751 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pan-akt kinase inhibitor gsk690693 n1=Bevacizumab | n2=en:pan-akt kinase inhibitor gsk690693 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pan-fgfr tyrosine kinase inhibitor bay1163877 n1=Bevacizumab | n2=en:pan-fgfr tyrosine kinase inhibitor bay1163877 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pan-fgfr tyrosine kinase inhibitor jnj-42756493 n1=Bevacizumab | n2=en:pan-fgfr tyrosine kinase inhibitor jnj-42756493 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pan-her kinase inhibitor ac480 n1=Bevacizumab | n2=en:pan-her kinase inhibitor ac480 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pan-idh mutant inhibitor ag-881 n1=Bevacizumab | n2=en:pan-idh mutant inhibitor ag-881 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pan-pi3k inhibitor clr457 n1=Bevacizumab | n2=en:pan-pi3k inhibitor clr457 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pan-pi3k/mtor inhibitor pqr309 n1=Bevacizumab | n2=en:pan-pi3k/mtor inhibitor pqr309 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pan-pi3k/mtor inhibitor sf1126 n1=Bevacizumab | n2=en:pan-pi3k/mtor inhibitor sf1126 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pan-pim inhibitor incb053914 n1=Bevacizumab | n2=en:pan-pim inhibitor incb053914 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pan-pim kinase inhibitor azd1208 n1=Bevacizumab | n2=en:pan-pim kinase inhibitor azd1208 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pan-raf inhibitor lxh254 n1=Bevacizumab | n2=en:pan-raf inhibitor lxh254 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pan-raf inhibitor ly3009120 n1=Bevacizumab | n2=en:pan-raf inhibitor ly3009120 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pan-raf kinase inhibitor cct3833 n1=Bevacizumab | n2=en:pan-raf kinase inhibitor cct3833 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pan-raf kinase inhibitor tak-580 n1=Bevacizumab | n2=en:pan-raf kinase inhibitor tak-580 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pan-selectin antagonist gmi-1070 n1=Bevacizumab | n2=en:pan-selectin antagonist gmi-1070 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pan-vegfr/tie2 tyrosine kinase inhibitor cep-11981 n1=Bevacizumab | n2=en:pan-vegfr/tie2 tyrosine kinase inhibitor cep-11981 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pancrelipase n1=Bevacizumab | n2=en:pancrelipase | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:panitumumab n1=Bevacizumab | n2=en:panitumumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:panitumumab-irdye800 n1=Bevacizumab | n2=en:panitumumab-irdye800 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:panobinostat n1=Bevacizumab | n2=en:panobinostat | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pantoprazole sodium n1=Bevacizumab | n2=en:pantoprazole sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:papaverine n1=Bevacizumab | n2=en:papaverine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:parathyroid hormone-related protein (1-36) n1=Bevacizumab | n2=en:parathyroid hormone-related protein (1-36) | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:parecoxib sodium n1=Bevacizumab | n2=en:parecoxib sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:parenteral dosage form product n1=Bevacizumab | n2=en:parenteral dosage form product | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:paricalcitol n1=Bevacizumab | n2=en:paricalcitol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:paromomycin sulfate n1=Bevacizumab | n2=en:paromomycin sulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:paroxetine hydrochloride n1=Bevacizumab | n2=en:paroxetine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:parp 1/2 inhibitor e7449 n1=Bevacizumab | n2=en:parp 1/2 inhibitor e7449 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:parp inhibitor azd2461 n1=Bevacizumab | n2=en:parp inhibitor azd2461 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:parp inhibitor bgb-290 n1=Bevacizumab | n2=en:parp inhibitor bgb-290 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:parp inhibitor cep-9722 n1=Bevacizumab | n2=en:parp inhibitor cep-9722 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:parp inhibitor e7016 n1=Bevacizumab | n2=en:parp inhibitor e7016 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:parp-1/2 inhibitor abt-767 n1=Bevacizumab | n2=en:parp-1/2 inhibitor abt-767 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:parsatuzumab n1=Bevacizumab | n2=en:parsatuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:parvovirus h-1 n1=Bevacizumab | n2=en:parvovirus h-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pasireotide n1=Bevacizumab | n2=en:pasireotide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:patent blue v dye n1=Bevacizumab | n2=en:patent blue v dye | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:patient-specific follicular lymphoma-derived anti-idiotype vaccine n1=Bevacizumab | n2=en:patient-specific follicular lymphoma-derived anti-idiotype vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:patritumab n1=Bevacizumab | n2=en:patritumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:patupilone n1=Bevacizumab | n2=en:patupilone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pazopanib hydrochloride n1=Bevacizumab | n2=en:pazopanib hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pbcar3 phosphopeptide-tetanus peptide vaccine n1=Bevacizumab | n2=en:pbcar3 phosphopeptide-tetanus peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pbcar3/pirs2-phosphopeptide-tetanus peptide vaccine n1=Bevacizumab | n2=en:pbcar3/pirs2-phosphopeptide-tetanus peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pbi-shrna stmn1 lipoplex n1=Bevacizumab | n2=en:pbi-shrna stmn1 lipoplex | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pbn derivative okn-007 n1=Bevacizumab | n2=en:pbn derivative okn-007 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pbtl cd19car-28 zeta n1=Bevacizumab | n2=en:pbtl cd19car-28 zeta | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pc-spes n1=Bevacizumab | n2=en:pc-spes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pcnu n1=Bevacizumab | n2=en:pcnu | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pcv regimen n1=Bevacizumab | n2=en:pcv regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pd l 506 n1=Bevacizumab | n2=en:pd l 506 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pd0325901 n1=Bevacizumab | n2=en:pd0325901 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pdcd-1 knockout autologous t-lymphocytes n1=Bevacizumab | n2=en:pdcd-1 knockout autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pdgfr alpha/kit mutant-specific inhibitor blu-285 n1=Bevacizumab | n2=en:pdgfr alpha/kit mutant-specific inhibitor blu-285 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pdk1 inhibitor ar-12 n1=Bevacizumab | n2=en:pdk1 inhibitor ar-12 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pdm08 n1=Bevacizumab | n2=en:pdm08 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pe/hpv16 e7/kdel fusion protein tvgv-1 n1=Bevacizumab | n2=en:pe/hpv16 e7/kdel fusion protein tvgv-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pediatric nutritional supplement drink n1=Bevacizumab | n2=en:pediatric nutritional supplement drink | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pefloxacin n1=Bevacizumab | n2=en:pefloxacin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:peg recombinant human megakaryocyte growth and development factor n1=Bevacizumab | n2=en:peg recombinant human megakaryocyte growth and development factor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:peg-3350/sodium sulfate/sodium chloride/potassium chloride/sodium ascorbate/ascorbic acid-based laxative n1=Bevacizumab | n2=en:peg-3350/sodium sulfate/sodium chloride/potassium chloride/sodium ascorbate/ascorbic acid-based laxative | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:peg-based laxative ner1006 n1=Bevacizumab | n2=en:peg-based laxative ner1006 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:peg-interleukin-2 n1=Bevacizumab | n2=en:peg-interleukin-2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:peg-linked l-rna oligonucleotide hepcidin-targeting agent nox-h94 n1=Bevacizumab | n2=en:peg-linked l-rna oligonucleotide hepcidin-targeting agent nox-h94 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:peg-pei-cholesterol lipopolymer-encased il-12 dna plasmid vector gen-1 n1=Bevacizumab | n2=en:peg-pei-cholesterol lipopolymer-encased il-12 dna plasmid vector gen-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:peg-proline-interferon alfa-2b n1=Bevacizumab | n2=en:peg-proline-interferon alfa-2b | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegamotecan n1=Bevacizumab | n2=en:pegamotecan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegaptanib n1=Bevacizumab | n2=en:pegaptanib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegaptanib sodium n1=Bevacizumab | n2=en:pegaptanib sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegaspargase n1=Bevacizumab | n2=en:pegaspargase | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegdinetanib n1=Bevacizumab | n2=en:pegdinetanib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegfilgrastim n1=Bevacizumab | n2=en:pegfilgrastim | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegfilgrastim anti-neutropenic factor n1=Bevacizumab | n2=en:pegfilgrastim anti-neutropenic factor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegfilgrastim biosimilar la-ep2006 n1=Bevacizumab | n2=en:pegfilgrastim biosimilar la-ep2006 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:peginesatide n1=Bevacizumab | n2=en:peginesatide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:peginterferon alfa-2a n1=Bevacizumab | n2=en:peginterferon alfa-2a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:peginterferon alfa-2b n1=Bevacizumab | n2=en:peginterferon alfa-2b | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegol sihematide n1=Bevacizumab | n2=en:pegol sihematide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegvisomant n1=Bevacizumab | n2=en:pegvisomant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegylated anti-gfr antibody fragment n1=Bevacizumab | n2=en:pegylated anti-gfr antibody fragment | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegylated arginine deiminase n1=Bevacizumab | n2=en:pegylated arginine deiminase | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegylated granulocyte colony stimulating factor maxy-g34 n1=Bevacizumab | n2=en:pegylated granulocyte colony stimulating factor maxy-g34 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegylated human recombinant arginase 1 aeb1102 n1=Bevacizumab | n2=en:pegylated human recombinant arginase 1 aeb1102 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegylated interferon alfa n1=Bevacizumab | n2=en:pegylated interferon alfa | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegylated irinotecan n1=Bevacizumab | n2=en:pegylated irinotecan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegylated liposomal belotecan n1=Bevacizumab | n2=en:pegylated liposomal belotecan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegylated liposomal doxorubicin hydrochloride n1=Bevacizumab | n2=en:pegylated liposomal doxorubicin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegylated liposomal irinotecan n1=Bevacizumab | n2=en:pegylated liposomal irinotecan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegylated liposomal mitomycin c lipid-based prodrug n1=Bevacizumab | n2=en:pegylated liposomal mitomycin c lipid-based prodrug | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegylated liposomal nanoparticle-based docetaxel prodrug mnk-010 n1=Bevacizumab | n2=en:pegylated liposomal nanoparticle-based docetaxel prodrug mnk-010 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegylated paclitaxel n1=Bevacizumab | n2=en:pegylated paclitaxel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegylated recombinant human arginase i bct-100 n1=Bevacizumab | n2=en:pegylated recombinant human arginase i bct-100 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegylated recombinant human hyaluronidase ph20 n1=Bevacizumab | n2=en:pegylated recombinant human hyaluronidase ph20 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegylated recombinant human interleukin-10 am0010 n1=Bevacizumab | n2=en:pegylated recombinant human interleukin-10 am0010 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pegylated recombinant l-asparaginase erwinia chrysanthemi n1=Bevacizumab | n2=en:pegylated recombinant l-asparaginase erwinia chrysanthemi | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:peldesine n1=Bevacizumab | n2=en:peldesine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pelitinib n1=Bevacizumab | n2=en:pelitinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pelitrexol n1=Bevacizumab | n2=en:pelitrexol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pembrolizumab n1=Bevacizumab | n2=en:pembrolizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pemetrexed disodium n1=Bevacizumab | n2=en:pemetrexed disodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:penberol n1=Bevacizumab | n2=en:penberol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:penclomedine n1=Bevacizumab | n2=en:penclomedine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:penicillamine n1=Bevacizumab | n2=en:penicillamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:penicillin v potassium n1=Bevacizumab | n2=en:penicillin v potassium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pentamethylmelamine n1=Bevacizumab | n2=en:pentamethylmelamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pentamidine n1=Bevacizumab | n2=en:pentamidine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pentamidine isethionate n1=Bevacizumab | n2=en:pentamidine isethionate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pentavalent klh conjugate vaccine n1=Bevacizumab | n2=en:pentavalent klh conjugate vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pentetic acid n1=Bevacizumab | n2=en:pentetic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pentetic acid calcium n1=Bevacizumab | n2=en:pentetic acid calcium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pentosan polysulfate sodium n1=Bevacizumab | n2=en:pentosan polysulfate sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pentostatin n1=Bevacizumab | n2=en:pentostatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pentoxifylline n1=Bevacizumab | n2=en:pentoxifylline | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pep-3-klh conjugate vaccine n1=Bevacizumab | n2=en:pep-3-klh conjugate vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pep-cmv vaccine n1=Bevacizumab | n2=en:pep-cmv vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:peplomycin n1=Bevacizumab | n2=en:peplomycin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:peptichemio n1=Bevacizumab | n2=en:peptichemio | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:peptide 946 melanoma vaccine n1=Bevacizumab | n2=en:peptide 946 melanoma vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:peptide 946-tetanus peptide conjugate melanoma vaccine n1=Bevacizumab | n2=en:peptide 946-tetanus peptide conjugate melanoma vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:peptides hydrolases n1=Bevacizumab | n2=en:peptides hydrolases | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:perampanel n1=Bevacizumab | n2=en:perampanel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:peretinoin n1=Bevacizumab | n2=en:peretinoin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:perflenapent emulsion n1=Bevacizumab | n2=en:perflenapent emulsion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:perflubron n1=Bevacizumab | n2=en:perflubron | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:perflubutane n1=Bevacizumab | n2=en:perflubutane | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:perflutren n1=Bevacizumab | n2=en:perflutren | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:perflutren lipid microspheres n1=Bevacizumab | n2=en:perflutren lipid microspheres | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:perflutren protein-type a microspheres n1=Bevacizumab | n2=en:perflutren protein-type a microspheres | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:perfosfamide n1=Bevacizumab | n2=en:perfosfamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:perifosine n1=Bevacizumab | n2=en:perifosine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:perillyl alcohol n1=Bevacizumab | n2=en:perillyl alcohol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:perindopril erbumine n1=Bevacizumab | n2=en:perindopril erbumine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:personalized polyepitope plasmid dna breast cancer vaccine n1=Bevacizumab | n2=en:personalized polyepitope plasmid dna breast cancer vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:personalized synthetic long peptide breast cancer vaccine n1=Bevacizumab | n2=en:personalized synthetic long peptide breast cancer vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pertuzumab n1=Bevacizumab | n2=en:pertuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:peruvian balsam / trypsin n1=Bevacizumab | n2=en:peruvian balsam / trypsin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pesticide n1=Bevacizumab | n2=en:pesticide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:petrolatum-mineral oil-lanolin-ceresin ointment n1=Bevacizumab | n2=en:petrolatum-mineral oil-lanolin-ceresin ointment | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pevonedistat n1=Bevacizumab | n2=en:pevonedistat | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pexastimogene-devacirepvec n1=Bevacizumab | n2=en:pexastimogene-devacirepvec | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pexidartinib n1=Bevacizumab | n2=en:pexidartinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pg13-cd19-h3 (anti-cd19 car) retroviral vector-transduced peripheral blood lymphocytes n1=Bevacizumab | n2=en:pg13-cd19-h3 (anti-cd19 car) retroviral vector-transduced peripheral blood lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pgg beta-glucan n1=Bevacizumab | n2=en:pgg beta-glucan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pgla/peg copolymer-based paclitaxel n1=Bevacizumab | n2=en:pgla/peg copolymer-based paclitaxel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ph20 hyaluronidase-expressing adenovirus vcn-01 n1=Bevacizumab | n2=en:ph20 hyaluronidase-expressing adenovirus vcn-01 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:phaleria macrocarpa extract dlbs-1425 n1=Bevacizumab | n2=en:phaleria macrocarpa extract dlbs-1425 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pharmaceutic aids n1=Bevacizumab | n2=en:pharmaceutic aids | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pharmaceutical base or inactive agent n1=Bevacizumab | n2=en:pharmaceutical base or inactive agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pharmaceutical dosage form n1=Bevacizumab | n2=en:pharmaceutical dosage form | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pharmaceutical fluid or solution agent n1=Bevacizumab | n2=en:pharmaceutical fluid or solution agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pharmaceutical preparations, dental n1=Bevacizumab | n2=en:pharmaceutical preparations, dental | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pharmacokinetic aspects n1=Bevacizumab | n2=en:pharmacokinetic aspects | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:phellodendron amurense bark extract n1=Bevacizumab | n2=en:phellodendron amurense bark extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:phenazopyridine + butabarbital + hyoscyamine n1=Bevacizumab | n2=en:phenazopyridine + butabarbital + hyoscyamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:phenelzine sulfate n1=Bevacizumab | n2=en:phenelzine sulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:phenesterin n1=Bevacizumab | n2=en:phenesterin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:phenethyl isothiocyanate n1=Bevacizumab | n2=en:phenethyl isothiocyanate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:phenethyl isothiocyanate-containing watercress juice n1=Bevacizumab | n2=en:phenethyl isothiocyanate-containing watercress juice | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:phenformin hydrochloride n1=Bevacizumab | n2=en:phenformin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:phenobarbital n1=Bevacizumab | n2=en:phenobarbital | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:phenoxybenzamine hydrochloride n1=Bevacizumab | n2=en:phenoxybenzamine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:phenprocoumon n1=Bevacizumab | n2=en:phenprocoumon | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:phentolamine mesylate n1=Bevacizumab | n2=en:phentolamine mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:phenyl acetate n1=Bevacizumab | n2=en:phenyl acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:phosphaplatin pt-112 n1=Bevacizumab | n2=en:phosphaplatin pt-112 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:phosphatidylcholine-bound silybin n1=Bevacizumab | n2=en:phosphatidylcholine-bound silybin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:phosphomannopentaose sulfate n1=Bevacizumab | n2=en:phosphomannopentaose sulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:phosphorodiamidate morpholino oligomer avi-4126 n1=Bevacizumab | n2=en:phosphorodiamidate morpholino oligomer avi-4126 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:phosphorus p-32 n1=Bevacizumab | n2=en:phosphorus p-32 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:photocyanine n1=Bevacizumab | n2=en:photocyanine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:photosensitizer luz 11 n1=Bevacizumab | n2=en:photosensitizer luz 11 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:photosensitizing agent n1=Bevacizumab | n2=en:photosensitizing agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:physiological aspects n1=Bevacizumab | n2=en:physiological aspects | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:phytochemical n1=Bevacizumab | n2=en:phytochemical | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:phytochlorin sodium-polyvinylpyrrolidone complex n1=Bevacizumab | n2=en:phytochlorin sodium-polyvinylpyrrolidone complex | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:phytonadione n1=Bevacizumab | n2=en:phytonadione | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k alpha inhibitor mln1117 n1=Bevacizumab | n2=en:pi3k alpha inhibitor mln1117 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k alpha/beta inhibitor bay1082439 n1=Bevacizumab | n2=en:pi3k alpha/beta inhibitor bay1082439 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k alpha/mtor inhibitor pwt33597 mesylate n1=Bevacizumab | n2=en:pi3k alpha/mtor inhibitor pwt33597 mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k delta/gamma inhibitor ipi-145 n1=Bevacizumab | n2=en:pi3k delta/gamma inhibitor ipi-145 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k delta/gamma inhibitor rp6530 n1=Bevacizumab | n2=en:pi3k delta/gamma inhibitor rp6530 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k family kinase inhibitor xl147 n1=Bevacizumab | n2=en:pi3k family kinase inhibitor xl147 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k inhibitor acp-319 n1=Bevacizumab | n2=en:pi3k inhibitor acp-319 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k inhibitor bgt226 n1=Bevacizumab | n2=en:pi3k inhibitor bgt226 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k inhibitor ch5132799 n1=Bevacizumab | n2=en:pi3k inhibitor ch5132799 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k inhibitor gdc-0084 n1=Bevacizumab | n2=en:pi3k inhibitor gdc-0084 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k inhibitor gdc-0941 bismesylate n1=Bevacizumab | n2=en:pi3k inhibitor gdc-0941 bismesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k inhibitor gsk1059615 n1=Bevacizumab | n2=en:pi3k inhibitor gsk1059615 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k inhibitor gsk2126458 n1=Bevacizumab | n2=en:pi3k inhibitor gsk2126458 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k inhibitor px-866 n1=Bevacizumab | n2=en:pi3k inhibitor px-866 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k inhibitor wx-037 n1=Bevacizumab | n2=en:pi3k inhibitor wx-037 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k inhibitor zstk474 n1=Bevacizumab | n2=en:pi3k inhibitor zstk474 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k p110beta/delta inhibitor ka2237 n1=Bevacizumab | n2=en:pi3k p110beta/delta inhibitor ka2237 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k-beta inhibitor gsk2636771 n1=Bevacizumab | n2=en:pi3k-beta inhibitor gsk2636771 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k-beta inhibitor sar260301 n1=Bevacizumab | n2=en:pi3k-beta inhibitor sar260301 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k-delta inhibitor amg 319 n1=Bevacizumab | n2=en:pi3k-delta inhibitor amg 319 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k-delta inhibitor incb050465 n1=Bevacizumab | n2=en:pi3k-delta inhibitor incb050465 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k-delta inhibitor pwt143 n1=Bevacizumab | n2=en:pi3k-delta inhibitor pwt143 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k-delta inhibitor tgr-1202 n1=Bevacizumab | n2=en:pi3k-delta inhibitor tgr-1202 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k-gamma inhibitor ipi-549 n1=Bevacizumab | n2=en:pi3k-gamma inhibitor ipi-549 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k/hdac inhibitor cudc-907 n1=Bevacizumab | n2=en:pi3k/hdac inhibitor cudc-907 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k/mtor inhibitor bez235 n1=Bevacizumab | n2=en:pi3k/mtor inhibitor bez235 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k/mtor inhibitor ly3023414 n1=Bevacizumab | n2=en:pi3k/mtor inhibitor ly3023414 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k/mtor kinase inhibitor ds-7423 n1=Bevacizumab | n2=en:pi3k/mtor kinase inhibitor ds-7423 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k/mtor kinase inhibitor pf-04691502 n1=Bevacizumab | n2=en:pi3k/mtor kinase inhibitor pf-04691502 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k/mtor kinase inhibitor vs-5584 n1=Bevacizumab | n2=en:pi3k/mtor kinase inhibitor vs-5584 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k/mtor/alk-1/dna-pk inhibitor p7170 n1=Bevacizumab | n2=en:pi3k/mtor/alk-1/dna-pk inhibitor p7170 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3k/mtorc1/mtorc2 inhibitor dcbci0901 n1=Bevacizumab | n2=en:pi3k/mtorc1/mtorc2 inhibitor dcbci0901 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3ka/mtor inhibitor pki-179 n1=Bevacizumab | n2=en:pi3ka/mtor inhibitor pki-179 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3kalpha inhibitor azd8835 n1=Bevacizumab | n2=en:pi3kalpha inhibitor azd8835 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3kbeta inhibitor azd8186 n1=Bevacizumab | n2=en:pi3kbeta inhibitor azd8186 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3kdelta inhibitor gs-9901 n1=Bevacizumab | n2=en:pi3kdelta inhibitor gs-9901 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pi3kdelta inhibitor incb040093 n1=Bevacizumab | n2=en:pi3kdelta inhibitor incb040093 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pibenzimol n1=Bevacizumab | n2=en:pibenzimol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pibrozelesin n1=Bevacizumab | n2=en:pibrozelesin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:picibanil n1=Bevacizumab | n2=en:picibanil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:picoplatin n1=Bevacizumab | n2=en:picoplatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:picropodophyllin n1=Bevacizumab | n2=en:picropodophyllin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pidilizumab n1=Bevacizumab | n2=en:pidilizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pigmenting agent n1=Bevacizumab | n2=en:pigmenting agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pilocarpine hydrochloride n1=Bevacizumab | n2=en:pilocarpine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pim kinase inhibitor lgh447 n1=Bevacizumab | n2=en:pim kinase inhibitor lgh447 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pim kinase inhibitor sgi-1776 n1=Bevacizumab | n2=en:pim kinase inhibitor sgi-1776 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pimasertib n1=Bevacizumab | n2=en:pimasertib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pimecrolimus n1=Bevacizumab | n2=en:pimecrolimus | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pimonidazole n1=Bevacizumab | n2=en:pimonidazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pimonidazole hydrochloride n1=Bevacizumab | n2=en:pimonidazole hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pinaverium bromide n1=Bevacizumab | n2=en:pinaverium bromide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pioglitazone hydrochloride n1=Bevacizumab | n2=en:pioglitazone hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pipendoxifene n1=Bevacizumab | n2=en:pipendoxifene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:piperacillin sodium n1=Bevacizumab | n2=en:piperacillin sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:piperacillin-tazobactam n1=Bevacizumab | n2=en:piperacillin-tazobactam | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:piperazinedione n1=Bevacizumab | n2=en:piperazinedione | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:piperine extract (standardized) n1=Bevacizumab | n2=en:piperine extract (standardized) | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pirarubicin n1=Bevacizumab | n2=en:pirarubicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pirfenidone n1=Bevacizumab | n2=en:pirfenidone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:piritramide n1=Bevacizumab | n2=en:piritramide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:piritrexim n1=Bevacizumab | n2=en:piritrexim | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pirotinib n1=Bevacizumab | n2=en:pirotinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:piroxantrone n1=Bevacizumab | n2=en:piroxantrone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:piroxicam n1=Bevacizumab | n2=en:piroxicam | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pirs2 phosphopeptide-tetanus peptide vaccine n1=Bevacizumab | n2=en:pirs2 phosphopeptide-tetanus peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pivaloyloxymethylbutyrate n1=Bevacizumab | n2=en:pivaloyloxymethylbutyrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pixantrone dimaleate n1=Bevacizumab | n2=en:pixantrone dimaleate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:placebo administration n1=Bevacizumab | n2=en:placebo administration | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pladienolide derivative e7107 n1=Bevacizumab | n2=en:pladienolide derivative e7107 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:plant extracts n1=Bevacizumab | n2=en:plant extracts | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:plant-derived hematopoiesis enhancer pg2 n1=Bevacizumab | n2=en:plant-derived hematopoiesis enhancer pg2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:plasmacytoid dendritic cell vaccine n1=Bevacizumab | n2=en:plasmacytoid dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:plasmid encoding antiangiogenic metargidin peptide n1=Bevacizumab | n2=en:plasmid encoding antiangiogenic metargidin peptide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:plectin-1 targeting agent ptp-01 n1=Bevacizumab | n2=en:plectin-1 targeting agent ptp-01 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pled-based mnsod mimetic n1=Bevacizumab | n2=en:pled-based mnsod mimetic | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pleiotropic pathway modifier cc-122 hydrochloride n1=Bevacizumab | n2=en:pleiotropic pathway modifier cc-122 hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:plerixafor n1=Bevacizumab | n2=en:plerixafor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:plevitrexed n1=Bevacizumab | n2=en:plevitrexed | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:plicamycin n1=Bevacizumab | n2=en:plicamycin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:plinabulin n1=Bevacizumab | n2=en:plinabulin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:plitidepsin n1=Bevacizumab | n2=en:plitidepsin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:plk1 inhibitor tak-960 n1=Bevacizumab | n2=en:plk1 inhibitor tak-960 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:plozalizumab n1=Bevacizumab | n2=en:plozalizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:plx73086 n1=Bevacizumab | n2=en:plx73086 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pm00104 n1=Bevacizumab | n2=en:pm00104 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pneumococcal 13-valent conjugate vaccine n1=Bevacizumab | n2=en:pneumococcal 13-valent conjugate vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pneumococcal 7-valent conjugate vaccine n1=Bevacizumab | n2=en:pneumococcal 7-valent conjugate vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pneumococcal polyvalent vaccine n1=Bevacizumab | n2=en:pneumococcal polyvalent vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pngvl3-hicd vaccine n1=Bevacizumab | n2=en:pngvl3-hicd vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pngvl4a-crt/e7(detox) dna vaccine n1=Bevacizumab | n2=en:pngvl4a-crt/e7(detox) dna vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pngvl4a-sig/e7(detox)/hsp70 dna vaccine n1=Bevacizumab | n2=en:pngvl4a-sig/e7(detox)/hsp70 dna vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pnp-expressing ovine atadenovirus fp253 n1=Bevacizumab | n2=en:pnp-expressing ovine atadenovirus fp253 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:poisoning aspects n1=Bevacizumab | n2=en:poisoning aspects | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pol i inhibitor cx5461 n1=Bevacizumab | n2=en:pol i inhibitor cx5461 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polaprezinc n1=Bevacizumab | n2=en:polaprezinc | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polatuzumab vedotin n1=Bevacizumab | n2=en:polatuzumab vedotin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:policosanol n1=Bevacizumab | n2=en:policosanol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polifeprosan 20 with carmustine implant n1=Bevacizumab | n2=en:polifeprosan 20 with carmustine implant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polihexanide solution n1=Bevacizumab | n2=en:polihexanide solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polo-like kinase 1 inhibitor gsk461364 n1=Bevacizumab | n2=en:polo-like kinase 1 inhibitor gsk461364 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polo-like kinase 1 inhibitor mk1496 n1=Bevacizumab | n2=en:polo-like kinase 1 inhibitor mk1496 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polo-like kinase 1 inhibitor nms-1286937 n1=Bevacizumab | n2=en:polo-like kinase 1 inhibitor nms-1286937 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polo-like kinase 4 inhibitor cfi-400945 fumarate n1=Bevacizumab | n2=en:polo-like kinase 4 inhibitor cfi-400945 fumarate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:poly (adp-ribose) polymerase inhibitor n1=Bevacizumab | n2=en:poly (adp-ribose) polymerase inhibitor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:poly au n1=Bevacizumab | n2=en:poly au | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:poly ic n1=Bevacizumab | n2=en:poly ic | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:poly iclc n1=Bevacizumab | n2=en:poly iclc | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:poly-alendronate dextran-guanidine conjugate n1=Bevacizumab | n2=en:poly-alendronate dextran-guanidine conjugate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:poly-gamma glutamic acid n1=Bevacizumab | n2=en:poly-gamma glutamic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polyacrylamide hydrogel n1=Bevacizumab | n2=en:polyacrylamide hydrogel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polyamine analogue n1=Bevacizumab | n2=en:polyamine analogue | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polyamine analogue pg11047 n1=Bevacizumab | n2=en:polyamine analogue pg11047 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polyamine synthesis inhibitor n1=Bevacizumab | n2=en:polyamine synthesis inhibitor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polycarbophil/carbomer/glycerin/palm oil glyceride/mineral oil-containing vaginal moisturizer n1=Bevacizumab | n2=en:polycarbophil/carbomer/glycerin/palm oil glyceride/mineral oil-containing vaginal moisturizer | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polydextrose n1=Bevacizumab | n2=en:polydextrose | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polyethylene glycol n1=Bevacizumab | n2=en:polyethylene glycol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polyethylene glycol 3350-containing enema ner1008 n1=Bevacizumab | n2=en:polyethylene glycol 3350-containing enema ner1008 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polyethylene glycol polymer surgical sealant n1=Bevacizumab | n2=en:polyethylene glycol polymer surgical sealant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polyethylene glycol recombinant endostatin n1=Bevacizumab | n2=en:polyethylene glycol recombinant endostatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polyethyleneglycol-7-ethyl-10-hydroxycamptothecin dfp-13318 n1=Bevacizumab | n2=en:polyethyleneglycol-7-ethyl-10-hydroxycamptothecin dfp-13318 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polyglutamate camptothecin n1=Bevacizumab | n2=en:polyglutamate camptothecin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polymeric camptothecin prodrug xmt-1001 n1=Bevacizumab | n2=en:polymeric camptothecin prodrug xmt-1001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polymyxin b n1=Bevacizumab | n2=en:polymyxin b | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polysaccharide-k n1=Bevacizumab | n2=en:polysaccharide-k | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polyunsaturated fatty acid n1=Bevacizumab | n2=en:polyunsaturated fatty acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polyvalent antigen-klh conjugate vaccine n1=Bevacizumab | n2=en:polyvalent antigen-klh conjugate vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polyvalent melanoma vaccine n1=Bevacizumab | n2=en:polyvalent melanoma vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:polyvinylpyrrolidone-sodium hyaluronate gel n1=Bevacizumab | n2=en:polyvinylpyrrolidone-sodium hyaluronate gel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pomalidomide n1=Bevacizumab | n2=en:pomalidomide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pomegranate juice n1=Bevacizumab | n2=en:pomegranate juice | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pomegranate liquid extract n1=Bevacizumab | n2=en:pomegranate liquid extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pomegranate-extract pill n1=Bevacizumab | n2=en:pomegranate-extract pill | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ponatinib hydrochloride n1=Bevacizumab | n2=en:ponatinib hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ponesimod n1=Bevacizumab | n2=en:ponesimod | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:porcupine inhibitor etc-1922159 n1=Bevacizumab | n2=en:porcupine inhibitor etc-1922159 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:porcupine inhibitor wnt974 n1=Bevacizumab | n2=en:porcupine inhibitor wnt974 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:porfimer sodium n1=Bevacizumab | n2=en:porfimer sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:porfiromycin n1=Bevacizumab | n2=en:porfiromycin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:posaconazole n1=Bevacizumab | n2=en:posaconazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:povidone-iodine n1=Bevacizumab | n2=en:povidone-iodine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:poziotinib n1=Bevacizumab | n2=en:poziotinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ppe-expressing replication-defective hsv-1 vector np2 n1=Bevacizumab | n2=en:ppe-expressing replication-defective hsv-1 vector np2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ppi-2458 n1=Bevacizumab | n2=en:ppi-2458 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pr-104 n1=Bevacizumab | n2=en:pr-104 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pr1 leukemia peptide vaccine n1=Bevacizumab | n2=en:pr1 leukemia peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pracinostat n1=Bevacizumab | n2=en:pracinostat | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pralatrexate n1=Bevacizumab | n2=en:pralatrexate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:prame-targeting t-cell receptor/inducible caspase 9 bpx-701 n1=Bevacizumab | n2=en:prame-targeting t-cell receptor/inducible caspase 9 bpx-701 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pramipexole dihydrochloride n1=Bevacizumab | n2=en:pramipexole dihydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:prasterone n1=Bevacizumab | n2=en:prasterone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pravastatin sodium n1=Bevacizumab | n2=en:pravastatin sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:prednimustine n1=Bevacizumab | n2=en:prednimustine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:prednisolone n1=Bevacizumab | n2=en:prednisolone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:prednisone n1=Bevacizumab | n2=en:prednisone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pregabalin n1=Bevacizumab | n2=en:pregabalin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:preimplantation factor pif-1 n1=Bevacizumab | n2=en:preimplantation factor pif-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:prescription drugs n1=Bevacizumab | n2=en:prescription drugs | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:prexasertib n1=Bevacizumab | n2=en:prexasertib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:prilocaine hydrochloride n1=Bevacizumab | n2=en:prilocaine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:prima-1 analog apr-246 n1=Bevacizumab | n2=en:prima-1 analog apr-246 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:primary prostate cancer tissue/htert/survivin mrna-loaded autologous dendritic cell vaccine n1=Bevacizumab | n2=en:primary prostate cancer tissue/htert/survivin mrna-loaded autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:prinomastat n1=Bevacizumab | n2=en:prinomastat | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:probenecid n1=Bevacizumab | n2=en:probenecid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:procarbazine n1=Bevacizumab | n2=en:procarbazine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:procarbazine hydrochloride n1=Bevacizumab | n2=en:procarbazine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:procaspase activating compound-1 vo-100 n1=Bevacizumab | n2=en:procaspase activating compound-1 vo-100 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:prochlorperazine n1=Bevacizumab | n2=en:prochlorperazine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:prodrugs n1=Bevacizumab | n2=en:prodrugs | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:product bases and inactive substances n1=Bevacizumab | n2=en:product bases and inactive substances | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:proflavine n1=Bevacizumab | n2=en:proflavine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:proflavine hemisulfate n1=Bevacizumab | n2=en:proflavine hemisulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:progenipoietin n1=Bevacizumab | n2=en:progenipoietin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:progesterone vaginal insert n1=Bevacizumab | n2=en:progesterone vaginal insert | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:progestin n1=Bevacizumab | n2=en:progestin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:prohibitin-targeting peptide 1 n1=Bevacizumab | n2=en:prohibitin-targeting peptide 1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:proliferant agent n1=Bevacizumab | n2=en:proliferant agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:promegapoietin n1=Bevacizumab | n2=en:promegapoietin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:promestriene n1=Bevacizumab | n2=en:promestriene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:promethazine hydrochloride n1=Bevacizumab | n2=en:promethazine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pronase oral solution n1=Bevacizumab | n2=en:pronase oral solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:propacetamol n1=Bevacizumab | n2=en:propacetamol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:propofol n1=Bevacizumab | n2=en:propofol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:propranolol hydrochloride n1=Bevacizumab | n2=en:propranolol hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:propylthiouracil n1=Bevacizumab | n2=en:propylthiouracil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:prostate cancer vaccine ony-p1 n1=Bevacizumab | n2=en:prostate cancer vaccine ony-p1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:prostate cancer vaccine pf-06755990 n1=Bevacizumab | n2=en:prostate cancer vaccine pf-06755990 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:prostate cancer vaccine pf-06755992 n1=Bevacizumab | n2=en:prostate cancer vaccine pf-06755992 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:prostate health cocktail dietary supplement n1=Bevacizumab | n2=en:prostate health cocktail dietary supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:prostate tumor antigen-activated autologous dendritic cell vaccine n1=Bevacizumab | n2=en:prostate tumor antigen-activated autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:prostatic acid phosphatase-sargramostim fusion protein n1=Bevacizumab | n2=en:prostatic acid phosphatase-sargramostim fusion protein | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:proteasome inhibitor n1=Bevacizumab | n2=en:proteasome inhibitor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:protective agent n1=Bevacizumab | n2=en:protective agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:protein e7, human papillomavirus type 16 n1=Bevacizumab | n2=en:protein e7, human papillomavirus type 16 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:protein kinase c inhibitor lxs196 n1=Bevacizumab | n2=en:protein kinase c inhibitor lxs196 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:protein phosphatase 2a inhibitor lb-100 n1=Bevacizumab | n2=en:protein phosphatase 2a inhibitor lb-100 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:protein stabilized liposomal docetaxel nanoparticles n1=Bevacizumab | n2=en:protein stabilized liposomal docetaxel nanoparticles | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:protein tyrosine kinase 2 inhibitor bi 853520 n1=Bevacizumab | n2=en:protein tyrosine kinase 2 inhibitor bi 853520 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:psa rna-pulsed dendritic cell vaccine n1=Bevacizumab | n2=en:psa rna-pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:psa-pap/klh-pulsed autologous dendritic cell vaccine n1=Bevacizumab | n2=en:psa-pap/klh-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:psa:154-163(155l) peptide vaccine n1=Bevacizumab | n2=en:psa:154-163(155l) peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:psa/il-2/gm-csf vaccine n1=Bevacizumab | n2=en:psa/il-2/gm-csf vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:psa/psma dna plasmid ino-5150 n1=Bevacizumab | n2=en:psa/psma dna plasmid ino-5150 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pseudomonas aeruginosa preparation n1=Bevacizumab | n2=en:pseudomonas aeruginosa preparation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:psicrip-mfg-s-tk1-67 n1=Bevacizumab | n2=en:psicrip-mfg-s-tk1-67 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:psilocybine n1=Bevacizumab | n2=en:psilocybine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:psma-targeted docetaxel nanoparticles bind-014 n1=Bevacizumab | n2=en:psma-targeted docetaxel nanoparticles bind-014 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:psma-targeted tubulysin b-containing conjugate ec1169 n1=Bevacizumab | n2=en:psma-targeted tubulysin b-containing conjugate ec1169 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:psma/tarp peptide vaccine n1=Bevacizumab | n2=en:psma/tarp peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:psoralen n1=Bevacizumab | n2=en:psoralen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:psychopharmacologic agent n1=Bevacizumab | n2=en:psychopharmacologic agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ptef-b/cdk9 inhibitor bay1251152 n1=Bevacizumab | n2=en:ptef-b/cdk9 inhibitor bay1251152 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ptvg-hp plasmid dna vaccine n1=Bevacizumab | n2=en:ptvg-hp plasmid dna vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pumvc3-higfbp-2 multi-epitope plasmid dna vaccine n1=Bevacizumab | n2=en:pumvc3-higfbp-2 multi-epitope plasmid dna vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pumvc3-igfbp2-her2-igf1r plasmid dna vaccine n1=Bevacizumab | n2=en:pumvc3-igfbp2-her2-igf1r plasmid dna vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:purple grape juice n1=Bevacizumab | n2=en:purple grape juice | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pv-10 n1=Bevacizumab | n2=en:pv-10 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pv701 n1=Bevacizumab | n2=en:pv701 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pva microporous hydrospheres n1=Bevacizumab | n2=en:pva microporous hydrospheres | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pva microporous hydrospheres/doxorubicin hydrochloride n1=Bevacizumab | n2=en:pva microporous hydrospheres/doxorubicin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pvaxrcpsav53l dna vaccine n1=Bevacizumab | n2=en:pvaxrcpsav53l dna vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pyrazinamide n1=Bevacizumab | n2=en:pyrazinamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pyrazine diazohydroxide n1=Bevacizumab | n2=en:pyrazine diazohydroxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pyrazofurin n1=Bevacizumab | n2=en:pyrazofurin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pyrazole derivative n1=Bevacizumab | n2=en:pyrazole derivative | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pyrazoloacridine n1=Bevacizumab | n2=en:pyrazoloacridine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pyridoxine hydrochloride n1=Bevacizumab | n2=en:pyridoxine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pyridyl cyanoguanidine chs 828 n1=Bevacizumab | n2=en:pyridyl cyanoguanidine chs 828 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pyrimethamine n1=Bevacizumab | n2=en:pyrimethamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pyrimethamine-sulfadoxine n1=Bevacizumab | n2=en:pyrimethamine-sulfadoxine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pyrogen n1=Bevacizumab | n2=en:pyrogen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pyrotinib n1=Bevacizumab | n2=en:pyrotinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pyroxamide n1=Bevacizumab | n2=en:pyroxamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:pyruvate kinase inhibitor tln-232 n1=Bevacizumab | n2=en:pyruvate kinase inhibitor tln-232 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:qs21 n1=Bevacizumab | n2=en:qs21 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine n1=Bevacizumab | n2=en:quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:quarfloxin n1=Bevacizumab | n2=en:quarfloxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:quaternary ammonium polyethylenimine nanoparticles n1=Bevacizumab | n2=en:quaternary ammonium polyethylenimine nanoparticles | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:quercetin n1=Bevacizumab | n2=en:quercetin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:quinacrine hydrochloride n1=Bevacizumab | n2=en:quinacrine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:quinidine n1=Bevacizumab | n2=en:quinidine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:quinine n1=Bevacizumab | n2=en:quinine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:quinoline n1=Bevacizumab | n2=en:quinoline | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:quisinostat n1=Bevacizumab | n2=en:quisinostat | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:quizartinib n1=Bevacizumab | n2=en:quizartinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:r 7160 n1=Bevacizumab | n2=en:r 7160 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:r-(-)-gossypol acetic acid n1=Bevacizumab | n2=en:r-(-)-gossypol acetic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:r-chop regimen n1=Bevacizumab | n2=en:r-chop regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:r-cvp regimen n1=Bevacizumab | n2=en:r-cvp regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:r-epoch regimen n1=Bevacizumab | n2=en:r-epoch regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:r-ice regimen n1=Bevacizumab | n2=en:r-ice regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:r(+)xk469 n1=Bevacizumab | n2=en:r(+)xk469 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:r1 cooling gel plus r2 moisturizing/sun protecting lotion n1=Bevacizumab | n2=en:r1 cooling gel plus r2 moisturizing/sun protecting lotion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rabeprazole sodium n1=Bevacizumab | n2=en:rabeprazole sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rabusertib n1=Bevacizumab | n2=en:rabusertib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:racotumomab n1=Bevacizumab | n2=en:racotumomab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:radiopharmaceutical agent n1=Bevacizumab | n2=en:radiopharmaceutical agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:radiopharmaceutical bay1862864 n1=Bevacizumab | n2=en:radiopharmaceutical bay1862864 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:radiopharmaceutical compound n1=Bevacizumab | n2=en:radiopharmaceutical compound | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:radioprotective agent n1=Bevacizumab | n2=en:radioprotective agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:radiosensitizer rrx-001 n1=Bevacizumab | n2=en:radiosensitizer rrx-001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:radiosensitizing agent n1=Bevacizumab | n2=en:radiosensitizing agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:radium ra 223 dichloride n1=Bevacizumab | n2=en:radium ra 223 dichloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:radix angelicae sinensis/radix astragali herbal supplement n1=Bevacizumab | n2=en:radix angelicae sinensis/radix astragali herbal supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:radotinib hydrochloride n1=Bevacizumab | n2=en:radotinib hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:raf kinase inhibitor hm95573 n1=Bevacizumab | n2=en:raf kinase inhibitor hm95573 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:raf kinase inhibitor lgx818 n1=Bevacizumab | n2=en:raf kinase inhibitor lgx818 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:raf kinase inhibitor xl281 n1=Bevacizumab | n2=en:raf kinase inhibitor xl281 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:raf/mek serine/threonine kinase inhibitor ro5126766 n1=Bevacizumab | n2=en:raf/mek serine/threonine kinase inhibitor ro5126766 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:raloxifene n1=Bevacizumab | n2=en:raloxifene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:raltegravir potassium n1=Bevacizumab | n2=en:raltegravir potassium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:raltitrexed n1=Bevacizumab | n2=en:raltitrexed | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ramelteon n1=Bevacizumab | n2=en:ramelteon | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ramipril n1=Bevacizumab | n2=en:ramipril | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ramosetron hydrochloride n1=Bevacizumab | n2=en:ramosetron hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ramucirumab n1=Bevacizumab | n2=en:ramucirumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ranibizumab n1=Bevacizumab | n2=en:ranibizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ranimustine n1=Bevacizumab | n2=en:ranimustine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ranitidine hydrochloride/bismuth potassium citrate/sucralfate hydrate formulation n1=Bevacizumab | n2=en:ranitidine hydrochloride/bismuth potassium citrate/sucralfate hydrate formulation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ranolazine n1=Bevacizumab | n2=en:ranolazine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ranpirnase n1=Bevacizumab | n2=en:ranpirnase | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rapamycin-polarized th1/tc1 autologous t lymphocytes n1=Bevacizumab | n2=en:rapamycin-polarized th1/tc1 autologous t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rar-alpha agonist vtp195183 n1=Bevacizumab | n2=en:rar-alpha agonist vtp195183 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ras peptide cancer vaccine n1=Bevacizumab | n2=en:ras peptide cancer vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rasburicase n1=Bevacizumab | n2=en:rasburicase | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ravuconazole n1=Bevacizumab | n2=en:ravuconazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:razoxane n1=Bevacizumab | n2=en:razoxane | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rbl001/rbl002 vaccine n1=Bevacizumab | n2=en:rbl001/rbl002 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:realgar-indigo naturalis formulation n1=Bevacizumab | n2=en:realgar-indigo naturalis formulation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rebamipide n1=Bevacizumab | n2=en:rebamipide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rebastinib tosylate n1=Bevacizumab | n2=en:rebastinib tosylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rebimastat n1=Bevacizumab | n2=en:rebimastat | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:receptor tyrosine kinase inhibitor r1530 n1=Bevacizumab | n2=en:receptor tyrosine kinase inhibitor r1530 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant 70-kd heat-shock protein n1=Bevacizumab | n2=en:recombinant 70-kd heat-shock protein | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant adenovirus 5 encoding tumor necrosis factor-related apoptosis-inducing ligand n1=Bevacizumab | n2=en:recombinant adenovirus 5 encoding tumor necrosis factor-related apoptosis-inducing ligand | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant adenovirus encoding p53 n1=Bevacizumab | n2=en:recombinant adenovirus encoding p53 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant adenovirus-hifn-beta n1=Bevacizumab | n2=en:recombinant adenovirus-hifn-beta | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant adenovirus-interferon sch 721015 n1=Bevacizumab | n2=en:recombinant adenovirus-interferon sch 721015 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant adenovirus-interferon/syn3 n1=Bevacizumab | n2=en:recombinant adenovirus-interferon/syn3 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant adenovirus-l523s vaccine n1=Bevacizumab | n2=en:recombinant adenovirus-l523s vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant adenovirus-p53 sch-58500 n1=Bevacizumab | n2=en:recombinant adenovirus-p53 sch-58500 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant anti-wt1 immunotherapeutic gsk2302024a n1=Bevacizumab | n2=en:recombinant anti-wt1 immunotherapeutic gsk2302024a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant attenuated salmonella typhimurium expressing il-2 n1=Bevacizumab | n2=en:recombinant attenuated salmonella typhimurium expressing il-2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant b. pertussis adenylate cyclase toxin-tyrosinase a2 epitope vaccine n1=Bevacizumab | n2=en:recombinant b. pertussis adenylate cyclase toxin-tyrosinase a2 epitope vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant bispecific single-chain antibody rm28 n1=Bevacizumab | n2=en:recombinant bispecific single-chain antibody rm28 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant cd40-ligand n1=Bevacizumab | n2=en:recombinant cd40-ligand | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant cell-surface anchored sialidase das181 n1=Bevacizumab | n2=en:recombinant cell-surface anchored sialidase das181 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant dher2 vaccine n1=Bevacizumab | n2=en:recombinant dher2 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant dna-l523s vaccine n1=Bevacizumab | n2=en:recombinant dna-l523s vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant ephb4-hsa fusion protein n1=Bevacizumab | n2=en:recombinant ephb4-hsa fusion protein | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant flt3 ligand n1=Bevacizumab | n2=en:recombinant flt3 ligand | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant fowlpox gm-csf vaccine adjuvant n1=Bevacizumab | n2=en:recombinant fowlpox gm-csf vaccine adjuvant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant fowlpox-b7.1 vaccine n1=Bevacizumab | n2=en:recombinant fowlpox-b7.1 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant fowlpox-cea(6d)/tricom vaccine n1=Bevacizumab | n2=en:recombinant fowlpox-cea(6d)/tricom vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant fowlpox-prostate specific antigen vaccine n1=Bevacizumab | n2=en:recombinant fowlpox-prostate specific antigen vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant fowlpox-tricom vaccine n1=Bevacizumab | n2=en:recombinant fowlpox-tricom vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant fowlpox-tyrosinase vaccine n1=Bevacizumab | n2=en:recombinant fowlpox-tyrosinase vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant gonadorelin n1=Bevacizumab | n2=en:recombinant gonadorelin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant granulocyte-macrophage colony-stimulating factor n1=Bevacizumab | n2=en:recombinant granulocyte-macrophage colony-stimulating factor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant human 6ckine n1=Bevacizumab | n2=en:recombinant human 6ckine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant human adenovirus type 5 h101 n1=Bevacizumab | n2=en:recombinant human adenovirus type 5 h101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant human albumin-human granulocyte colony-stimulating factor n1=Bevacizumab | n2=en:recombinant human albumin-human granulocyte colony-stimulating factor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant human angiotensin converting enzyme 2 apn01 n1=Bevacizumab | n2=en:recombinant human angiotensin converting enzyme 2 apn01 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant human apolipoprotein(a) kringle v mg1102 n1=Bevacizumab | n2=en:recombinant human apolipoprotein(a) kringle v mg1102 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant human chorionic gonadotropin n1=Bevacizumab | n2=en:recombinant human chorionic gonadotropin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant human egf-rp64k/montanide isa 51 vaccine n1=Bevacizumab | n2=en:recombinant human egf-rp64k/montanide isa 51 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant human endostatin n1=Bevacizumab | n2=en:recombinant human endostatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant human fusion protein l19tnfalpha n1=Bevacizumab | n2=en:recombinant human fusion protein l19tnfalpha | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant human granulocyte colony stimulating factor n1=Bevacizumab | n2=en:recombinant human granulocyte colony stimulating factor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant human hsp110-gp100 chaperone complex vaccine n1=Bevacizumab | n2=en:recombinant human hsp110-gp100 chaperone complex vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant human hyaluronidase n1=Bevacizumab | n2=en:recombinant human hyaluronidase | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant human interleukin-15 n1=Bevacizumab | n2=en:recombinant human interleukin-15 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant human papillomavirus nonavalent vaccine n1=Bevacizumab | n2=en:recombinant human papillomavirus nonavalent vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant human serum amyloid p/pentraxin 2 n1=Bevacizumab | n2=en:recombinant human serum amyloid p/pentraxin 2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant interferon n1=Bevacizumab | n2=en:recombinant interferon | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant interferon alfa n1=Bevacizumab | n2=en:recombinant interferon alfa | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant interferon alfa-1b n1=Bevacizumab | n2=en:recombinant interferon alfa-1b | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant interferon alfa-2a n1=Bevacizumab | n2=en:recombinant interferon alfa-2a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant interferon alfa-2b n1=Bevacizumab | n2=en:recombinant interferon alfa-2b | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant interferon alpha 2b-like protein n1=Bevacizumab | n2=en:recombinant interferon alpha 2b-like protein | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant interferon beta n1=Bevacizumab | n2=en:recombinant interferon beta | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant interferon gamma n1=Bevacizumab | n2=en:recombinant interferon gamma | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant interleukin-1-alpha n1=Bevacizumab | n2=en:recombinant interleukin-1-alpha | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant interleukin-1-beta n1=Bevacizumab | n2=en:recombinant interleukin-1-beta | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant interleukin-12 n1=Bevacizumab | n2=en:recombinant interleukin-12 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant interleukin-18 n1=Bevacizumab | n2=en:recombinant interleukin-18 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant interleukin-3 n1=Bevacizumab | n2=en:recombinant interleukin-3 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant interleukin-7 n1=Bevacizumab | n2=en:recombinant interleukin-7 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant leukocyte interleukin n1=Bevacizumab | n2=en:recombinant leukocyte interleukin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant macrophage colony-stimulating factor n1=Bevacizumab | n2=en:recombinant macrophage colony-stimulating factor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant mage-3.1 antigen n1=Bevacizumab | n2=en:recombinant mage-3.1 antigen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant mip1-alpha variant eci301 n1=Bevacizumab | n2=en:recombinant mip1-alpha variant eci301 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant modified vaccinia ankara-5t4 vaccine n1=Bevacizumab | n2=en:recombinant modified vaccinia ankara-5t4 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant nematode anticoagulant protein c2 n1=Bevacizumab | n2=en:recombinant nematode anticoagulant protein c2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant oncolytic poliovirus pvs-ripo n1=Bevacizumab | n2=en:recombinant oncolytic poliovirus pvs-ripo | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant oxytocin n1=Bevacizumab | n2=en:recombinant oxytocin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant parathyroid hormone n1=Bevacizumab | n2=en:recombinant parathyroid hormone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant platelet factor 4 n1=Bevacizumab | n2=en:recombinant platelet factor 4 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant prame protein plus as15 adjuvant gsk2302025a n1=Bevacizumab | n2=en:recombinant prame protein plus as15 adjuvant gsk2302025a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant saccharomyces cerevisia-cea(610d)-expressing vaccine gi-6207 n1=Bevacizumab | n2=en:recombinant saccharomyces cerevisia-cea(610d)-expressing vaccine gi-6207 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant soluble human cd4 protein n1=Bevacizumab | n2=en:recombinant soluble human cd4 protein | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant soluble t4 n1=Bevacizumab | n2=en:recombinant soluble t4 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant super-compound interferon n1=Bevacizumab | n2=en:recombinant super-compound interferon | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant thymosin n1=Bevacizumab | n2=en:recombinant thymosin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant thyroglobulin n1=Bevacizumab | n2=en:recombinant thyroglobulin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant thyroid-stimulating hormone n1=Bevacizumab | n2=en:recombinant thyroid-stimulating hormone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant thyrotropin alfa n1=Bevacizumab | n2=en:recombinant thyrotropin alfa | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant transforming growth factor-beta-2 n1=Bevacizumab | n2=en:recombinant transforming growth factor-beta-2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant tumor necrosis factor family protein n1=Bevacizumab | n2=en:recombinant tumor necrosis factor family protein | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant tyrosinase-related protein-2 n1=Bevacizumab | n2=en:recombinant tyrosinase-related protein-2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant urokinase n1=Bevacizumab | n2=en:recombinant urokinase | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant vaccinia df3/muc1 vaccine n1=Bevacizumab | n2=en:recombinant vaccinia df3/muc1 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant vaccinia psa vaccine n1=Bevacizumab | n2=en:recombinant vaccinia psa vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant vaccinia viral vector ro5217790 n1=Bevacizumab | n2=en:recombinant vaccinia viral vector ro5217790 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant vaccinia-b7.1 vaccine n1=Bevacizumab | n2=en:recombinant vaccinia-b7.1 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant vaccinia-cea(6d)-tricom vaccine n1=Bevacizumab | n2=en:recombinant vaccinia-cea(6d)-tricom vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant vaccinia-muc-1 vaccine n1=Bevacizumab | n2=en:recombinant vaccinia-muc-1 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant vaccinia-multiepitope melanoma peptides-b7.1-b7.2 vaccine n1=Bevacizumab | n2=en:recombinant vaccinia-multiepitope melanoma peptides-b7.1-b7.2 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant vaccinia-ny-eso-1 vaccine n1=Bevacizumab | n2=en:recombinant vaccinia-ny-eso-1 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant vaccinia-tricom vaccine n1=Bevacizumab | n2=en:recombinant vaccinia-tricom vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant vascular endothelial growth factor n1=Bevacizumab | n2=en:recombinant vascular endothelial growth factor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:recombinant vesicular stomatitis virus-expressing interferon-beta n1=Bevacizumab | n2=en:recombinant vesicular stomatitis virus-expressing interferon-beta | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rectal dosage form product n1=Bevacizumab | n2=en:rectal dosage form product | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:red tomato juice n1=Bevacizumab | n2=en:red tomato juice | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:reduced glutathione-l-cysteine-anthocyanins gel n1=Bevacizumab | n2=en:reduced glutathione-l-cysteine-anthocyanins gel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:refametinib n1=Bevacizumab | n2=en:refametinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:regadenoson n1=Bevacizumab | n2=en:regadenoson | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:regorafenib n1=Bevacizumab | n2=en:regorafenib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:relcovaptan n1=Bevacizumab | n2=en:relcovaptan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:remestemcel-l n1=Bevacizumab | n2=en:remestemcel-l | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:remifentanil hydrochloride n1=Bevacizumab | n2=en:remifentanil hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:renal agents n1=Bevacizumab | n2=en:renal agents | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:renal cell carcinoma peptides vaccine ima901 n1=Bevacizumab | n2=en:renal cell carcinoma peptides vaccine ima901 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:renal cell carcinoma/cd40l rna-transfected autologous dendritic cell vaccine ags-003 n1=Bevacizumab | n2=en:renal cell carcinoma/cd40l rna-transfected autologous dendritic cell vaccine ags-003 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:repaglinide n1=Bevacizumab | n2=en:repaglinide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:reparixin n1=Bevacizumab | n2=en:reparixin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:replacement agent n1=Bevacizumab | n2=en:replacement agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:reproductive system drug n1=Bevacizumab | n2=en:reproductive system drug | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:resiniferatoxin n1=Bevacizumab | n2=en:resiniferatoxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:resiquimod n1=Bevacizumab | n2=en:resiquimod | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:resiquimod topical gel n1=Bevacizumab | n2=en:resiquimod topical gel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:resistant starch n1=Bevacizumab | n2=en:resistant starch | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:reslizumab n1=Bevacizumab | n2=en:reslizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:resminostat n1=Bevacizumab | n2=en:resminostat | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:respiratory form lucinactant n1=Bevacizumab | n2=en:respiratory form lucinactant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:respiratory form tiotropium n1=Bevacizumab | n2=en:respiratory form tiotropium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:respiratory system agents n1=Bevacizumab | n2=en:respiratory system agents | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:resveratrol n1=Bevacizumab | n2=en:resveratrol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:resveratrol formulation srt501 n1=Bevacizumab | n2=en:resveratrol formulation srt501 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:retaspimycin hydrochloride n1=Bevacizumab | n2=en:retaspimycin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:retinoic acid agent n1=Bevacizumab | n2=en:retinoic acid agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:retinoid 9cuab30 n1=Bevacizumab | n2=en:retinoid 9cuab30 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:retinoid analogue nrx 195183 n1=Bevacizumab | n2=en:retinoid analogue nrx 195183 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:retinyl acetate n1=Bevacizumab | n2=en:retinyl acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:retrovector encoding mutant anti-cyclin g1 n1=Bevacizumab | n2=en:retrovector encoding mutant anti-cyclin g1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:retrovirus vector ln n1=Bevacizumab | n2=en:retrovirus vector ln | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:revm10 gene n1=Bevacizumab | n2=en:revm10 gene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:revm10 gene/polas gene n1=Bevacizumab | n2=en:revm10 gene/polas gene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rexinoid nrx 194204 n1=Bevacizumab | n2=en:rexinoid nrx 194204 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rft5-dga immunotoxin n1=Bevacizumab | n2=en:rft5-dga immunotoxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rg 12915 n1=Bevacizumab | n2=en:rg 12915 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rhenium re 188 bmeda-labeled liposomes n1=Bevacizumab | n2=en:rhenium re 188 bmeda-labeled liposomes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rhenium re 188 p2045 n1=Bevacizumab | n2=en:rhenium re 188 p2045 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rhenium re-186 hydroxyethylidene diphosphonate n1=Bevacizumab | n2=en:rhenium re-186 hydroxyethylidene diphosphonate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rhenium re-188 ethiodized oil n1=Bevacizumab | n2=en:rhenium re-188 ethiodized oil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rhizoxin n1=Bevacizumab | n2=en:rhizoxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rhubarb/licorice herbal supplement n1=Bevacizumab | n2=en:rhubarb/licorice herbal supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ribavirin n1=Bevacizumab | n2=en:ribavirin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ribociclib n1=Bevacizumab | n2=en:ribociclib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:riboflavin n1=Bevacizumab | n2=en:riboflavin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ribonuclease qbi-139 n1=Bevacizumab | n2=en:ribonuclease qbi-139 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ribosome-inactivating protein cy503 n1=Bevacizumab | n2=en:ribosome-inactivating protein cy503 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ribozyme rpi.4610 n1=Bevacizumab | n2=en:ribozyme rpi.4610 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rice bran n1=Bevacizumab | n2=en:rice bran | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ricin immunoconjugate n1=Bevacizumab | n2=en:ricin immunoconjugate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ricolinostat n1=Bevacizumab | n2=en:ricolinostat | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ridaforolimus n1=Bevacizumab | n2=en:ridaforolimus | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rifabutin n1=Bevacizumab | n2=en:rifabutin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rifampin n1=Bevacizumab | n2=en:rifampin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rifaximin n1=Bevacizumab | n2=en:rifaximin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rigosertib sodium n1=Bevacizumab | n2=en:rigosertib sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rilimogene galvacirepvec n1=Bevacizumab | n2=en:rilimogene galvacirepvec | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rilotumumab n1=Bevacizumab | n2=en:rilotumumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:riluzole n1=Bevacizumab | n2=en:riluzole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rimiducid n1=Bevacizumab | n2=en:rimiducid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rindopepimut n1=Bevacizumab | n2=en:rindopepimut | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rintatolimod n1=Bevacizumab | n2=en:rintatolimod | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:risedronate sodium n1=Bevacizumab | n2=en:risedronate sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ritonavir n1=Bevacizumab | n2=en:ritonavir | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rituximab n1=Bevacizumab | n2=en:rituximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rivaroxaban n1=Bevacizumab | n2=en:rivaroxaban | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rivastigmine tartrate n1=Bevacizumab | n2=en:rivastigmine tartrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rizatriptan benzoate n1=Bevacizumab | n2=en:rizatriptan benzoate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rk-0202 n1=Bevacizumab | n2=en:rk-0202 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rna electroporated cd19car-cd3zeta-4-1bb-expressing autologous t-lymphocytes n1=Bevacizumab | n2=en:rna electroporated cd19car-cd3zeta-4-1bb-expressing autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rnr inhibitor coh29 n1=Bevacizumab | n2=en:rnr inhibitor coh29 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ro6874813 n1=Bevacizumab | n2=en:ro6874813 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ro6895882 n1=Bevacizumab | n2=en:ro6895882 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:robatumumab n1=Bevacizumab | n2=en:robatumumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rocuronium bromide n1=Bevacizumab | n2=en:rocuronium bromide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rofecoxib n1=Bevacizumab | n2=en:rofecoxib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:roflumilast n1=Bevacizumab | n2=en:roflumilast | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rogletimide n1=Bevacizumab | n2=en:rogletimide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rolapitant hydrochloride n1=Bevacizumab | n2=en:rolapitant hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:romidepsin n1=Bevacizumab | n2=en:romidepsin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:romiplostim n1=Bevacizumab | n2=en:romiplostim | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:roniciclib n1=Bevacizumab | n2=en:roniciclib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ropidoxuridine n1=Bevacizumab | n2=en:ropidoxuridine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ropinirole hydrochloride n1=Bevacizumab | n2=en:ropinirole hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ropivacaine hydrochloride n1=Bevacizumab | n2=en:ropivacaine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:roquinimex n1=Bevacizumab | n2=en:roquinimex | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ror1 car-specific autologous t-lymphocytes n1=Bevacizumab | n2=en:ror1 car-specific autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rosabulin n1=Bevacizumab | n2=en:rosabulin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rosiglitazone maleate n1=Bevacizumab | n2=en:rosiglitazone maleate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rosuvastatin calcium n1=Bevacizumab | n2=en:rosuvastatin calcium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rotavirus vaccine n1=Bevacizumab | n2=en:rotavirus vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rotigotine n1=Bevacizumab | n2=en:rotigotine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:roxithromycin n1=Bevacizumab | n2=en:roxithromycin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rsv fusion inhibitor gs-5806 n1=Bevacizumab | n2=en:rsv fusion inhibitor gs-5806 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rubidium rb-82 n1=Bevacizumab | n2=en:rubidium rb-82 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rubitecan n1=Bevacizumab | n2=en:rubitecan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rucaparib phosphate n1=Bevacizumab | n2=en:rucaparib phosphate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ruthenium ru-106 n1=Bevacizumab | n2=en:ruthenium ru-106 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ruthenium-based transferrin targeting agent nkp-1339 n1=Bevacizumab | n2=en:ruthenium-based transferrin targeting agent nkp-1339 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:rutin n1=Bevacizumab | n2=en:rutin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ruxolitinib n1=Bevacizumab | n2=en:ruxolitinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ruxolitinib phosphate n1=Bevacizumab | n2=en:ruxolitinib phosphate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:s-3304 n1=Bevacizumab | n2=en:s-3304 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:s-adenosyl-l-methionine disulfate p-toluene-sulfonate n1=Bevacizumab | n2=en:s-adenosyl-l-methionine disulfate p-toluene-sulfonate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:s-adenosylmethionine n1=Bevacizumab | n2=en:s-adenosylmethionine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:s-equol n1=Bevacizumab | n2=en:s-equol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:s1p receptor agonist krp203 n1=Bevacizumab | n2=en:s1p receptor agonist krp203 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sabarubicin n1=Bevacizumab | n2=en:sabarubicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:saccharomyces boulardii preparation n1=Bevacizumab | n2=en:saccharomyces boulardii preparation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:saccharomyces boulardii probiotic supplement n1=Bevacizumab | n2=en:saccharomyces boulardii probiotic supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sacituzumab govitecan n1=Bevacizumab | n2=en:sacituzumab govitecan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:safingol n1=Bevacizumab | n2=en:safingol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sagopilone n1=Bevacizumab | n2=en:sagopilone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:salirasib n1=Bevacizumab | n2=en:salirasib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:salmonella vnp20009 n1=Bevacizumab | n2=en:salmonella vnp20009 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:salvia hispanica seed n1=Bevacizumab | n2=en:salvia hispanica seed | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:salvia officinalis extract tablet n1=Bevacizumab | n2=en:salvia officinalis extract tablet | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sam68 modulator cwp232291 n1=Bevacizumab | n2=en:sam68 modulator cwp232291 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:samarium sm-153 lexidronam pentasodium n1=Bevacizumab | n2=en:samarium sm-153 lexidronam pentasodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:saob-0401 n1=Bevacizumab | n2=en:saob-0401 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sapacitabine n1=Bevacizumab | n2=en:sapacitabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sapanisertib n1=Bevacizumab | n2=en:sapanisertib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:saperconazole n1=Bevacizumab | n2=en:saperconazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sapitinib n1=Bevacizumab | n2=en:sapitinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:saponin-based immunoadjuvant obi-821 n1=Bevacizumab | n2=en:saponin-based immunoadjuvant obi-821 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:saponin-cholesterol-phospholipid adjuvant n1=Bevacizumab | n2=en:saponin-cholesterol-phospholipid adjuvant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:saquinavir mesylate n1=Bevacizumab | n2=en:saquinavir mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:saracatinib n1=Bevacizumab | n2=en:saracatinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sarcnu n1=Bevacizumab | n2=en:sarcnu | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sardomozide n1=Bevacizumab | n2=en:sardomozide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sargramostim plasmid dna hepatocellular carcinoma vaccine adjuvant n1=Bevacizumab | n2=en:sargramostim plasmid dna hepatocellular carcinoma vaccine adjuvant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sargramostim plasmid dna melanoma vaccine adjuvant n1=Bevacizumab | n2=en:sargramostim plasmid dna melanoma vaccine adjuvant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sargramostim plasmid dna pancreatic tumor cell vaccine n1=Bevacizumab | n2=en:sargramostim plasmid dna pancreatic tumor cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sargramostim plasmid dna sarcoma vaccine n1=Bevacizumab | n2=en:sargramostim plasmid dna sarcoma vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:saridegib n1=Bevacizumab | n2=en:saridegib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:satraplatin n1=Bevacizumab | n2=en:satraplatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:saw palmetto berry extract n1=Bevacizumab | n2=en:saw palmetto berry extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:saxagliptin hydrochloride n1=Bevacizumab | n2=en:saxagliptin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sb as-2 n1=Bevacizumab | n2=en:sb as-2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sb injection n1=Bevacizumab | n2=en:sb injection | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sb-743921 n1=Bevacizumab | n2=en:sb-743921 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sb-as02b adjuvant n1=Bevacizumab | n2=en:sb-as02b adjuvant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sb-as15 adjuvant n1=Bevacizumab | n2=en:sb-as15 adjuvant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:scb01a n1=Bevacizumab | n2=en:scb01a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sdf-1-targeted agent nox-a12 n1=Bevacizumab | n2=en:sdf-1-targeted agent nox-a12 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:secretin human n1=Bevacizumab | n2=en:secretin human | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:secukinumab n1=Bevacizumab | n2=en:secukinumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sedoxantrone trihydrochloride n1=Bevacizumab | n2=en:sedoxantrone trihydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:selatinib ditosilate n1=Bevacizumab | n2=en:selatinib ditosilate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:selective androgen receptor modulator ly2452473 n1=Bevacizumab | n2=en:selective androgen receptor modulator ly2452473 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:selective estrogen receptor degrader arn-810 n1=Bevacizumab | n2=en:selective estrogen receptor degrader arn-810 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:selective estrogen receptor degrader azd9496 n1=Bevacizumab | n2=en:selective estrogen receptor degrader azd9496 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:selective estrogen receptor degrader lsz102 n1=Bevacizumab | n2=en:selective estrogen receptor degrader lsz102 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:selective estrogen receptor degrader srn-927 n1=Bevacizumab | n2=en:selective estrogen receptor degrader srn-927 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:selective estrogen receptor degrader/modulator rad1901 n1=Bevacizumab | n2=en:selective estrogen receptor degrader/modulator rad1901 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:selective estrogen receptor modulator n1=Bevacizumab | n2=en:selective estrogen receptor modulator | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:selenium n1=Bevacizumab | n2=en:selenium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:seliciclib n1=Bevacizumab | n2=en:seliciclib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:selinexor n1=Bevacizumab | n2=en:selinexor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:selumetinib n1=Bevacizumab | n2=en:selumetinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:semaxanib n1=Bevacizumab | n2=en:semaxanib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:semuloparin n1=Bevacizumab | n2=en:semuloparin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:semustine n1=Bevacizumab | n2=en:semustine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:seneca valley virus-001 n1=Bevacizumab | n2=en:seneca valley virus-001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:senna extract n1=Bevacizumab | n2=en:senna extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:senna fruit n1=Bevacizumab | n2=en:senna fruit | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:seocalcitol n1=Bevacizumab | n2=en:seocalcitol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sepantronium bromide n1=Bevacizumab | n2=en:sepantronium bromide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:seribantumab n1=Bevacizumab | n2=en:seribantumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:serine protease inhibitor wx-671 n1=Bevacizumab | n2=en:serine protease inhibitor wx-671 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:serine/threonine kinase inhibitor xl418 n1=Bevacizumab | n2=en:serine/threonine kinase inhibitor xl418 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:serotonin 5-ht1 receptor agonists n1=Bevacizumab | n2=en:serotonin 5-ht1 receptor agonists | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sertraline hydrochloride n1=Bevacizumab | n2=en:sertraline hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:serum-derived bovine immunoglobulin protein isolate n1=Bevacizumab | n2=en:serum-derived bovine immunoglobulin protein isolate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sevacizumab n1=Bevacizumab | n2=en:sevacizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sevoflurane n1=Bevacizumab | n2=en:sevoflurane | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sh u04722 n1=Bevacizumab | n2=en:sh u04722 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:shark cartilage n1=Bevacizumab | n2=en:shark cartilage | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:shark cartilage extract ae-941 n1=Bevacizumab | n2=en:shark cartilage extract ae-941 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sheddase inhibitor incb007839 n1=Bevacizumab | n2=en:sheddase inhibitor incb007839 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sheng-mai san n1=Bevacizumab | n2=en:sheng-mai san | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sheng-yu-tang n1=Bevacizumab | n2=en:sheng-yu-tang | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:shi pi yin herbal decoction n1=Bevacizumab | n2=en:shi pi yin herbal decoction | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sho-saiko-to n1=Bevacizumab | n2=en:sho-saiko-to | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:short chain fatty acid hqk-1004 n1=Bevacizumab | n2=en:short chain fatty acid hqk-1004 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:shu yu wan formula n1=Bevacizumab | n2=en:shu yu wan formula | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sialyl lewis-keyhole limpet hemocyanin conjugate vaccine n1=Bevacizumab | n2=en:sialyl lewis-keyhole limpet hemocyanin conjugate vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sialyl tn antigen n1=Bevacizumab | n2=en:sialyl tn antigen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sig12d loder n1=Bevacizumab | n2=en:sig12d loder | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:signal transduction inhibition n1=Bevacizumab | n2=en:signal transduction inhibition | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:signal transduction inhibitor n1=Bevacizumab | n2=en:signal transduction inhibitor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:silatecan ar-67 n1=Bevacizumab | n2=en:silatecan ar-67 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sildenafil citrate n1=Bevacizumab | n2=en:sildenafil citrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:silicon phthalocyanine 4 n1=Bevacizumab | n2=en:silicon phthalocyanine 4 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:silmitasertib n1=Bevacizumab | n2=en:silmitasertib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:silodosin n1=Bevacizumab | n2=en:silodosin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:siltuximab n1=Bevacizumab | n2=en:siltuximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:silver nitrate n1=Bevacizumab | n2=en:silver nitrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:silver sulfadiazine n1=Bevacizumab | n2=en:silver sulfadiazine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:silymarin n1=Bevacizumab | n2=en:silymarin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:simethicone n1=Bevacizumab | n2=en:simethicone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:simmitecan hydrochloride n1=Bevacizumab | n2=en:simmitecan hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:simo decoction n1=Bevacizumab | n2=en:simo decoction | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:simotinib hydrochloride n1=Bevacizumab | n2=en:simotinib hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:simtrazene n1=Bevacizumab | n2=en:simtrazene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:simtuzumab n1=Bevacizumab | n2=en:simtuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:simvastatin n1=Bevacizumab | n2=en:simvastatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sinomenine n1=Bevacizumab | n2=en:sinomenine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:siplizumab n1=Bevacizumab | n2=en:siplizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sipuleucel-t n1=Bevacizumab | n2=en:sipuleucel-t | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sirna-expressing sv40 vector n1=Bevacizumab | n2=en:sirna-expressing sv40 vector | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sirna-transfected peripheral blood mononuclear cells apn401 n1=Bevacizumab | n2=en:sirna-transfected peripheral blood mononuclear cells apn401 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sirolimus n1=Bevacizumab | n2=en:sirolimus | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sirpa-fc fusion protein tti-621 n1=Bevacizumab | n2=en:sirpa-fc fusion protein tti-621 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sitagliptin phosphate n1=Bevacizumab | n2=en:sitagliptin phosphate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sivifene n1=Bevacizumab | n2=en:sivifene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sizofiran n1=Bevacizumab | n2=en:sizofiran | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:skeletal muscle relaxants n1=Bevacizumab | n2=en:skeletal muscle relaxants | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:smac mimetic gdc-0152 n1=Bevacizumab | n2=en:smac mimetic gdc-0152 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:smac mimetic gdc-0917 n1=Bevacizumab | n2=en:smac mimetic gdc-0917 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:smac mimetic lcl161 n1=Bevacizumab | n2=en:smac mimetic lcl161 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:smoked plum n1=Bevacizumab | n2=en:smoked plum | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:smokeless tobacco n1=Bevacizumab | n2=en:smokeless tobacco | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:smooth muscle relaxant n1=Bevacizumab | n2=en:smooth muscle relaxant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:smoothened antagonist bms-833923 n1=Bevacizumab | n2=en:smoothened antagonist bms-833923 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:smoothened antagonist lde225 topical n1=Bevacizumab | n2=en:smoothened antagonist lde225 topical | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:smoothened antagonist leq506 n1=Bevacizumab | n2=en:smoothened antagonist leq506 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:smoothened antagonist tak-441 n1=Bevacizumab | n2=en:smoothened antagonist tak-441 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sn-38-loaded polymeric micelles nk012 n1=Bevacizumab | n2=en:sn-38-loaded polymeric micelles nk012 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sns01-t nanoparticles n1=Bevacizumab | n2=en:sns01-t nanoparticles | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:soblidotin n1=Bevacizumab | n2=en:soblidotin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium alginate microspheres n1=Bevacizumab | n2=en:sodium alginate microspheres | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium bicarbonate n1=Bevacizumab | n2=en:sodium bicarbonate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium bicarbonate solution n1=Bevacizumab | n2=en:sodium bicarbonate solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium bicarbonate/potassium bicarbonate/anhydrous citric acid n1=Bevacizumab | n2=en:sodium bicarbonate/potassium bicarbonate/anhydrous citric acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium borocaptate n1=Bevacizumab | n2=en:sodium borocaptate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium butyrate n1=Bevacizumab | n2=en:sodium butyrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium carboxymethylcellulose dressing n1=Bevacizumab | n2=en:sodium carboxymethylcellulose dressing | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium citrate n1=Bevacizumab | n2=en:sodium citrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium dibunate n1=Bevacizumab | n2=en:sodium dibunate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium dichloroacetate n1=Bevacizumab | n2=en:sodium dichloroacetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium ferric gluconate complex in sucrose n1=Bevacizumab | n2=en:sodium ferric gluconate complex in sucrose | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium fluoride n1=Bevacizumab | n2=en:sodium fluoride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium glycididazole n1=Bevacizumab | n2=en:sodium glycididazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium hyaluronate topical hydrogel n1=Bevacizumab | n2=en:sodium hyaluronate topical hydrogel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium iodide i-131 n1=Bevacizumab | n2=en:sodium iodide i-131 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium metaarsenite n1=Bevacizumab | n2=en:sodium metaarsenite | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium phenylbutyrate n1=Bevacizumab | n2=en:sodium phenylbutyrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium phosphate n1=Bevacizumab | n2=en:sodium phosphate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium phosphate/sodium biphosphate laxative n1=Bevacizumab | n2=en:sodium phosphate/sodium biphosphate laxative | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium picosulfate/magnesium oxide/citric acid laxative n1=Bevacizumab | n2=en:sodium picosulfate/magnesium oxide/citric acid laxative | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium salicylate n1=Bevacizumab | n2=en:sodium salicylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium selenite n1=Bevacizumab | n2=en:sodium selenite | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium stibogluconate n1=Bevacizumab | n2=en:sodium stibogluconate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium sulfate/potassium sulfate/magnesium sulfate-based laxative n1=Bevacizumab | n2=en:sodium sulfate/potassium sulfate/magnesium sulfate-based laxative | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sodium thiosulfate n1=Bevacizumab | n2=en:sodium thiosulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sofosbuvir n1=Bevacizumab | n2=en:sofosbuvir | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:solifenacin succinate n1=Bevacizumab | n2=en:solifenacin succinate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:solitomab n1=Bevacizumab | n2=en:solitomab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:solution n1=Bevacizumab | n2=en:solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:somatropin n1=Bevacizumab | n2=en:somatropin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sonepcizumab n1=Bevacizumab | n2=en:sonepcizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sonidegib n1=Bevacizumab | n2=en:sonidegib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sorafenib n1=Bevacizumab | n2=en:sorafenib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sorafenib tosylate n1=Bevacizumab | n2=en:sorafenib tosylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sorghum bicolor supplement n1=Bevacizumab | n2=en:sorghum bicolor supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sorivudine n1=Bevacizumab | n2=en:sorivudine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sotagliflozin n1=Bevacizumab | n2=en:sotagliflozin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sotatercept n1=Bevacizumab | n2=en:sotatercept | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sotrastaurin acetate n1=Bevacizumab | n2=en:sotrastaurin acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:soy isoflavones n1=Bevacizumab | n2=en:soy isoflavones | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:soy lecithin/glycerol dioleate-based oral spray n1=Bevacizumab | n2=en:soy lecithin/glycerol dioleate-based oral spray | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:soy protein isolate n1=Bevacizumab | n2=en:soy protein isolate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sparfosic acid n1=Bevacizumab | n2=en:sparfosic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:spebrutinib n1=Bevacizumab | n2=en:spebrutinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sphingosine kinase-2 inhibitor abc294640 n1=Bevacizumab | n2=en:sphingosine kinase-2 inhibitor abc294640 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:spiramycin n1=Bevacizumab | n2=en:spiramycin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:spirogermanium n1=Bevacizumab | n2=en:spirogermanium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:spiromustine n1=Bevacizumab | n2=en:spiromustine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:spironolactone n1=Bevacizumab | n2=en:spironolactone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:spiroplatin n1=Bevacizumab | n2=en:spiroplatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:spleen tyrosine kinase inhibitor tak-659 n1=Bevacizumab | n2=en:spleen tyrosine kinase inhibitor tak-659 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:splicing inhibitor h3b-8800 n1=Bevacizumab | n2=en:splicing inhibitor h3b-8800 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:squalamine lactate n1=Bevacizumab | n2=en:squalamine lactate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sr-t100 gel n1=Bevacizumab | n2=en:sr-t100 gel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sr31747a n1=Bevacizumab | n2=en:sr31747a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:src kinase inhibitor kx2-391 n1=Bevacizumab | n2=en:src kinase inhibitor kx2-391 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:src kinase inhibitor kx2-391 ointment n1=Bevacizumab | n2=en:src kinase inhibitor kx2-391 ointment | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:src/abl kinase inhibitor azd0424 n1=Bevacizumab | n2=en:src/abl kinase inhibitor azd0424 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:src/tubulin inhibitor kx02 n1=Bevacizumab | n2=en:src/tubulin inhibitor kx02 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ss1(dsfv)-pe38 immunotoxin n1=Bevacizumab | n2=en:ss1(dsfv)-pe38 immunotoxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ssr411298 n1=Bevacizumab | n2=en:ssr411298 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:st. john's wort n1=Bevacizumab | n2=en:st. john's wort | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:stabilized sulphur hexafluoride microbubble-based contrast agent n1=Bevacizumab | n2=en:stabilized sulphur hexafluoride microbubble-based contrast agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:standardized freeze-dried table grape powder n1=Bevacizumab | n2=en:standardized freeze-dried table grape powder | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:stanford v regimen n1=Bevacizumab | n2=en:stanford v regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:stanozolol n1=Bevacizumab | n2=en:stanozolol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:staphage lysate n1=Bevacizumab | n2=en:staphage lysate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:staphylococcal enterotoxin a n1=Bevacizumab | n2=en:staphylococcal enterotoxin a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:staphylococcal enterotoxin b n1=Bevacizumab | n2=en:staphylococcal enterotoxin b | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:staphylococcus aureus protein a n1=Bevacizumab | n2=en:staphylococcus aureus protein a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:stat inhibitor opb-111077 n1=Bevacizumab | n2=en:stat inhibitor opb-111077 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:stat3 antisense oligonucleotide isis 481464 n1=Bevacizumab | n2=en:stat3 antisense oligonucleotide isis 481464 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:stat3 decoy oligonucleotide n1=Bevacizumab | n2=en:stat3 decoy oligonucleotide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:stat3 inhibitor opb-31121 n1=Bevacizumab | n2=en:stat3 inhibitor opb-31121 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:stat3 inhibitor opb-51602 n1=Bevacizumab | n2=en:stat3 inhibitor opb-51602 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:stavudine n1=Bevacizumab | n2=en:stavudine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:stimulant/agonist n1=Bevacizumab | n2=en:stimulant/agonist | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sting-activating cyclic dinucleotide agonist miw815 n1=Bevacizumab | n2=en:sting-activating cyclic dinucleotide agonist miw815 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:strawberry-blackberry-black raspberry-blueberry mixture n1=Bevacizumab | n2=en:strawberry-blackberry-black raspberry-blueberry mixture | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:street drugs n1=Bevacizumab | n2=en:street drugs | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:streptavidin n1=Bevacizumab | n2=en:streptavidin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:streptonigrin n1=Bevacizumab | n2=en:streptonigrin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:streptozocin n1=Bevacizumab | n2=en:streptozocin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:strontium chloride sr-89 n1=Bevacizumab | n2=en:strontium chloride sr-89 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:su014813 n1=Bevacizumab | n2=en:su014813 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:substance p-saporin n1=Bevacizumab | n2=en:substance p-saporin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:substance p/neurokinin 1 receptor antagonist n1=Bevacizumab | n2=en:substance p/neurokinin 1 receptor antagonist | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sucralfate n1=Bevacizumab | n2=en:sucralfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sufentanil citrate n1=Bevacizumab | n2=en:sufentanil citrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sufentanil transdermal system n1=Bevacizumab | n2=en:sufentanil transdermal system | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sugammadex sodium n1=Bevacizumab | n2=en:sugammadex sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sulfasalazine n1=Bevacizumab | n2=en:sulfasalazine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sulfate-based laxative bli850 n1=Bevacizumab | n2=en:sulfate-based laxative bli850 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sulfatinib n1=Bevacizumab | n2=en:sulfatinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sulforaphane n1=Bevacizumab | n2=en:sulforaphane | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sulforaphane-cyclodextrin complex n1=Bevacizumab | n2=en:sulforaphane-cyclodextrin complex | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sulfur hexafluoride n1=Bevacizumab | n2=en:sulfur hexafluoride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sulindac n1=Bevacizumab | n2=en:sulindac | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sulofenur n1=Bevacizumab | n2=en:sulofenur | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sumac/black cumin powder n1=Bevacizumab | n2=en:sumac/black cumin powder | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sumatriptan succinate n1=Bevacizumab | n2=en:sumatriptan succinate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sun protection agent md-3511356 n1=Bevacizumab | n2=en:sun protection agent md-3511356 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sun's soup n1=Bevacizumab | n2=en:sun's soup | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sunitinib malate n1=Bevacizumab | n2=en:sunitinib malate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sunless tanning lotion n1=Bevacizumab | n2=en:sunless tanning lotion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sunscreen n1=Bevacizumab | n2=en:sunscreen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:superagonist interleukin-15:interleukin-15 receptor alphasu/fc fusion complex alt-803 n1=Bevacizumab | n2=en:superagonist interleukin-15:interleukin-15 receptor alphasu/fc fusion complex alt-803 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:supersaturated calcium phosphate rinse n1=Bevacizumab | n2=en:supersaturated calcium phosphate rinse | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:suramin n1=Bevacizumab | n2=en:suramin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:surface-active agent n1=Bevacizumab | n2=en:surface-active agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:survivin antigen n1=Bevacizumab | n2=en:survivin antigen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:survivin antigen vaccine dpx-survivac n1=Bevacizumab | n2=en:survivin antigen vaccine dpx-survivac | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:survivin mrna antagonist ezn-3042 n1=Bevacizumab | n2=en:survivin mrna antagonist ezn-3042 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:survivin sur1m2 peptide vaccine n1=Bevacizumab | n2=en:survivin sur1m2 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:survivin/p53/her2 antigen-loaded autologous dendritic cell vaccine n1=Bevacizumab | n2=en:survivin/p53/her2 antigen-loaded autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sustained-release lipid inhaled cisplatin n1=Bevacizumab | n2=en:sustained-release lipid inhaled cisplatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:sustained-release mitomycin c hydrogel formulation n1=Bevacizumab | n2=en:sustained-release mitomycin c hydrogel formulation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:suvorexant n1=Bevacizumab | n2=en:suvorexant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:svn53-67/m57-klh peptide vaccine n1=Bevacizumab | n2=en:svn53-67/m57-klh peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:syk inhibitor hmpl-523 n1=Bevacizumab | n2=en:syk inhibitor hmpl-523 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:syk-jak inhibitor prt062070 n1=Bevacizumab | n2=en:syk-jak inhibitor prt062070 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:synbiotic supplement n1=Bevacizumab | n2=en:synbiotic supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:synchrotope ta2m plasmid dna vaccine n1=Bevacizumab | n2=en:synchrotope ta2m plasmid dna vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:synchrovax sem plasmid dna vaccine n1=Bevacizumab | n2=en:synchrovax sem plasmid dna vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:synthesis inhibitors, dna n1=Bevacizumab | n2=en:synthesis inhibitors, dna | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:synthetic antiandrogen n1=Bevacizumab | n2=en:synthetic antiandrogen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:synthetic antiestrogen n1=Bevacizumab | n2=en:synthetic antiestrogen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:synthetic brain tumor peptides-pulsed autologous dendritic cell vaccine n1=Bevacizumab | n2=en:synthetic brain tumor peptides-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:synthetic breast cancer peptides-tetanus toxoid-montanide isa-51 vaccine n1=Bevacizumab | n2=en:synthetic breast cancer peptides-tetanus toxoid-montanide isa-51 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:synthetic breast cancer peptides-tetanus toxoid-poly iclc vaccine n1=Bevacizumab | n2=en:synthetic breast cancer peptides-tetanus toxoid-poly iclc vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:synthetic glioblastoma mutated tumor-specific peptides vaccine therapy apvac2 n1=Bevacizumab | n2=en:synthetic glioblastoma mutated tumor-specific peptides vaccine therapy apvac2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:synthetic glioblastoma tumor-associated peptides vaccine therapy apvac1 n1=Bevacizumab | n2=en:synthetic glioblastoma tumor-associated peptides vaccine therapy apvac1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:synthetic htert dna vaccine ino-1400 n1=Bevacizumab | n2=en:synthetic htert dna vaccine ino-1400 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:synthetic human papillomavirus 16 e6 peptide n1=Bevacizumab | n2=en:synthetic human papillomavirus 16 e6 peptide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:synthetic hypericin n1=Bevacizumab | n2=en:synthetic hypericin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:synthetic long e6/e7 peptides vaccine hpv-01 n1=Bevacizumab | n2=en:synthetic long e6/e7 peptides vaccine hpv-01 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:synthetic melanoma-associated antigens vaccine n1=Bevacizumab | n2=en:synthetic melanoma-associated antigens vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:synthetic peptides e-pra and e-psm vaccine n1=Bevacizumab | n2=en:synthetic peptides e-pra and e-psm vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:syp-0704a n1=Bevacizumab | n2=en:syp-0704a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:t-type calcium channel blocker abt-639 n1=Bevacizumab | n2=en:t-type calcium channel blocker abt-639 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:t1e28z car-expressing autologous cd4-positive t lymphocytes n1=Bevacizumab | n2=en:t1e28z car-expressing autologous cd4-positive t lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:t4n5 liposomal lotion n1=Bevacizumab | n2=en:t4n5 liposomal lotion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:t900607 n1=Bevacizumab | n2=en:t900607 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tabalumab n1=Bevacizumab | n2=en:tabalumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tac regimen n1=Bevacizumab | n2=en:tac regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tacedinaline n1=Bevacizumab | n2=en:tacedinaline | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tacrolimus n1=Bevacizumab | n2=en:tacrolimus | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tadalafil n1=Bevacizumab | n2=en:tadalafil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tafamidis meglumine n1=Bevacizumab | n2=en:tafamidis meglumine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tak-448 n1=Bevacizumab | n2=en:tak-448 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:talabostat mesylate n1=Bevacizumab | n2=en:talabostat mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:talactoferrin alfa n1=Bevacizumab | n2=en:talactoferrin alfa | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:taladegib n1=Bevacizumab | n2=en:taladegib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:talampanel n1=Bevacizumab | n2=en:talampanel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:talaporfin sodium n1=Bevacizumab | n2=en:talaporfin sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:talazoparib n1=Bevacizumab | n2=en:talazoparib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:talc n1=Bevacizumab | n2=en:talc | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:taliglucerase alfa n1=Bevacizumab | n2=en:taliglucerase alfa | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:talimogene laherparepvec n1=Bevacizumab | n2=en:talimogene laherparepvec | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tallimustine n1=Bevacizumab | n2=en:tallimustine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:talmapimod n1=Bevacizumab | n2=en:talmapimod | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:talotrexin ammonium n1=Bevacizumab | n2=en:talotrexin ammonium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:taltirelin hydrate n1=Bevacizumab | n2=en:taltirelin hydrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tamibarotene n1=Bevacizumab | n2=en:tamibarotene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tamoxifen citrate n1=Bevacizumab | n2=en:tamoxifen citrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tamsulosin hydrochloride n1=Bevacizumab | n2=en:tamsulosin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tandutinib n1=Bevacizumab | n2=en:tandutinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tanespimycin n1=Bevacizumab | n2=en:tanespimycin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tanezumab n1=Bevacizumab | n2=en:tanezumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tangerine tomato juice n1=Bevacizumab | n2=en:tangerine tomato juice | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tanibirumab n1=Bevacizumab | n2=en:tanibirumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tanomastat n1=Bevacizumab | n2=en:tanomastat | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tapentadol hydrochloride n1=Bevacizumab | n2=en:tapentadol hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tarenflurbil n1=Bevacizumab | n2=en:tarenflurbil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tarextumab n1=Bevacizumab | n2=en:tarextumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tariquidar n1=Bevacizumab | n2=en:tariquidar | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tarp 27-35 peptide vaccine n1=Bevacizumab | n2=en:tarp 27-35 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tarp 29-37-9v peptide vaccine n1=Bevacizumab | n2=en:tarp 29-37-9v peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tas-108 n1=Bevacizumab | n2=en:tas-108 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:taselisib n1=Bevacizumab | n2=en:taselisib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tasidotin n1=Bevacizumab | n2=en:tasidotin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tasisulam n1=Bevacizumab | n2=en:tasisulam | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tasisulam sodium n1=Bevacizumab | n2=en:tasisulam sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tasquinimod n1=Bevacizumab | n2=en:tasquinimod | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:taurolidine n1=Bevacizumab | n2=en:taurolidine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tauromustine n1=Bevacizumab | n2=en:tauromustine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:taurultam n1=Bevacizumab | n2=en:taurultam | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:taxane analogue mst-997 n1=Bevacizumab | n2=en:taxane analogue mst-997 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:taxane analogue tpi 287 n1=Bevacizumab | n2=en:taxane analogue tpi 287 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:taxol analogue sid 530 n1=Bevacizumab | n2=en:taxol analogue sid 530 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:taxonomic n1=Bevacizumab | n2=en:taxonomic | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tazarotene n1=Bevacizumab | n2=en:tazarotene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tazemetostat n1=Bevacizumab | n2=en:tazemetostat | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tazobactam sodium n1=Bevacizumab | n2=en:tazobactam sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tc 99m monoclonal antibody 170 n1=Bevacizumab | n2=en:tc 99m monoclonal antibody 170 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc 94m sestamibi n1=Bevacizumab | n2=en:technetium tc 94m sestamibi | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 n1=Bevacizumab | n2=en:technetium tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc 99m epratuzumab n1=Bevacizumab | n2=en:technetium tc 99m epratuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc 99m galactosyl human serum albumin n1=Bevacizumab | n2=en:technetium tc 99m galactosyl human serum albumin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc 99m mip 1405 n1=Bevacizumab | n2=en:technetium tc 99m mip 1405 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc 99m trofolastat n1=Bevacizumab | n2=en:technetium tc 99m trofolastat | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc 99m-3prgd2 n1=Bevacizumab | n2=en:technetium tc 99m-3prgd2 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc 99m-labeled albumin microspheres n1=Bevacizumab | n2=en:technetium tc 99m-labeled albumin microspheres | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc 99m-labeled rhenium sulfide nanocolloid n1=Bevacizumab | n2=en:technetium tc 99m-labeled rhenium sulfide nanocolloid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc 99m-labeled tilmanocept n1=Bevacizumab | n2=en:technetium tc 99m-labeled tilmanocept | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc-99m n1=Bevacizumab | n2=en:technetium tc-99m | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc-99m albumin aggregated n1=Bevacizumab | n2=en:technetium tc-99m albumin aggregated | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc-99m demobesin-4 n1=Bevacizumab | n2=en:technetium tc-99m demobesin-4 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc-99m dextran n1=Bevacizumab | n2=en:technetium tc-99m dextran | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc-99m dtpa n1=Bevacizumab | n2=en:technetium tc-99m dtpa | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc-99m ethylenedicysteine-deoxyglucose n1=Bevacizumab | n2=en:technetium tc-99m ethylenedicysteine-deoxyglucose | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc-99m glycopeptide n1=Bevacizumab | n2=en:technetium tc-99m glycopeptide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc-99m human serum albumin colloid n1=Bevacizumab | n2=en:technetium tc-99m human serum albumin colloid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc-99m hydroxydiphosphonate n1=Bevacizumab | n2=en:technetium tc-99m hydroxydiphosphonate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc-99m mebrofenin n1=Bevacizumab | n2=en:technetium tc-99m mebrofenin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc-99m medronate n1=Bevacizumab | n2=en:technetium tc-99m medronate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc-99m sestamibi n1=Bevacizumab | n2=en:technetium tc-99m sestamibi | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc-99m sodium pertechnetate n1=Bevacizumab | n2=en:technetium tc-99m sodium pertechnetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc-99m sulfur colloid n1=Bevacizumab | n2=en:technetium tc-99m sulfur colloid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:technetium tc-99m-nc100692 n1=Bevacizumab | n2=en:technetium tc-99m-nc100692 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tecogalan sodium n1=Bevacizumab | n2=en:tecogalan sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:teduglutide n1=Bevacizumab | n2=en:teduglutide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tegafur n1=Bevacizumab | n2=en:tegafur | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tegafur-gimeracil-oteracil potassium n1=Bevacizumab | n2=en:tegafur-gimeracil-oteracil potassium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tegafur-gimeracil-oteracil potassium-leucovorin calcium oral formulation n1=Bevacizumab | n2=en:tegafur-gimeracil-oteracil potassium-leucovorin calcium oral formulation | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tegafur-uracil n1=Bevacizumab | n2=en:tegafur-uracil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:teglarinad n1=Bevacizumab | n2=en:teglarinad | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:teglarinad chloride n1=Bevacizumab | n2=en:teglarinad chloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:teicoplanin n1=Bevacizumab | n2=en:teicoplanin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:telaprevir n1=Bevacizumab | n2=en:telaprevir | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:telapristone acetate n1=Bevacizumab | n2=en:telapristone acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:telatinib mesylate n1=Bevacizumab | n2=en:telatinib mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:telavancin hydrochloride n1=Bevacizumab | n2=en:telavancin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:telbivudine n1=Bevacizumab | n2=en:telbivudine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:telomerase peptide vaccine gv1001 n1=Bevacizumab | n2=en:telomerase peptide vaccine gv1001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:telomerase-specific type 5 adenovirus obp-301 n1=Bevacizumab | n2=en:telomerase-specific type 5 adenovirus obp-301 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:telomerase: 540-548 peptide vaccine n1=Bevacizumab | n2=en:telomerase: 540-548 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:telotristat etiprate n1=Bevacizumab | n2=en:telotristat etiprate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:teloxantrone hydrochloride n1=Bevacizumab | n2=en:teloxantrone hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:temoporfin n1=Bevacizumab | n2=en:temoporfin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:temozolomide n1=Bevacizumab | n2=en:temozolomide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:temsirolimus n1=Bevacizumab | n2=en:temsirolimus | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tenifatecan n1=Bevacizumab | n2=en:tenifatecan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:teniposide n1=Bevacizumab | n2=en:teniposide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tenofovir n1=Bevacizumab | n2=en:tenofovir | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tenofovir disoproxil fumarate n1=Bevacizumab | n2=en:tenofovir disoproxil fumarate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tepotinib n1=Bevacizumab | n2=en:tepotinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:teprotumumab n1=Bevacizumab | n2=en:teprotumumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:terameprocol n1=Bevacizumab | n2=en:terameprocol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:teratogen n1=Bevacizumab | n2=en:teratogen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:terephthalamidine n1=Bevacizumab | n2=en:terephthalamidine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:terfluranol n1=Bevacizumab | n2=en:terfluranol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tergenpumatucel-l n1=Bevacizumab | n2=en:tergenpumatucel-l | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:teroxirone n1=Bevacizumab | n2=en:teroxirone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tesetaxel n1=Bevacizumab | n2=en:tesetaxel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tesevatinib n1=Bevacizumab | n2=en:tesevatinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tesmilifene n1=Bevacizumab | n2=en:tesmilifene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:testolactone n1=Bevacizumab | n2=en:testolactone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:testosterone cypionate n1=Bevacizumab | n2=en:testosterone cypionate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:testosterone enanthate n1=Bevacizumab | n2=en:testosterone enanthate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:testosterone gel n1=Bevacizumab | n2=en:testosterone gel | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:testosterone undecanoate n1=Bevacizumab | n2=en:testosterone undecanoate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:testosterone vaginal cream n1=Bevacizumab | n2=en:testosterone vaginal cream | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tetanus peptide melanoma vaccine n1=Bevacizumab | n2=en:tetanus peptide melanoma vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tetanus toxoid helper peptide n1=Bevacizumab | n2=en:tetanus toxoid helper peptide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tetanus toxoid vaccine n1=Bevacizumab | n2=en:tetanus toxoid vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tetanus-cmv fusion peptide vaccine n1=Bevacizumab | n2=en:tetanus-cmv fusion peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tetracycline antibiotic n1=Bevacizumab | n2=en:tetracycline antibiotic | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tetracycline hydrochloride n1=Bevacizumab | n2=en:tetracycline hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tetradecanoylphorbol acetate n1=Bevacizumab | n2=en:tetradecanoylphorbol acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tetrahydrouridine n1=Bevacizumab | n2=en:tetrahydrouridine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tetraphenyl chlorin disulfonate n1=Bevacizumab | n2=en:tetraphenyl chlorin disulfonate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tetravalent rna-lipoplex cancer vaccine n1=Bevacizumab | n2=en:tetravalent rna-lipoplex cancer vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tetrodotoxin n1=Bevacizumab | n2=en:tetrodotoxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tezacitabine n1=Bevacizumab | n2=en:tezacitabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tf(c)-klh conjugate vaccine n1=Bevacizumab | n2=en:tf(c)-klh conjugate vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tgf-beta-resistant lmp-specific cytotoxic t-lymphocytes n1=Bevacizumab | n2=en:tgf-beta-resistant lmp-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tgfa-pe38 immunotoxin n1=Bevacizumab | n2=en:tgfa-pe38 immunotoxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tgfbdnrii-transduced autologous tumor infiltrating lymphocytes n1=Bevacizumab | n2=en:tgfbdnrii-transduced autologous tumor infiltrating lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:thalicarpine n1=Bevacizumab | n2=en:thalicarpine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:thalidomide n1=Bevacizumab | n2=en:thalidomide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:theophylline n1=Bevacizumab | n2=en:theophylline | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:theramide n1=Bevacizumab | n2=en:theramide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:therapeutic allogeneic cytotoxic t-lymphocytes n1=Bevacizumab | n2=en:therapeutic allogeneic cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:therapeutic allogeneic lymphocytes n1=Bevacizumab | n2=en:therapeutic allogeneic lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:therapeutic androstanolone n1=Bevacizumab | n2=en:therapeutic androstanolone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:therapeutic angiotensin-(1-7) n1=Bevacizumab | n2=en:therapeutic angiotensin-(1-7) | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:therapeutic autologous dendritic cells n1=Bevacizumab | n2=en:therapeutic autologous dendritic cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:therapeutic autologous lymphocytes n1=Bevacizumab | n2=en:therapeutic autologous lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:therapeutic breast/ovarian/prostate peptide cancer vaccine dpx-0907 n1=Bevacizumab | n2=en:therapeutic breast/ovarian/prostate peptide cancer vaccine dpx-0907 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:therapeutic cortisone n1=Bevacizumab | n2=en:therapeutic cortisone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:therapeutic dendritic cells/cytokine-induced killer cells n1=Bevacizumab | n2=en:therapeutic dendritic cells/cytokine-induced killer cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:therapeutic epinephrine n1=Bevacizumab | n2=en:therapeutic epinephrine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:therapeutic estetrol n1=Bevacizumab | n2=en:therapeutic estetrol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:therapeutic estradiol n1=Bevacizumab | n2=en:therapeutic estradiol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:therapeutic estrone n1=Bevacizumab | n2=en:therapeutic estrone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:therapeutic gamma delta t-lymphocytes n1=Bevacizumab | n2=en:therapeutic gamma delta t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:therapeutic hemin n1=Bevacizumab | n2=en:therapeutic hemin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:therapeutic hepatitis c immune globulin n1=Bevacizumab | n2=en:therapeutic hepatitis c immune globulin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:therapeutic hydrocortisone n1=Bevacizumab | n2=en:therapeutic hydrocortisone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:therapeutic immune globulin n1=Bevacizumab | n2=en:therapeutic immune globulin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:therapeutic insulin n1=Bevacizumab | n2=en:therapeutic insulin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:therapeutic melatonin n1=Bevacizumab | n2=en:therapeutic melatonin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:therapeutic progesterone n1=Bevacizumab | n2=en:therapeutic progesterone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:therapeutic testosterone n1=Bevacizumab | n2=en:therapeutic testosterone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:therapeutic tumor infiltrating lymphocytes n1=Bevacizumab | n2=en:therapeutic tumor infiltrating lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:therapeutic use - qualifier n1=Bevacizumab | n2=en:therapeutic use - qualifier | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:thiabendazole n1=Bevacizumab | n2=en:thiabendazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:thiamine n1=Bevacizumab | n2=en:thiamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:thiarabine n1=Bevacizumab | n2=en:thiarabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:thioguanine n1=Bevacizumab | n2=en:thioguanine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:thioinosine n1=Bevacizumab | n2=en:thioinosine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:thioredoxin-1 inhibitor px-12 n1=Bevacizumab | n2=en:thioredoxin-1 inhibitor px-12 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:thiotepa n1=Bevacizumab | n2=en:thiotepa | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:thioureidobutyronitrile n1=Bevacizumab | n2=en:thioureidobutyronitrile | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:thl-p n1=Bevacizumab | n2=en:thl-p | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:thomsen-friedenreich antigen n1=Bevacizumab | n2=en:thomsen-friedenreich antigen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:threonine tyrosine kinase inhibitor cfi-402257 n1=Bevacizumab | n2=en:threonine tyrosine kinase inhibitor cfi-402257 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:thrombopoietin receptor agonist lgd-4665 n1=Bevacizumab | n2=en:thrombopoietin receptor agonist lgd-4665 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:thymidine n1=Bevacizumab | n2=en:thymidine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:thymidylate synthase inhibitor dfp-11207 n1=Bevacizumab | n2=en:thymidylate synthase inhibitor dfp-11207 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:thymopentin n1=Bevacizumab | n2=en:thymopentin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:thyroid extract n1=Bevacizumab | n2=en:thyroid extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:thyrotropin alfa n1=Bevacizumab | n2=en:thyrotropin alfa | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:thyroxine n1=Bevacizumab | n2=en:thyroxine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tiazofurin n1=Bevacizumab | n2=en:tiazofurin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tibolone n1=Bevacizumab | n2=en:tibolone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ticarcillin n1=Bevacizumab | n2=en:ticarcillin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tigapotide n1=Bevacizumab | n2=en:tigapotide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tigatuzumab n1=Bevacizumab | n2=en:tigatuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tigecycline n1=Bevacizumab | n2=en:tigecycline | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:til 1383i t cell receptor-transduced autologous t cells n1=Bevacizumab | n2=en:til 1383i t cell receptor-transduced autologous t cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tilarginine n1=Bevacizumab | n2=en:tilarginine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tilorone n1=Bevacizumab | n2=en:tilorone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:timcodar dimesylate n1=Bevacizumab | n2=en:timcodar dimesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:timolol maleate gel forming solution n1=Bevacizumab | n2=en:timolol maleate gel forming solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:timonacic n1=Bevacizumab | n2=en:timonacic | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tin ethyl etiopurpurin n1=Bevacizumab | n2=en:tin ethyl etiopurpurin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tin sn 117m dtpa n1=Bevacizumab | n2=en:tin sn 117m dtpa | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tinidazole n1=Bevacizumab | n2=en:tinidazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tinzaparin sodium n1=Bevacizumab | n2=en:tinzaparin sodium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tiomolibdate diammonium n1=Bevacizumab | n2=en:tiomolibdate diammonium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tiotropium bromide monohydrate n1=Bevacizumab | n2=en:tiotropium bromide monohydrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tipifarnib n1=Bevacizumab | n2=en:tipifarnib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tirapazamine n1=Bevacizumab | n2=en:tirapazamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:titanium dioxide/zinc oxide sunscreen n1=Bevacizumab | n2=en:titanium dioxide/zinc oxide sunscreen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tivantinib n1=Bevacizumab | n2=en:tivantinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tivozanib n1=Bevacizumab | n2=en:tivozanib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tizanidine hydrochloride n1=Bevacizumab | n2=en:tizanidine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tlr 7/8 agonist medi9197 n1=Bevacizumab | n2=en:tlr 7/8 agonist medi9197 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tlr agonist cadi-05 n1=Bevacizumab | n2=en:tlr agonist cadi-05 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tlr-directed cationic lipid-dna complex jvrs-100 n1=Bevacizumab | n2=en:tlr-directed cationic lipid-dna complex jvrs-100 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tlr4 agonist gla-se n1=Bevacizumab | n2=en:tlr4 agonist gla-se | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tlr4 agonist gsk1795091 n1=Bevacizumab | n2=en:tlr4 agonist gsk1795091 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tlr7 agonist 852a n1=Bevacizumab | n2=en:tlr7 agonist 852a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tlr7 agonist ana773 tosylate n1=Bevacizumab | n2=en:tlr7 agonist ana773 tosylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tlr7/8/9 antagonist imo-8400 n1=Bevacizumab | n2=en:tlr7/8/9 antagonist imo-8400 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tlr8 agonist vtx-2337 n1=Bevacizumab | n2=en:tlr8 agonist vtx-2337 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tlr9 agonist duk-cpg-001 n1=Bevacizumab | n2=en:tlr9 agonist duk-cpg-001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tlr9 agonist emd 1201081 n1=Bevacizumab | n2=en:tlr9 agonist emd 1201081 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tlr9 agonist mgn1703 n1=Bevacizumab | n2=en:tlr9 agonist mgn1703 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tlr9 agonist sd-101 n1=Bevacizumab | n2=en:tlr9 agonist sd-101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tn(c)-klh conjugate vaccine n1=Bevacizumab | n2=en:tn(c)-klh conjugate vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tobramycin sulfate n1=Bevacizumab | n2=en:tobramycin sulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tocilizumab n1=Bevacizumab | n2=en:tocilizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tocladesine n1=Bevacizumab | n2=en:tocladesine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tocolytic agents n1=Bevacizumab | n2=en:tocolytic agents | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tocopherol n1=Bevacizumab | n2=en:tocopherol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tocophersolan n1=Bevacizumab | n2=en:tocophersolan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tocotrienol n1=Bevacizumab | n2=en:tocotrienol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tocotrienol-rich fraction n1=Bevacizumab | n2=en:tocotrienol-rich fraction | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tofacitinib n1=Bevacizumab | n2=en:tofacitinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tolazamide n1=Bevacizumab | n2=en:tolazamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tolbutamide n1=Bevacizumab | n2=en:tolbutamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tolfenamic acid n1=Bevacizumab | n2=en:tolfenamic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:toll-like receptor 9 agonist imo-2125 n1=Bevacizumab | n2=en:toll-like receptor 9 agonist imo-2125 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tolnidamine n1=Bevacizumab | n2=en:tolnidamine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tolvaptan n1=Bevacizumab | n2=en:tolvaptan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tomato-soy juice n1=Bevacizumab | n2=en:tomato-soy juice | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topical agent ad17137 n1=Bevacizumab | n2=en:topical agent ad17137 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topical betulinic acid n1=Bevacizumab | n2=en:topical betulinic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topical calcitriol n1=Bevacizumab | n2=en:topical calcitriol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topical cocaine hydrochloride n1=Bevacizumab | n2=en:topical cocaine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topical dosage form n1=Bevacizumab | n2=en:topical dosage form | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topical fluorouracil n1=Bevacizumab | n2=en:topical fluorouracil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topical gemcitabine hydrochloride n1=Bevacizumab | n2=en:topical gemcitabine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topical keratin n1=Bevacizumab | n2=en:topical keratin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topical lfx453 n1=Bevacizumab | n2=en:topical lfx453 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topical menthol cream n1=Bevacizumab | n2=en:topical menthol cream | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topical myristyl nicotinate cream n1=Bevacizumab | n2=en:topical myristyl nicotinate cream | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topical phenylephrine solution n1=Bevacizumab | n2=en:topical phenylephrine solution | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topical piperidine nitroxide mts-01 n1=Bevacizumab | n2=en:topical piperidine nitroxide mts-01 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topical pvdf/sirolimus n1=Bevacizumab | n2=en:topical pvdf/sirolimus | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topical sirolimus n1=Bevacizumab | n2=en:topical sirolimus | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topical trichloroacetic acid n1=Bevacizumab | n2=en:topical trichloroacetic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topical vitamin e n1=Bevacizumab | n2=en:topical vitamin e | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topical wound spray hp802-247 n1=Bevacizumab | n2=en:topical wound spray hp802-247 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topiramate n1=Bevacizumab | n2=en:topiramate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topoisomerase i inhibitor genz-644282 n1=Bevacizumab | n2=en:topoisomerase i inhibitor genz-644282 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topoisomerase i inhibitor lmp400 n1=Bevacizumab | n2=en:topoisomerase i inhibitor lmp400 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topoisomerase i inhibitor lmp776 n1=Bevacizumab | n2=en:topoisomerase i inhibitor lmp776 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topoisomerase i/ii inhibitor nev-801 n1=Bevacizumab | n2=en:topoisomerase i/ii inhibitor nev-801 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topoisomerase inhibitor n1=Bevacizumab | n2=en:topoisomerase inhibitor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topoisomerase-ii inhibitor n1=Bevacizumab | n2=en:topoisomerase-ii inhibitor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topotecan hydrochloride n1=Bevacizumab | n2=en:topotecan hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topotecan hydrochloride liposomes n1=Bevacizumab | n2=en:topotecan hydrochloride liposomes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:topsalysin n1=Bevacizumab | n2=en:topsalysin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:torc1/2 kinase inhibitor ds-3078a n1=Bevacizumab | n2=en:torc1/2 kinase inhibitor ds-3078a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:toremifene n1=Bevacizumab | n2=en:toremifene | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tosedostat n1=Bevacizumab | n2=en:tosedostat | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tositumomab n1=Bevacizumab | n2=en:tositumomab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tositumomab and iodine i 131 tositumomab n1=Bevacizumab | n2=en:tositumomab and iodine i 131 tositumomab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:total tumor rna-loaded dendritic cell vaccine n1=Bevacizumab | n2=en:total tumor rna-loaded dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:toxicity aspects n1=Bevacizumab | n2=en:toxicity aspects | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tozasertib lactate n1=Bevacizumab | n2=en:tozasertib lactate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tp40 immunotoxin n1=Bevacizumab | n2=en:tp40 immunotoxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tpf regimen n1=Bevacizumab | n2=en:tpf regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tpo receptor agonist ono-7746 n1=Bevacizumab | n2=en:tpo receptor agonist ono-7746 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trabectedin n1=Bevacizumab | n2=en:trabectedin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trabedersen n1=Bevacizumab | n2=en:trabedersen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trametinib n1=Bevacizumab | n2=en:trametinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tranexamic acid n1=Bevacizumab | n2=en:tranexamic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trans sodium crocetinate n1=Bevacizumab | n2=en:trans sodium crocetinate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:transdermal 17beta-estradiol gel bhr-200 n1=Bevacizumab | n2=en:transdermal 17beta-estradiol gel bhr-200 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:transdermal 4-hydroxytestosterone n1=Bevacizumab | n2=en:transdermal 4-hydroxytestosterone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:transdermal estrogen n1=Bevacizumab | n2=en:transdermal estrogen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:transferrin receptor-targeted anti-rrm2 sirna calaa-01 n1=Bevacizumab | n2=en:transferrin receptor-targeted anti-rrm2 sirna calaa-01 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:transferrin receptor-targeted liposomal p53 cdna n1=Bevacizumab | n2=en:transferrin receptor-targeted liposomal p53 cdna | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:transferrin-crm107 n1=Bevacizumab | n2=en:transferrin-crm107 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:transgenic lymphocyte immunization vaccine n1=Bevacizumab | n2=en:transgenic lymphocyte immunization vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:transthyretin antisense oligonucleotide isis-ttr rx n1=Bevacizumab | n2=en:transthyretin antisense oligonucleotide isis-ttr rx | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tranylcypromine sulfate n1=Bevacizumab | n2=en:tranylcypromine sulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trastuzumab n1=Bevacizumab | n2=en:trastuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trastuzumab emtansine n1=Bevacizumab | n2=en:trastuzumab emtansine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trastuzumab vc-seco-duba n1=Bevacizumab | n2=en:trastuzumab vc-seco-duba | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:traumeel s n1=Bevacizumab | n2=en:traumeel s | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trebananib n1=Bevacizumab | n2=en:trebananib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tremelimumab n1=Bevacizumab | n2=en:tremelimumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:treosulfan n1=Bevacizumab | n2=en:treosulfan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tretazicar n1=Bevacizumab | n2=en:tretazicar | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tretinoin n1=Bevacizumab | n2=en:tretinoin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tretinoin liposome n1=Bevacizumab | n2=en:tretinoin liposome | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tri-virus/gd2-specific allogeneic cytotoxic t-lymphocytes n1=Bevacizumab | n2=en:tri-virus/gd2-specific allogeneic cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:triamcinolone n1=Bevacizumab | n2=en:triamcinolone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:triamcinolone acetonide n1=Bevacizumab | n2=en:triamcinolone acetonide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:triapine n1=Bevacizumab | n2=en:triapine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:triazene derivative trin2755 n1=Bevacizumab | n2=en:triazene derivative trin2755 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:triazinate n1=Bevacizumab | n2=en:triazinate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tributyrin n1=Bevacizumab | n2=en:tributyrin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:triciribine phosphate n1=Bevacizumab | n2=en:triciribine phosphate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trientine hydrochloride n1=Bevacizumab | n2=en:trientine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trifluoperazine hydrochloride n1=Bevacizumab | n2=en:trifluoperazine hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trifluridine n1=Bevacizumab | n2=en:trifluridine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trifluridine/tipiracil hydrochloride combination agent tas-102 n1=Bevacizumab | n2=en:trifluridine/tipiracil hydrochloride combination agent tas-102 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trilostane n1=Bevacizumab | n2=en:trilostane | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trimethoprim n1=Bevacizumab | n2=en:trimethoprim | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trimethoprim-sulfamethoxazole n1=Bevacizumab | n2=en:trimethoprim-sulfamethoxazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trimethylcolchicinic acid n1=Bevacizumab | n2=en:trimethylcolchicinic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trimetrexate n1=Bevacizumab | n2=en:trimetrexate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trimetrexate glucuronate n1=Bevacizumab | n2=en:trimetrexate glucuronate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trioxifene mesylate n1=Bevacizumab | n2=en:trioxifene mesylate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:triptolide analog n1=Bevacizumab | n2=en:triptolide analog | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:triptorelin n1=Bevacizumab | n2=en:triptorelin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:triptorelin pamoate n1=Bevacizumab | n2=en:triptorelin pamoate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tris-acryl gelatin microspheres n1=Bevacizumab | n2=en:tris-acryl gelatin microspheres | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trivalent influenza vaccine n1=Bevacizumab | n2=en:trivalent influenza vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trivalent live-attenuated influenza vaccine n1=Bevacizumab | n2=en:trivalent live-attenuated influenza vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trk inhibitor azd6918 n1=Bevacizumab | n2=en:trk inhibitor azd6918 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trk inhibitor loxo-101 n1=Bevacizumab | n2=en:trk inhibitor loxo-101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trodusquemine n1=Bevacizumab | n2=en:trodusquemine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trofosfamide n1=Bevacizumab | n2=en:trofosfamide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:troglitazone n1=Bevacizumab | n2=en:troglitazone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tropisetron n1=Bevacizumab | n2=en:tropisetron | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tropisetron hydrochloride n1=Bevacizumab | n2=en:tropisetron hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tropomyosin receptor kinase inhibitor azd7451 n1=Bevacizumab | n2=en:tropomyosin receptor kinase inhibitor azd7451 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:troxacitabine n1=Bevacizumab | n2=en:troxacitabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trp2 mrna-electroporated autologous langerhans-type dendritic cell vaccine n1=Bevacizumab | n2=en:trp2 mrna-electroporated autologous langerhans-type dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:trpv6 calcium channel inhibitor sor-c13 n1=Bevacizumab | n2=en:trpv6 calcium channel inhibitor sor-c13 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tsp-1 mimetic fusion protein cvx-045 n1=Bevacizumab | n2=en:tsp-1 mimetic fusion protein cvx-045 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tti-237 n1=Bevacizumab | n2=en:tti-237 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tubercidin n1=Bevacizumab | n2=en:tubercidin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tubulin inhibitor alb 109564(a) n1=Bevacizumab | n2=en:tubulin inhibitor alb 109564(a) | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tubulin polymerization inhibitor ckd-516 n1=Bevacizumab | n2=en:tubulin polymerization inhibitor ckd-516 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tubulin-binding agent ssr97225 n1=Bevacizumab | n2=en:tubulin-binding agent ssr97225 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tucotuzumab celmoleukin n1=Bevacizumab | n2=en:tucotuzumab celmoleukin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tumor cell-derived dribbles vaccine n1=Bevacizumab | n2=en:tumor cell-derived dribbles vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tumor peptide-loaded myeloid dendritic cells n1=Bevacizumab | n2=en:tumor peptide-loaded myeloid dendritic cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tumor-associated antigen peptide vaccine grn-1201 n1=Bevacizumab | n2=en:tumor-associated antigen peptide vaccine grn-1201 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tumor-cells apoptosis factor hormone-peptide n1=Bevacizumab | n2=en:tumor-cells apoptosis factor hormone-peptide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tumor-homing peptide irgd n1=Bevacizumab | n2=en:tumor-homing peptide irgd | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tw1025 supplement n1=Bevacizumab | n2=en:tw1025 supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tyloxapol n1=Bevacizumab | n2=en:tyloxapol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:type of chemotherapy:type:pt:^patient:nom:phenx n1=Bevacizumab | n2=en:type of chemotherapy:type:pt:^patient:nom:phenx | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:typhoid vaccine n1=Bevacizumab | n2=en:typhoid vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tyroserleutide n1=Bevacizumab | n2=en:tyroserleutide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tyrosinase peptide n1=Bevacizumab | n2=en:tyrosinase peptide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tyrosinase related protein-1 n1=Bevacizumab | n2=en:tyrosinase related protein-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tyrosinase-klh n1=Bevacizumab | n2=en:tyrosinase-klh | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tyrosine kinase inhibitor n1=Bevacizumab | n2=en:tyrosine kinase inhibitor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tyrosine kinase inhibitor osi-930 n1=Bevacizumab | n2=en:tyrosine kinase inhibitor osi-930 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:tyrosine kinase inhibitor xl228 n1=Bevacizumab | n2=en:tyrosine kinase inhibitor xl228 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:uae inhibitor tak-243 n1=Bevacizumab | n2=en:uae inhibitor tak-243 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ubenimex n1=Bevacizumab | n2=en:ubenimex | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ubidecarenone injectable nanosuspension n1=Bevacizumab | n2=en:ubidecarenone injectable nanosuspension | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ublituximab n1=Bevacizumab | n2=en:ublituximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:udenafil n1=Bevacizumab | n2=en:udenafil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ulimorelin hyrdrochloride n1=Bevacizumab | n2=en:ulimorelin hyrdrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ulinastatin n1=Bevacizumab | n2=en:ulinastatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ulipristal acetate n1=Bevacizumab | n2=en:ulipristal acetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ulixertinib n1=Bevacizumab | n2=en:ulixertinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ulocuplumab n1=Bevacizumab | n2=en:ulocuplumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ultrastructure n1=Bevacizumab | n2=en:ultrastructure | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ulvwf multimer-targeting agent arc1779 n1=Bevacizumab | n2=en:ulvwf multimer-targeting agent arc1779 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:umbilical cord blood-derived hematopoietic cd34-positive progenitor cells n1=Bevacizumab | n2=en:umbilical cord blood-derived hematopoietic cd34-positive progenitor cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:umbilical cord blood-derived mesenchymal stem cells n1=Bevacizumab | n2=en:umbilical cord blood-derived mesenchymal stem cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:umbilical cord blood-derived natural killer cells n1=Bevacizumab | n2=en:umbilical cord blood-derived natural killer cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:umeclidinium n1=Bevacizumab | n2=en:umeclidinium | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:uncaria tomentosa extract n1=Bevacizumab | n2=en:uncaria tomentosa extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:uniformly-labeled [u-13c]glucose n1=Bevacizumab | n2=en:uniformly-labeled [u-13c]glucose | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:uracil n1=Bevacizumab | n2=en:uracil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:uracil ointment n1=Bevacizumab | n2=en:uracil ointment | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:urea n1=Bevacizumab | n2=en:urea | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:urea/lactic acid-based topical cream n1=Bevacizumab | n2=en:urea/lactic acid-based topical cream | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:urelumab n1=Bevacizumab | n2=en:urelumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:urethane n1=Bevacizumab | n2=en:urethane | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:uridine n1=Bevacizumab | n2=en:uridine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:uridine triacetate n1=Bevacizumab | n2=en:uridine triacetate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:urlc10 peptide vaccine n1=Bevacizumab | n2=en:urlc10 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:urlc10-cdca1-koc1 multipeptide vaccine n1=Bevacizumab | n2=en:urlc10-cdca1-koc1 multipeptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:urlc10-ttk-koc1-vegfr1-vegfr2 multipeptide vaccine n1=Bevacizumab | n2=en:urlc10-ttk-koc1-vegfr1-vegfr2 multipeptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:urokinase-derived peptide a6 n1=Bevacizumab | n2=en:urokinase-derived peptide a6 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ursodiol n1=Bevacizumab | n2=en:ursodiol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:usp14/uchl5 inhibitor vlx1570 n1=Bevacizumab | n2=en:usp14/uchl5 inhibitor vlx1570 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ustekinumab n1=Bevacizumab | n2=en:ustekinumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:uv1 telomerase peptide vaccine n1=Bevacizumab | n2=en:uv1 telomerase peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:v930 vaccine n1=Bevacizumab | n2=en:v930 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vaccine-sensitized draining lymph node cells n1=Bevacizumab | n2=en:vaccine-sensitized draining lymph node cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vaccinia cea vaccine n1=Bevacizumab | n2=en:vaccinia cea vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vaccinia virus dd-cdsr n1=Bevacizumab | n2=en:vaccinia virus dd-cdsr | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vaccinia-gm-csf vaccine n1=Bevacizumab | n2=en:vaccinia-gm-csf vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vaccinia-tyrosinase vaccine n1=Bevacizumab | n2=en:vaccinia-tyrosinase vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vaccinium myrtillus/macleaya cordata/echinacea angustifolia extract granules n1=Bevacizumab | n2=en:vaccinium myrtillus/macleaya cordata/echinacea angustifolia extract granules | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vadastuximab talirine n1=Bevacizumab | n2=en:vadastuximab talirine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vadimezan n1=Bevacizumab | n2=en:vadimezan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vaginal dosage form product n1=Bevacizumab | n2=en:vaginal dosage form product | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:valacyclovir n1=Bevacizumab | n2=en:valacyclovir | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:valdecoxib n1=Bevacizumab | n2=en:valdecoxib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:valerian n1=Bevacizumab | n2=en:valerian | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:valganciclovir n1=Bevacizumab | n2=en:valganciclovir | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:valproic acid n1=Bevacizumab | n2=en:valproic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:valrubicin n1=Bevacizumab | n2=en:valrubicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:valsartan n1=Bevacizumab | n2=en:valsartan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:valspodar n1=Bevacizumab | n2=en:valspodar | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vamp regimen n1=Bevacizumab | n2=en:vamp regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vancomycin n1=Bevacizumab | n2=en:vancomycin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vandetanib n1=Bevacizumab | n2=en:vandetanib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vandortuzumab vedotin n1=Bevacizumab | n2=en:vandortuzumab vedotin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vantictumab n1=Bevacizumab | n2=en:vantictumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vapreotide n1=Bevacizumab | n2=en:vapreotide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vardenafil hydrochloride trihydrate n1=Bevacizumab | n2=en:vardenafil hydrochloride trihydrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:varenicline n1=Bevacizumab | n2=en:varenicline | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:varicella-zoster virus strain oka/merck live antigen n1=Bevacizumab | n2=en:varicella-zoster virus strain oka/merck live antigen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:varlilumab n1=Bevacizumab | n2=en:varlilumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:varlitinib n1=Bevacizumab | n2=en:varlitinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vascular disrupting agent bnc105p n1=Bevacizumab | n2=en:vascular disrupting agent bnc105p | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vascular disrupting agent zd6126 n1=Bevacizumab | n2=en:vascular disrupting agent zd6126 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vascular endothelial growth factor n1=Bevacizumab | n2=en:vascular endothelial growth factor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vascular endothelial growth factor a n1=Bevacizumab | n2=en:vascular endothelial growth factor a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vascular endothelial growth factor antisense oligonucleotide n1=Bevacizumab | n2=en:vascular endothelial growth factor antisense oligonucleotide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vascular endothelial growth factor family n1=Bevacizumab | n2=en:vascular endothelial growth factor family | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vascular endothelial growth factor inhibitor n1=Bevacizumab | n2=en:vascular endothelial growth factor inhibitor | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vascular endothelial growth factor measurement n1=Bevacizumab | n2=en:vascular endothelial growth factor measurement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vatalanib n1=Bevacizumab | n2=en:vatalanib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vcl-cb01 vaccine n1=Bevacizumab | n2=en:vcl-cb01 vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vecuronium bromide n1=Bevacizumab | n2=en:vecuronium bromide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vedolizumab n1=Bevacizumab | n2=en:vedolizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vegf inhibitor ptc299 n1=Bevacizumab | n2=en:vegf inhibitor ptc299 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vegf-directed antibody interactions n1=Bevacizumab | n2=en:vegf-directed antibody interactions | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vegf/hgf-targeting darpin mp0250 n1=Bevacizumab | n2=en:vegf/hgf-targeting darpin mp0250 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vegfr inhibitor krn951 n1=Bevacizumab | n2=en:vegfr inhibitor krn951 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vegfr-2 dna vaccine vxm01 n1=Bevacizumab | n2=en:vegfr-2 dna vaccine vxm01 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vegfr/fgfr inhibitor odm-203 n1=Bevacizumab | n2=en:vegfr/fgfr inhibitor odm-203 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vegfr/pdgfr dual kinase inhibitor x-82 n1=Bevacizumab | n2=en:vegfr/pdgfr dual kinase inhibitor x-82 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vegfr/pdgfr tyrosine kinase inhibitor tak-593 n1=Bevacizumab | n2=en:vegfr/pdgfr tyrosine kinase inhibitor tak-593 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vegfr1-1084 peptide vaccine n1=Bevacizumab | n2=en:vegfr1-1084 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vegfr2 tyrosine kinase inhibitor pf-00337210 n1=Bevacizumab | n2=en:vegfr2 tyrosine kinase inhibitor pf-00337210 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vegfr2-169 peptide vaccine n1=Bevacizumab | n2=en:vegfr2-169 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vegfr2-targeted contrast agent br55 n1=Bevacizumab | n2=en:vegfr2-targeted contrast agent br55 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:veip regimen n1=Bevacizumab | n2=en:veip regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:velafermin n1=Bevacizumab | n2=en:velafermin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:veliparib n1=Bevacizumab | n2=en:veliparib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:veltuzumab n1=Bevacizumab | n2=en:veltuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vemurafenib n1=Bevacizumab | n2=en:vemurafenib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:venetoclax n1=Bevacizumab | n2=en:venetoclax | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:venlafaxine n1=Bevacizumab | n2=en:venlafaxine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vepoloxamer n1=Bevacizumab | n2=en:vepoloxamer | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:verapamil n1=Bevacizumab | n2=en:verapamil | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:verpasep caltespen n1=Bevacizumab | n2=en:verpasep caltespen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:verteporfin n1=Bevacizumab | n2=en:verteporfin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:verubulin hydrochloride n1=Bevacizumab | n2=en:verubulin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:veterinary drugs n1=Bevacizumab | n2=en:veterinary drugs | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:viagenpumatucel-l n1=Bevacizumab | n2=en:viagenpumatucel-l | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vidarabine n1=Bevacizumab | n2=en:vidarabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vigabatrin n1=Bevacizumab | n2=en:vigabatrin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vilazodone n1=Bevacizumab | n2=en:vilazodone | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vildagliptin n1=Bevacizumab | n2=en:vildagliptin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vinblastine n1=Bevacizumab | n2=en:vinblastine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vinblastine sulfate n1=Bevacizumab | n2=en:vinblastine sulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vinca alkaloid compound n1=Bevacizumab | n2=en:vinca alkaloid compound | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vincristine n1=Bevacizumab | n2=en:vincristine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vincristine sulfate n1=Bevacizumab | n2=en:vincristine sulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vincristine sulfate liposome n1=Bevacizumab | n2=en:vincristine sulfate liposome | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vindesine n1=Bevacizumab | n2=en:vindesine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vinflunine n1=Bevacizumab | n2=en:vinflunine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vinfosiltine n1=Bevacizumab | n2=en:vinfosiltine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vinorelbine tartrate n1=Bevacizumab | n2=en:vinorelbine tartrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vinorelbine tartrate emulsion n1=Bevacizumab | n2=en:vinorelbine tartrate emulsion | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vinorelbine tartrate oral n1=Bevacizumab | n2=en:vinorelbine tartrate oral | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vintafolide n1=Bevacizumab | n2=en:vintafolide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vinzolidine n1=Bevacizumab | n2=en:vinzolidine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vip regimen n1=Bevacizumab | n2=en:vip regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:virulizin n1=Bevacizumab | n2=en:virulizin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:visilizumab n1=Bevacizumab | n2=en:visilizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vismodegib n1=Bevacizumab | n2=en:vismodegib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vistusertib n1=Bevacizumab | n2=en:vistusertib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vitamin n1=Bevacizumab | n2=en:vitamin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vitamin / trace element n1=Bevacizumab | n2=en:vitamin / trace element | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vitamin a compound n1=Bevacizumab | n2=en:vitamin a compound | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vitamin e compound n1=Bevacizumab | n2=en:vitamin e compound | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vitamin k1-containing urea skin cream n1=Bevacizumab | n2=en:vitamin k1-containing urea skin cream | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vitespen n1=Bevacizumab | n2=en:vitespen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vlp-encapsulated tlr9 agonist cmp-001 n1=Bevacizumab | n2=en:vlp-encapsulated tlr9 agonist cmp-001 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vocimagene amiretrorepvec n1=Bevacizumab | n2=en:vocimagene amiretrorepvec | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:voglibose n1=Bevacizumab | n2=en:voglibose | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:volasertib n1=Bevacizumab | n2=en:volasertib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:volitinib n1=Bevacizumab | n2=en:volitinib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:volociximab n1=Bevacizumab | n2=en:volociximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:von hippel-lindau peptide vaccine n1=Bevacizumab | n2=en:von hippel-lindau peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:voriconazole n1=Bevacizumab | n2=en:voriconazole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vorinostat n1=Bevacizumab | n2=en:vorinostat | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vorozole n1=Bevacizumab | n2=en:vorozole | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vorsetuzumab-mafodotin n1=Bevacizumab | n2=en:vorsetuzumab-mafodotin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vortioxetine hydrobromide n1=Bevacizumab | n2=en:vortioxetine hydrobromide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vosaroxin n1=Bevacizumab | n2=en:vosaroxin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:voxtalisib n1=Bevacizumab | n2=en:voxtalisib | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:vx-803 n1=Bevacizumab | n2=en:vx-803 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:warfarin n1=Bevacizumab | n2=en:warfarin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:water o-15 n1=Bevacizumab | n2=en:water o-15 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:water-based vaginal lubricant n1=Bevacizumab | n2=en:water-based vaginal lubricant | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:water, mineral or uric acid metabolism drug n1=Bevacizumab | n2=en:water, mineral or uric acid metabolism drug | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:wee1 inhibitor azd1775 n1=Bevacizumab | n2=en:wee1 inhibitor azd1775 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:weight control agent n1=Bevacizumab | n2=en:weight control agent | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:wheatgrass juice n1=Bevacizumab | n2=en:wheatgrass juice | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:whey protein isolate n1=Bevacizumab | n2=en:whey protein isolate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:white button mushroom extract n1=Bevacizumab | n2=en:white button mushroom extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:white carrot n1=Bevacizumab | n2=en:white carrot | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:white wine n1=Bevacizumab | n2=en:white wine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:wild-type reovirus n1=Bevacizumab | n2=en:wild-type reovirus | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:wnt signaling inhibitor sm04755 n1=Bevacizumab | n2=en:wnt signaling inhibitor sm04755 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:wnt-5a mimic hexapeptide foxy-5 n1=Bevacizumab | n2=en:wnt-5a mimic hexapeptide foxy-5 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:wobe-mugos e n1=Bevacizumab | n2=en:wobe-mugos e | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:wt1 124-138 peptide vaccine n1=Bevacizumab | n2=en:wt1 124-138 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:wt1 126-134 peptide vaccine n1=Bevacizumab | n2=en:wt1 126-134 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:wt1 235-243 peptide vaccine n1=Bevacizumab | n2=en:wt1 235-243 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:wt1 247-261 peptide vaccine n1=Bevacizumab | n2=en:wt1 247-261 peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:wt1 analog peptide vaccine n1=Bevacizumab | n2=en:wt1 analog peptide vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:wt1 mrna-electroporated autologous dendritic cell vaccine n1=Bevacizumab | n2=en:wt1 mrna-electroporated autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:wt1 peptide vaccine ocv-501 n1=Bevacizumab | n2=en:wt1 peptide vaccine ocv-501 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:wt1 peptide vaccine wt2725 n1=Bevacizumab | n2=en:wt1 peptide vaccine wt2725 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:wt1 protein-derived peptide vaccine dsp-7888 n1=Bevacizumab | n2=en:wt1 protein-derived peptide vaccine dsp-7888 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:wt1-a10/as01b immunotherapeutic gsk2130579a n1=Bevacizumab | n2=en:wt1-a10/as01b immunotherapeutic gsk2130579a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:wt1-sensitized t cells n1=Bevacizumab | n2=en:wt1-sensitized t cells | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:wu-ling-san n1=Bevacizumab | n2=en:wu-ling-san | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:wx-uk1 n1=Bevacizumab | n2=en:wx-uk1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:xaliproden hydrochloride n1=Bevacizumab | n2=en:xaliproden hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:xanthohumol n1=Bevacizumab | n2=en:xanthohumol | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:xbp1-us/xbp1-sp/cd138/cs1 multipeptide vaccine pvx-410 n1=Bevacizumab | n2=en:xbp1-us/xbp1-sp/cd138/cs1 multipeptide vaccine pvx-410 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:xeliri regimen n1=Bevacizumab | n2=en:xeliri regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:xelox regimen n1=Bevacizumab | n2=en:xelox regimen | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:xenobiotics n1=Bevacizumab | n2=en:xenobiotics | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:xenogeneic tyrosinase dna vaccine n1=Bevacizumab | n2=en:xenogeneic tyrosinase dna vaccine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:xenon n1=Bevacizumab | n2=en:xenon | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:xianling gubao n1=Bevacizumab | n2=en:xianling gubao | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:xiap/ciap1 antagonist astx660 n1=Bevacizumab | n2=en:xiap/ciap1 antagonist astx660 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:xl820 n1=Bevacizumab | n2=en:xl820 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:xonrid cream n1=Bevacizumab | n2=en:xonrid cream | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:xpo1 inhibitor kpt-8602 n1=Bevacizumab | n2=en:xpo1 inhibitor kpt-8602 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:xpo1 inhibitor sl-801 n1=Bevacizumab | n2=en:xpo1 inhibitor sl-801 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:y 90 monoclonal antibody cc49 n1=Bevacizumab | n2=en:y 90 monoclonal antibody cc49 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:y 90 monoclonal antibody hmfg1 n1=Bevacizumab | n2=en:y 90 monoclonal antibody hmfg1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:y 90 monoclonal antibody lym-1 n1=Bevacizumab | n2=en:y 90 monoclonal antibody lym-1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:y 90 monoclonal antibody m170 n1=Bevacizumab | n2=en:y 90 monoclonal antibody m170 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:y 90 monoclonal antibody m195 n1=Bevacizumab | n2=en:y 90 monoclonal antibody m195 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:y-shape branched pegylated filgrastim n1=Bevacizumab | n2=en:y-shape branched pegylated filgrastim | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yangzheng xiaoji extract n1=Bevacizumab | n2=en:yangzheng xiaoji extract | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yangzheng xiaoji supplement n1=Bevacizumab | n2=en:yangzheng xiaoji supplement | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yellow wax n1=Bevacizumab | n2=en:yellow wax | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ym598 n1=Bevacizumab | n2=en:ym598 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yoshi-864 n1=Bevacizumab | n2=en:yoshi-864 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y 90 anti-cd19 monoclonal antibody bu12 n1=Bevacizumab | n2=en:yttrium y 90 anti-cd19 monoclonal antibody bu12 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y 90 anti-cd45 monoclonal antibody ahn-12 n1=Bevacizumab | n2=en:yttrium y 90 anti-cd45 monoclonal antibody ahn-12 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y 90 anti-cd45 monoclonal antibody bc8 n1=Bevacizumab | n2=en:yttrium y 90 anti-cd45 monoclonal antibody bc8 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y 90 anti-cd66 monoclonal antibody bw 250/183 n1=Bevacizumab | n2=en:yttrium y 90 anti-cd66 monoclonal antibody bw 250/183 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y 90 anti-cdh3 monoclonal antibody ff-21101 n1=Bevacizumab | n2=en:yttrium y 90 anti-cdh3 monoclonal antibody ff-21101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y 90 anti-cea monoclonal antibody ct84.66 n1=Bevacizumab | n2=en:yttrium y 90 anti-cea monoclonal antibody ct84.66 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y 90 basiliximab n1=Bevacizumab | n2=en:yttrium y 90 basiliximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y 90 colloid n1=Bevacizumab | n2=en:yttrium y 90 colloid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y 90 daclizumab n1=Bevacizumab | n2=en:yttrium y 90 daclizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y 90 dota anti-cea monoclonal antibody m5a n1=Bevacizumab | n2=en:yttrium y 90 dota anti-cea monoclonal antibody m5a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y 90 glass microspheres n1=Bevacizumab | n2=en:yttrium y 90 glass microspheres | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y 90 monoclonal antibody b3 n1=Bevacizumab | n2=en:yttrium y 90 monoclonal antibody b3 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y 90 monoclonal antibody bre-3 n1=Bevacizumab | n2=en:yttrium y 90 monoclonal antibody bre-3 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y 90 monoclonal antibody hu3s193 n1=Bevacizumab | n2=en:yttrium y 90 monoclonal antibody hu3s193 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y 90 monoclonal antibody idec-159 n1=Bevacizumab | n2=en:yttrium y 90 monoclonal antibody idec-159 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y 90 monoclonal antibody mn-14 n1=Bevacizumab | n2=en:yttrium y 90 monoclonal antibody mn-14 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y 90 resin microspheres n1=Bevacizumab | n2=en:yttrium y 90 resin microspheres | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y 90-dota-biotin n1=Bevacizumab | n2=en:yttrium y 90-dota-biotin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y 90-dota-di-hsg peptide imp-288 n1=Bevacizumab | n2=en:yttrium y 90-dota-di-hsg peptide imp-288 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y 90-edotreotide n1=Bevacizumab | n2=en:yttrium y 90-edotreotide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y 90-labeled anti-fzd10 monoclonal antibody otsa101 n1=Bevacizumab | n2=en:yttrium y 90-labeled anti-fzd10 monoclonal antibody otsa101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y-90 clivatuzumab tetraxetan n1=Bevacizumab | n2=en:yttrium y-90 clivatuzumab tetraxetan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y-90 epratuzumab tetraxetan n1=Bevacizumab | n2=en:yttrium y-90 epratuzumab tetraxetan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y-90 ibritumomab tiuxetan n1=Bevacizumab | n2=en:yttrium y-90 ibritumomab tiuxetan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y-90 tacatuzumab tetraxetan n1=Bevacizumab | n2=en:yttrium y-90 tacatuzumab tetraxetan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium y-90-dota-girentuximab n1=Bevacizumab | n2=en:yttrium y-90-dota-girentuximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:yttrium-90 polycarbonate brachytherapy plaque n1=Bevacizumab | n2=en:yttrium-90 polycarbonate brachytherapy plaque | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:z-360 n1=Bevacizumab | n2=en:z-360 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:z-endoxifen hydrochloride n1=Bevacizumab | n2=en:z-endoxifen hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zalcitabine n1=Bevacizumab | n2=en:zalcitabine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zalutumumab n1=Bevacizumab | n2=en:zalutumumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zanamivir n1=Bevacizumab | n2=en:zanamivir | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zanolimumab n1=Bevacizumab | n2=en:zanolimumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zd0101 n1=Bevacizumab | n2=en:zd0101 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zen003365 n1=Bevacizumab | n2=en:zen003365 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zeniplatin n1=Bevacizumab | n2=en:zeniplatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zhongyao fufang n1=Bevacizumab | n2=en:zhongyao fufang | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zibotentan n1=Bevacizumab | n2=en:zibotentan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ziconotide n1=Bevacizumab | n2=en:ziconotide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zidovudine n1=Bevacizumab | n2=en:zidovudine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zileuton n1=Bevacizumab | n2=en:zileuton | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zinc finger nuclease zfn-603 n1=Bevacizumab | n2=en:zinc finger nuclease zfn-603 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zinc finger nuclease zfn-758 n1=Bevacizumab | n2=en:zinc finger nuclease zfn-758 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zinc gluconate n1=Bevacizumab | n2=en:zinc gluconate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zinc oxide n1=Bevacizumab | n2=en:zinc oxide | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zinc oxide/aluminum starch octenylsuccinate/glycyrrhetinic phytosome/vitamin e/botanical extracts-based skin protectant paste n1=Bevacizumab | n2=en:zinc oxide/aluminum starch octenylsuccinate/glycyrrhetinic phytosome/vitamin e/botanical extracts-based skin protectant paste | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zinc sulfate n1=Bevacizumab | n2=en:zinc sulfate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zinostatin n1=Bevacizumab | n2=en:zinostatin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zirconium zr 89 bevacizumab n1=Bevacizumab | n2=en:zirconium zr 89 bevacizumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zirconium zr 89 cetuximab n1=Bevacizumab | n2=en:zirconium zr 89 cetuximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zirconium zr 89 desferrioxamine b monoclonal antibody huj591 n1=Bevacizumab | n2=en:zirconium zr 89 desferrioxamine b monoclonal antibody huj591 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zirconium zr 89 df-iab2m n1=Bevacizumab | n2=en:zirconium zr 89 df-iab2m | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zirconium zr 89 dfo-mstp2109a n1=Bevacizumab | n2=en:zirconium zr 89 dfo-mstp2109a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zirconium zr 89 girentuximab n1=Bevacizumab | n2=en:zirconium zr 89 girentuximab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zirconium zr 89 trastuzumab n1=Bevacizumab | n2=en:zirconium zr 89 trastuzumab | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zirconium zr 89-labeled anti-ca19-9 monoclonal antibody 5b1 n1=Bevacizumab | n2=en:zirconium zr 89-labeled anti-ca19-9 monoclonal antibody 5b1 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zirconium zr 89-labeled anti-pd-l1 monoclonal antibody mpdl3280a n1=Bevacizumab | n2=en:zirconium zr 89-labeled anti-pd-l1 monoclonal antibody mpdl3280a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zirconium zr 89-labeled anti-pigf monoclonal antibody ro5323441 n1=Bevacizumab | n2=en:zirconium zr 89-labeled anti-pigf monoclonal antibody ro5323441 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zirconium zr 89-labeled monoclonal antibody mmot0530a n1=Bevacizumab | n2=en:zirconium zr 89-labeled monoclonal antibody mmot0530a | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zirconium zr 89-labeled ro5479599 n1=Bevacizumab | n2=en:zirconium zr 89-labeled ro5479599 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:ziv-aflibercept n1=Bevacizumab | n2=en:ziv-aflibercept | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zoledronic acid n1=Bevacizumab | n2=en:zoledronic acid | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zolmitriptan n1=Bevacizumab | n2=en:zolmitriptan | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zolpidem tartrate n1=Bevacizumab | n2=en:zolpidem tartrate | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zoptarelin doxorubicin n1=Bevacizumab | n2=en:zoptarelin doxorubicin | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zorubicin hydrochloride n1=Bevacizumab | n2=en:zorubicin hydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zosuquidar trihydrochloride n1=Bevacizumab | n2=en:zosuquidar trihydrochloride | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> en:zyc300 n1=Bevacizumab | n2=en:zyc300 | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> facteur de croissance de l'endothélium vasculaire n1=Bevacizumab | n2=facteur de croissance de l'endothélium vasculaire | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> Gougerot n1=Bevacizumab | n2=Gougerot | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> inhibiteurs de l'angiogenèse n1=Bevacizumab | n2=inhibiteurs de l'angiogenèse | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> maladie n1=Bevacizumab | n2=maladie | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> maladie de Beurmann et Gougerot n1=Bevacizumab | n2=maladie de Beurmann et Gougerot | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> maladies n1=Bevacizumab | n2=maladies | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> médecine n1=Bevacizumab | n2=médecine | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> tumeur colo-rectale n1=Bevacizumab | n2=tumeur colo-rectale | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> tumeur colorectale n1=Bevacizumab | n2=tumeur colorectale | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> tumeur maligne d'un ovaire n1=Bevacizumab | n2=tumeur maligne d'un ovaire | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> tumeur maligne de l'ovaire n1=Bevacizumab | n2=tumeur maligne de l'ovaire | rel=r_associated | relid=0 | w=5 Bevacizumab -- r_associated #0: 5 / 1 -> tumeur maligne ovarienne n1=Bevacizumab | n2=tumeur maligne ovarienne | rel=r_associated | relid=0 | w=5

≈ 0 relations entrantes